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Summary 
Exosomes are small, nanometre-sized, vesicles secreted by cells into the extracellular milieu. 
They have shown good potential for biomarkers of disease as they are peripherally available, 
and therefore non-invasively obtained, and are representative of the source cell. Discovering 
novel biomarkers of Alzheimer’s disease is a desperate need that exosomes may address. 
This thesis explored the utility of RNA within exosomes for biomarkers of Alzheimer’s 
disease. 
Initially exosomes were isolated from H4 (neuroglioma) and IMR-32 (neuroblastoma) cell-
lines in culture. The exosomes were thoroughly characterised and the cell-lines used to 
establish bulk stocks of neural-derived exosomes for downstream assay development and 
analyses. 
As a pre-requisite of capturing neural-derived exosomes directly from biological fluids, a 
number of protein ligands were tested for affinity isolation of cell culture-derived exosomes. 
A working assay could not be developed so the direction of this thesis changed to a systems-
wide approach. 
A large RNA sequencing dataset was produced from RNA derived from H4 cells and 
exosomes. By performing whole transcriptome sequencing, novel insights into exosomal-
RNA were made. It was determined that the profile of RNA within exosomes is distinct from 
the source cell and enriched for species that suggested that RNA was actively sorted into 
these vesicles. 
A method was then developed for isolating exosomal-RNA from small volumes of plasma and 
measuring gene expression for multiple targets by quantitative polymerase chain reaction. 
This method was validated by showing sensitivity to small changes in exosome dose and able 
to detect brain-enriched gene targets. 
In conclusion, RNA appears to be non-randomly sorted into exosomes and thus sensitive to 
the state of the source cell. A method has been developed, and validated, for isolating 
exosomal-RNA from small volumes of plasma. This could prove of great use in the future for 
discovering novel, peripherally available, biomarkers of Alzheimer’s disease. 
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1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia accounting for 60-80% of all 
cases (Imtiaz et al., 2014). The prevalence of dementias, including AD, is a rapidly growing, 
global problem. In 2001, an estimated 24.3 million people, worldwide, were suffering with 
dementia and it has been predicted that this will rise to 81.1 million by 2040 (Prince et al., 
2013). 
In the United Kingdom 850,000 individuals were living with AD in 2015 
((https://www.alzheimers.org.uk/statistics), 2015). AD is a devastating disease for the 
sufferer, the family members and the caregivers. There is a financial burden on the economy 
that outweighs stroke, heart disease and cancer (Lowin et al., 2001). The direct cost of long-
term care to people with cognitive impairment was £5.4 billion in 2002 and projected to be 
£16.7 billion in 2031; this equates to be between 0.83-1.11% Gross Domestic Product 
(Comas-Herrera et al., 2007). Furthermore, an additional £11 billion was saved per year by 
family carers which, if included, would have resulted in a total cost of £26 billion in 2013 for 
dementia, in general (Prince et al., 2014).  
The elderly population in the UK and Europe is escalating, with the number of over-65s being 
estimated to exceed 1 billion in Europe by 2020 (Murray and Lopez, 1996). Thus the cost of 
AD to society and to the economy will increase over the coming years. 
1.1.1 History of Alzheimer’s disease 
The German Neurologist, Alois Alzheimer, first described a “peculiar disease of the cerebral 
cortex” at a meeting in Munich in 1906 (Wilkins and Brody, 1969, Alzheimer et al., 1995). His 
case was Auguste Deter, a housewife who was hospitalised at the age of 51 and died four 
and a half years later. Her symptoms included impaired memory, disorientation to time and 
place, persecutory delusions, auditory hallucinations and language abnormalities. General 
brain atrophy was observed at autopsy without macroscopic lesions but, using 
Bielschowsky's silver staining method, degenerating neurons with neurofibrillary tangles and 
senile plaques throughout the cortex were observed microscopically (Zilka and Novak, 2006). 
These two observations are now considered pathological hallmarks of AD and are required 
for post-mortem diagnosis. In 1910, Emil Kraepelin, Alois Alzheimer’s superior, designated 
this disorder “Alzheimer’s disease” to describe the presenile form (onset prior to the age of 
65). However the senile form (onset after the age of 65) has since been recognised (Blessed 
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et al., 1968) and often the two forms are distinguished as Early Onset Alzheimer’s disease 
(EOAD) and Late Onset Alzheimer’s disease (LOAD). 
1.1.2 Symptoms of Alzheimer’s disease 
Cognitive symptoms 
Progressive decline of memory is the classic symptom of AD (Desai and Grossberg, 2005, 
White and Clare, 2002). Patients typically forget recent memories, such as where they placed 
their keys, which progresses to difficulty in performing tasks such as making a cup of tea. 
Eventually, this leads to disorientation in space and time. This symptom is coupled with 
progressive decline of other higher functions. These include language; for example, Alois 
Alzheimer’s original patient was unable to name a cup so instead referred to one as a “milk-
pourer”  (Wilkins and Brody, 1969). Eventually speech becomes repetitive, incoherent or 
even mute. Over time patients develop agnosia whereby they can visually perceive an object 
or face but are unable to correctly identify or recognise the object or person (Baudic et al., 
2006, Rainville et al., 2002). Visuospatial awareness deteriorates over time with patients 
easily getting lost and disorientated (Mendez, 2000, Cummings and Cole, 2002); this is 
typically tested with the clock-drawing task (Figure 1.1) (Faison, 2005). Patients can also 
develop apraxia whereby simple motor tasks become difficult or impossible because ideas 
and thoughts cannot be translated (Desai and Grossberg, 2005, White and Clare, 2002). 
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Figure 1.1: Visuospatial impairment in Alzheimer’s disease causes patients to draw abnormal clocks. 
This picture, collated by Faison (2005), shows that the progressive neurodegeneration in AD can lead 
to abnormal clock drawings as the disease becomes more severe. 
 
Non-cognitive symptoms 
Psychotic symptoms, such as hallucinations and delusions, can occur in Alzheimer’s disease 
(Jeste et al., 1992, Stern et al., 1994a). Hallucinations are disturbances in perception that 
have not occurred in reality (Behrendt, 1998). In the case of AD patients, this can be the 
perception that they have spoken to a friend or relative who has long been deceased. 
Delusions are the irrational belief that something is real despite contradictory evidence 
(Manschreck and Khan, 2006). Such was the case with Auguste Deter: 
 
“Sometimes she greets the doctor as if he were a visitor […] on other occasions she screams 
that he wants to cut her open” 
 
Behavioural symptoms can include: apathy, agitation, aggression, anxiety, depression, 
insomnia and wandering (Desai and Grossberg, 2005, White and Clare, 2002, Burns et al., 
1990a, Burns et al., 1990b, Burns et al., 1990c, Burns et al., 1990d, Burns, 1992). Physical 
symptoms can become apparent as the disease progresses, including impairment of gait and 
balance, myoclonic jerks, seizures and eventually incontinence (McKhann et al., 1984, 
Villareal and Morris, 1999). 
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Disease progression 
Mild cognitive impairment (MCI) is a state of impaired memory without other cognitive 
symptoms. It is considered a transition state prior to AD as 15% of patients with MCI go on 
to develop the disease within one year and up to 70% in 4–5 years (de Leon et al., 1997, 
Bobinski et al., 1999). However, it is possible that MCI will not develop to AD in an individual’s 
lifetime and, likewise, someone may present AD symptoms in the clinic without prior MCI. 
Typically patients will live for 7-10 years (mean survival is 10.3 years) from symptom onset 
(Mann et al., 1992) but the range can reach up to 20 years (Bracco et al., 1994, Larson et al., 
2004). 
The disease progresses through three stages with defined clinical features (Mendez and 
Cummings, 2003). Stage I is a pre-clinical stage with a duration of 1-3 years. Symptoms 
include mild impairment of memory, perception, language and changes in behaviour. Stage 
II can span years 2-10 with more-severe impairments of memory, perception, language, 
motor system and more pronounced behaviour changes, including delusions in some cases. 
Stage III can span years 8-12 with severe cognitive deficits and speech and motor difficulties 
(Mendez and Cummings, 2003). 
The age of disease onset varies considerably between individuals and can range from 30 to 
over 90 years of age. Typically disease onset is after the age of 65 accounting for 95% cases 
(Shastry and Giblin, 1999) and termed Late Onset Alzheimer’s disease (LOAD). Both DSM-IV 
(Diagnostic and Statistical Manual of Mental Disorders) and NINCDS-ADRDA’s (National 
Institute of Neurological and Communication Disorders and Stroke and the Alzheimer’s 
disease and Related Disorders Associations) diagnostic criteria make a distinction between 
patients with disease onset over the age of 65 (LOAD) and those under the age of 65 (EOAD) 
(McKhann et al., 1984). Whilst clinical and neuropathological features overlap between these 
two forms, EOAD is characteristically more severe in terms of disease progression and 
survival time (Koss et al., 1996, Sevush et al., 1993, Villareal and Morris, 1999). 
Therapeutic interventions are few and limited in their efficacy. There is no cure for AD so 
therapies only address the symptoms or slow the rate of decline. In the UK, drug 
interventions are limited to Acetyl cholinesterase inhibitors such as Donepezil, galantamine 
and rivastigmine. Such interventions only provide a mild benefit to cognition, behaviour and 
rate of decline (Desai and Grossberg, 2005, Cummings and Cole, 2002). Recently, Eli Lilly 
developed a drug called solanezumab; a monoclonal antibody designed to clear amyloid-β 
(Aβ) from the brain. It was hoped that this would be a much anticipated disease-modifying 
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treatment but, unfortunately, whilst evidence showed that it could clear Aβ, it was not of 
therapeutic benefit and failed a large phase-3 clinical trial in November 2016 (Sacks et al., 
2017). As such, there has been a stagnation in new drugs becoming available and there 
continues to be a desperate need for new pharmaceutical therapies. 
Diagnosis of Alzheimer’s disease 
Definitive diagnosis of AD is only possible with a post-mortem examination of brain tissue 
showing senile plaques and neurofibrillary tangles. Measurements of tau deposition can be 
made by evaluating the distribution of tangles across the cortical mantle and a Braak stage 
determined (Qian et al., 2017). At Braak stage I deposits are observed in medial temporal 
lobe but this can develop to Braak stage VI where this is observed across all cortical areas. 
The frequency of neuritic plaques can also be determined by autopsy (Qian et al., 2017). 
However, this can be problematic as it has been shown that 50–60% of people who do show 
these neuropathological hallmarks had no cognitive deficits in life (Knopman et al., 2003). 
During life a “probable” diagnosis of AD can be made using physical and cognitive 
examinations coupled with patient history. The DSM-IV (American Psychiatric Association, 
1994) and NINCDS-ADRDA (McKhann et al., 1984) diagnostic criteria have been used in both 
research and clinical settings. It is worth noting that AD can present in the clinic very similarly, 
or even co-morbidly, to other dementias. Therefore the exclusion criteria of a probable AD 
diagnosis include concomitant cerebrovascular disease, core features of Dementia with Lewy 
bodies, prominent features of frontotemporal dementia or primary progressive aphasia, or 
evidence of other neurological disease or medication-induced cognitive changes (McKhann 
et al., 2011). This “probable AD” diagnosis has proved reliable and valid (O'Connor et al., 
1996, Becker et al., 1994, Foy et al., 2007, Gearing et al., 1995, Holmes et al., 1999) and 
diagnosis of mixed dementias can be also be made. 
1.1.3 Risk Factors of Alzheimer’s disease 
Alzheimer’s disease is a complex neurodegenerative disorder. Multiple interrelated and 
interacting factors can contribute to disease onset and severity; factors that are both 
environmental and genetic (Imtiaz et al., 2014). 
Environmental risk factors of Alzheimer’s disease 
Longitudinal studies have highlighted a number of cardiovascular risk factors in midlife which  
can elevate the risk of AD years later (Reijmer et al., 2012, Virta et al., 2013, Whitmer et al., 
2005, Kivipelto et al., 2005). These risks include hypertension in mid and late life (Kivipelto 
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et al., 2001, Korf et al., 2004, Skoog et al., 1996); high levels of blood cholesterol (Kivipelto 
et al., 2001, van Vliet et al., 2009, Solomon et al., 2007); high body mass index (BMI) in midlife 
and low BMI in late life (Tolppanen et al., 2014, Whitmer et al., 2007); and Diabetes Mellitus 
(Tolppanen et al., 2013).  
Lifestyle factors have also been implicated with AD risk. The effects of these factors include 
education reducing the risk of AD (Stern et al., 1994b, Ngandu et al., 2007b); physical activity 
in midlife reducing cardiovascular risk factors and thus AD risk (Chang et al., 2010, Sofi et al., 
2011); smoking and alcohol use have provided inconsistent evidence on affecting the risk of 
AD but it appears that mild alcohol intake is protective whilst heavy intake is detrimental 
(Ngandu et al., 2007a, Piazza-Gardner et al., 2013, Panza et al., 2012, Kim et al., 2012, 
Sinforiani et al., 2011) and smoking has a complicated interaction with an individual’s genetic 
background (Rusanen et al., 2010); and a healthy diet that is low in saturated fats reduces 
the risk of AD (Barberger-Gateau et al., 2007, Morris et al., 2003, Devore et al., 2010, 
Scarmeas et al., 2006). 
Genetic risk factors of Alzheimer’s disease 
The genetic landscape of AD has changed dramatically over the last few decades (Robinson 
et al., 2017) (Figure 1.2). Early studies identified mutations in the amyloid precursor protein 
(APP) gene as well as proteins that are involved in the enzymatic cleavage of APP to toxic β-
amyloid (Aβ) namely presenilin-1 (PSEN1) and presnilin-2 (PSEN2) (Tanzi and Bertram, 2005). 
These mutations, however, were found in familial cases of EOAD with low prevalence 
elsewhere. More recent advances in Genome-wide Association Studies (GWAS), sequencing 
and bioinformatics have begun to unveil the complex genetic architecture of the sporadic 
form of AD (Medway and Morgan, 2014, Jones et al., 2010, Tosto and Reitz, 2013). GWAS 
were able to uncover common variants with high frequency in the population that 
individually carried low risk. What was particularly striking about such discoveries was the 
implication of systems outside of the APP processing pathway such as cholesterol 
metabolism, immunity and endocytosis (Figure 1.2). Advances in DNA-sequencing 
technologies show promise of continuing these discoveries. The genetic risk factors of AD 
will be discussed in more detail below. 
Early Onset Alzheimer’s disease genetics 
The APP gene resides on chromosome 21 and the first suggestion of an AD associated gene 
on this chromosome came from individuals with Down’s syndrome who inherit a third copy 
of the chromosome. Patients with Trisomy 21 commonly develop the clinical and 
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neuropathological features of AD (Mann, 1988a, Mann, 1988b). Subsequently the first 
genetic linkage was found between a locus on 21q and autosomal dominant EOAD (St 
George-Hyslop et al., 1987). Later, the first point mutation on APP was discovered (Goate et 
al., 1991) followed by other mutations since found in autosomal dominant EOAD families 
(Weggen and Beher, 2012). PSEN1 was implicated by genetic linkage on chromosome 14q 
and PSEN2 on chromosome 1q (Sherrington et al., 1995, Van Broeckhoven et al., 1992, Levy-
Lahad et al., 1995b, Levy-Lahad et al., 1995a, Rogaev et al., 1995). Thus, it emerged that APP 
and APP-modifying genes were implicated in EOAD. A subsequent risk gene, ADAM10, was 
identified; ADAM10 is the major α-secretase that cleaves APP in amyloidogenesis (discussed 
in section 1.1.4) (Karch and Goate, 2015). The majority of mutations identified within these 
genes act in a fully penetrant, autosomal dominant manner, meaning that carriers will 
develop AD. 
Late Onset Alzheimer’s disease genetics 
Linkage studies in LOAD families implicated a locus on chromosome 19 (Pericak-Vance et al., 
1991) later identifying the APOE gene (Corder et al., 1993). The protein encoded by this gene 
can be one of three isoforms with unique structural features: ApoE2, ApoE3 or ApoE4 
(Mahley et al., 2006). The APOE genotypes that encode these isoforms can be determined in 
a number of ways including single nucleotide polymorphism (SNP) genotyping of rs7412 and 
rs429358 (Butchart et al., 2015, Ide et al., 2016). Carrying the ε2 allele has a protective effect 
(Daw et al., 2000) whilst one or two copies of the ε4 allele confers a greater risk of AD 
(Robinson et al., 2017). 
Since 2009, GWAS studies have dramatically changed the understanding of AD genetics. 
Common variants of small effect size were first found in the genes ABCA7, BIN1, CD33, CLU, 
CR1, CD2AP, EPHA1, MS4A6A–MS4A4E and PICALM (Lambert et al., 2009, Harold et al., 2009, 
Seshadri et al., 2010, Hollingworth et al., 2011, Naj et al., 2011). Subsequently, a large meta-
analysis using these datasets confirmed many of the loci and uncovered others namely: 
INPP5D, MEF2C, HLA-DRB5, NME8, ZCWPW1, PTK2B, CELF1, SORL1, FERMT2, SLC24A4 and 
CASS4 (Lambert et al., 2013). A follow-up study identified TRIP4 as a novel genome-wide 
significant locus (Ruiz et al., 2014). It is worth noting that the genes referred to may not be 
directly implicated in AD pathology as many of the SNPs found in association are intronic or 
intergenic. Therefore, these SNP associations may affect other genes at the locus and further 
analysis is required to determine the functional consequence. Exome studies have identified 
rare coding variants in TREM2 (Guerreiro et al., 2013, Jonsson et al., 2013) and, more 
recently, in PLCG2, ABI3 and again in TREM2 (Sims et al., 2017). This evidence directly 
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implicates these genes as the mutations identified directly alter the protein encoded by 
these genes and further supports the role of microglia in AD aetiology. Whole genome 
sequencing analysis has identified mutations in the APP gene which protect against AD and 
cognitive decline (Jonsson et al., 2012). In summary, there are a number of risk and 
protective loci that have been associated with AD; from these associations, coupled with 
environmental risk factors, AD can be described as a complex disorder. 
Additional analyses of GWAS data have unveiled a more detailed understanding of AD 
genetics. For example, pathway analysis using the Association LIst Go AnnoTatOR 
(ALIGATOR) method (Holmans et al., 2009) found the immune system and cholesterol 
metabolism as statistically over-represented in GWAS data (Jones et al., 2010). An additional 
utility of this was the development of a polygenic risk score to predict case-control status 
(Escott-Price et al., 2015, Escott-Price et al., 2017). Individuals carry multiple loci and this 
infers an aggregate risk of developing AD. The polygenic risk score is a method that assesses 
these aggregate genetic effects, including those that have not been associated at genome-
wide significance at an individual level, to determine a person’s risk of developing AD. 
The advent of next-generation and third-generation sequencing platforms shows great 
promise in further unravelling the genetics of AD. Whole exome sequencing allows the 
capture of coding regions whilst whole genome sequencing allows the entirety of the 
genome to be sequenced. Relatively small studies have been performed but not yet to the 
scale of GWAS; the generation, storage and analysis of such large datasets can be 
computationally challenging. For example, a cohort of 928 EOAD patients and 980 controls 
implicated novel coding mutations in the ABCA7 gene (De Roeck et al., 2017). In 2014 the 
much anticipated and far more affordable “$1000 genome” became possible 
(https://www.nature.com/news/technology-the-1-000-genome-1.14901). Thus, with costs 
being driven down rapidly the possibility of large studies, on the scale of previous GWAS 
studies, is drawing closer. It is likely to be of tremendous utility to match the scale of GWAS 
studies with the depth of data produced by these new sequencing technologies; the costs 
and computational challenges of next-generation sequencing means that this is not possible 
yet. 
Understanding the underlying causal genetics of AD has, and will continue to have, far-
reaching benefits. The implication of coding variants (Sims et al., 2017) and biological 
pathways (Jones et al., 2010) is offering new targets for therapeutic intervention. Indeed, 
incorporating rich genetic data into clinical trials provides better success rates in general 
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(Nelson et al., 2015). Particularly noteworthy is that these findings have dramatically 
changed the understanding of the underlying pathology of AD, as will be discussed next. 
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Figure 1.2: The genetic landscape of Alzheimer’s disease (Robinson et al., 2017).  
The familial genes APP, PSEN1 and PSEN2, carry near certain risk of developing EOAD but have low prevalence. The APOE gene carries the highest risk of sporadic AD. GWAS 
studies have implicated a number of common variants which individually carry low risk. Additional loci have been added in approximate positions. EOAD genes in blue text, 
rare coding variants in green text and common variants in black text. 
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1.1.4 Pathology of Alzheimer’s disease 
Neuropathology of Alzheimer’s disease 
The pathological hallmarks of AD are senile plaques and neurofibrillary tangles. Senile 
plaques are extracellular deposits of Aβ protein and referred to as neuritic plaques when 
associated with distorted neuronal cell processes. Particularly the APP cleavage products 
Aβ40 and Aβ42 (designated by their amino acid length) are fibrillary forms of Aβ found within 
neuritic plaques (Jarrett et al., 1993). Neuritic plaques have a core of Aβ surrounded by 
microglia, astrocytes and dystrophic neurites which often contain paired helical filaments 
(Cummings et al., 1998) (Figure 1.3).  
Neurofibrillary tangles are intracellular aggregates of abnormally phosphorylated tau 
protein. They form paired helical filaments that can occupy the cell body of neurons; they 
may extend into the dendrites but are absent from axons (Cummings and Cole, 2002) 
(Figure 1.3). Tau filaments that undergo abnormal phosphorylation dissociate from 
microtubules and no longer stabilise these intracellular transport structures (Clark et al., 
1997, Lee et al., 1991) and ultimately lead to cell death. In AD, plaques and tangles are 
predominately found in the hippocampus, entorhinal cortex and association areas of the 
neocortex, giving rise to the cognitive impairments observed in the clinic (Cummings, 2003). 
A prospective study has predicted that the process of Aβ deposition is slow and protracted, 
spanning over 2 decades and certainly occurring for a number of years prior to clinical 
manifestation (Villemagne et al., 2013). 
Additional neuropathologies include amyloid angiopathy and neuronal loss. Amyloid 
angiopathy is principally caused by fibrillar deposits of Aβ40 in the small arterioles, venules 
and capillaries of the cerebral cortex (Suzuki et al., 1994a). Neuronal loss can occur in the 
basal forebrain, locus coeruleus and raphe nuclei (Lantos and Cairns, 2000). 
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Figure 1.3: Morphology of Neuritic Plaques and Neurofibrillary Tangles (Cummings and Cole, 2002). 
Neuritic plaques were labelled with a monoclonal antibody against Aβ and counterstained with 
diaminobenzidine and hematoxylin (x2500 magnification). Neurofibrillary Tangles were visualised with 
Gallyas silver stain (x2500 magnification). 
 
Neurochemistry of Alzheimer’s disease 
Synaptic dysfunction precedes neuronal loss in AD (Coleman et al., 2004). As mentioned 
previously, neuronal loss occurs in the basal forebrain, locus coeruleus and raphe nuclei and 
these lead to deficits in the cholinergic, noradrenergic and serotonergic systems (Cummings 
and Cole, 2002). The hippocampus, substantia inominata, locus coeruleus and tempoparietal 
and frontal cortices have reduced levels of choline acetyltransferase (Hauw and Duyckaerts, 
2001, White and Clare, 2002). 
Pathogenesis of Alzheimer’s disease 
At a cellular level the pathogenesis of AD begins with the proteolytic cleavage of APP, a 
process referred to as amyloidogenesis. The APP transcript can undergo alternative splicing 
into one of eight isoforms; in particular, the isoform APP695 is predominantly expressed in 
neuronal cells of the Central Nervous System (CNS) (Bayer et al., 1999). APP is a 
transmembrane protein that is translated in the endoplasmic reticulum, undergoes post-
translational modifications in the Golgi and thereafter is transported to the plasma 
membrane (Kang et al., 1987, Russo et al., 2001, Shioi et al., 1992, Shioi et al., 1993, Suzuki 
et al., 1994b, Thinakaran et al., 1995). 
APP can undergo amyloidogenic and non-amyloidogenic proteolytic cleavage (Chapman et 
al., 2001). Pre-dominantly non-amyloidogenic cleavage occurs in most cells via α-secretase 
and subsequent γ-secretase cleavage. The first proteolytic cleavage occurs between Lys16 
and Leu17; it occurs in the middle of the Aβ sequence so preventing the formation of the 
toxic protein. A soluble APP fragment is liberated (APPsα) and the c-terminal product (α-CTF) 
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is cleaved by γ-secretase to the p3 peptide and APP intracellular domain (Nitsch et al., 1992, 
Thinakaran and Koo, 2008). 
Amyloidogenic cleavage of APP is caused by initial cleavage by the β-secretase enzymes 
BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) (Hussain et al., 1999, Lin et 
al., 2000, Sinha et al., 1999, Vassar et al., 1999, Yan et al., 1999). BACE1 cleaves APP at either 
the β site (Asp1) or β’ site (Glu11) to liberate a soluble APP fragment (APPsβ) and a β-c 
terminal fragment (β-CTF). Subsequently γ-secretase cleaves the β-CTF to an APP 
intracellular domain and Aβ (Gouras et al., 1998, Thinakaran and Koo, 2008). 
The convergence of BACE1 and its substrate, APP, occurs in the early endosome (Rajendran 
et al., 2006) where optimal pH conditions initiate amyloidogenesis (Vassar, 2001). The 
trafficking of these two proteins from the plasma membrane occurs by different mechanisms 
however. APP is internalised via clathrin-mediated endocytosis in contrast to BACE1 which is 
internalised via clathrin-independent endocytosis and is thus dependent on the small GTPase 
ARF6 (Sannerud et al., 2011). It has been shown, by in vitro analysis, that this convergence is 
not typical and that the two proteins are normally spatially segregated. APP is normally 
trafficked to the Golgi, but induction of neural activity in cultured hippocampal neurons 
altered this trafficking to endosomes instead (Das et al., 2013). Indeed, in the same study 
this phenomenon was reflected in vivo with co-localisation experiments using fractionated 
brain homogenates from AD patients and age-matched controls. Toxic Aβ can be expelled 
from the cell in soluble form (Thinakaran et al., 1996, Seubert et al., 1992, Haass et al., 1992) 
or via multi-vesicular bodies and secreted in exosomes (Rajendran et al., 2006, Morel et al., 
2013). 
There is an emerging story of non-neuronal cells contributing to the pathogenesis of AD. 
Microglia are the main immune cells of the brain and, in adults, microglia cycle between 
stable/surveillant (Nimmerjahn et al., 2005), proliferative and apoptosing forms (Gomez-
Nicola and Perry, 2014, Askew and Gomez-Nicola, 2017). Microglia have been shown to be 
present in the brain parenchyma in increased numbers for numerous neurodegenerative 
disorders (Gómez-Nicola et al., 2013, Brites and Vaz, 2014, Olmos-Alonso et al., 2016). It 
remains under debate whether this increase is caused by infiltration of monocytes from the 
periphery or increased proliferation of resident microglia (Askew and Gomez-Nicola, 2017). 
It is also unclear, at the moment, what effect this dysregulation of the microglia population 
has on the pathology of the AD brain. One observation using an AD mouse-model (APP-PS1) 
is that microglia can exhibit a different phenotype, termed “dark microglia”, that is rarely 
Chapter 1. Introduction 
15 
 
present under normal conditions (Bisht et al., 2016). These so-called “dark microglia” appear 
to play a role in pathological remodelling of neuronal circuits and synapses. Another 
observation is that neuronal hyperactivity decreases the phagocytic potential of microglia 
and thus perturbs the normal dynamics of apoptosis in the diseased brain (Abiega et al., 
2016). Another study demonstrated that activated microglia secrete pro-inflammatory 
cytokines that induce a sub-phenotype of astrocytes (Liddelow et al., 2017). This sub-
phenotype loses many properties that promote neuron survival and instead induces the 
death of neurons and oligodendrocytes. Together, these studies suggest that microglia 
dysregulation can have a number of adverse effects of microglia dysregulation in AD. 
Genetic evidence affirms these lines of investigation. TREM2 is expressed amongst a “core 
profile” of genes in microglia (Hickman et al., 2013). It is a receptor-signalling protein that 
functions in microglial phagocytosis (Takahashi et al., 2005). Genetic evidence that has found 
AD associated variants in TREM2 therefore implicates microglia in disease pathogenesis 
(Guerreiro et al., 2013, Jonsson et al., 2013, Sims et al., 2017). Thus, complimentary lines of 
evidence highlight that there are processes beyond the amyloid cascade that are at play in 
AD pathology. Following these up is vital to better understand the disease and discover new 
therapeutics. 
1.1.5 Biomarkers of Alzheimer’s disease 
Clinical biomarkers of Alzheimer’s disease 
The clinical symptoms of AD are observed by physical and cognitive examinations, coupled 
with patient history, to determine a “probable AD” diagnosis (McKhann et al., 1984, 
McKhann et al., 2011). To compliment these assessments, five AD biomarkers have been 
sufficiently validated for use in the clinic (Jack and Holtzman, 2013). These can broadly be 
divided into two categories by what is being measured. 
The first category of biomarkers are measurements of Aβ deposition. One biomarker is 
decreased concentrations of Aβ42 protein in the cerebrospinal fluid (CSF) (Fagan et al., 2007, 
Bouwman et al., 2009, Mattsson et al., 2009, Shaw et al., 2009, Visser et al., 2009). A second 
biomarker uses positron emission tomography (PET), a neuroimaging technique that most 
commonly uses the agent carbon-11-labelled Pittsburgh compound B (¹¹C-PiB) to measure 
Aβ deposition by calculating uptake and retention of the tracer (Klunk et al., 2004, Drzezga, 
2010, Rowe et al., 2010, Villemagne et al., 2011, Rodrigue et al., 2012, Nordberg et al., 2013). 
These techniques correlate well (Fagan et al., 2006, Jagust et al., 2009, Tolboom et al., 2009, 
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Weigand et al., 2011) and have been validated by post mortem examination (Strozyk et al., 
2003, Ikonomovic et al., 2008, Clark et al., 2011, Fleisher et al., 2011, Sojkova et al., 2011, 
Tapiola et al., 2009). 
The second category of biomarkers are measurements of neurodegeneration. One such 
biomarker is the measurement of elevated tau (total) and phosphorylated tau in patient CSF 
(Fagan et al., 2009, Mattsson et al., 2009, Shaw et al., 2009, Visser et al., 2009). Tau burden 
increases over the disease course and Braak stages can be determined at post-mortem 
examination (Qian et al., 2017).   A second biomarker is the use of structural MRI to measure 
atrophy which is increased in AD and with Aβ burden (Hua et al., 2008, Morra et al., 2009, 
Desikan et al., 2009, Vemuri et al., 2009, Dickerson and Wolk, 2012). A third biomarker is 
hypometabolism in disease measured by [18F]fluorodeoxyglucose PET imaging (Jagust et al., 
2010). Again these correlate well with post-mortem results (Bobinski et al., 2000, Jack et al., 
2002, Zarow et al., 2005, Buerger et al., 2006, Vemuri et al., 2008, Whitwell et al., 2008, 
Tapiola et al., 2009). 
Potential peripheral biomarkers of Alzheimer’s disease 
To date there are no clinically-used peripheral biomarkers of AD. Yet, the invasive nature of 
lumbar puncture for CSF and cost of neuroimaging make this an unmet and important clinical 
need. There have been a number of studies of peripheral biomarkers that show potential 
diagnostic utility that will be discussed below. 
Small RNAs found in the periphery have shown association with AD in a number of studies 
(Kumar and Reddy, 2016). The up-regulation and down-regulation of numerous miRNAs have 
been reported in whole blood (Satoh et al., 2015), serum (Geekiyanage et al., 2012, 
Galimberti et al., 2014, Tan et al., 2014a, Tan et al., 2014b, Dong et al., 2015) and plasma 
(Kumar et al., 2013). In addition to these free circulating miRNAs, it has been reported that 
plasma- (Lugli et al., 2015) and serum- (Cheng et al., 2014) derived exosomes carry potential 
miRNA biomarkers. There was, though, little consensus between these studies indicating 
that these biomarkers are not yet of clinical utility and further work is needed. 
In addition to the miRNA carried within peripheral exosomes, the proteins that reside within 
exosomes have also shown promise with regard to peripheral biomarkers of disease. A 
proportion of Aβ can be secreted from N2a cells bound to exosomes (Rajendran et al., 2006). 
Exosomes can pass bi-directionally over the blood-brain barrier (Skog et al., 2008, Alvarez-
Erviti et al., 2011) and thus brain-derived exosomes are present in peripheral circulation. The 
up-regulation and down-regulation of a number of proteins have been found to be 
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associated with AD including: low-density lipoprotein receptor-related protein 6 (LRP6), 
heat-shock factor-1 (HSF), repressor element 1-silencing transcription factor (REST), 
cathepsin D, lysosome-associated membrane protein 1 (LAMP-1), ubiquitin, heat-shock 
protein 70 (HSP70), total tau, P-T181-tau, P-S396-tau and Aβ1–42 (Goetzl et al., 2015a, 
Goetzl et al., 2015b, Fiandaca et al., 2015). 
Longitudinal studies suggest that the damaging effects of Aβ deposition occur years prior to 
symptom onset (Villemagne et al., 2013), increasing the need for biomarkers that can detect 
AD in this pre-clinical stage. Peripheral biomarkers would be an ideal solution as they do not 
require an invasive lumbar puncture or costly neuroimaging. The prospect of utilising 
exosomes as biomarkers of AD shows promise and is the focus of this study. 
1.2 Exosomes 
1.2.1 History 
One of the first observations of small, 40 nm diameter vesicles was in 1981 as a 
subpopulation of vesicles secreted from rat glioma cells (Trams et al., 1981). The term 
“exosome” was proposed to refer to these secreted vesicles. The mechanism by which they 
were secreted was unknown until two years later with the pioneering work of Clifford V. 
Harding and colleagues. 
The landmark discovery of multivesicular endosomes (MVEs) was made by the surprising 
observations of transferrin receptors being internalised and trafficked in rat reticulocytes 
(Harding et al., 1983). At that time it was presumed that transferrin receptors were 
internalised and degraded in the lysosome as reticulocytes matured into erythrocytes. What 
Harding et al. observed by electron microscopy (EM), however, was that 98% of gold-labelled 
transferrin receptors internalised to acid phosphatase-negative compartments (Figure 1.4). 
The receptors localised to small vesicles, now known to be exosomes, within MVEs instead 
of the lysosome. Furthermore they observed the exocytosis of these small vesicles when 
MVEs fused with the plasma membrane (Harding et al., 1983).  
Simultaneously, another research group discovered that sheep reticulocytes secreted similar 
vesicles that contained transferrin receptors, measured using radio-labelled antibodies (Pan 
and Johnstone, 1983). At the time, this group hypothesised that the mechanism of vesicle 
shedding was direct fusion with the plasma membrane rather than fusion of MVEs. 
Nevertheless, these studies complemented each other and subsequent studies further 
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validated the model of MVE fusion with the plasma membrane for exosome secretion 
(Harding et al., 1984, Pan et al., 1985). 
 
 
Figure 1.4: Electron micrographs of MVEs in rat reticulocytes (Harding et al., 2013).  
Left – a MVE sparsely labelled with colloidal gold-transferrin. Right – MVE exocytosis by fusion with 
the plasma membrane. These exquisite micrographs were the first report of MVEs fusing with the 
plasma membrane for the secretion of exosomes. In time this phenomenon became appreciated as an 
important feature of vesicle trafficking, far beyond the reticulocyte-transferrin model described then. 
  
Harding continued his work using the reticulocyte-transferrin model by investigating the 
mechanisms by which vesicles were released; he challenged the accepted ideas at that time 
that exosomes fused directly with the plasma membrane. A kinetics experiment revealed 
that internalised transferrin receptor was recycled down two pathways: a fast recycling 
pathway and a slower shedding pathway (Harding et al., 1984) (Figure 1.5). By investigating 
the kinetics they found that this second pathway was the major driver of reticulocyte 
maturation. It was the MVE-exosome pathway that Harding had uncovered a year earlier 
(Harding et al., 1983). 
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Figure 1.5: Clifford Harding’s two proposed pathways of transferrin trafficking (Harding et al., 2013).  
A fast recycling pathway, where transferrin is directly recycled to the plasma membrane, and a slower 
shedding pathway through MVEs. The kinetics of this second pathway matches that of reticulocyte 
maturation (Harding et al., 1984). 
 
More evidence emerged in later years that reinforced the existence if this pathway. Rather 
than molecules being recycled to the plasma membrane solely from early endocytic 
compartments, studies were proving that markers of the late endocytic compartments were 
indeed being trafficked to the plasma membrane. Some of these will be discussed below. 
The lysosomal membrane glycoprotein LEP100, now more commonly referred to as LAMP-
1, was found to be present in lysosomes, endosomes and the plasma membrane (Lippincott-
Schwartz and Fambrough, 1987). Blocking the endo-lysosomal pathway, using chloroquine, 
caused 30% of LAMP-1 molecules to be redirected to clathrin-coated pits on the plasma 
membrane. This supported Harding’s model of a distinct pathway of MVE fusion with the 
plasma membrane. Harding himself investigated further by looking at MHC class II-binding 
peptides (Harding et al., 1991). He found that these immunogenic peptides were most 
efficiently processed in lysosomes and then trafficked to the plasma membrane via endocytic 
compartments. Furthermore, MHC class II protein was found to be expressed on exosomes 
released from B lymphoblastoid cells and these vesicles were able to stimulate adaptive 
immune responses in T-cells (Raposo et al., 1996). The historical position was that exosomes 
were considered cell waste, however, Raposo showed a direct and immediate function of B-
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cell vesicles. This was a momentous discovery that challenges the dogma that a cell is the 
smallest autonomous entity in biology. Thus, the phenomenon was observed and validated 
in cell-types beyond the original reticulocyte model. 
Since this time the field of exosome and extracellular vesicle biology has dramatically grown 
(Harding et al., 2013, Lotvall et al., 2014) and has now developed to have wide-ranging 
impacts in health and disease.  
1.2.2 Defining exosomes and other extracellular vesicles by their 
composition 
Exosomes are a class of extracellular vesicle (EV) with two general defining characteristics: 
typically small with a diameter of 40–120 nm and originating from the endo-lysosomal 
pathway (El Andaloussi et al., 2013). This biogenesis differentiates them from other classes 
of extracellular vesicles, microvesicles and apoptopic bodies, which emanate from direct 
outward budding of the plasma membrane (Raposo and Stoorvogel, 2013).  These other 
types of EVs have characteristically different size ranges of 50–1000 nm for microvesicles and 
500–2000 nm for apoptopic bodies as they are not size-constrained by virtue of endosomal 
origin. 
It is important to note that subclasses of EVs cannot be defined merely by size alone. The 
sizes overlap between different subclasses (Lo Cicero et al., 2015b) so that any population of 
EVs maybe enriched for one type but are not necessarily distinct from others (Colombo et 
al., 2014). It is commonplace to generalise that defined populations of EVs have been isolated 
using differential centrifugation. For example, it has been reported that a 2,000 x g 
centrifugation will isolate apoptotic bodies, a 12,200 x g centrifugation will isolate 
microvesicles and a 120,000 x g centrifugation will isolate exosomes (Crescitelli et al., 2013). 
Whilst it is convenient to make such distinctions, it is appropriate to consider these as broad 
definitions of EV populations. 
Exosome proteins 
Exosomes can be defined by their protein content. Typically, exosomes are considered 
enriched for the tetraspanins CD63, CD81 and CD9 (Lamparski et al., 2002, Escola et al., 1998, 
Heijnen et al., 1999); and components of the endosomal-sorting complex required for 
transport (ESCRT) machinery such as TSG101 (Stoorvogel et al., 2002) and ALIX (Roucourt et 
al., 2015, Stoorvogel, 2015). An unbiased proteomic analysis of exosomes was first described 
in 1999, using exosomes derived from mouse dendritic cells (Thery et al., 1999, Thery et al., 
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2001). Many studies have since been performed with exosomes from other cell types 
(Mathivanan et al., 2010). These datasets have been compiled into publically available 
databases such as Exocarta (Mathivanan et al., 2012, Simpson et al., 2012), EVpedia (Kim et 
al., 2013) and Vesiclepedia (Kalra et al., 2012). Such studies have identified cell-specific 
exosomal proteins and others which are common across cell types. Proteins from the 
nucleus, mitochondria, ER and Golgi are commonly absent from exosomes, suggesting that 
exosomes represent a sub-proteome of the cell that particularly reflects membrane and 
endosomal contents (Colombo et al., 2014).  
Whilst demonstrating the presence of ESCRT-related proteins, such as TSG101 and ALIX, on 
vesicles was once considered a definitive indicator of MVE origin, more recently ESCRT 
components were also identified adjacent to the plasma membrane and may also be part of 
micro-vesicles (Scourfield and Martin-Serrano, 2017). Accordingly, the International Society 
of Extracellular Vesicles (ISEV) has called for the reporting of multiple proteins as a minimal 
requirement in EV studies (Lotvall et al., 2014). 
Proteomic analysis of other EV subtypes suggests that there is some overlap in the proteins 
expressed on all EVs (Turiak et al., 2011). It appears that CD9 is relatively ubiquitous across 
EV subtypes rather than specifically associated with MVE-derived vesicles (Bobrie et al., 
2012a). In a separate study, exosomes of small size (<50 nm) were enriched for CD63, whilst 
larger exosomes were enriched for MHC class II (Colombo et al., 2013). The presentation of 
proteins on the surface of EVs is complex and highlights the heterogeneous nature of 
exosome preparations.  
Exosome lipids 
EVs, in general, are typically enriched for saturated fatty acids, sphingomyelin, 
phosphatidylserine, and cholesterol (Laulagnier et al., 2004, Llorente et al., 2013, Trajkovic 
et al., 2008, Wubbolts et al., 2003). Sphingomyelin and cholesterol, in particular, are enriched 
in lipid rafts, subdomains of the plasma membrane that are resistant to detergents (Ikonen, 
2001). Indeed lipid raft-associated proteins are features of the exosome surface: e.g. GPI-
anchored proteins and flotillins (Colombo et al., 2014). 
On EVs the phospholipid phosphatidylserine is sensitive to binding by the peptide agent 
Annexin V (Dachary-Prigent et al., 1993). Indeed, it is commonplace to use Annexin V to block 
phosphatidylserine on exosomes or alter exosome secretion by altering the activity of 
neutral sphingomyelinase 2 or sphingomyelin synthase 2 (Yuyama et al., 2012), although N-
SMase2 inhibition is cell-type dependent and often toxic. Phosphatidylserine is situated on 
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the inner leaflet of the plasma membrane (Hugel et al., 2005) so its enrichment on the 
surface of EVs is likely to be due to the initial inward budding of vesicles prior to secretion. It 
has also been reported that ceramide is differentially enriched on exosomes over the course 
of reticulocyte maturation (Carayon et al., 2011). Thus it appears, as previously discussed for 
proteins, that there is a non-random sorting of lipids onto the bilayer of exosomes. 
Exosome nucleic acids 
The presence of RNA within EVs was first described with the horizontal transfer of messenger 
RNA (mRNA) from murine embryonic stem cells and human carcinomas (Ratajczak et al., 
2006a, Baj-Krzyworzeka et al., 2006, Baj-Krzyworzeka et al., 2007, Ratajczak et al., 2006b) 
and miRNA in mast cells (Valadi et al., 2007). Indeed, mRNA from exosomes is functional: 
successful in vitro translation and in vivo translation in recipient cells have been reported 
(Valadi et al., 2007). Thus there is genuine exchange of genetic material via exosomes rather 
than mere random elimination of RNA from the cell. 
Using electrophoretic analysis, it has been widely reported that exosomes contain little to no 
ribosomal RNA (rRNA), compared to cells which are replete with this species of RNA (Shelke 
et al., 2014). However, rRNA has been reported in apoptotic bodies and, in some cases, 
microvesicles (Crescitelli et al., 2013). This highlights the greater incorporation of cellular 
material in these larger EVs, particularly apoptotic bodies, and that it is a challenge to 
eliminate cellular contaminants in EV preparations. 
It has been reported that specific miRNAs in plasma, such as let-7a and miR-142-3p, have 
been associated with EVs rather than bound to the RNA-binding protein Argonaute2 (Arroyo 
et al., 2011). Indeed, these targets have since been used to validate a methodology for the 
isolation of RNA from EVs in plasma (Enderle et al., 2015). 
A particular feature of the RNA in exosomes is the protection from nuclease activity. 
Exosomal-RNA is encapsulated in a lipid-bounded vesicle so that it is not exposed, or 
susceptible, to nucleases such as RNase A (Cheng et al., 2014). It would be considered 
common practice to treat exosome preparations with Proteinase K and RNase A prior to 
extraction to ensure that intra-luminal RNAs are isolated (Shelke et al., 2014). Such 
protection within the vesicle makes exosomal-RNA uniquely stable and it has been reported 
that plasma samples, frozen at -80°C for over 12 years, can yield high-quality RNA (Enderle 
et al., 2015). 
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The profile of RNA within exosomes can be representative of the source cell (Skog et al., 
2008). It has been reported that the disease-specific transcript variant, EGFRvIII, is secreted 
via neuroglioma exosomes and detectable in patient serum (Skog et al., 2008). The state of 
the source cells also determines the RNA profile of exosomes with changes shown in 
response to hypoxia (Li et al., 2016a, Gray et al., 2015, Yang et al., 2016) and oxidative stress 
(de Jong et al., 2012, Eldh et al., 2010). Thus, as discussed for proteins and lipids, the sorting 
of RNA into exosomes seems to be a regulated process, although this is still to be determined 
mechanistically. 
1.2.3 Exosome biogenesis, trafficking and secretion 
EM studies have since complemented Harding and colleagues observations: confirmation 
with another reticulocyte maturation model (Pan et al., 1985), observation of MHC class II 
exosomes being secreted via MVE fusion with the plasma membrane in B lymphoblastoid 
cells (Raposo et al., 1996) and, similarly, MHC class I and II exosomes being secreted from 
murine dendritic cells (Zitvogel et al., 1998), revealing structural evidence for the MVE-origin 
of small vesicles.  
Exosomes undergo three general stages prior to secretion (Figure 1.6). Firstly, there is the 
biogenesis of intra-luminal vesicles within the MVE. The MVE is then trafficked to the plasma 
membrane and fusion results in release of exosomes into the extracellular milieu (Colombo 
et al., 2014). 
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Figure 1.6: The biogenesis, trafficking and secretion of exosomes. 
Exosomes arise by the biogenesis of intra-luminal vesicles in MVEs (here labelled MVB, multi-vesicular 
body), trafficking to the plasma membrane and fusion to release the contents. Diagram adapted from 
Colombo et al., 2014. 
 
The formation of exosomes in the MVE is preceded by the sorting of proteins by the 
endosomal-sorting complex required for transport (ESCRT) machinery. Typically, proteins are 
tagged by mono-ubiquitinylation for the recruitment of ESCRT proteins (Babst, 2005, de 
Gassart et al., 2004). They then undergo a 3-stage process of cargo recognition/sorting to 
cargo concentration on the endosomal membrane to MVE vesicle formation and then into 
the endosomal lumen. 
Due to high conservation in eukaryotes, yeast 2 hybrid assays have helped describe the 
numerous proteins and interactions that are involved in this process (Martin-Serrano et al., 
2003, Bowers et al., 2004, von Schwedler et al., 2003). At the endosome membrane, 
ubiquitin-binding proteins, such as the Vps27/HRS complex or ESCRT-0, bind to clathrin to 
form a clathrin coat and to recruit ESCRT-I. ESCRT-I is a trimeric complex of Vps23, Vps37 and 
Vps28 which interacts with mono-ubiquitinylated proteins. ESCRT-I activates ESCRT-II, a 
trimer of Vps22, Vps36 and Vps25. ESCRT-II inititiates the formation of ESCRT-III by 
oligomerisation of Vps20, Vps24, Vps2 and Snf7. ESCRT-III acts by concentrating the protein 
cargo and recruits a number of other factors; these factors include Bro1 which in turn recruits 
the de-ubiquitinating enzyme Dos4, and Vps4, which dissociates the ESCRT machinery 
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(Figure 1.7). Proteins are then internalised into the MVE vesicles and can be trafficked to the 
lysosome for degradation or the plasma membrane for secretion in exosomes. 
 
 
Figure 1.7: A model of protein sorting in MVE vesicles as proposed by Babst et al. (2005).  
Members of the ESCRT protein family are recruited to mono-ubiquitinylated cargo proteins by the 
Vps27/HRS complex. Cargo protein is concentrated on the endosomal membrane prior to inward 
blebbing of the vesicle. 
 
This process has been described in the context of dendritic cell (DC) maturation (van Niel et 
al., 2006, van Niel et al., 2008). Immature DCs tag MHC class II proteins by ubiquitination 
whereby it is trafficked to late endocytic compartments and subsequently degraded. In 
activated DCs, the ubiquitination of MHC class II is suppressed and thus the antigen is 
trafficked to the cell membrane for presentation on the cell surface. By mutating MHC class 
II to lack the ubiquitination site, MHC class II was presented at the plasma membrane 
regardless of activation state (van Niel et al., 2006).  
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A distinct pathway, independent of ESCRT, has also been described. Spontaneous 
invagination of vesicles into MVEs can be dependent on ceramide (Trajkovic et al., 2008). It 
has been proposed that this sphingolipid can promote domain-induced budding and 
curvature of the membrane leaflets in MVEs. This study reported that exosomes secreted by 
Oli-neu cells were enriched for ceramide and that inhibition of neutral sphingomyelinases 
caused a decrease in the number of exosome secreted. However, there may also be other 
processes that underlie the assembly of vesicles within MVEs that are not directly ESCRT or 
ceramide dependent, highlighting that vesicle biogenesis is a complex, multi-factorial 
process that is not fully understood. 
Another study performed Nanoparticle Tracking Analysis (NTA) with the NCI-60 panel of 
human cancer cell-lines and cross-referenced these data with publically available 
transcriptomics data to find suggestive evidence of gene expression that correlates with EV 
secretion (Hurwitz et al., 2016). They defined the cell-types in the panel by the size of 
particles they secreted and found that some predominantly secrete small vesicles <150 nm 
diameter (typically exosomes) and others to secrete large vesicles >150 nm (typically 
microvesicles). They then used CellMiner to identify gene expression that correlated with 
these definitions (Table 1.1 & Table 1.2). As expected, different genes were enriched for each 
vesicle type, consistent with the different known mechanisms and location of origin. 171 of 
the 350 genes associated with small vesicles overlapped with large vesicle secretion. Thus, 
whilst there appears to be some commonality between the secretion of each vesicle type, 
there is certainly an element of uniqueness in the genes and pathways involved in exosome 
secretion. 
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Gene symbol Gene name Corr Gene product function 
CYTH3 Cytohesin 3 0.496 Guanine nucleotide exchange and phospholipid interaction; membrane trafficking 
VPS41 Vacuolar protein sorting 41 0.467 Vesicle-mediated protein sorting; formation and fusion of Golgi Vesicles 
NPC2 Niemann-Pick disease, type C2 0.429 Mobilizes cholesterol within the late endosome 
RAB17 Member Ras oncogene family 0.408 GTPase; recruitment of effectors for vesicle formation, tethering and fusion 
SNX24 Sorting nexin 24 0.390 Phosphatidylinositol binding and intracellular trafficking 
SNX9 Sorting nexin 9 0.388 Involved in endocytosis and intracellular vesicle trafficking 
AP1S2 Adaptor-related protein complex 1 0.388 Recruitment of clathrin to membranes and recognition of sorting signals within the 
cytosolic tails of transmembrane cargo molecules 
ALS2 Amyotrophic lateral sclerosis 2 
(juvenile) 
0.383 GTPase regulator, associates with Rab5 on early endosomal compartments to mediate 
endosomal dynamics 
ZFYVE9 Zinc finger, FYVE domain 
containing 9 
0.372 Early endosome protein; regulates TGF-mediated signalling 
RAB9A Rab9A, member Ras oncogene 
Family 
0.366 GTPase involved in transport of proteins between the endosomes and the trans Golgi 
network 
 
Table 1.1: The top ten genes that correlate with small vesicle (<150 nm) secretion in the NCI-60 cancer cell-line panel.  
CellMiner was used to find correlative gene expression (Corr) combined with Nanoparticle tracking analysis data (Hurwitz et al., 2016).  
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Gene symbol Gene name Corr Gene product function 
TLN2 Talin 2 0.512 Assembly of actin filaments; spreading and migration 
AMPH Amphiphysin 0.496 Exocytosis in synapses and certain endocrine cells; participates in membrane-associated 
cytoskeleton 
TIAM2 T-cell lymphoma invasion and 
metastasis 2 
0.488 Modulates the activity of Rho-like proteins and connects extracellular signals to 
cytoskeletal activities 
CYTH3 Cytohesin 3 0.484 Regulation of protein sorting and membrane trafficking; promotes guanine nucleotide 
exchange on ARF1 and ARF6 
TIMP2 TIMP metallopeptidase inhibitor 2 0.448 Inhibitor of the matrix metalloproteinases 
ARHGDIA Rho GDP dissociation inhibitor 
(GDI) α 
0.437 Inhibits the disassociation of Rho family members from GDP 
OPHN1 Oligophrenin 1 0.420 Stimulates GTP hydrolysis of members of the Rho family; critical for the regulation of 
synaptic vesicle endocytosis at presynaptic terminals 
MAPK8IP1 Mitogen-activated protein kinase 8 
interacting protein 
0.414 May function as a regulator of vesicle transport through interactions with the JNK-
signalling components and motor proteins 
CD151 CD151 0.414 Tetraspanin involved in cell adhesion; may regulate integrin trafficking and/or function 
SH3BP4 SH3-domain-binding protein 4 0.413 Cargo-specific control of clathrin-mediated endocytosis 
 
Table 1.2: The top ten genes that correlate with large vesicle (>150 nm) secretion in the NCI-60 cancer cell-line panel.  
CellMiner was used to find correlative gene expression (Corr) combined with Nanoparticle Tracking Analysis data (Hurwitz et al., 2016). 
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One of the enriched functional terms for small vesicle secretion in the Hurwitz et al. (2016) 
data was “GTPase activity” and, from direct experimental evidence, the Rab GTPases have 
long been implicated in MVE trafficking (Colombo et al., 2014).  
The Rab family of GTPases consists of >60 members (Colombo et al., 2014). Rab11 was the 
first to be implicated with exosomes secretion: it showed decreased secretion of exosomes 
in an erythroleukemia cell-line when a dominant-negative form was expressed (Savina et al., 
2002). This was later confirmed in Drosophila melanogaster cells (Koles et al., 2012, Beckett 
et al., 2013) and retinal epithelial cells (Abrami et al., 2013). Rab27a and Rab27b have both 
been implicated in MVE docking with the plasma membrane for exosome secretion 
(Ostrowski et al., 2010). The knock down of Rab27a, by RNA interference, caused 
enlargement of MVEs in HeLa cells suggesting a deficit in MVE processing and an 
accumulation of MVE content as a consequence. This has been confirmed in a number of 
tumour cell-lines (Bobrie et al., 2012b, Hoshino et al., 2013, Peinado et al., 2012, Webber et 
al., 2015). Knock down of Rab27b caused MVEs to accumulate in the perinuclear region, 
showing a deficit in distribution. Rab35 has been implicated in the docking and tethering of 
MVBs at the plasma membrane (Hsu et al., 2010). Knock down of Rab35 led to the 
accumulation of MVBs and decreased exosome secretion in oligodendrocytes. This was 
confirmed in primary oligodendrocytes (Fruhbeis et al., 2013). 
It remains a challenge to dissect the roles of different Rab GTPases. It has been proposed 
that a subset of exosomes are secreted from late endosomes in a Rab27-dependent manner 
(Colombo et al., 2014). This subset are enriched for late endosome markers such as CD63, 
ALIX and TSG101. However, a different subset of exosomes are secreted from early 
endosomes in a Rab35/Rab11-dependent manner and enriched for flotillin (Colombo et al., 
2014). 
Another important, but less well studied, family of proteins in exosome secretion are the 
SNARE (Soluble NSF Attachment Protein Receptor) proteins. In general, SNAREs bind to SNAP 
proteins to cause membrane fusion between two surfaces (Zylbersztejn and Galli, 2011). 
Secretory lysosomes can fuse with the plasma membrane by SNAP-23’s association with the 
SNARE VAMP8 in mast cells (Puri and Roche, 2008, Tiwari et al., 2008) and VAMP7 in 
epithelial cells, eosinophils and neutrophils (Rao et al., 2004, Logan et al., 2006). VAMP7 
appears to play a role in MVB fusion with the plasma membrane, as demonstrated by RNAi 
in human leukemic cells (Fader et al., 2009). Thus, the precise mechanisms and components 
for exosome biogenesis, intracellular trafficking and secretion are still not fully known and 
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appear to differently controlled dependent on the cell type being studied. This aspect 
requires further investigation. 
1.2.4 Exosome functions 
Exosomes convey signals between cells. Loaded with RNA, lipid and protein cargo they are 
present interstitially and in biological fluids (El Andaloussi et al., 2013). The functions of these 
EVs is wide and varied with implications in both health and disease. 
Exosome functions in cancer 
Exosomes, in general, play an intriguing and pivotal role in cancer biology (Rak and Guha, 
2012, Peinado et al., 2012). This is underpinned by the capacity of cancer-derived exosomes 
to promote a favourable tumour niche such as the reprogramming of bone marrow 
progenitor cells to a pro-vasculogenic phenotype (Peinado et al., 2012). Exosomes are a 
route of communication between cancer and stroma cells (Camussi et al., 2011, Webber et 
al., 2010) and can promote tumour progression via numerous processes. 
Cancer cells can be broadly defined as cells that undergo uncontrolled proliferation. To 
propagate this proliferation, exosomes can stimulate recipient cells. Oncogenic epidermal 
growth factor receptor (EGFRvIII) can be secreted from glioma cells via EVs (Al-Nedawi et al., 
2008). Endothelial cells exposed to exosomes harbouring EGFRvIII will exhibit changes that 
support angiogenesis (Al-Nedawi et al., 2009). Simultaneously, it was demonstrated that 
glioma-derived exosomes deliver translatable mRNA to recipient cells; a pro-angiogenic 
phenotype was promoted in endothelial cells and proliferation was induced in glioma cells 
in a self-promoting manner (Skog et al., 2008). Thus, exosomes can encourage the hazardous 
proliferation of cells in cancer and reorganisation of the cancer microenvironment. 
Cancer cells can communicate with the surrounding stroma via exosomes (Camussi et al., 
2011, Webber et al., 2010). This was described as a novel route of communication between 
NCI-H460 tumour cells and fibroblasts for the transfer of the oncogenic glycoprotein 
EMMPRIN (Sidhu et al., 2004). Downstream this led to extracellular matrix degradation; a 
process that promotes tumour invasion and metastasis. Oral Squamous Carcinoma cells have 
been shown to secrete exosomes with altered RNA content under hypoxic conditions (Li et 
al., 2016a). This study particularly found that miR-21 was differentially expressed in the 
exosomes of hypoxic cells and that these promoted pro-metastatic behaviours when 
delivered to normoxic cells. Thus, exosomes provide a route for tumour cells to escape the 
stresses of a hypoxic environment. 
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Importantly, exosomes can cause cancers to escape immune response. Tumour-derived EVs 
have been shown to selectively inhibit proliferation and induce apoptosis in anti-tumour 
CD8+ T cells (Wieckowski et al., 2009). In the specific example of oral squamous cell 
carcinoma the Fas ligand (FasL) has been observed on EVs in patient serum (Kim et al., 2005). 
FasL+ exosomes promoted apoptosis via caspase-3 cascade, cytochrome-c release, reduced 
membrane potential in mitochondria, and reduction of TCR-zeta chain expression; overall for 
a reduced immune response. Also, FasL+ exosomes increase MMP9 expression and, thus, the 
tumour invasion potential of B16 melanoma and 3LL lung cancer cells in mice (Cai et al., 
2012). Furthermore, TGF-β1 positive tumour-derived exosomes block the lymphocytic 
response to interleukin-2 in effector but not regulatory T-cells (Clayton et al., 2007). This 
included activating the function of regulatory T cells and inhibiting the cytotoxic activation 
of Natural Killer (NK) cells. NKG2D, an activating receptor for NK cells, is down-regulated by 
exosomal TGF-β1 as an additional mechanism (Clayton et al., 2008). Thus, exosomes have a 
variety of functions in the propagation of cancer including facilitation of uncontrolled 
proliferation, modulating the tumour microenvironment and evading the immune response. 
Exosome functions in infectious disease 
Several studies in the context of viral infections have indicated the possible manipulation of 
exosome pathways for propagating infectious disease. For example, in cell-models, the cell-
surface receptor CCR5 can be transferred via EVs as a pre-requisite for HIV-1 infection (Mack 
et al., 2000). CCR5 can be transferred to deficient cells rendering them susceptible to viral 
invasion. More recently, the trans-activation response element (TAR) miRNA can be 
transported via exosomes secreted from HIV infected cells and in patient serum (Narayanan 
et al., 2013). Furthermore, the miRNA processing machinery, Dicer and Drosha, was found in 
exosomes from infected cells. Thus, the machinery required to make recipient cells more 
susceptible to HIV-1 infection and viral-infected cells protected from apoptosis, is housed 
within exosomes. 
The transfer of functionally active RNAs has also been described in relation to Epstein-Barr 
virus (EBV). B lymphocytes infected with EBV secrete exosomes containing EBV-specific 
miRNAs (Pegtel et al., 2010). These exosomes caused dose-dependent repression of gene 
expression such as the immuno-regulatory gene CXCL11/ITAC, attenuating an anti-viral T-cell 
response. 
Prions are transmissible agents that act in a comparable epidemiology to viruses. The 
misfolded scrapie (PrPsc) form of Prion protein (PrP) has prionogenic properties in infected 
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cells (Fevrier et al., 2004). Prion diseases affect the central nervous system (CNS) and it has 
been hypothesised that PrPsc can be acquired through the diet and be transported from 
peripheral tissues to the brain via exosomes. Cells infected with sheep prions release PrPsc 
via exosomes and these have infectious capabilities (Fevrier et al., 2004). More recently, it 
has been shown that neuronal cell-derived exosomes can transfer infectious PrPsc to 
neuronal and non-neuronal  cells (and vice versa) (Vella et al., 2007). Furthermore, these 
exosomes caused Prion disease when injected into mice (Vella et al., 2007). 
Thus, exosomes serve as a route for propagating infectious diseases, including viral infection 
and Prion disease. The internal machinery of cells can be hijacked by these hosts for the 
transfer of pro-infectious material. 
Exosome functions in cardiovascular disease 
Exosomes play a functional role in cardiovascular diseases. One study has demonstrated the 
therapeutic potential of exosomes secreted by hypoxic cardiac-progenitor cells after 
ischemia-reperfusion injury (Gray et al., 2015). Exosomes from hypoxia-treated cells showed 
differential expression of miRNAs and caused improved cardiac function and reduced fibrosis 
when used to treat a rat model of myocardial infarction. Taken further, exosomes from acute 
myocardial infarction patient serum were enriched for miR-30a (Yang et al., 2016). This study 
also found that miR-30a in exosomes was regulated by hypoxia inducible factor-1α and 
directly linked the regulation of autophagy in cardiomyocytes with the release of miR-30a-
containing exosomes. Indeed, the presence of exosomes with biomarker potential are 
rapidly available in patient plasma after myocardial infarction (Deddens et al., 2016). Thus, 
exosomes play a pivotal role in paracrine signalling in response to cardiac injury. This has 
been reported more generally in an epithelial cell-model of the vasculature (de Jong et al., 
2012) and a mouse mast-cell model of oxidative stress (Eldh et al., 2010).  
Exosome functions in immunity 
Exosomes play a role in the normal functioning of the immune system. It was first 
demonstrated, in 1996, that exosomes present antigens such as MHC class II for immune 
activation via helper T lymphocytes (Raposo et al., 1996). Indeed, this study reported that 
MHC class II was enriched in the MVBs of antigen presenting cells (B lymphocytes) and that 
the kinetics of MHC class II release suggested that exosomes were a significant route of 
exocytosis rather than the presumed direct fusion with the plasma membrane.  
Furthermore, it has been observed that tumour-derived exosomes also present antigens 
which are taken up by dendritic cells and confer a T lymphocyte mediated anti-tumour 
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response (Wolfers et al., 2001). Taken further, tumour-derived exosomes can carry an array 
of known surface antigens dependent on tumour type (Baj-Krzyworzeka et al., 2006). These 
exosomes present antigens and contain RNA that activates an anti-tumour response by 
altering the biological activity of monocytes (Baj-Krzyworzeka et al., 2007). Thus, exosomes 
provide a route for activating and amplifying the immune system through the presentation 
of vesicle-surface antigens. 
Exosome functions in blood coagulation 
Another physiological function of exosomes is their role in the coagulation cascade. P-
selectin glycoprotein ligand-1 is present on the surface of monocyte and macrophage-
derived exosomes and can bind to activated platelets (Del Conde et al., 2005). This study 
found that exosomes fused with activated platelets in a P-selectin glycoprotein ligand-1 
dependent manner and that this increased the proteolytic activity of Tissue Factor-VIIa. 
Exosome functions in tissue repair 
Exosomes also play a role in tissue repair. For example, exosomes derived from mesenchymal 
stem cells (MSCs) have been shown to decrease the risk of acute kidney injury through the 
inhibition of apoptosis and by stimulating the proliferation of tubular epithelial cell after 
ischaemia-reperfusion injury (Gatti et al., 2011). Similar protective roles have been described 
for MSC-derived exosomes in cardiovascular disease (Lai et al., 2011).The therapeutic 
potential of utilising exosomes for tissue repair, in general, has also been proposed 
(Ratajczak et al., 2012). 
Other exosome functions 
Many other functions of exosomes can be discussed including synaptic plasticity (Lachenal 
et al., 2011, Chivet et al., 2012), sperm maturation (Brewis and Gadella, 2010, Frenette et al., 
2002, Saez et al., 2003, Sullivan et al., 2005) and as constituents of breast milk (Zonneveld et 
al., 2014, van Herwijnen et al., 2016). Exosomes appear to play a wide variety of functions in 
both health and disease. 
1.2.5 Exosome purification strategies 
Even over 10 years after the pioneering studies of Clifford Harding (Harding et al., 1983, 
Harding et al., 1984, Harding et al., 2013), studies that reported on extracellular vesicles 
undertook the work required to demonstrate that these were genuine exosomes by 
demonstrating MVB fusion in the source cell (Raposo et al., 1996). Yet the exponential 
growth of the field has now come to the point that, typically, the intrinsic properties of 
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exosomes themselves, isolated separately from the source cells, are measured and reported 
rather than demonstrating MVB fusion (Lotvall et al., 2014). 
As discussed above, the RNA, lipids and proteins carried on exosomes play a wide variety of 
roles in paracrine signalling. Isolating exosomes from cell culture medium or biological fluids 
provides an opportunity to investigate signals secreted from a source cell prior to reaching 
the destination; this can be in the context of health or disease. Many purification strategies 
are available for the isolation of exosomes (Thery et al., 2006) and will be discussed below. 
Purifying exosomes by differential ultra-centrifugation 
Differential ultra-centrifugation is the process by which an exosome-containing fluid is 
subjected to several steps of increasing centrifugal forces (Raposo et al., 1996). It has been 
used as the most basic method for exosome purification for many years. In short: the first 
step is to centrifuge the fluid at a low centrifugal force (e.g. 300 x g for 10 min) to pellet cells 
and large cellular debris; the supernatant is taken into the second step with an increased 
centrifugal force (e.g. 2,000 x g for 20 min) that will pellet apoptotic bodies; the third step is 
to pellet microvesicles (e.g. 12,200 x g for 20 min); and the fourth step is to pellet exosomes 
(e.g. 120,000 x g for 70 min) (Crescitelli et al., 2013). Different combinations of these steps 
are used depending on the extracellular vesicle of interest (Figure 1.8). 
In addition to the steps of increasing centrifugal force, a filtration step is often included 
(Thery et al., 2001, Ji et al., 2008). For example, the use of a 0.2 µm filter prior to ultra-
centrifugation will aid the removal of large particles and aggregates that may be in the fluid; 
thus, resulting in a purer preparation of exosomes. Nevertheless, this methodology is prone 
to indiscriminate pelleting of proteins and small debris, in addition to the exosomes of 
interest. This poses a major challenge when purifying exosomes from biological fluids such 
as plasma. In this scenario, differential ultra-centrifugation will co-isolate high 
concentrations of albumin in addition to exosomes (Welton et al., 2015). Proteins, such as 
albumin, can produce strong signals in proteomic analyses which are likely to mask proteins 
of low abundance in the preparation. RNA-binding proteins, such as Argonaute (Arroyo et 
al., 2011) or high-density lipoproteins (Vickers et al., 2011), can also be co-isolated with this 
procedure. It is relatively straightforward, however, to remove such non-vesicular signals 
with the use of nuclease enzymes (Hill et al., 2013) and procedures are in place for doing so 
(Shelke et al., 2014).  
Detailed methods reporting, such as rotor types and k-factors is a major issue in this field. 
The same protocol used in different laboratories can produce very different results. A recent 
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paper has highlighted this issue and advocate transparent reporting of methods to reduce 
inter-laboratory variability (Van Deun et al., 2017). 
 
 
Figure 1.8: Differential ultra-centrifugation for the purification of exosomes and other extracellular 
vesicles.  
Subsequent steps of increasing centrifugal force are applied to cell culture medium or biological fluids 
to isolate different species of extracellular vesicle (Crescitelli et al., 2013). These steps can be re-
arranged according to the area of interest. 
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Purifying exosomes by continuous sucrose gradient 
As opposed to differential ultra-centrifugation, which indiscriminately co-isolates exosomes 
with other proteins and particles, it is possible to purify exosomes based on their density 
using a continuous sucrose density gradient (Raposo et al., 1996). Exosomes are 
characteristically buoyant at a density of 1.1 – 1.2 g/ml (Escola et al., 1998, Raposo et al., 
1996, Webber et al., 2014). In short, a continuous sucrose gradient using 0.2 M to 2.5 M 
solution is poured and overlaid, or under-laid, with a preparation of pelleted exosomes. This 
is then ultra-centrifuged overnight and fractions collected. Fractions can then be 
characterised by their density but require a wash with PBS and further ultra-centrifugation 
to obtain the purified exosomes. 
This method is time- and labour-intensive but does provide purer preparations of exosomes 
than possible by ultra-centrifugation. Thus it is a useful analytical tool but, due to the 
intensive time and labour requirements, cannot easily be scaled up for larger studies using 
multiple samples. An alternative to using sucrose is the inert agent iodixanol which can 
provide the same range of densities as sucrose. Iodixanol gradients can separate exosomes 
from HIV-1 particles in human plasma and can give better resolving power (Konadu et al., 
2016). However, the problem persists of this method being time- and labour-intensive. 
Purifying exosomes on a 30% sucrose cushion 
An alternative method which balances the ease of differential ultra-centrifugation but 
purifies based on the physical property of buoyant density is the 30% sucrose cushion 
method. This was first reported in 2002 for the isolation of exosomes from malignant ascites 
fluid (Andre et al., 2002). Later that year, the method was used in combination with cross-
flow ultrafiltration as an FDA-approved procedure for the isolation of clinical grade exosomes 
from monocyte-derived dendritic cells (Lamparski et al., 2002). 
This procedure involves overlaying the exosome-containing fluid on a 30% sucrose cushion 
made with deuterium oxide (D2O). This cushion is a density of 1.2 g/ml so the majority of 
exosomes in the fluid should collect in the cushion upon ultra-centrifugation. The sucrose is 
collected, washed with PBS and centrifuged again. This methodology, in combination with a 
number of the differential centrifugation steps, has been adopted by the Clayton laboratory 
in Cardiff University (Clayton et al., 2004, Clayton et al., 2005, Clayton et al., 2007, Clayton et 
al., 2008). Thus, the sucrose cushion method provides a good compromise between 
differential ultra-centrifugation and a continuous density gradient. 
Chapter 1. Introduction 
37 
 
Purifying exosomes by size exclusion chromatography 
As discussed above, the co-isolation of contaminating proteins in biological fluids is a 
particular challenge. One method to overcome this challenge is size exclusion 
chromatography (Welton et al., 2015). This procedure involves running the biological fluid 
through a bead-containing column. Fractions are collected whereby small particles are 
collected first and larger particles pass through the column more slowly and are collected in 
subsequent fractions. This has successfully demonstrated good separation of exosomes, by 
proteins such as CD9 and CD81, from the contaminant human serum albumin (Welton et al., 
2015). Fractions of interest can then be collected and pooled prior to ultra-centrifugation for 
exosome purification. This strategy is particularly useful for proteomic studies where 
albumin is present in such high abundance that it masks the detection of other proteins. 
However, it is imperfect as a single-step approach, as lipoproteins and other particulates can 
co-elute with exosomes. Additionally, the concentration of exosomes from enriched-
fractions has been reported to be inefficient with ultra-centrifugation and precipitation of 
exosomes having a 5% particle recovery rate (Welton et al., 2015). 
Purifying exosomes by immuno-isolation 
A method that does not require ultra-centrifugation is the immuno-isolation of exosomes 
based on ligands on the vesicle surface. Antibodies against the ligand of interest can be 
loaded onto magnetic beads (Clayton et al., 2001, Wubbolts et al., 2003) or polyacrylamide 
beads (Mustapic et al., 2017) for the isolation of exosomes directly from cell-culture medium 
or biological fluids. 
This method has been used to isolate exosomes based on a wide range of ligands including 
CD63 (Caby et al., 2005), MHC class II (Clayton et al., 2001, Wubbolts et al., 2003, Admyre et 
al., 2003), Her2 (Koga et al., 2005), EpCAM (Taylor et al., 2009, Rabinowits et al., 2009), 
NCAM and L1CAM (Goetzl et al., 2015b, Fiandaca et al., 2015, Hamlett et al., 2016, Mullins 
et al., 2017, Goetzl et al., 2015a, Mustapic et al., 2017).  
One consideration of this method is choosing one antigen of interest. By doing so, there is 
pre-selection of a subset of the population of exosomes. For example, choosing a ligand, such 
as CD63, might pre-select for exosomes of smaller size (Colombo et al., 2013) and thus 
introduce a bias in the experimental design. On the other hand, it has been suggested that 
CD9 might be ubiquitously expressed on exosomes and other subtypes of EVs (Bobrie et al., 
2012a), thus introducing an indiscriminate isolation procedure. Another consideration is the 
unknown factor of liberating exosomes from the bead and what effects that may have on 
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vesicle integrity. Furthermore, the immuno-isolation procedure may alter the functionality 
of the exosome. Finally, and particularly in the case of purifying from biological fluids, there 
is the possibility that abundant proteins, such as albumin, may reduce the efficacy of the 
procedure by blocking the antibody-antigen interaction or soluble variants of the target can 
make the method inefficient. These are caveats that require significant consideration as well 
as expense and suitability for upscaling. 
There are many strategies for purifying exosomes from both cell-culture medium and 
biological fluids. These have all been used widely as they each have their own merits and will 
have an appeal based on the requirements of the study. For example, a continuous sucrose 
gradient provides highly pure exosomes for analysis at the cost of time and labour intensity. 
Ultra-centrifugation may provide higher exosome yields than other methodologies whereas 
immuno-isolation provides the selection of a population subset if a narrower research 
question is being asked. As such, there is no consensus for one purification strategy as better 
than others. Nevertheless, there are many methodologies widely accepted and readily 
available for the purification of exosomes. 
1.3 Exosomes in Alzheimer’s disease 
1.3.1 Exosomes in Alzheimer’s disease pathology 
In 2006, the first study that directly linked exosomes with AD was published (Rajendran et 
al., 2006). Principally, the underlying endocytic system is utilised in amyloidogenesis for the 
proteolytic cleavage of APP to Aβ. The early endosome is the convergence site for APP and 
BACE1 to bind, followed by the trafficking of Aβ to MVBs (Rajendran et al., 2006, Morel et 
al., 2013). A comprehensive RNAi screen implicated a number of Rab GTPases in Aβ 
production (Udayar et al., 2013). In particular, Rab11 regulates the trafficking of BACE1 to 
the early endosome. Additionally, a cell model of amyloid metabolism has been used to 
further investigate these pathways (van Niel, 2016). Pigment cells have shown that APOE, in 
the intra-luminal vesicles and secreted exosomes, underlies the production of functional 
amyloid fibrils from the premelanosome protein (van Niel, 2016).  Indeed, it has been shown, 
using and independent cell-type (N2a), that Aβ can accumulate in MVBs and be secreted via 
exosomes (Rajendran et al., 2006). The same study found an enrichment of exosomal 
protein, ALIX, around small neuritic plaques and a moderate deposition within large diffuse 
plaques of AD patient brain slices, compared to age-matched control. Thus, the endocytic 
system is implicated in the amyloidogenic processing of APP and secretion of Aβ via 
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exosomes. This is affirmed by genetic data which has independently implicated endocytosis 
in AD (Jones et al., 2010, Lambert et al., 2013, Robinson et al., 2017). 
Exosomes play a number of roles in the CNS including paracrine signalling between neurons 
and synaptic plasticity (Lachenal et al., 2011, Chivet et al., 2012). Exosomes can also 
modulate the brain immune system under normal and pathological conditions (Cossetti et 
al., 2012). Indeed, bidirectional communication between oligodendrocytes and neurons via 
exosomes is important for neuronal integrity (Fruhbeis et al., 2012, Fruhbeis et al., 2013). 
Specifically in AD, exosomes can harbour Aβ and initiate a neuroinflammatory response 
(Gupta and Pulliam, 2014).  
Kohei Yuyama and colleagues have investigated the interaction between Aβ on exosomes 
and microglia (Yuyama and Igarashi, 2017). An initial study unveiled a novel mechanism 
whereby neuronal exosomes can drive conformational changes in extracellular Aβ to form 
non-toxic fibrils (Yuyama et al., 2012). In turn, these conformational changes promoted 
uptake of Aβ, associated with exosomes, into microglia for degradation; it is a process that 
was sensitive to Annexin V and changes to sphingolipid constitution of exosomes. Thus a 
potential mechanism of toxic extracellular Aβ being absorbed and degraded in the brain was 
identified. The same group confirmed this “scavenger” role of exosomes in the brain of APP-
transgenic mice (Yuyama et al., 2014). Intracerabral injection of neuroblastoma-derived 
exosomes alleviated the amyloid burden in these mice. These exosomes were highly 
enriched for glycosphingolipids and this was a requirement for the sequestering of Aβ. Later, 
it was distinguished that neuronal exosomes, rather than glial, drove this phenomenon 
(Yuyama et al., 2015). It has been suggested, independently, that the sequestering of Aβ on 
exosomes and degradation by microglia is an important process with potential therapeutic 
value (Tamboli et al., 2010). 
The endocytic trafficking processes appear to play an important role not just in Aβ toxicity 
but also in tau toxicity (Rajendran and Annaert, 2012, Xiao et al., 2017). It has been shown in 
M1C neuroblastoma cells that tau can be secreted via exosomes and is present in association 
with exosomes in human CSF (Saman et al., 2012). This study particularly demonstrated that 
AT270+ tau was significantly enriched in early AD and suggested that this secretion pathway 
may be responsible for the spread of lesions. The number of microglia in the brain correlated 
with tau levels and another study reported, both in vitro and in vivo, that microglia can 
propagate the spread of tau via exosome secretion (Asai et al., 2015). Indeed, the exosome-
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driven aggregation of tau can be dose-dependent, as reported in a mouse model (Polanco et 
al., 2016). 
Thus, it appears that the endocytic system, and exosomes directly, are important factors in 
AD. Unsurprisingly, this is a complicated picture with numerous roles; these roles include the 
interaction between exosomes and microglia for the beneficial sequestering and 
phagocytosis of exosomal-Aβ and detrimental propagation of tau aggregation. These roles 
may provide future opportunities for therapeutic intervention. 
1.3.2 Exosomes in Alzheimer’s disease therapeutics 
The intrinsic properties of exosomes may well have therapeutic potential. For example, it has 
been suggested that stem cell-derived exosomes exert a therapeutic effect via the delivery 
of their signalling cargo (Zhang et al., 2016a). More specifically, the potential of exosomes 
from adipose tissue-derived mesenchymal stem cells has been demonstrated by the 
presence of Neprilysin; an enzyme that degrades Aβ (Katsuda et al., 2015).  
It has been proposed that exosomes may serve as a delivery mechanism for pharmacological 
agents (Cunha et al., 2016). In a murine AD model, exosomes were engineered to deliver 
siRNA to the brain after intra-venous injection (Alvarez-Erviti et al., 2011). Exosomes were 
engineered to contain an RVG peptide to specifically target neuronal cells and deliver siRNA 
to knockdown BACE1. This mechanism reduced Aβ burden in the mouse brain more 
effectively than standard inhibitors. Furthermore, the exosomes were derived from cultured 
dendritic cells from the same animal to reduce immunogenicity and thus highlighted an 
additional benefit of the delivery strategy (Alvarez-Erviti et al., 2011). 
There is potential to use exosomes as therapeutic agents (Alvarez-Erviti et al., 2011). The 
biotechnological techniques to do so are being developed (Alvarez-Erviti et al., 2011) but this 
is far from a trivial undertaking and there seems to be a particular issue with reproducing 
this method of loading siRNA into exosomes. Furthermore, in the case of AD, reliable targets 
for therapeutic intervention still need to be identified; particularly as agents to clear Aβ have 
not proved successful in humans (Sacks et al., 2017). 
1.3.3 Exosomes in Alzheimer’s disease diagnosis 
Exosomes can pass bi-directionally over the blood brain barrier, although the precise 
mechanisms for this are not currently understood (Skog et al., 2008, Alvarez-Erviti et al., 
2011). As discussed in section 1.1.5, exosomes in peripheral circulation have the potential to 
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house biomarkers of relevance for CNS-diseases, such as AD (Cheng et al., 2013). Exosomal-
RNA is encapsulated in a lipid-bounded vesicle which provides protection from extra-
vesicular nucleases, whereas free circulating RNA is susceptible to degradation (Cheng et al., 
2014). 
To date, two studies have performed small RNA sequencing with peripherally-derived 
exosomes (Kumar and Reddy, 2016). One study isolated exosomes from 4 ml plasma to 
perform discovery analysis by Illumina small RNA sequencing in 35 cases and 35 controls 
(Lugli et al., 2015). Twenty differentially expressed miRNAs were identified, of which seven 
could predict case-control status with 83-89% accuracy in a machine-learning model. No 
replication was performed in this study (Lugli et al., 2015). A second study isolated exosomes 
from 1 ml serum to perform Ion Torrent small RNA sequencing in a case-control cohort of 49 
individuals (Cheng et al., 2015). This study went on to replicate the sequencing by qPCR in a 
separate cohort of 60 individuals. Sixteen miRNAs were found to have predictive value with 
87% sensitivity and 77% specificity (Cheng et al., 2015). Whilst these studies had good 
diagnostic utility, there was little overlap in the results (Kumar and Reddy, 2016). However, 
one miRNA, miR-342-3p, was down-regulated in AD across both studies. 
A number of studies have investigated protein concentrations on exosomes isolated from 
peripheral blood but enriched for a neural source (Mustapic et al., 2017). One of these 
studies measured typical AD-related proteins and found total tau, P-T181-tau, P-S396-tau 
and Aβ1–42 significantly enriched in cases compared to controls (Fiandaca et al., 2015). 
Another study measured typical lysosome-related proteins and found cathepsin D, 
lysosome-associated membrane protein 1 and ubiquitin significantly up-regulated and heat-
shock protein 70 significantly down-regulated in disease (Goetzl et al., 2015b). A third study 
measured the protein concentration of different cell-survival factors and found low-density 
lipoprotein receptor-related protein 6, heat-shock factor-1 and repressor element 1-
silencing transcription factor significantly down-regulated in disease (Goetzl et al., 2015a). 
This methodology has not yet been applied to proteomic analysis. 
It is apparent that exosomes have good potential for use in the diagnosis of AD. However, 
this conclusion has been made from only a handful of studies. Even so, particularly in the 
case of identified miRNAs (Kumar and Reddy, 2016), there is little consensus between the 
independent studies. As such, the utility of exosomes as peripheral biomarkers has not 
reached the same standards as CSF and as neuroimaging biomarkers; both of which have 
been verified for us in the clinic (Jack and Holtzman, 2013). Yet exosomes provide an exciting 
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prospect for biomarker discovery due to the availability of tissue-relevant material in the 
periphery.  
1.4 Aim of this Study 
The aim of this study was to investigate the utility of exosomes as biomarkers of Alzheimer’s 
disease; particularly investigating the potential to discriminate health from disease by 
isolating and analysing the RNA content of exosomes. 
To meet this aim, it was necessary to develop methods for exosome isolation from human 
plasma and to isolate the RNA cargo for analysis. Due to the inherent complexities of 
biological fluids, these methods were first established in cultured cell-lines prior to in vivo 
work. The H4 (neuroglioma) and IMR-32 (neuroblastoma) cell-lines were chosen to establish 
exosome stocks from a neural source (Chapter 3) for subsequent assay development 
(Chapter 4) and RNA analysis (Chapter 5). The analysis of gene-expression in plasma-derived 
exosomes was performed in a LOAD case-control cohort (Chapter 6). Therefore, the thesis 
aimed to answer the following questions: 
1. Can bulk stocks of neural-derived exosomes be established from cell-lines? 
2. Can an immuno-affinity assay be developed that can selectively isolate these neural-
derived exosomes and remove exosomes from non-neural sources? 
3. How does the RNA content of exosomes differ from the source cell? 
4. Can a method for isolating exosomal-RNA from small volumes of patient be 
developed and validated for distinguishing AD cases and controls? 
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2.1 Materials 
All general reagents, unless otherwise stated, were analytical grade and purchased from 
Thermo Fisher Scientific UK Ltd (Loughborough, UK), Sigma-Aldrich Co. Ltd (Dorset, UK) and 
VWR Ltd. (Leicestershire, UK). All water was purified using a Milli-Q Biocel system (Merck, 
Darmstadt, Germany). 
2.2 Cell strains and media 
2.2.1 Mammalian strains 
Cell cultures were established of two neural-based cell-lines as in vitro sources of neural-
derived exosomes: one neuroblastoma (IMR-32, ATCC® CCL127™) and one neuroglioma (H4, 
ATCC® HTB148™). To ensure the validity of these cultures new vials were purchased from 
ATCC (LGC Standards, Teddington, UK). Information on these cell-lines is detailed in 
Table 2.1. 
Cells were maintained in Opti-MEM® + GlutaMAX™ (Life Technologies, Waltham, MA, USA) 
supplemented with 4% Foetal Bovine Serum (FBS; Life Technologies, Waltham, MA, USA) for 
H4 cells and 10% FBS for IMR-32. Antibiotics and other supplements were not added. Every 
three months, or after recovering frozen cells, cultures were confirmed negative for 
mycoplasma contamination using the MycoAlert® mycoplasma detection kit (Lonza, Basel, 
Switzerland). 
Where stated, cells were maintained in medium containing exosome-depleted FBS. Bovine 
exosomes were removed by overnight ultra-centrifugation at 100,000 x g (Optima-LE 
ultracentrifuge, with 70 Ti rotor, k-factor = 44,  and Quickseal tubes, Beckman Coulter) and 
vacuum filtering the supernatant through 0.22 and 0.10 µm filters  (Merck, Darmstadt, 
Germany) as used previously (Webber et al., 2014). Aliquots were stored at -20°C. 
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Cell line Organism Tissue Disease Age Gender Morphology Growth properties 
H4 (ATCC® HTB148™) Human Brain Neuroglioma 37 years Male Epithelial Adherent 
IMR32 
(ATCC® CCL127™) 
Human Brain Neuroblastoma 13 months Male Fibroblast, neuroblast Adherent 
 
Table 2.1: Information on cell-lines used in this study. 
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2.2.2 Monolayer growth and maintenance of mammalian cell lines 
Cells were maintained at 37°C at 95-98% humidity in 75 cm3 flasks (Sigma-Aldrich Company 
Ltd., Dorset, UK) and media renewed every two or three days. Cell-lines were sub-cultured 
before reaching 90% confluence by removal of media, washing with 10 ml PBS (Life 
Technologies, Waltham, MA, USA) and detached using 0.25% (w/v) Trypsin-EDTA (Life 
Technologies, Waltham, MA, USA). No more than 20 sub-culturing passages were performed. 
2.2.3 Bioreactor culture using Integra CELLine™ flasks 
For high yield production of exosomes, H4 and IMR-32 cell-lines were cultured in CELLine AD 
1000 Bioreactor flasks (Integra, Zizers, Switzerland). This method was adapted to culture 
large densities of cells within a small volume of medium allowing the maximum quantity of 
exosomes to be isolated. However, a caveat to this method is that high density, potentially 
hypoxic and nutrient-limited conditions are unfavourable for maintaining cells with good 
viability (Mitchell et al., 2008a). These flasks contain an inner compartment for cells and an 
outer compartment for nutrient medium (Figure 2.1). Cells within the inner compartment 
are maintained in a small (15 ml) volume of growth medium and adhere to a woven 
polyethylene terephtalate (PET) matrix, providing a large surface area. The semi-permeable 
membrane between compartments allows the exchange of nutrients and waste. The outer 
compartment contains a large volume of growth medium (500 - 1000 ml) to maintain the 
high density of cells. The secreted exosomes are retained within the inner compartment, 
allowing purification from a much smaller volume than monolayer cultures. Therefore cost, 
labour and time are reduced using this methodology (Mitchell et al., 2008a). Bioreactor 
cultures were maintained weekly by replacement of media in the outer compartment and 
collection of exosome-rich media from the inner compartment using 25G blunt needles (BD, 
Oxford, UK). The collected media was centrifuged twice at 400 x g for 7 min and once at 2000 
x g for 15 min to remove cellular debris. Supernatants were then 0.22 µm syringe filtered 
(Merck, Darmstadt, Germany) and frozen at -80°C. 
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Figure 2.1: Integra CELLine™ AD1000 flask.  
Figure adapted from manufacturers handbook (Integra, Zizers, Switzerland). These bioreactor flasks 
contain an outer compartment that stores up to 1 L of cell culture medium and a cell compartment 
that stores high densities of adherent cells in 15 ml medium. Nutrients and waste products can pass 
bi-directionally between the two compartments through a 10 kDa semi-permeable membrane. 
Gaseous exchange occurs over a silicone membrane. As suggested in the figure, these flasks were 
originally designed for hybridoma culture and the collection of secreted proteins. However this 
technique has since been adapted for the culture of other cell-types and the collection of vesicles 
(Mitchell et al., 2008). 
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2.2.4 Brightfield microscopy of live cells 
Brightfield microscopy was used to assess the general morphology of live cells in standard 
monolayer culture. 80-100% confluent 75 cm3 culture flasks were imaged using EVOS FL Cell 
Imaging System (Life Technologies, Waltham, MA, USA). Brightfield images were taken using 
both 4x and 10x objective lenses. 
2.2.5 Preparation of cell lysates 
Live cells, grown by standard 2D cell-culture, were detached from tissue culture plastic using 
0.25% (w/v) Trypsin-EDTA (Life Technologies, Waltham, MA, USA), re-suspended in fresh 
media and counted using a glass haemocytometer and trypan blue staining. Cell lysates were 
prepared by centrifuging 1x106 cells at 400 x g for 7 min, washing with 1 ml PBS and re-
centrifuging. Cells were re-suspended in 100 µl lysis buffer (Cell Signalling Technology, 
Leiden, The Netherlands), homogenised by vortexing and incubated on ice for 10 minutes. 
The lysis buffer contained a cocktail of: 
 
20 mM Tris-HCl (pH 7.5) 
150 mM NaCl 
1 mM Na2EDTA 
1 mM EGTA 
1% Triton 
2.5 mM sodium pyrophosphate 
1 mM β-glycerophosphate 
1 mM Na3VO4 
1 µg/ml leupeptin 
 
The protease inhibitor, phenylmethane sulfonyl fluoride (PMSF, 1 mM), was added to the 
lysis buffer immediately prior to use. Samples were centrifuged at 14,000 x g for 10 minutes 
(4°C) and the subsequent supernatant was transferred to a fresh tube and stored at -20°C. 
Protein concentrations were determined (see section 2.5.2) by Micro-BCA assay (Thermo 
Fisher Scientific, Inc., Loughborough, UK). 
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2.3 Human plasma samples 
6 – 10 ml blood was drawn into lavender topped potassium-EDTA tubes. Plasma samples 
were collected for two purposes:  
i. Healthy donors were recruited to validate procedures for isolating exosomes. 
ii. Alzheimer’s disease patients were recruited with age-matched controls for 
biomarker discovery as part of a larger genetics project in Cardiff University. 
Blood samples were collected from healthy donors under informed consent and with ethical 
approval from Cardiff University, School of Medicine Research Ethics Committee, under the 
reference number 14/55. Participants voluntarily obtained information regarding the 
research project and provided informed consent to take part. Blood was drawn by 
phlebotomists at the Velindre Cancer Centre, Cardiff. 
Blood from healthy donors were initially centrifuged at 400 x g for 7 minutes. The top layer 
of supernatant was collected into 2 ml aliquots and centrifuged again at 6000 x g for 10 min 
(Welton et al., 2015). Supernatants were then passed through 0.22 µm syringe filters (Merck, 
Darmstadt, Germany) and stored at -80°C. 
Blood samples from AD patients and controls were collected as part of the ‘Detecting 
Susceptibility Genes for Late-onset Alzheimer’s disease’ study, which has received ethical 
approval from Wales REC 3 (previously MREC for Wales) (REC reference 04/9/030). All 
samples were used with the participants’ permission, having given their valid informed 
consent at the time the sample(s) were obtained. Where participants were unable to consent 
for themselves an appropriate consultee consented on their behalf. Participants and 
consultees provided their consent, understanding that their sample(s) or information may 
be used for future or other research studies. After blood was drawn potassium-EDTA tubes 
were centrifuged at 1600 x g for 15 minutes and 500 µl plasma aliquots stored at -80°C. 
2.4 Exosome isolation 
2.4.1 Pellet and PBS wash 
Where stated exosome preparations were obtained by a simple pellet and PBS-wash 
procedure (Webber and Clayton, 2013). Cell culture supernatants were pre-cleared of cells 
and cellular debris by: 
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Centrifuging at 400 x g for 7 min 
Collecting supernatant and centrifuging at 400 x g for 7 min 
Collecting supernatant and centrifuging at 2,000 x g for 15 min  
Filtering supernatant through 0.22 µm filters  
Supernatant was stored at -80°C. 
For exosome isolation, these pre-cleared supernatants were centrifuged at 200,000 x g for 2 
hours, 4°C (Optima-LE ultracentrifuge, with 70 Ti rotor, k-factor = 44, and Quickseal tubes, 
Beckman Coulter), supernatant removed by aspiration, pellet re-supended in 5 ml PBS and 
centrifuged again at 200,000 x g for 2 hours, 4°C (Optima-MAX ultracentrifuge, with TLA-110 
rotor, k-factor = 13, and Optiseal tubes, Beckman Coulter). Exosome pellets were re-
suspended in PBS and stored at -80°C.  
Plasma samples were similarly prepared by ultra-centrifugation. 0.5 ml plasma was topped 
up with 1 ml PBS to fill 1.5 ml capped ultra-centrifuge tubes (Beckman Coulter Inc., High 
Wycombe, UK) and centrifuged at 200,000 x g for 2 hours, 4°C (Optima-MAX ultracentrifuge, 
with TLA-110 rotor, k-factor = 13). Supernatants were aspirated, pellets re-suspended in 100 
µl PBS and stored at -80°C. 
2.4.2 Continuous sucrose gradient 
Sucrose gradients were poured by the bottom fill method using a Hoefer SG15 gradient 
maker (Hoefer Inc., Holliston, USA). 0.2 M and 2.25 M sucrose solutions were produced and 
confirmed to be the correct molarity by measuring the refractive index. The 0.2 M measured 
1.34277 (n=2) which corresponded to a molarity of 0.1984 M. The 2.25 M solution measured 
1.44123 (n=2) which corresponded to a molarity of 2.2413 M. These were calculated using a 
sucrose standard curve provided by Beckman Coulter (Figure 2.3) and the following 
equation: 
 
𝑦 = 2.1398𝑥2 + 14.792𝑥 − 23.522 
 
Where y corresponds to the sucrose molarity and x corresponds to the refractive index. Once 
the gradient maker had been prepared the left hand chamber was filled with 2.25 M sucrose, 
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the right hand chamber with 0.2 M sucrose and an 18G spinal needle (BD, Oxford, UK) 
connected the outflow (Figure 2.2) with the bottom of a 4.7 ml open-topped ultra-centrifuge 
tube (Beckman Coulter Inc., High Wycombe, UK). Gradients were poured and then overlaid 
with 2.3 mg exosomes collected from a pellet and PBS-wash of bioreactor supernatants. 
These were centrifuged overnight (Optima-MAX ultracentrifuge, with MLS-50 rotor, k-factor 
= 50) according to the following protocol: 
 
10,000 x g (1 hour) 
210,000 x g (15 hours) 
10,000 x g (1 hour) 
 
Sixteen fractions of 330 µl were collected and the refractive indices measured. The 
respective density of each fraction was calculated using a sucrose standard curve provided 
by the Beckman Coulter (Figure 2.4) and the following equation: 
 
𝑦 = −0.592𝑥2 + 4.2944𝑥 − 3.6748 
 
Where y corresponds to density and x corresponds to refractive index measurement. A 
simple, linear fit produced the following equation: 
 
𝑦 = 2.6507𝑥 − 2.5345 
 
Where, again, y corresponds to density and x corresponds to refractive index measurement. 
Using either linear or second binomial equations produced the same density values when 
fractions were analysed. Fractions were topped up to 1.5 ml with PBS in 1.5 ml capped ultra-
centrifuge tubes (Beckman Coulter Inc., High Wycombe, UK) and centrifuged at 120,000 x g 
for 45 minutes, 4°C (Optima-MAX ultracentrifuge, with TLA-110 rotor, k-factor = 13). 
Supernatants were aspirated, pellets re-suspended in 100 µl PBS and stored at -80°C.  
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Figure 2.2: A photograph of a Hoefer SG15 gradient maker. 
Left (L) and right (R) chambers are marked and were filled with 2.25 M sucrose and 0.2 M sucrose, 
respectively, for the pouring of sucrose density gradients. An 18G spinal needle was connected to the 
outflow (labelled). 
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Figure 2.3: Sucrose standard curve showing the relationship of sucrose molarity with refractive 
index. 
Second order polynomial equation is displayed on the graph which was used to calculate the sucrose 
molarity (y) from refractive index measurements (x). 
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Figure 2.4: Sucrose standard curve showing the relationship of density with refractive index. 
Second order polynomial equation and linear equation are displayed on the graph. Both equations 
were used to calculate the density (y) from refractive index measurements (x). 
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2.4.3 Sucrose cushion 
Exosomes were isolated from the supernatants of bioreactor flasks by centrifugation on a 
30% sucrose/D2O cushion (Thery et al., 2006). Cell culture medium collected from the inner 
chamber was pre-cleared of cells and cellular debris by differential centrifugation (see 
section 2.4.1) and supernatants were poured into Quickseal ultra-centrifuge tubes (Beckman 
Coulter Inc., High Wycombe, UK) through 25G blunt needles (BD, Oxford, UK) under gravity. 
Sucrose was dissolved in deuterium oxide (D2O) and 4 ml poured to the bottom using 18G 
spinal needles (BD, Oxford, UK) under gravity. The tubes were filled, from the top, with PBS 
until full and sealed. Cell culture supernatants were centrifuged at 100,000 x g for 90 
minutes, 4°C in a swing out rotor (SW32, k-factor = 204, Optima-LE ultracentrifuge). 2.5 ml 
sucrose solution was collected from the bottom of the tube, transferred to a fresh Quickseal 
ultra-centrifuge tube (Beckman Coulter Inc., High Wycombe, UK) and topped up with PBS 
until filled. A second centrifugation was performed at 100,000 x g for 90 minutes, 4°C in a 
fixed angle rotor (70 Ti, k-factor = 44, Optima-LE ultracentrifuge) to pellet exosomes. 
Supernatants were removed, pellets re-suspended in PBS and stored at -80°C. 
2.4.4 Size exclusion chromatography 
Exosomes were isolated from plasma using size exclusion chromatography as previously 
described (Welton et al., 2015). After the initial draining under gravity, Exo-spin™ columns 
(Cell Guidance Systems, Cambridge, UK) were washed twice with 10 ml PBS-EDTA. 0.5 ml 
plasma was diluted to 1 ml in PBS-EDTA and loaded onto the columns before two 0.5 ml 
fractions were collected. PBS-EDTA was then added at 500 µl intervals for each of the 
remaining 30 fractions. Fractions were stored at -80°C. 
2.5 Exosome analysis 
2.5.1 Nanoparticle Tracking Analysis (NTA) 
NTA visualises nanometre-sized particles in liquid using laser illumination. A high-intensity 
laser beam is sent through a chamber containing the sample under fluid flow (Figure 2.5); 
nanoparticles scatter light that is then detected by a x20 magnification microscope and high-
sensitivity camera. Video files are produced that allow nanoparticles to be tracked over 
multiple frames, the particle velocity to be determined and particle size (diameter) to be 
calculated using the Stokes Einstein equation: 
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𝐷𝑡 =
𝑇𝐾𝐵 
3𝜋𝜂𝑑
 
 
Where Dt is the Diffusion constant (product of diffusion coefficient D and time t), T is the 
temperature, KB is the Boltzmann’s constant, η is the solvent viscosity and d is the diameter 
of the spherical particle. 
NTA allows the detection and tracking of individual particles. The combination of high-
intensity laser beams and low-background optical configuration allows, in the case of 
biological particles such as exosomes, the size of particles to be determined down to a 30 nm 
resolution.  
Particle concentrations and sizes were calculated by NTA with the Nanosight™ NS300 system 
(Malvern Instruments Ltd., Worcestershire, UK) configured with a high-sensitivity sCMOS 
Camera System (OrcaFlash 2.8, Hamamatsu C11440, Hamamatsu City, Japan), syringe-pump 
and temperature regulated 488 nm laser module.  
Prior to taking measurements of biological samples the instrument was tested using 100 nm 
latex beads (Malvern Instruments Ltd., Worcestershire, UK). Three videos, of 30 s duration, 
were recorded of beads under fluid flow to confirm that size measurements were accurate. 
Measurements were averaged using the mode. Unless otherwise stated six videos, of 30 s 
duration, were recorded of vesicles, from biological samples, under fluid flow. Biological 
samples were diluted in nanoparticle-free water (Fresenius Kabi, Runcorn, UK) and dilution 
factor recorded by the NTA 3.1 software (version 3.1, build 3.1.54). Before commencing the 
six-video recording a one-video recording was performed to ensure that less than 100 events 
were detected per frame. This short video was used to ensure that the correct dilution factor 
was being used to keep the particle concentration within the linear range of the Nanosight™ 
instrument.  
Samples were run through the sample chamber and the syringe pump set to 50 for a constant 
flow. The temperature control system was set to 25°C. Particle size distribution plots were 
determined by batch analysis of videos using the NTA software; the camera sensitivity was 
set to 14-16 and detection threshold set to 1-3.  
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Figure 2.5: The instrumentation for Nanoparticle Tracking Analysis (Malvern Instruments Ltd.). 
A high-intensity laser beam passes through the liquid-containing sample chamber and scattered light 
is detected by a x20 magnification microscope. A high-sensitivity camera captures video files of 
particles moving under Brownian motion. The Stokes Einstein equation is used to calculate the 
hydrodynamic diameters of individual particles and provides the user with readouts of particle size and 
concentration. 
 
2.5.2 Quantification of total exosomal protein 
Protein concentrations were calculated using the Micro BCA Protein Assay kit (Thermo Fisher 
Scientific, Inc., Loughborough, UK). Exosomes were diluted 1 in 8 and compared in duplicate 
against a serially diluted Bovine Serum Albumin (BSA) standard curve. Protein concentrations 
were extrapolated from this curve using a second-order polynomial equation: 
 
𝑦 = 𝑎𝑥2 + 𝑏𝑥 + 𝑐 
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Where y corresponds to protein concentration and x corresponds to colorimetric 
measurement. The protein concentrations of whole cell lysates were similarly quantified. 
2.5.3 Quality check of exosome purity using particle:protein ratio 
Vesicle purity was assessed by calculating the particle : protein (P:P) ratio as previously 
described (Webber and Clayton, 2013). The particle concentration (as calculated by NTA) was 
divided by the protein concentration (as calculated by BCA assay): 
 
𝑃: 𝑃 𝑟𝑎𝑡𝑖𝑜 =
𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
 
 
The original study that described this procedure provided guidelines for vesicle purity. Ratios 
>3 x 1010 would be considered highly pure, 2 x 109 – 2 x 1010 would be considered low purity 
and <1.5 x 109 as impure (Webber and Clayton, 2013). Vesicle purity was measured for all 
exosome preparations in this study and qualified as highly pure if a P:P ratio of >3 x 1010 was 
recorded. 
2.5.4 Electron Microscopy 
Electron microscopy was performed by David Gil Carton and Juan M. Falcón-Pérez of CIC 
bioGUNE, Bilboa, Spain. 5 µl of exosome preparation was directly adsorbed onto glow-
discharged holey carbon grids (QUANTIFOIL). Grids were blotted at 95% humidity and rapidly 
plunged into liquid ethane with the aid of VITROBOT (Maastricht Instruments BV). Vitrified 
samples were imaged at liquid nitrogen temperature using a JEM-2200FS/CR transmission 
cryo-electron microscope (JEOL), equipped with a field emission gun and operated at an 
acceleration voltage of 200 kV (Welton et al., 2016). 
2.6 Protein analysis 
2.6.1 Immunoblotting 
20 µg of whole cell lysates/exosome preparations were reduced and loaded onto NuPAGE® 
Bis-Tris polyacrylamide gels (Life Technologies, Waltham, MA, USA). Electrophoresed gels 
were transferred onto polyvinylidene difluoride (PVDF) membranes and incubated with 
primary antibodies in 5% milk-PBS-T for 1 hour at room temperature. Secondary antibodies, 
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conjugated with horse radish peroxidase (HRP), were applied for 1 hour at room 
temperature. Chemiluminescence was detected by incubating PVDF membranes with 
Enhanced Chemiluminescence (ECL) Western Blotting substrate (Thermo Fisher Scientific, 
Inc., Loughborough, UK) for 5 minutes at room temperature. Blots were read on the C-DiGit® 
Blot Scanner (LI-COR Inc., Nebraska, USA). 
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2.6.2 Primary antibodies used in this study 
Antibody Isotype Size (kDa) Supplier Catalogue 
number 
ALIX IgG1 95 Santa Cruz 
Biotechnology 
sc-166952 
CD63 IgG1 25 AbD Serotec MCA2142 
CD81 IgG1 26 BioRad MCA1847EL 
CD9 IgG2B 27 R&D Systems MAB1880 
CD9 (Rabbit) IgG 27 Santa Cruz 
Biotechnology 
sc-9148 
ENO2 IgG 47 Abcam ab53025 
GFAP IgG 55 Abcam ab7260 
GRIA4 IgG2A 132 Santa Cruz 
Biotechnology 
sc-271894 
GRID1 IgG2B 112 Abcam ab55163 
GRP94 IgG2B 94 Santa Cruz 
Biotechnology 
sc-393402 
L1CAM IgG1 200 Abcam ab24345 
NCAM IgG1 140, 160 Abcam ab9272 
NMDAR1 IgG1 105 Abcam ab134308 
TSG101 IgG2A 43 Santa Cruz 
Biotechnology 
sc-7964 
  
Table 2.2: Primary antibodies used in this study. 
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2.6.3 Immuno-phenotyping for specific protein targets by time resolved 
fluorescence 
Relative protein concentrations were detected by a plate-based immuno-phenotyping assay 
with the time-resolved fluorometry method (PerkinElmer, Coventry, UK) using Europium as 
the fluorophore (Webber et al., 2014). 2 µg whole cell lysate or exosome preparations, in 
duplicate, were loaded into each well of a high binding enzyme-linked immunosorbent assay 
(ELISA) plate (Greiner Bio-One Ltd., Stonehouse, UK) and incubated overnight at 4°C. Plates 
were blocked with 1% BSA at room temperature for 2 hours with agitation. Primary 
antibodies were prepared in 0.1% BSA and incubated for 2 hours at room temperature with 
agitation. Secondary antibodies conjugated with biotin were also prepared in 0.1% BSA and 
incubated for 1 hour at room temperature with agitation. Time resolved fluorescence (TRF) 
was detected using the lanthanide chelate Europium. Streptavidin-europium conjugate 
(PerkinElmer, Coventry, UK)  was diluted 1 in 1000 in red assay buffer (PerkinElmer, Coventry, 
UK) and incubated for 45 minutes at room temperature with agitation. Finally, the plates 
were incubated with enhancer solution (PerkinElmer, Coventry, UK) and read on a PHERAstar 
plate reader (BMG Labtech, Aylesbury, UK). 
Different assay configurations were used and these are detailed in Chapter 4. 
2.6.4 Conjugation of biotin to antibodies 
Biotin was conjugated to the GRIA4 primary antibody using the Lightning-Link® Biotin 
Conjugation Kit (Type B) (Innova Biosciences, Cambridge, UK). Manufacturer’s procedures 
were followed. In brief, 10 µl antibody was mixed gently with 1 µl LL-Modifier. This mixture 
was pipetted onto lyophilised biotin ligand and incubated at room temperature for 3 hours. 
1 µl LL-Quencher was added and incubated for a further 30 min before storage at 4°C. 
2.7 RNA isolation and quality control 
2.7.1 RNA isolation 
Ribonucleic acid (RNA) was extracted from cells and exosomes using the mirVana RNA 
isolation kit (Ambion, Waltham, MA, USA). For cellular-RNA, 1x106 cells were collected, 
washed with PBS and lysed using lysis solution provided by the manufacturer. Exosome 
pellets were obtained by pellet and PBS wash (section 2.4.1) and non-vesicular RNA removed 
by Proteinase K and RNase A digestion (Shelke et al., 2014) detailed in section 2.7.2. 
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Exosomal-RNA was also isolated directly from plasma samples using exoRNeasy 
Serum/Plasma Midi Kit (Qiagen, Crawley, UK). Plasma aliquots were thawed and filtered 
using 0.8 µm syringe filter (Merck, Darmstadt, Germany) to remove any large aggregates. 0.5 
ml filtered plasma was mixed with Buffer XBP in a 1:1 ratio and centrifuged in an exoEasy 
spin column at 500 x g for 5 min. The column was washed with 3.5 ml Buffer XWP and 
centrifuged at 3500 x g for 5 min. Exosomes were lysed on the column with 700 µl QIAzol 
and collected by centrifugation at 3500 x g for 5 min. Lysates were mixed by vortexing and 
allowed to stand at room temperature for 5 min. 90 µl chloroform was added, mixed by 
vigorous shaking for 15 s and allowed to stand at room temperature for 3 min. Lysates were 
centrifuged at 12,000 x g for 15 min at 4°C. The upper aqueous phase was transferred to a 
fresh tube and 100% ethanol added in a 2:1 ratio. Precipitated exosomal-RNA was 
transferred to an RNeasy MinElute spin column by centrifugation at 12,000 x g for 15 s. 
Columns were washed with 700 µl Buffer RWT and twice with 500 µl Buffer RPE. Columns 
were dried and 14 µl RNA eluted using nuclease-free water. RNA was immediately reverse 
transcribed and remaining eluate stored at -80°C for long term storage. 
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Figure 2.6: Procedure for isolating exosomal-RNA directly from plasma using exoRNeasy 
Serum/Plasma Midi Kit (Qiagen). 
In this study, 0.5 ml human plasma, per individual, was processed using this procedure. 
 
2.7.2 Proteinase K/RNase A digestion of non-vesicular RNA 
To dissociate non-vesicular RNA from RNA-binding proteins, such as Argonaute (Arroyo et 
al., 2011), exosomes were incubated with 0.05 µg/µl Proteinase K (Sigma-Aldrich Co. Ltd., 
Dorset, UK) for 10 min at 37°C. Proteinase K was inactivated by incubation with 5 mM PMSF 
(Sigma-Aldrich Co. Ltd., Dorset, UK) for 10 min at room temperature followed by incubation 
at 90°C for 5 min. These samples were incubated with 0.5 µg/µl RNase A (Thermo Fisher 
Scientific, Inc., Loughborough, UK) to digest non-vesicular RNA that was liberated in this 
procedure. The mirVana kit was then used for the isolation of genuine intra-luminal RNA 
from exosomes (Shelke et al., 2014). 
2.7.3 RNA quantification 
RNA was quantified using the Qubit® RNA (high sensitivity) assay (Life Technologies, 
Waltham, MA, USA). In brief Qubit® RNA HS Reagent was diluted 1 in 200 using Qubit® RNA 
HS Buffer to make a working solution. RNA standards were made by mixing 10 µl RNA 
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standards with 190 µl working solution. RNA samples were diluted by mixing 1 µl RNA sample 
with 199 µl working solution, vortexing for 3 s and incubating at room temperature for 2 min. 
Fluorometric reading of standards and samples were obtained on a Qubit® 3.0 instrument 
(Life Technologies, Waltham, MA, USA). 
Spectrophotometric readings were obtained using Nanodrop™ 8000 instrumentation 
(Nanodrop, Waltham, MA, USA) to give an assessment of protein and organic compound 
contamination.  
2.7.4 Electrophoretic analysis of RNA 
During this study electrophoretic analysis of RNA samples was performed using the Agilent 
2100 Bioanalyser system (Agilent Technologies, Santa Clara, CA, USA) with both RNA 6000 
Nano and RNA 6000 Pico kits. Manufacturer’s instructions were followed. In brief gel matrix 
was prepared by centrifugation on a spin filter at 1500 x g for 10 min at room temperature. 
65 µl filtered gel was mixed with 1 µl RNA dye concentrate and centrifuged at 13000 x g for 
10 min at room temperature. 9 µl gel-dye mix was pipetted into the well “G” (Figure 2.7) and 
dispersed across the chip using the syringe provided. Two additional wells, also marked “G”, 
were filled with 9 µl gel-dye mix. In the case of the Pico chip, 9 µl RNA conditioning solution 
was added to the well “CS”. 5 µl RNA marker was added to each remaining well and 1 µl 
sample or ladder. Chips were vortexed at 2400 rpm for 1 minute and immediately read on 
the Bioanalyser instrument. The instrumentation was cleaned before and after use with 
RNaseZap™ RNase Decontamination Solution (Thermo Fisher Scientific, Inc., Loughborough, 
UK) and nuclease-free water. 
After electrophoresis was completed, data files and reports were exported from the 
instrumentation. An RNA integrity (RIN) score was automatically calculated and, in the case 
of cellular-RNA, gave an assessment of degradation within the sample. However this score is 
calculated by taking into account the 18S and 28S ribosomal RNA (rRNA) peaks on the 
electropherogram. RNA from exosomes is deplete of rRNA (Shelke et al., 2014) and thus the 
RIN score was not an accurate assessment of RNA integrity. Therefore, an additional 
assessment of sample quality was used: the DV200 calculation. This calculates the percentage 
of RNA in the trace of greater length than 200 nucleotides and has been used previously to 
assess the quality of formalin-fixed paraffin-embedded tissue prior to RNA sequencing 
(Eikrem et al., 2016). DV200 scores were calculated using a Smear Analysis in the advanced 
settings of the Bioanalyser software. A region from 200 bp to the end of the trace was drawn 
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and the percentage for that region was displayed underneath the trace for each sample. 
According to manufacturer’s guidelines, the exosomal-RNA samples used in this study were 
of good quality for sequencing. 
 
 
Figure 2.7: Photograph of RNA Pico and Nano chips used with the Agilent 2100 Bioanalyser system. 
 
2.8 RNA analysis 
2.8.1 Construction of RNA sequencing libraries 
Construction of libraries and sequencing on the Illumina HiSeq 2500 were performed at the 
Wales Gene Park, Cardiff University. Three biological replicates of H4 cellular-RNA and 
exosomal-RNA were established. 0.1 – 1.0 µg RNA was provided for each sample.  
Total RNA libraries were constructed using the TruSeq Stranded Total RNA kit with Ribo-Zero 
Gold ribosomal RNA depletion step. This was chosen to obtain the fullest reading of the 
transcriptome without contamination with highly abundant ribosomal RNA (Benes et al., 
2011). The final libraries were quantified by Qubit® double-stranded DNA (high sensitivity) 
assay (Life Technologies, Waltham, MA, USA), sizes measured using Bioanalyser 
instrumentation (Agilent Technologies, Santa Clara, CA, USA) and normalised to 4 nM before 
pooling. A small sequencing run was performed on the Illumina MiSeq prior to the main 
sequencing run to test the sequencing quality of the libraries but data were not used in the 
analysis. 
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2.8.2 Sequencing on Illumina HiSeq 2500  
Pooled libraries were loaded onto two lanes of an 8-lane flowcell for cluster formation and 
sequencing, producing >89 gigabases of data. Wales Gene Park performed the initial 
conversion and de-multiplexing of sequencing files using the bcl2fastq software (Illumina 
Inc., San Diego, CA, USA) before making .fastq files available for download. In total twenty-
four .fastq files were generated: six samples, each sequenced on two lanes, and each lane 
generating two read files. 
2.8.3 Analysis of RNA sequencing 
The quality of the sequencing was assessed using FASTQC (v0.11.2; Babraham 
Bioinformatics, Cambridge, UK). A FASTQC report was generated for each .fastq file providing 
a plethora of tests (discussed in section 5.3.2) to determine the quality of the sequencing 
run. These were assessed with the caveat that the software was optimised for whole exome 
and genome sequencing rather than RNA sequencing. 
A modified .gtf gene model annotation file, detailing gene location, was required prior to 
read alignment and mapping. The original file was downloaded from ensembl 
(http://ftp.ensembl.org/pub/release-74/gtf/homo_sapiens/; accessed May 2016) and 
chromosome positions altered to a “chr1” format rather than the original “1” format using 
an awk script. Raw reads were mapped and aligned to hg19 using TopHat (v2.0.11; Johns 
Hopkins University, Baltimore, MD, USA). The Bowtie 2 hg19 index was downloaded from 
http://bowtie-bio.sourceforge.net/bowtie2/manual.shtml (accessed May 2016). 
During the analysis the read mapping rate was investigated further by comparison with 
different alignment software. The Burrows-Wheeler Aligner (BWA, v0.5.9; Cambridge, UK) 
was used with the same modified gene model annotation file as used for TopHat alignment. 
The resultant .bam files were analysed for the number of reads using SAMtools (v1.2; 
Cambridge, UK) flagstat tool and insert sizes using Picard (v2.4.1; Broad Institute, Cambridge, 
MA, USA) CollectInsertSizeMetrics tool. 
The TopHat alignment software was chosen in this study. Resulting .bam files, for each 
sample in each lane, were sorted by read names using SAMtools (v1.2; Cambridge, UK) sort 
tool and merged to produce one .bam file per sample using SAMtools merge tool. To obtain 
a global annotation of the samples the Picard (v2.4.1; Broad Institute, Cambridge, MA, USA) 
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CollectRnaSeqMetrics tool was used. Thus, the percentage of exonic, intronic, intergenic and 
untranslated region (UTR) reads was obtained. 
Gene count files were obtained from mapped reads using HTSeq (v0.6.1p1; EMBL, 
Heidelburg). In this study long non-coding RNA (lncRNA) and introns were investigated. The 
Human lincRNA Catalog (Broad Institute, Cambridge, MA, USA) was used as an annotation 
file for lncRNAs as it has defined >8000 lncRNAs (Cabili et al., 2011) and has been used 
independently of the Broad Institute (Huang et al., 2016). A gene model annotation file was 
also required to itemise introns and their chromosomal positions. To generate this file, the 
table browser on UCSC (https://genome.ucsc.edu/cgi-bin/hgTables, accessed November 
2016) was used to download intron locations, +50 bases flanking sequence, in .bed format 
(hg19). An awk script was used to process the text into a .gtf format, in particular inserting a 
third column with “intron” in all rows, which HTSeq requires to perform the count function. 
Differential expression analysis of lncRNA and introns was performed using DESeq2 (v1.14.0; 
Harvard, MA, USA) on R (v3.3.2; open source). In brief, gene count files were read into R and 
converted to DESeq2 datasets. Rows were removed where no counts were made across all 
6 samples to improve computation times. The data were transformed using the regularised-
logarithm transformation (rlog) as suggested in the software workflow (Love et al., 2014). 
This stabilises the variance across the mean making the data approximately homoscedastic. 
Euclidean distances and Principle Component Analysis (PCA) were used to assess the 
variance between samples. Individual lncRNA/intron expression differences were visualised 
by heatmap and Minus-Average (MA) plot. The false discovery rate threshold was reduced 
to an adjusted Bonferroni p-value of 6.27x10-6 for lncRNA analysis and 8.799873x10-7 for 
intron analysis. 
To gain functional insight from the lncRNA data, co-expressed coding genes were identified 
using Co-LncRNA (http://www.bio-bigdata.com/Co-LncRNA/, accessed November 2016). 
Differentially expressed lncRNAs were sorted by log fold change and the top 10, for cells and 
exosomes separately, were uploaded into the web interface with coding gene expression 
profiles from the sequencing data. Genes with correlative expression were identified and 
functional annotation of genes was performed using the Database for Annotation, 
Visualisation and Integrated Discovery (DAVID, v6.8; Leidos Biomedical Research, Inc., 
Frederick, MD, USA). Enrichment maps were drawn using Cytoscape (v3.4.0; open source). 
The same analysis was performed for differentially expressed introns without the need to 
identify co-expressed genes. 
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2.8.4 Validation of RNA sequencing results 
A separate method, using independent samples, was used to validate the results of the RNA 
sequencing. Three biological replicates of the H4 cell-line were established again and RNA 
isolated from both cells and exosomes. Quantitative polymerase chain reaction (qPCR) using 
SYBR™ Green was chosen to validate differential lncRNA expression. 
Primers were designed for six lncRNAs: three that were up-regulated in cells (XLOC_000670, 
XLOC_011226 and XLOC_008152) and three that were up-regulated in exosomes 
(XLOC_009577, XLOC_001047 and XLOC_006043). Chromosomal positions for these lncRNAs 
were identified from the gene model annotation file and DNA sequences were downloaded 
from the University of California Santa Cruz (UCSC) genome browser. Exonic regions of three 
housekeeping genes (GAPDH, TUBA1A and PPIA) were downloaded also. Primers were 
designed by submitting DNA sequences to Primer3 (Heidelberg, Germany) and requesting 
amplicons of 80 – 100 bp in length. These primer sets were confirmed to amplify the correct 
genomic region using the in silico PCR tool provided by UCSC and ordered from eurofins 
(Ebersberg, Germany). 
2.8.5 Reverse transcription 
RNA samples were reverse-transcribed to complimentary DNA (cDNA) using SuperScript™ IV 
VILO™ Master Mix with ezDNase™ Enzyme (Thermo Fisher Scientific, Inc., Loughborough, 
UK). A total of 8 µl RNA was mixed with 1 µl 10X ezDNase buffer, 1 µl exDNase enzyme and 
incubated at 37°C for two minutes on a BioRad S1000™ Thermal Cycler (Bio-Rad 
Laboratories, Inc., Watford, UK) to digest any contaminating genomic DNA (gDNA). In the 
case of quantifiable RNA (H4 cells and cell-derived exosomes), 80 ng RNA was put into this 
reaction for normalisation. In the case of un-quantifiable RNA (from plasma samples) the 
volume of sample input provided the normalisation. Reverse transcription was performed by 
addition of 4 µl SuperScript™ IV VILO™ Master Mix, 6 µl nuclease-free water and incubation 
with the following protocol: 
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25°C for 10 min to anneal primers 
50°C for 10 min to reverse transcribe RNA to cDNA 
65°C for 10 min to reverse transcribe RNA to cDNA 
85°C for 5 min to inactivate enzyme 
 
Samples were stored at -80°C for long term storage. 
2.8.6 Polymerase chain reaction 
Primers were tested by standard polymerase chain reaction (PCR) prior to qPCR. 4 µl cDNA 
was mixed with the following PCR cocktail: 
 
Reagent Volume (µl) 
Nuclease-free water 4.34 
10X Buffer* 1.2 
5 mM dNTPs* 1.2 
5 ng/µl forward and reverse primers 0.6 
5 u/µl Hot start Taq polymerase* 0.06 
cDNA 4 
 
*(Thermo Fisher Scientific, Inc., Loughborough, UK) 
 
PCR plates were run on BioRad S1000™ Thermal Cycler (Bio-Rad Laboratories, Inc., Watford, 
UK) using the following protocol: 
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95°C for 15 min 
35 cycles of: 
94°C for 45 s (Denaturation) 
58°C for 45 s (Annealing of primers) 
72°C for 60s (Extension of double-stranded DNA) 
Final extension of 72°C for 10 min 
 
2.8.7 Agarose gel electrophoresis 
PCR products were visualised by agarose gel electrophoresis. 1% agarose gels were cast by 
melting 1 g agarose (Sigma-Aldrich Co. Ltd., Dorset, UK) in 100 ml Tris-Borate-EDTA (TBE) 
buffer and adding 2 µl ethidium bromide (1% w:v ; Sigma-Aldrich Co. Ltd., Dorset, UK), once 
cooled. PCR product was mixed in a 1:1 ratio with loading dye (New England BioLabs® Inc., 
Ipswich, MA, USA) and 10 µl loaded into each well of the agarose gel. 5 µl 100 bp ladder (New 
England BioLabs® Inc., Ipswich, MA, USA) was loaded in a well for size discrimination. Agarose 
gels were electrophoresed at 100 V for 30 min or until the dye front had travelled sufficiently 
far through the gel. PCR products were visualised on the gels using UV exposure on a Gel 
Doc™ XR+ Gel Documentation System (Bio-Rad Laboratories, Inc., Watford, UK). 
2.8.8 qPCR using SYBR™ green 
Once suitable primer sets had been confirmed by conventional PCR and gel electrophoresis 
qPCR was performed. The comparative CT method (Schmittgen and Livak, 2008) was chosen 
to assess relative coding gene and lncRNA expression. 
2 µl cDNA product was mixed with 2 µl nuclease-free water, 1 µl forward/reverse primers (5 
ng/µl) and 5 µl PowerUp™ SYBR™ Green Master Mix (2X). Samples were prepared in 
duplicate or triplicate. Quantitative PCR was performed using StepOnePlus™ Real-Time PCR 
System (Thermo Fisher Scientific, Inc., Loughborough, UK) in standard cycling conditions: 
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50°C for 2 min 
95°C for 2 min 
40 cycles of: 
95°C for 15 s (denaturation) 
60 °C for 1 min (primer annealing/extension) 
 
Melt curves were run and analysed for additional PCR products using the following protocol: 
 
95°C for 15 s (1.6°C per s Ramp) 
60°C for 1 min (1.6°C per s Ramp) 
95°C for 15 s (0.15°C per s Ramp) 
 
Dissociation curves were visualised for each primer set, the number of peaks and melting 
temperature recorded. 
Analysis parameters for amplification plots were set to an automatic baseline and a 0.1 
fluorescent units threshold as described elsewhere (Enderle et al., 2015).  
2.8.9 qPCR using Taqman® with pre-amplification 
In addition to SYBR™ Green qPCR, Taqman® gene expression analysis was performed with an 
additional step of pre-amplifying selected targets after reverse transcription. 10 µl of 20X 
TaqMan® gene expression assay, for each target, was pooled with other assays and diluted 
to 0.2X in Tris-EDTA (TE) buffer. 12.5 µl pooled assay mix (0.2X) was mixed with 12.5 µl cDNA 
and 25 µl TaqMan® PreAmp Master Mix (2X). The pre-amplification reaction was followed: 
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95°C for 10 min 
10 cycles of: 
95°C for 15 s 
60°C for 4 min 
 
Samples were diluted 1:5 in TE buffer, aliquoted and frozen at -20°C. Quantitative PCR was 
performed using StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific, Inc., 
Loughborough, UK) in standard cycling conditions: 
 
50°C for 2 min 
95°C for 2 min 
40 cycles of: 
95°C for 15 s (denaturation) 
60 °C for 1 min (primer annealing/extension) 
 
No melt curve analysis was required for TaqMan® and the same analysis parameters were 
applied: automatic baseline and a 0.1 fluorescent unit threshold. 
2.9 DNA isolation and quality control 
2.9.1 DNA isolation from whole blood 
As part of the AD Genetics project whole blood was collected in lavender top EDTA tubes for 
DNA isolation. Genomic DNA was extracted using Nucleon BACC Genomic DNA Extraction 
Kits (GE Healthcare, Buckinghamshire, UK). In brief, blood samples were mixed in a 1:4 ratio 
with Reagent A (1X) for red blood cell lysis. Intact white blood cells were pelleted by 
centrifugation at 1600 x g for 5 min and supernatant discarded into bleach. Cells were lysed 
in 2 ml Reagent B. Nucleic acids were separated from proteins by mixing with 500 µl sodium 
perchlorate, 2 ml chloroform, 300 µl nucleon resin and phases separated by centrifugation 
at 1600 x g for 3 min. DNA was precipitated from the upper, aqueous phase by mixing with 
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100% ethanol in a 1:1 ratio. DNA was pelleted by centrifugation at 3500 x g for 5 min. DNA 
pellets were washed with 2 ml 70% ethanol, centrifuged again and re-suspended in 100 – 
650 µl TE buffer dependent on DNA pellet size. 
2.9.2 DNA quantification by PicoGreen 
Double stranded gDNA was quantified using the Quant-iT PicoGreen dsDNA Assay Kit 
(Thermo Fisher Scientific, Inc., Loughborough, UK). PicoGreen was diluted to a working 
concentration in TE buffer and protected from light. 2 µl DNA was diluted in 98 µl working 
PicoGreen solution in 96-well black, flat-bottom microplates. Fluorescence was measured by 
excitation at 485 nm and emission at 520 nm using an Infinite® 200 PRO microplate reader 
(Tecan Group Ltd., Männedorf, Switzerland). DNA quantitations were calculated using a 
standard curve of λ DNA standard. 
2.10 DNA analysis 
2.10.1 APOE genotyping 
APOE genotypes were determined by single nucleotide polymorphism (SNP) genotyping as 
described previously (Butchart et al., 2015, Ide et al., 2016). TaqMan (Life Technologies, 
Waltham, MA, USA) genotyping was performed for rs7412 and KASP™ (LGC Ltd., Teddington, 
UK) genotyping for rs429358. DNA samples were diluted to a working concentration of 2.5 
ng/µl. 
TaqMan genotyping was performed by mixing 11.25 µl DNA with 12.5 µl TaqMan genotyping 
mastermix (2X) and 1.25 µl rs7412 primer mix (20X). Standard genotyping procedure was 
performed using the using StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific, 
Inc., Loughborough, UK): 
 
95°C for 10 min 
40 cycles of: 
95°C for 15 s (denaturation) 
60°C for 1 min (primer annealing/extension) 
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Fluorometric recording of VIC, FAM and ROX dyes was performed by the StepOnePlus™ 
instrumentation and Allelic Discrimination Plot automatically displayed. 
Kompetitive Allele Specific PCR (KASP™) genotyping was performed by mixing 5 µl DNA with 
5 µl KASP™ mastermix (2X) and 0.14 µl rs429358 primer mix. Amplification was performed 
using BioRad S1000™ Thermal Cycler (Bio-Rad Laboratories, Inc., Watford, UK) on a touch-
down PCR protocol: 
 
94°C for 15 min 
10 cycles of: 
94°C for 20 s 
68°C for 1 min (reducing -0.5°C each cycle) 
26 cycles of: 
94°C for 20 s 
62°C for 1 min 
 
This was followed by three more cycles to improve clustering of data-points: 
 
3 cycles of: 
94°C for 20 s 
57°C for 1 min 
 
Fluorescence of FAM, HEX and ROX dyes were measured using an Infinite® 200 PRO 
microplate reader (Tecan Group Ltd., Männedorf, Switzerland). 
Two negative controls and six positive controls, of each APOE genotype, were included for 
both assays to validate correct genotype calling. 
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2.11 Statistical analyses 
Unless otherwise stated, statistical calculations were performed using SPSS Statistics 20 
package (IBM). Differential expression analyses were performed using DESeq2 (v1.14.0) on 
R (v3.3.2). 
Where possible, three or more biological and technical replicates were prepared in the 
experiment design so that the distribution of the resultant data could be analysed. It is 
acknowledged, by the author, that ideally these numbers of replicates should have been 
performed in every experiment, however, the limitations of exosome sample and antibody 
quantity made it necessary for some experiments to be performed with a lower number of 
repeats. Where this was the case the limitations are discussed and careful interpretation of 
the results follow.  
Prior to performing specific statistical tests, the suitability of each dataset was considered by 
performing a Shapiro-Wilk test for normality using SPSS Statistic 20 package (IBM). Normally 
distributed data was subjected to parametric tests, such as t-test or analysis of variance 
(ANOVA), where the mean of each group is used in the test. When data were not normally 
distributed, non-parametric tests, such as Mann-Whitney U tests, were performed.  
2.12 Experimental design 
Throughout this study, general principles of good working practice were followed. For 
example, exosome stocks were routinely quality checked by BCA and NTA, detailed note-
keeping was performed in the laboratory and samples were handled with care to avoid cross-
contamination. Chapters 5 and 6, in particular, contained experiments that required 
additional forethought of experiment design. 
In chapter 5, an RNA sequencing experiment was performed and steps were taken to reduce 
any batch effects. These included: extracting RNA from biological replicates simultaneously 
with the same extraction kit, handling RNA for quantitation and reverse transcription at the 
same time for all samples, using central wells of thermal cycler blocks rather than edge wells, 
performing library preparation of all samples simultaneously and performing sequencing 
with all libraries pooled and run over 2 lanes. 
In chapter 6, a case:control cohort was used to validate a qPCR-based assay. Although cases 
and controls had been pre-selected, sample IDs were numeric to aid with anonymisation in 
the laboratory and reduce human bias. Again, steps were taken to reduce batch effects 
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including: performing all RNA extractions on the same day, handling cases and controls at 
the same time, performing reverse transcription of all samples on the same day and each 
gene expression candidate was tested with all samples on one plate at a time. In the future, 
with larger cohorts for a discovery experiment, these practices would again be adopted with 
additional steps. Double-blinding would be performed to further reduce any possibility of 
human bias or batch effects in sample handling. Power calculations will be performed to 
ensure an adequate cohort size is chosen. 
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3.1 Introduction 
Multi-vesicular bodies fuse with the plasma membrane to release exosomes into the 
extracellular space (Thery et al., 2002). Biological fluids are complex tissues containing a 
heterogeneous pool of cells and particles (Hoog and Lotvall, 2015). This poses significant 
challenges for the isolation of pure exosomes.  
As an alternative to biological fluids, cell culture media gives an opportunity to obtain 
exquisitely pure exosomes; it is far easier to control for which co-isolates are present. For 
example, foetal bovine serum (FBS) is a common additive that can introduce bovine 
exosomes which then mix with those secreted by the cultured cells (Shelke et al., 2014). 
Bovine exosomes can be depleted with relative efficiency using ultra-centrifugation. Thus, 
cell cultures can offer an accessible and consistent source of exosomes. 
Choosing a cell-line to use is a significant consideration. Primary cells can provide a tissue- or 
disease-relevant source of exosomes and therefore, representative of what may be found in 
biological fluids. However, primary cells are susceptible to reaching senescence and can be 
technically difficult for long-term or high-density cell culture. Alternatively, immortalised 
cell-lines are less susceptible to reaching senescence and, generally speaking, more robust. 
Despite being less technically challenging to maintain immortalised cell-lines than primary 
cells there can be differences between different cell-types. An analysis of a panel of cancer 
cell-lines found that growth characteristics varied between cell-lines, and indeed, the 
quantity and size of exosomes differed also (Hurwitz et al., 2016). 
The isolation of neural-derived exosomes is an exciting prospect for analysing vesicles 
relevant to diseases of the CNS, such as Alzheimer’s disease. Primarily, an abundant source 
of neural-derived exosomes was required in this study so immortalised cell-lines were 
chosen, rather than primary cells. Neuroglioma (H4) and neuroblastoma (IMR-32) cell-lines 
were chosen as they were cells sourced from the CNS.  
Whilst these cell-lines provided a source of neural-derived exosomes, both H4 and IMR-32 
had previously been used as cell-models of AD, so provide future potential for AD-relevant 
analyses. For example, the H4 cell-line has been manipulated to express the Swedish mutant 
form of APP assigned “H4-sw”. One study reported that H4-sw exhibited elevated expression 
of Heme Oxygenase 1, driven by epigenetic alterations in the promoter region of the gene 
(Sung et al., 2016). This phenomenon was also apparent in the primary T lymphocyte Jurkat 
cells of AD patients and methylation analyses of the HMOX1 gene correlated with disease 
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status and Mini-Mental State Examination. This is a prime example of translating 
observations from a cell-model into clinical relevance. The PS1 gene has been knocked-down 
in the IMR-32 cell-line and this caused decreased Aβ-42 (Kandimalla et al., 2012). Another 
study reported that Aloe arborescens extract protected the IMR-32 cell-line from Aβ-induced 
toxicity through the reduction of Reactive Oxygen Species (Clementi et al., 2015).  
The investigation of exosomes from these cell-lines has only been reported once to date. The 
H4 cell-line was used to study the PARK9 ATPase in relation to Kufor-Rakeb Syndrome 
(Tsunemi et al., 2014). PARK9 over-expression promoted the secretion of exosomes and α-
synuclein via exosomes. Therefore, the thorough characterisation and study of exosomes 
from these cell-lines is a novel avenue of research.  
A major challenge in collecting exosomes from cell cultures is handling large volumes of 
media to maximise yields. One example of this is a study that required 3.2 L of media to 
obtain sufficient protein for one 2D Electrophoresis gel experiment (Staubach et al., 2009). 
Such work is cumbersome, expensive and inefficient. Unfortunately this is unavoidable with 
traditional cell culture techniques where the surface area : volume ratio (SA:V) does not 
allow adherent cells to grow in high densities. However, it is possible with standard cell 
culture techniques to have ready access to viable cells and their secreted exosomes at the 
same time. This is a benefit when wanting to study transiently expressed molecules such as 
RNA (Skog et al., 2008). 
To overcome this issue with traditional cell culture, one option is to adopt a 3D culture 
system and a novel method was developed in the Clayton lab at Cardiff University for 
exosome production. Bioreactor flasks (Integra CELLine™ flasks) were used to culture 
adherent cells in a high density but low media volume (Mitchell et al., 2008a). Cells are 
seeded into the inner chamber of the bioreactor and encapsulated in a matrix of plastic to 
allow adhesion. The volume of culture medium is typically 10 - 15 ml for the inner chamber 
and this is maintained by the outer chamber containing 500 – 1000 ml medium. Nutrients 
and waste products can pass bi-directionally over a membrane that separates the inner and 
outer chambers to maintain the cells; however, exosomes remain within the inner 
compartment. This technique allows exosomes from high density cell-culture to be isolated 
from a small media volume. A caveat of this method is that, by reducing the SA:V ratio, cells 
are cultured in a more stressful and hypoxic environment, and that cell viability cannot be 
controlled or monitored easily (Mitchell et al., 2008a). 
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Once isolated there are a number of characteristics that define exosomes from other 
extracellular vesicles. One characteristic is size, with exosomes ranging from 40-120 nm 
diameter (El Andaloussi et al., 2013). The gold standard method for measuring particle size 
is electron microscopy (EM) as accurately measuring particles smaller than 300 nm using 
optical methods is technically challenging. Scanning EM (SEM) and Transmission EM (TEM) 
have both be utilised for the measurement of exosome size (Wu et al., 2015). It has been 
observed that TEM consistently shows “cup-shaped” vesicles; these structures are not true 
morphology but artefacts of sample preparation as common fixatives, such as 
glutaraldehyde, cause sample dehydration and structural collapse. This central depression is 
not observed with SEM; rather exosomes appear spherical in structure. Despite this 
difference, TEM offers the well-established utility of immuno-gold labelling of particles, 
which is not commonplace with SEM, to date. An alternative to these methodologies is cryo-
EM that, like SEM, does not have the “cup-shaped” artefact (Xu et al., 2015). Cryo-EM does 
not involve staining or fixing of samples, instead they are plunge frozen in their native state, 
which is advantageous for observing true exosome structure (Welton et al., 2016). 
Electron microscopy is an expensive, time- and labour-intensive procedure for measuring 
exosome size. It would be technically challenging to utilise it for routine quality-control of 
vesicle preparations. Alternative technologies have been developed namely, Tuneable 
Resistive Pulse Sensing (TRPS) and Nanoparticle Tracking Analysis (NTA). TRPS technology 
was brought to the market by Izon Science Ltd., with the qNano instrumentation. It can be 
used to measure exosome size, concentration in solution and electric charge (Akers et al., 
2016). In principle, particles in an electrolyte fluid pass through a nanopore and a resistive 
pulse signal is detected and measured. NTA technology was brought to the market by 
Malvern Instruments Ltd., with the Nanosight instrumentation. It can be used to measure 
exosome size and concentration in solution (Livshts et al., 2015). Particles, moving under 
Brownian motion, scatter light from a laser beam and the velocity and motion is proportional 
to particle size. This relationship is described by the Stokes-Einstein equation. An additional 
application of NTA is the measurement of particles fluorescently labelled for an antigen of 
interest (Stern et al., 2016). Both technologies have been adopted for measuring exosome 
size to date and offer a far more tractable quality-control step than electron microscopy. The 
Clayton lab has adopted NTA for routine measurements of exosome size. The dynamic light 
scattering used in NTA can be applied to measure poly-disperse particles, whereas TRPS 
requires different pore sizes dependent on the size range of particles being analysed. 
Therefore, NTA has been used in this study. 
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A second defining characteristic of exosomes is density: ranging from 1.1 – 1.2 g/ml (Escola 
et al., 1998, Raposo et al., 1996, Webber et al., 2014). To measure this, vesicle preparations 
can be under- or over-laid on a continuous sucrose gradient and centrifuged at a high-speed 
overnight before fractions are collected and analysed. As an alternative to sucrose gradients, 
iodixanol, an isotonic dense medium marketed as OptiPrep™ and used in medical imaging as 
an inert contrast reagent, has been used in similar density separation procedures (Konadu et 
al., 2016). These are useful analytical tools but not widely used as exosome preparation 
techniques, due to them being time- and labour-intensive. A consequent method was 
developed, based on trapping vesicles of relevant density, termed the “sucrose cushion 
method” whereby exosomes are isolated with a sucrose/D2O solution (Andre et al., 2002, 
Lamparski et al., 2002, Thery et al., 2006). This can be used as a routine isolation procedure 
as a single density cushion is prepared far more quickly than a gradient and ultra-
centrifugation times are much shorter. 
A third characteristic feature of exosomes is protein content. A number of proteins are 
known to be expressed and enriched in exosomes: the tetraspanins CD63, CD81 and CD9 
(Lamparski et al., 2002, Escola et al., 1998, Heijnen et al., 1999); and components of the 
ESCRT machinery, TSG101 (Stoorvogel et al., 2002) and ALIX (Roucourt et al., 2015, 
Stoorvogel, 2015). These proteins have been used to validate the isolation of exosomes in 
the Clayton laboratory at Cardiff University (Clayton et al., 2007, Clayton et al., 2004, Clayton 
et al., 2005) and elsewhere (Lamparski et al., 2002, Caby et al., 2005). However, the 
distribution of these typical proteins on different sub-types of EVs, such as those of plasma 
membrane origin, remains in debate, as discussed previously. 
Not only can specific protein markers be analysed but the total protein content of exosome 
preparations can be used on a global level to assess purity. The Clayton laboratory developed 
the methodology of combining particle concentration, measured by NTA, and protein 
concentration, measured by BCA assay, to produce a particle : protein (P:P) ratio (Webber 
and Clayton, 2013). This gives an assessment of the number of particles in a preparation 
against the concentration of vesicular, non-vesicular and contaminating proteins. A similar 
method has been proposed that used a sulfophosphovanilin (SPV) assay to measure total 
lipid concentration and from that calculate a lipid : protein ratio (Osteikoetxea et al., 2015). 
Both methods were developed to provide a basic assessment of vesicle purity as a much 
needed quality control read-out. These reports additionally highlighted the relative difficulty 
of isolating pure exosomes from biological fluids compared to cell-culture medium. This is 
likely due to the problem of co-isolating proteins regardless of which isolation method used. 
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A fourth feature of exosomes is their morphology. With electron microscopy spherical 
structures with a lipid bilayer are observed (Wu et al., 2015, Xu et al., 2015). As discussed 
above, TEM can produce “cup-shaped” artefacts that are not observed with SEM or cryo-EM. 
These techniques also provide an opportunity to assess contamination with other debris. 
One study recorded approximately 1500 extracellular structures, observed by cryo-EM, from 
an un-prepared biological fluid (Hoog and Lotvall, 2015). This is in contrast with a pure 
exosome preparation where heterogeneity is expected but only within a subtype of small, 
<120nm, size range of bilayer vesicles. 
In a 2014 position statement a set of biochemical, biophysical and functional criteria were 
proposed by the International Society of Extracellular Vesicles (Lotvall et al., 2014). The aim 
of this was to standardise the minimal experimental requirements to report the genuine 
isolation of exosomes. With the exception of particle density, this statement lists the same 
features as mentioned above. The first of these is protein content with the suggestion that 
3 or more proteins are reported in at least a semi-quantitative manner. The report suggested 
the assessment of both transmembrane and intra-luminal proteins that are expected to be 
present or enriched in exosomes. This requires measuring proteins on exosomes in their 
native form and within exosomes using a reducing agent. Additionally proteins not expected 
within exosomes should be measured to rule out cellular contamination. In the case of 
studies that use cell culture-derived exosomes, these proteins should be evaluated in respect 
to the source cells. The report also suggested that two techniques are employed to 
characterise individual exosomes. For example, showing both electron micrographs and size 
distribution plots by NTA or TRPS. These suggestions provide a helpful guideline and were 
followed in this study, in combination with the established systems used in the Clayton lab, 
to provide strong evidence of isolating exosome vesicles of good purity. 
Therefore, guidelines have been established for isolating and characterising exosomes 
secreted from the H4 and IMR-32 cell-lines. Utilising these cell-lines for high-yield production 
of exosomes would provide an abundant source of neural-derived exosomes. This would 
provide some of the materials and methodology required for subsequent chapters in this 
study. 
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3.2 Aims 
The aim of this chapter was to generate a bulk stock of exosomes to be used for the 
remainder of the thesis, particularly, for developing an affinity capture assay and for RNA 
analysis. To achieve this aim the following objectives were addressed: 
 Establish cell cultures from neural sources 
 Establish methods for the isolation of exosomes from these cell cultures 
 Characterise exosomes based on their size, protein content, density and structure 
 Establish quality control measures for exosome preparations and a stock of exosomes 
for downstream assay development and RNA analysis 
 
3.3 Results 
3.3.1 Cell-line characterisation and validation 
Immortalised cell-lines were chosen to allow the scale-up of exosome isolation, as the cells 
should robustly handle large scale culture. Human cell-lines, from a neural source, were 
purchased from American Type Culture Collection (ATCC): one neuroglioma (H4, ATCC® 
HTB148™) and one neuroblastoma (IMR-32, ATCC® CCL127™). Upon receipt of ampoules, 
cell validation data was requested from the supplier. The H4 cell-line was validated by short 
tandem repeat (STR) analysis with a unique DNA profile that matched the expected profile 
(Table 3.1). The IMR-32 cell-line was validated by STR analysis and an isoenzyme analysis that 
was positive for G6PD type B (Table 3.2). These data, provided by the supplier, confirm that 
the cells used in this study are from the neural sources as stated. 
To avoid cross contamination these cell-lines were handled in isolation from each other. 
Incubator space was shared with other cell-lines but sub-culturing was performed at 
different times and safety cabinets decontaminated between uses. Passage counts started 
at passage 1 upon receipt of the cells. Multiple aliquots of cells were frozen at passage 2 and 
passage 5 as a banked resource. Sub-culturing never exceeded passage 20. Mycoplasma 
testing was performed every 3 months if the cells had been in uninterrupted culture or 
periodically when new ampoules were started. Together these procedures reduced the risk 
of cross-contamination between cell-lines and with mycoplasma. 
Chapter 3. Establishing and characterising an abundant source of neural-derived 
exosomes 
84 
 
Brightfield microscopy was used to routinely assess cell morphology and thus identify a 
cross-contamination event or fungal/bacterial contamination had it occurred. The H4 cell-
line maintained an epithelial morphology (Figure 3.1) and the IMR-32 cell-line was a 
neuroblast-like morphology (Figure 3.2) as expected from supplier’s instructions. Therefore, 
the cell-lines used were indeed from the neural sources stated and thus suitable for 
establishing stocks of exosomes and performing further analyses.  
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Test Specifications Results 
Post-freeze viability  ≥ 50.0% 95.0% 
Growth properties  
 
Adherent Adherent 
Morphology Epithelial-like Epithelial-like 
Test for mycoplasma 
contamination  
Hoechst DNA stain (indirect)  
Agar culture (direct)  
 
None detected 
None detected 
 
None detected 
None detected 
Species determination: COI assay 
(interspecies) 
Human Human 
Species determination: STR 
analysis (intraspecies) 
Human (Unique DNA 
Profile) 
D5S818: 10, 12  
D13S317: 12  
D7S820: 8, 11  
D16S539: 11, 12  
vWA: 14, 18  
THO1: 7, 9  
Amelogenin: X, Y  
TPOX: 8, 11  
CSF1PO: 10, 12 
Human (Unique DNA 
Profile) 
D5S818: 10, 12  
D13S317: 12  
D7S820: 8, 11  
D16S539: 11, 12  
vWA: 14, 18  
THO1: 7, 9  
Amelogenin: X, Y  
TPOX: 8, 11  
CSF1PO: 10, 12 
Sterility test (BacT/ALERT 3D) 
iAST bottle (aerobic) at 32°C  
iNST bottle (anaerobic) at 32°C 
 
No growth 
No growth 
 
No growth 
No growth 
 
Table 3.1: Cell validation for the H4 cell-line (ATCC® HTB148™) Lot Number 57637310 (provided by 
supplier).  
Cells were viable after freezing and confirmed to be sterile and free of mycoplasma. STR analysis, 
performed by the supplier, revealed a DNA profile consistent with expected data to confirm that this 
lot contained the expected population of cells without cross-contamination. Cell viability and 
morphology were routinely assessed by the user during sub-culturing. 
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Test Specifications Results 
Post-freeze viability  ≥ 50.0% average 91.1% average (range 
of 88.6% to 92.6%) 
Morphology Neuroblast-like and/or 
rounded 
Neuroblast-like 
Mycoplasma contamination 
(Hoechst DNA Stain and Direct 
Culture Methods) 
 
None detected 
 
 
None detected 
Post-Freeze Cell Growth Cells are able to be 
successfully subcultured 
for two passages post-
freeze 
Cells are able to be 
successfully 
subcultured for two 
passages post-freeze 
Interspecies Determination 
(Isoenzyme Analysis) 
Human, G6PD type B Human, G6PD type B 
Intraspecies Determination (STR 
Analysis) 
Pass (DNA profile is 
consistent with all other 
DNA profiles on record 
for this cell line) 
Pass 
Bacterial and Fungal 
Contamination 
None detected None detected 
 
Table 3.2: Cell validation for the IMR-32 cell-line (ATCC® CCL127™) Lot Number 5087900 (provided 
by supplier).  
Cells were viable after freezing and confirmed to be sterile and free of mycoplasma. STR analysis, 
performed by the supplier, revealed a DNA profile consistent with expected data and isoenzyme 
analysis was positive for G6PD type B. These data confirm that this lot contained the expected 
population of cells without cross-contamination. Cell viability and morphology were routinely assessed 
by the user during sub-culturing. 
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Figure 3.1: Morphology of the H4 cell-line.  
Brightfield microscopy images were taken of live cells with 10x magnification. One example is given 
but representative of routine inspections of cells throughout this study. Cell morphology remained 
consistent whilst confluency varied during sub-culturing stages. Described as “epithelial-like” these 
cells showed polygonal shape, were adherent to the cell-culture flask and grew in a monolayer. White 
bar is representative of 400 µm.  
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Figure 3.2: Morphology of the IMR-32 cell-line.  
Light microscopy images were taken of live cells with 10x magnification. One example is given but 
representative of routine inspections of cells throughout this study. Cell morphology remained 
consistent whilst confluency varied during sub-culturing stages. Described as “neuroblast-like” these 
cells showed elongated shape, were adherent to the cell-culture flask and grew in a monolayer. White 
bar is representative of 400 µm. 
 
3.3.2 Exosome size 
Some researchers suggest that exosomes can be defined by their size: ranging from 40 -120 
nm diameter (El Andaloussi et al., 2013). The H4 and IMR-32 cell-lines were tested to see if 
typically-sized exosomes could be isolated with standard techniques. These cells were grown 
as monolayers on standard tissue culture plastic with culture medium that was 
supplemented with exosome-depleted FBS; cell-culture medium was collected for exosome 
isolation. In the first instance, cell culture supernatants were cleared of cells and cellular 
debris by differential centrifugation (see chapter 2) and passed through 0.2 µm filters. For 
exosome preparation, these filtered supernatants were centrifuged at 200,000 x g for 2h, 
the pellet was washed with PBS and centrifuged again at 200,000 x g for 2h (Webber and 
Clayton, 2013). These preparations were analysed by NTA for particle size and concentration 
(Figure 3.3).  
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The particles had an average size of 81.7 ± 3.5 nm for the H4 cell-line and 62.3 ± 2.3 nm for 
the IMR-32 cell-line (n=6); both within the accepted range for exosomes. Furthermore, the 
histograms showed a uniform distribution giving the appearance of a single population of 
vesicles being isolated. Together these data suggest that the isolation procedure was 
effective in selecting the appropriate sized vesicles. This technique provided a satisfactory 
first evaluation of exosome size. All subsequent preparations in this study were assessed in 
the same way acting as a quality control measure.  
A second parameter measured by NTA was particle concentration. The H4 preparation 
recorded an average concentration of 1.02x1014 ± 4.25x1012 particles/ml whilst the IMR-32 
preparation recorded 7.02x1013 ± 2.49x1012 particles/ml (n=6) (Table 3.3). Taken in 
conjunction with BCA measurements of total protein these data were used to produce 
particle : protein ratios as an indication of the purity of the preparation (reported and 
discussed more fully in section 3.3.4). These ratios were 2.03x1010 for H4 and 5.06x1010 for 
IMR-32 which were close to the approximate 3x1010 P:P ratio to be considered of high purity 
(Webber and Clayton, 2013). This quality control measure was also used in all subsequent 
exosome preparations throughout this study. The particle concentrations were primarily 
used for calculating P:P ratio, rather than giving an assessment of the relative abundance of 
vesicles secreted by each cell-line. To do this assessment cell count data prior to exosome 
isolation would be required. 
It is worth noting that NTA measures particles without distinguishing vesicles from other co-
isolates of the same size. Therefore, other molecular analyses were also performed to 
confirm the isolation of exosomes and adhere to the minimal requirement guidelines 
recommended by ISEV (Lotvall et al., 2014). 
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Figure 3.3: A Histogram showing overall size distribution of particles isolated from H4 and IMR-32 
cell-lines.  
Particle concentrations were calculated by NTA (n=6 videos per cell-line) and averaged to provide a 
single line for each cell-line. Size distribution plots were drawn for H4 (light blue) and IMR-32 (dark 
blue) exosome preparations. Average mode size was 81.7 ± 3.5 nm for the H4 cell-line and 62.3 ± 2.3 
nm for the IMR-32 cell-line. 
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3.3.3 Exosome density 
Exosomes characteristically float at a sucrose density of 1.1 – 1.2 g/ml (Escola et al., 1998, 
Raposo et al., 1996, Webber et al., 2014). Density gradients were produced to fractionate 
either H4 or IMR-32 derived vesicles using sucrose ranging from 0.2 – 2.25 M (n=1, per cell-
line); this provided the appropriate density range to carry out this analysis. After an overnight 
ultra-centrifugation the refractive index (η) of sixteen equal volume fractions from each 
gradient were measured (Figure 3.4). The densities (ρ) of these fractions were calculated 
using a second order polynomial equation calculated from a sucrose standard curve provided 
by the manufacturer (Beckman-Coulter, High Wycombe, UK). The density range was 1.01 – 
1.24 g/ml for the H4 gradient and 1.01 – 1.25 g/ml for IMR-32. Both of these gradients were 
satisfactory for identifying the presence or absence of exosomes floating at the expected 
density range. Due to exosome sample limitation only one gradient was performed per cell-
line, therefore, the following results will be used primarily for confirming the suitability of 
sucrose cushion isolation which is also based on density. It would be preferable to perform 
three or more biological replicates to conclusively make these observations but sample 
limitation did not make this a possibility in this study. 
The protein and particle concentration of each of the fractions was calculated by BCA assay 
and NTA, respectively (Figure 3.5). For the H4 cell-line, these concentrations were below the 
detectable range of the assays until fraction 12 which corresponded to a density of 1.16 g/ml. 
This continued for the remainder of the density gradient with a large concentration of 
particles and protein detected in fraction 16 (1.24 g/ml). This is likely to be caused by deposits 
of aggregated vesicles, non-vesicular particles and large protein aggregates. However, to 
fully clarify this, measurements of exosome-specific protein markers needed to be made. 
The IMR-32 gradient showed a similar detection of particles and proteins at fraction 10 which 
corresponded to a density of 1.15 g/ml (Figure 3.5). Again this continued for the remainder 
of the density gradient before detecting high concentrations of particles and protein in 
fraction 16 (1.25 g/ml).  
From these observations, of both gradients, it can be suggested that an abundance of 
material was co-isolating with exosomes and therefore being detected in the same fractions. 
This was particularly noticeable in fraction 16, of both gradients, that contained high 
concentrations of particles and proteins outside the expected density range for exosomes. 
NTA and BCA assay are global measures of particle and protein concentrations, respectively, 
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therefore non-vesicular material could be contributing to the detected signal. Further 
analyses of specific protein markers were performed to clarify what was being detected in 
each fraction. 
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Figure 3.4: The refractive of index of sixteen fractions collected from sucrose density gradients.  
Refractive indexes (η, blue bars) were measured in duplicate and the density (ρ, light blue line) of the 
respective fractions has been overlaid as a line for the H4 (Top) and IMR-32 (Bottom) cell-lines. The 
density range was 1.01 – 1.24 g/ml for the H4 gradient and 1.01 – 1.25 g/ml for IMR-32. Due to sample 
limitations, one gradient was run per cell-line. 
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Figure 3.5: The protein and particle concentrations of sixteen fractions collected from sucrose 
density gradients.  
Protein concentration was calculated by BCA assay (n=2) and averaged to be displayed as blue bars. 
Particle concentration was calculated by NTA (n=6) and averaged to be displayed as light blue lines. 
Due to sample limitation, one gradient was run each for the H4 (Top) and IMR-32 (Bottom) cell-lines. 
1.1 – 1.2 g/ml
1.1 – 1.2 g/ml
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To test if the material detected in these density gradient fractions comprised of exosomes, 
the relative concentrations of tetraspanins CD63, CD81 and CD9 were measured by a plate-
based adsorption assay that measured TRF as a readout (see chapter 2). 
A sharp peak was detected for all three proteins in fractions 10 and 11 for the H4 cell-line 
(Figure 3.6). This corresponded to a density range of 1.11 – 1.14 g/ml, as expected for 
exosomes. A shallow tail extended after these peaks to fraction 16. As a negative control, a 
mouse IgG1 antibody was used to measure non-specific background signal caused by the 
primary antibodies; the isotype control signal was less than 5000 TRF units in all fractions 
indicating minimal background signal and that the tetraspanin measurements were genuine.  
These observations clarify that the high protein and particle measurements, made by BCA 
and NTA, in fraction 16 were not caused by exosomes (Figure 3.5). The material detected in 
the final fraction did not have a corresponding tetraspanin signal so is likely to have been 
caused by non-vesicular and large protein aggregates.  
To fully determine the presence, or absence, of cellular or non-cellular contaminants direct 
measurements would need to have been made. For example, lipoproteins or Argonaute 
proteins may be present in the same fractions as the detected exosomes. Therefore, it 
cannot be concluded that exosomes were prepared with absolute purity. 
It was only possible to perform one sucrose gradient per cell-line due to the availability of 
exosomes. It would be preferable to have performed additional gradients so that statistical 
tests could have been performed rather than the qualitative assessment performed here. 
Nevertheless, this confirms that exosomes can be isolated from H4 cells grown in culture and 
that the sucrose cushion method of isolation (Andre et al., 2002, Lamparski et al., 2002, Thery 
et al., 2006) is open to be used for exosome isolation with this cell-line. The advantage of 
using this cushion technique is that it isolates particles based on their density, yet is more 
readily scaled up for bulk preparations than gradient techniques. Isolation using the sucrose 
cushion method is less time-consuming and labour-intensive in terms of sample handling and 
centrifugation time. Furthermore, it has been included as part of an FDA-approved protocol 
for exosome isolation from dendritic cells, so a well-tested method for this purpose 
(Lamparski et al., 2002). 
The three tetraspanins were detected in fraction 10 for the IMR-32 cell-line (Figure 3.7). This 
corresponded to a density of 1.15 g/ml. A broader tail extended after this peak when 
compared to the sharp peak observed in the H4 cell-line (Figure 3.6). This broader tail 
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suggests that exosomes were present in later fractions and this was likely caused by the 
aggregation of vesicles as well as non-vesicular and protein aggregates. It may be a particular 
feature of this cell-line, compared to H4, that the vesicles are more prone to aggregation. 
Nevertheless, accepting the caveats of sample size and being unable to rule out other 
contaminants, exosomes were detected in the expected density range for both cell-lines and 
thus subsequent preparations were predicted to be compatible with the sucrose cushion 
method. 
These data have shown that other particles were present in the original preparations prior 
to density gradient separation. Therefore selecting particles based on their density should 
provide a purer specimen for analysis. From this point onward the sucrose cushion method 
of isolation was chosen as the preferred and routine method. Quality checks of subsequent 
exosome preparations confirmed the suitability of this method. 
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Figure 3.6: Bar chart showing relative levels of the tetraspanins CD63, CD81 and CD9 in fractions 
from sucrose density gradient (H4 cell-line).  
Time-resolved fluorescence (TRF, y-axis) measurements were taken for H4 exosomes overlaid on a 
sucrose gradient (n=1). The relative levels of CD63 (navy), CD81 (dark blue), CD9 (teal) and IgG1 
(turquoise) are represented as bars for each of the sixteen fractions obtained (x-axis). The density 
(g/ml) of each fraction is also indicated on the x-axis. 
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Figure 3.7: Bar chart showing relative levels of the tetraspanins CD63, CD81 and CD9 in fractions 
from sucrose density gradient (IMR-32 cell-line).  
Time-resolved fluorescence (TRF, y-axis) measurements were taken for IMR-32 exosomes overlaid on 
a sucrose gradient (n=1). The relative levels of CD63 (navy), CD81 (dark blue), CD9 (teal) and IgG1 
(turquoise) are represented as bars for each of the sixteen fractions obtained (x-axis). The density 
(g/ml) of each fraction is also indicated on the x-axis. 
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3.3.4 Exosome purity and protein content 
The purity of exosomes isolated by different preparation techniques was assessed using a 
P:P ratio (Webber and Clayton, 2013). Bioreactors containing H4 and IMR-32 cell-lines were 
established to investigate if greater yields of exosomes could be obtained whilst sample 
purity was maintained by adopting the sucrose cushion method. Exosome preparations were 
analysed by NTA and BCA.  
The media collected from 2D-cultures were subjected to the pellet and PBS wash protocol 
for exosome isolation whereas the bioreactor supernatants followed the sucrose cushion 
protocol (Andre et al., 2002, Lamparski et al., 2002, Thery et al., 2006). Particle counts were 
calculated to be 1.02x1014 ± 4.25x1012 particles/ml for H4 and 7.02x1013 ± 2.49x1012 
particles/ml for IMR-32 cell-lines cultured two-dimensionally (Table 3.3). This was after 200 
ml media was collected from twenty T75 flasks. Exosomes isolated from bioreactor flasks 
with the sucrose cushion method had particle concentrations of 4.26x1013 ± 1.06x1012 
particles/ml for H4 and 3.07x1013 ± 1.64x1012 particles/ml for IMR-32 cell-lines. This was after 
45 ml supernatant was collected.  
As an assessment of the abundancy of particles in the different culture formats ratios of 
particles/ml media were calculated (Table 3.3). The H4 cell-line was calculated to give 
5.61x1013 particles per ml media for 2D cultures compared with 1.04x1014 particles per ml 
media for bioreactor format. Similarly the IMR-32 cell-line produced 3.86x1013 particles per 
ml media for 2D cultures and 7.50x1013 particles per ml media for bioreactor format. Thus 
approximately double the number of particles per millilitre of media was obtained using the 
bioreactor format. However, these assessments of particle abundance must be interpreted 
carefully as the number of cells seeded into each culture format have not been accounted 
for. The number and viability of the cells was not determined prior to collecting the media 
so this comparison does not fully determine that the bioreactor format achieves greater 
exosome yields. Primarily, the NTA measurements were used in conjunction with protein 
concentrations to calculate the P:P ratio and test if purity was compromised with the 
bioreactor format. 
To determine if purity of preparation was maintained, whilst getting these greater particle 
yields, protein concentrations were calculated by BCA assay. Protein concentrations were 
5023 µg/ml for H4 and 1386 µg/ml for IMR-32 cell-lines cultured two-dimensionally 
(Table 3.3). From bioreactor flasks these concentrations were 1769 µg/ml for H4 and 1203 
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µg/ml for IMR-32. To assess the abundance of protein, despite lower media volumes being 
used in the bioreactor format, ratios of protein/ml media were calculated. The H4 cell-line 
produced 2.76 µg protein per ml of media in 2D format compared to 4.32 µg protein per ml 
of media in bioreactors. Therefore, the bioreactor format produced almost double the 
quantity of protein per millilitre of media compared to the 2D format. The IMR-32 cell-line 
produced 0.76 µg protein per ml media for 2D format and 2.94 µg protein per ml media for 
bioreactor. Thus, almost four times the quantity in the bioreactor format compared to 2D 
format. Again these assessments must be carefully interpreted as the number and viability 
of the cells had not been determined. Regardless, the bioreactor method was less labour-
intensive, as fewer tissue culture flasks were used, and the ultra-centrifugation volumes 
were lower, giving the potential to scale up the size of exosome preparations. Although the 
benefits of the bioreactor format have been highlighted the next stage was to determine if 
the purity of exosome preparations had been compromised.  
Using both NTA and BCA assay results, P:P ratios were calculated to assess the purity of the 
preparations. In 2D cultures these were 2.03x1010 particles/µg and 5.06x1010 particles/µg for 
H4 and IMR-32, respectively (Table 3.3). Similar ratios were observed for bioreactor cultures: 
2.41x1010 particles/µg for H4 and 2.55x1010 particles/µg for IMR-32. Therefore, purity was 
consistent across cell-lines and culture methods and all of high purity according to Webber 
and Clayton (2013) who define “ratios approaching 3x1010” as being highly pure. 
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Cell line Exo-Prep Prep 
volume 
(µl) 
Particle 
concn 
(particles/ml) 
Particle 
yield 
(particles) 
Protein 
concn 
(µg/ml) 
Protein 
yield (µg) 
P:P ratio 
(particles/µg) 
Media 
volume 
(ml) 
Particles/ml 
media 
Protein/ml 
media 
(µg/ml) 
H4 Pellet & 
wash 
110 1.02x1014 
±4.25x1012 
1.12x1016 5023 ±804 553 2.03x1010 200 5.61x1013 2.76 
IMR-32 Pellet & 
wash 
110 7.02x1013 
±2.49x1012 
7.72x1015 1386 ±261 152 5.06x1010 200 3.86x1013 0.76 
H4 Sucrose 
cushion 
110 4.26x1013 
±1.06x1012 
4.69x1015 1769 ±87 195 2.41x1010 45 1.04x1014 4.32 
IMR-32 Sucrose 
cushion 
110 3.07x1013 
±1.64x1012 
3.38x1015 
 
1203 ±4 
 
132 
 
2.55x1010 
 
45 7.50x1013 
 
2.94 
 
 
Table 3.3: Protein and particle yield of exosomes isolated from H4 and IMR-32 cell-lines.  
Protein concentrations were calculated using BCA assay (n=2) and particle concentrations by Nanoparticle Tracking Analysis (n=6). Average concentrations are displayed with 
standard deviations. Particle:protein (P:P) ratios were calculated for each preparation by dividing the concentration of particles by the protein concentration. Particles isolated 
by a pellet and wash protocol correspond to 2D-cultures where 200 ml media was collected from twenty T75 flasks for one preparation. Particles isolated by the sucrose 
cushion method correspond to supernatants collected from bioreactor flasks on three occasions and pooled into one preparation. These volumes were used to calculate yields 
of particles and proteins per millilitre of media. 
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To fully validate that exosomes were being isolated, analysis of specific proteins was 
performed. Immuno-phenotyping of whole cell lysates, exosome preparations and exosome-
free supernatants was performed by a plate-based adsorption assay that measured TRF as a 
readout. The primary assessment was for enrichment of protein markers in exosomes 
compared to the source cell. Comparison with exosome-free supernatants provided an 
additional assessment of the concentration of target protein from the culture medium. 1 µg 
of protein was loaded per well and TRF measurements made in duplicate. Sample sizes were 
limited by the availability of exosomes so a qualitative assessment of protein enrichment was 
performed. 
Across both cell-lines the tetraspanins CD63, CD81 and CD9 were enriched in exosome 
preparations over cell lysates and exosome-depleted media (Figure 3.8), as expected (Lotvall 
et al., 2014). Exosome sample was a limitation in this experiment so only 2 replicates could 
be performed, however, it would have been ideal to do 3 repeats so that statistical analyses 
could be applied. With the caveat of sample size highlighted, these observations validated 
the sucrose cushion method to be used for the isolation of exosomes from these cell-lines. 
The low measurements, less than 5000 TRF units, observed in the exosome-free supernatant 
suggest that there was minimal target protein present and that the isolation method was 
efficient. This TRF method of immuno-phenotyping measures the protein content of 
exosomes in their non-reduced, native state therefore only proteins present on the vesicle 
surface were compared.  
To investigate the relative concentrations of intra-luminal proteins, exosomes and whole cell 
lysates were reduced in 20 mM DTT and boiled in SDS-reducing buffer to liberate intra-
luminal and intra-cellular proteins for Western Blot analysis. 20 µg of protein was reduced, 
loaded per well (n=1) and the relative concentrations of ALIX, TSG101 and GRP94 were 
measured (Figure 3.9). ALIX and TSG101, were enriched in the exosome wells as expected 
(Stoorvogel et al., 2002, Roucourt et al., 2015, Stoorvogel, 2015). GRP94, primarily found in 
the endoplasmic reticulum, was present in both cell lysates, had a reduced signal in the IMR-
32 exosomes and was undetected in the H4 exosomes. This suggests that there was no 
cellular contamination in the H4 exosome preparations and minimal contamination in the 
IMR-32 preparations. However, both exosome preparations were performed identically so 
another explanation may be that GRP94 is mal-distributed in IMR-32 cells. To conclusively 
determine the extent of contamination in these samples would require a direct 
measurement of other proteins. 
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Figure 3.8: Relative concentrations of CD63, CD81 and CD9 tetraspanins in H4 (top) and IMR-32 
(bottom) cell-lines.  
Exosomes were prepared by the sucrose cushion method of isolation and Time-resolved fluorescence 
(TRF) measurements recorded with whole cell lysates and supernatants (n=2 per protein). Each bar 
represents averaged measurements and error bars represent 95% confidence intervals. Navy bars 
represent exosome-free supernatant, purple bars represent whole cell lysates and light blue bars 
represent exosomes.  
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Figure 3.9: Western blots showing relative levels of ALIX, TSG101 and GRP94 with 20 µg total protein 
loaded into each well.  
The relative concentrations of ALIX, TSG101 and GRP94 were visualised by enhanced 
chemiluminescence. Band sizes are indicated on the left side in kilodaltons (kDa). Cell lysates and 
exosome preparations were obtained for the H4 (left two lanes) and IMR-32 (right two lanes) cell-lines 
(n=1). 
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3.3.5 Exosome structure 
NTA has already revealed that exosome preparations from H4 and IMR-32 culture medium 
were of the correct size. However this method, using light scattering from a laser source, has 
insufficient resolution to provide any structural detail on the particles present. To provide 
this detail cryo-EM was performed. 
Exosome preparations, for both cell-lines, were transferred to CIC bioGUNE, Bilbao, Spain for 
cryo-EM, thanks to collaboration with Dr David Gil Carton and Professor Juan M. Falcón-
Pérez. 5 µl of each exosome preparation was directly adsorbed onto glow-discharged holey 
carbon grids (QUANTIFOIL). Grids were blotted at 95% humidity and rapidly plunged into 
liquid ethane with the aid of VITROBOT (Maastricht Instruments BV). Vitrified samples were 
imaged at liquid nitrogen temperature using a JEM-2200FS/CR transmission cryo-electron 
microscope (JEOL), equipped with a field emission gun and operated at an acceleration 
voltage of 200 kV (Welton et al., 2016). This methodology aims to preserve the native vesicle 
structure, without the need for fixatives or embedding that may cause dehydration and 
vesicle collapse. Heterogeneous populations of vesicles of spherical structure with 
unilaminar lipid bilayers were visualised for both cell-lines (Figure 3.10). No cup-like artefacts 
were present as previously been seen with TEM (Wu et al., 2015).  
There was some heterogeneity in the size and appearance of the structures visualised but 
little evidence of non-vesicular contamination. A general observation was that H4 exosomes 
were larger in size than IMR-32 which would be consistent with the NTA data (Figure 3.3). 
However, a detailed analysis was not performed on a sufficient number of micrographs to 
confirm this general observation. Overall, these images confirmed that exosomes of the 
correct structure and size were isolated. 
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Figure 3.10: Cryo-electron micrographs of H4 and IMR-32 exosomes.  
Exosome preparations were made using the sucrose-cushion isolation procedure. A heterogeneous 
population of vesicles of spherical structure with unilaminar lipid bilayers was observed for both H4 
(top) and IMR-32 (bottom) cell-lines. Images are representative of numerous micrographs obtained by 
the Falcon-Perez group.   
. 
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3.4 Discussion 
This chapter aimed to establish cell cultures from neural sources and validate procedures for 
isolating exosomes from the media. H4 and IMR-32 cell-lines were successfully cultured in 
traditional 2D and high-density 3D formats. Exosome preparations were thoroughly 
characterised before upscaling using the bioreactor format of cell culture coupled with 
sucrose cushion isolation. This has provided the materials and methodology for bulk-
exosome collection for subsequent chapters in this study. 
Exosomes, from both cell-lines were of the expected size (El Andaloussi et al., 2013) 
measured by NTA and cryo-EM. The structure of the exosomes was also determined by cryo-
EM and, for both cell-lines, spherical shaped vesicles with a unilaminar lipid bilayer were 
observed. Sucrose density gradients determined that the exosomes were buoyant at the 
expected density of 1.1 - 1.2 g/ml (Escola et al., 1998, Raposo et al., 1996, Webber et al., 
2014). These density data were a pre-requisite for routinely using the sucrose cushion 
method of isolation (Andre et al., 2002, Lamparski et al., 2002, Thery et al., 2006). The 
relative expression of different proteins were compared between exosome preparations and 
whole cell lysates. Exosomes were significantly enriched for the tetraspanins CD63, CD81 and 
CD9, as expected (Escola et al., 1998) and enriched for intraluminal ALIX and TSG101, as 
expected  (Stoorvogel et al., 2002, Roucourt et al., 2015, Stoorvogel, 2015). Furthermore, 
GRP94, typically expressed in the endoplasmic reticulum, was less abundant in exosome 
preparations compared to whole cell lysates indicating that the preparations were relatively 
devoid of cellular contamination, although, this was more conclusive for H4 exosomes than 
IMR-32 exosomes (Lotvall et al., 2014). 
A comparison has been made between exosomes isolated from 2D cell cultures and 
bioreactor culture format. Across both cell-lines greater yields of particles and protein were 
obtained from bioreactor cultures per millilitre of culture medium. These observations 
should be carefully interpreted as the number and viability of cells was not assessed. 
Therefore, the particle and protein concentrations were primarily used to produce a P:P ratio 
and this showed that vesicle purity was not compromised using the bioreactor format.  
These observations, of yield and purity, are particularly useful when considering the 
scalability of the different cell culture options. The limiting step in exosome isolation is the 
volume of media that can be processed on the ultra-centrifuge. By reducing the volume of 
media in bioreactor cultures, yet maintaining vesicle purity, there is far more scope to scale 
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these cell-lines up for high yield isolation of neural-derived exosomes. Other benefits of the 
bioreactor technique include reduced incubator space and far easier handling of fewer cell-
culture vessels. 
A caveat of using the bioreactor technique is that the cells are cultured in a high densities. 
This is likely to cause a more stressful environment than standard 2D-culture and the cells 
may be hypoxic (Mitchell et al., 2008a). However, the characterisation of exosomes in this 
study has shown that the benefit of this technique is that increased yields can be produced 
by scaling up this culture method, without compromising on vesicle purity. Furthermore, the 
H4 and IMR-32 cell-lines coped in culture as bioreactor flasks were established and 
maintained for over 6 months.  
It is likely that other cell-types may not cope with this culture technique; for example, 
primary cells may reach senescence within the time frame of 6 months, dependent on the 
seeding passage and tissue-type. Therefore, whilst accepting the caveats of high density cell 
culture, this method, of culturing H4 and IMR-32 cells in bioreactor flasks, provided an 
abundant source of exosomes without compromising on sample purity. 
Demonstrating the compatibility of these cell-lines with bioreactor culture, and the methods 
for isolating exosomes, offers potential for future studies. For example, it may be possible to 
culture H4 cells, harbouring AD-relevant mutations, in bioreactor vessels for the high yield 
production of exosomes. The H4 cell-line has been used previously to stably express a mutant 
form of the APP gene (Sung et al., 2016). This may be a particularly relevant line of inquiry if 
an endocytosis-related gene, such as CD2AP, is perturbed; this has been demonstrated in 
HEK293 cells (Kwon et al., 2016). However, these examples are beyond the scope of this 
study and, primarily, the aim was to validate the methods of mass-producing neural-derived 
exosomes. 
Procedures have been established for the production and isolation of neural-derived 
exosomes en masse. The exosomes have been thoroughly characterised by size, density, 
protein content and structure, in keeping with minimal experiment requirements published 
by Lotval et al. (2014). This provided the neural-derived exosome stocks, and methodologies 
of isolation, required for subsequent chapters. 
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4.1 Introduction 
Exosomes are present in the peripheral circulation (Kalra et al., 2013) but represent a number 
of sub-populations from different cell-types within perfused tissues/organs. For example, 
exosomes have reportedly been secreted by hepatocytes (Hirsova et al., 2016), dendritic cells 
(Kowal et al., 2016), adipocytes (Connolly et al., 2015), cardiomyocytes (Garcia et al., 2015), 
prostate (Hosseini-Beheshti et al., 2016), myoblasts (Choi et al., 2016), osteoblasts (Cui et al., 
2016), keratinocytes (Lo Cicero et al., 2015a), astrocytes (Ipas et al., 2015), platelets (Tan et 
al., 2016), lymphocytes (Bosque et al., 2016) and endothelial cells (Li et al., 2016b). Exosomes 
secreted by these cell-types, and others, collect in biological fluids to become a vastly 
heterogeneous population. Many studies have isolated cell-types of interest to be cultured 
in vitro for the isolation of cell type-specific exosomes. However, the collection of vesicles 
originating from a particular cell-type directly from complex biological fluids remains a 
challenging prospect. 
The isolation of cell type- or tissue-specific exosomes is desirable for identifying disease-
relevant biomarkers. Exosomes have been implicated in a number of different diseases 
including neuroglioma (Skog et al., 2008), prostate cancer (Royo et al., 2016), pancreatic 
cancer (Melo et al., 2015), breast cancer (Green et al., 2015), heart disease (Iaconetti et al., 
2016), and Alzheimer’s disease (Rajendran et al., 2006). It is feasible that by selecting a sub-
population of exosomes relevant to the tissue of disease then biomarker studies could be 
improved by reducing the noise carried by other, unwanted tissue types. 
Affinity systems for capturing vesicles based on proteins that are exhibited in high densities 
on the exosome surface, such as the tetraspanins CD9 or CD63, have already been developed 
and reported for use with numerous sources including cell-cultures (Wiley and Gummuluru, 
2006), urine (Duijvesz et al., 2015) and plasma (Zarovni et al., 2015). Adopting disease-
specific ligands has also been reported. For example, an 8-amino-acid peptide aptamer to 
capture HSP70+ exosomes from multiple cancers (Gobbo et al., 2016) and the A33 protein in 
colorectal cancer (Mathivanan et al., 2010). Capturing vesicles based on the expression of 
Neural Cell Adhesion Molecule (NCAM) and L1 Cell Adhesion Molecule (L1CAM) has been 
used to identify disease biomarkers relevant to the central nervous system (CNS) (Fiandaca 
et al., 2015, Goetzl et al., 2015b). 
A possible utility of capturing vesicles from a sub-population of cells is to then measure a 
readout that is indicative of a diseased tissue. This has been the case in studies performed at 
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the Goetzl laboratory where neural-derived exosomes were isolated from plasma for the 
study of Alzheimer’s disease (AD). Using this method, a case-control analysis revealed 
elevated levels of total tau, P-S396-tau, P-T181-tau and amyloid-β 1-42 in AD (Fiandaca et 
al., 2015). These proteins represent the state of diseased brain tissue where neurofibrillary 
tau tangles and amyloid-β (Aβ) plaques are pathological hallmarks (Forman et al., 2004). 
Furthermore, these proteins are also elevated in patient CSF (Bateman et al., 2012) and it 
has been suggested that proteins, such as Aβ, are pathologically active in the CNS prior to 
clinical manifestation (Villemagne et al., 2013). Therefore, it is particularly noteworthy that 
exosomal Aβ1-42 was significantly elevated in the plasma of both AD and pre-clinical groups 
over controls (Fiandaca et al., 2015). Thus, the isolation of neural-derived exosomes has the 
potential for identifying biomarkers of clinical and pre-clinical AD. 
Nevertheless, one could argue that selecting a sub-population of exosomes may not be an 
appropriate route to biomarker discovery. By selecting one population it is possible that only 
a small fraction of disease-relevant vesicles is isolated and key information can be lost from 
other relevant, but unexpected, sources. For example, in AD, there is increasing evidence 
that the immune system could play a pathological role. One such study reported increased 
TREM2 expression in peripheral leukocytes for AD patients over controls (Mori et al., 2015). 
Given that the relationship between exosomes and AD remains largely unknown, it is difficult 
to be certain of what sub-population(s) is disease-informing. Additionally, the isolation or 
profiling methods may yield insufficient quantity of the specimen for analysis. Affinity 
selection can miss the identification of important, pathologically-relevant processes, such as 
the role of inflammation, and as such a systems-wide examination of disease may be useful. 
For example, small RNA sequencing of exosomes isolated peripherally, from plasma and 
serum in different studies, without enrichment of sub-populations, has determined potential 
miRNA candidates for AD biomarkers (Cheng et al., 2015, Lugli et al., 2015). 
Therefore, developing an affinity isolation method for neural-derived exosomes could be of 
benefit for identifying biomarkers of AD. By enriching for the tissue-type of known relevance 
to disease it should be easier to discover disease-associated changes in patient samples. 
However, the relevance of adopting a systems-wide approach should not be disregarded. 
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4.2 Aim 
The aim of this chapter was to develop a means of affinity-isolation of neural-derived 
exosomes from cell culture medium. To achieve this aim the following objectives were 
addressed: 
 Identify proteins that are selectively expressed in the human brain. 
 Identify commercial antibodies that may have utility in capturing neural-derived 
exosomes. 
 Screen cell-cultured exosomes for vesicle surface proteins also expressed in the 
human brain. 
 Using information from the objectives above, establish a micro-titre plate assay for 
selectively capturing neural-derived exosomes from cultured cell-lines that could be 
of future use with biological fluids. 
4.3 Results 
4.3.1 In silico selection of protein candidates 
To address the aim of isolating neural-derived exosomes, a selective feature of this vesicle 
population needed to be identified. Proteins present on the surface of exosomes represent 
the source cell, to a large extent, and thus provide features that could be exploited for affinity 
capture. The CNS contains a plethora of proteins, such as neurotransmitter receptors and 
cell surface adhesion molecules, which are selectively expressed in those tissues. Therefore, 
a number of in silico steps were followed to identify a shortlist of candidates that had good 
potential for the isolation of neural-derived exosomes. 
The first pre-requisite for selecting protein candidates was to ensure that they were 
selectively expressed in tissues of the CNS. The Genotype-Tissue Expression (GTEx) Project 
(release: 2014-01-17 (dbGaP phs000424.v4.p1)) was accessed to test this. The GTEx project 
was chosen because it is a publically available dataset that has used microarray and next-
generation sequencing to measure global RNA expression across a comprehensive range of 
tissues. The online browser, http://www.gtexportal.org/home/ (accessed April 2014), was 
used to search for tissue-specific gene expression of potential protein candidates. The gene 
expression plots across the tissue range were downloaded and assessed for preferential 
expression in brain tissues. The tetraspanin CD9, an exosome protein marker, showed 
constitutive expression throughout the tissues analysed and therefore, as expected, would 
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be a poor candidate for the basis of selective exosomes isolation (Figure 4.1). CD9 was 
particularly strongly expressed in the oesophagus, salivary gland, vagina and bladder so 
particularly representing a feature of mucosal surfaces. Relative to other tissues CD9 was 
less abundantly expressed in brain tissues.  
Seven candidates, however, showed CNS-enriched expression, namely ENO2, GFAP, GRIA4, 
GRID1, L1CAM, NCAM and NMDAR1 (Figure 4.1). Of these candidates, GFAP and NMDAR1 
showed highly selective expression in brain tissues and undetectable expression in tissues 
outside of the CNS, therefore ideal for affinity selection. GFAP was particularly strongly 
expressed in the spinal cord and NMDAR1 was strongly expressed throughout the brain 
tissues but enriched in cortical regions, which could be particularly relevant for AD as this is 
a pathological site of degenerating neurons, Aβ plaques and tau tangles (Zilka and Novak, 
2006). GRIA4 and ENO2 were also highly selectively expressed in brain tissues and had 
minimal detectable signal in other tissues. GRIA4 was strongly expressed in cerebral tissues 
with relatively low expression in mammary tissue of the breast, the pituitary gland, the small 
intestine and the stomach. ENO2 also showed enriched expression in cerebral tissues and a 
relatively low expression across the range of other tissues. Three of the candidates showed 
less selective expression than the others but, nevertheless, would be good candidates for 
enriching for exosomes of a CNS source. L1CAM showed enriched expression in cerebral 
tissues and detectable expression in the Tibial nerve, colon and oesophagus. GRID1 was 
enriched in brain tissues but had relatively high expression in the cervix and uterus. Similarly, 
NCAM had a good discriminatory signal in the CNS but only a small margin of difference with 
the expression in the heart. Together, L1CAM, GRID1 and NCAM may be good candidates to 
enrich for exosomes of a CNS source but may introduce exosomes from other tissues outside 
of the CNS. Overall, these seven candidates had satisfactory expression profiles to take 
further into assay development and have also highlighted that different tissues within the 
CNS could potentially be selected, for example, GRIA4 was particularly strongly expressed in 
the cerebellum whilst NMDAR1 was strongly expressed in the cortex. 
The next important feature to be assessed was cellular localisation. The downstream 
application would be an assay that captures intact exosomes without permeabilisation of the 
membrane, so suitable protein candidates would need to expose antigens on the exterior 
surface of the exosome. The cellular localisation of the seven protein candidates was 
investigated using the UniProt database (www.uniprot.org, accessed April 2014). This was 
chosen because it is a publically available database that contains protein sequence and 
functional information. Six of the seven candidates were confirmed to be membrane-bound 
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or transmembrane and thus potentially could localise to the surface of vesicles (Table 4.1). 
GFAP was an exception, as it was a cytoskeletal protein and less likely to be present on the 
exterior surface of the exosome. However, components of the cytoskeleton may well 
interact in the biogenesis and secretion of exosome (Hurwitz et al., 2016) so GFAP was not 
excluded at this stage. 
To confirm if these candidates had already been identified on the surface of exosomes the 
ExoCarta database was accessed (http://exocarta.org/, accessed April 2014). ExoCarta is a 
database of lipids, RNA and proteins associated with exosomes from different species. The 
seven candidates were searched for by their gene symbol to confirm if they had been 
previously identified in humans. Five of the seven had entries (ENO2, GFAP, GRID1, L1CAM, 
and NCAM) on ExoCarta (Table 4.1). However, GRIA4 and NMDAR1 were still included in this 
study as they may represent novel exosomal proteins. 
Finally, commercial retailer websites (for Abcam and Santa Cruz) were accessed to identify 
antibodies against the human protein orthologue. Antibodies were chosen where the 
immunogen was situated on an extracellular portion of the protein because these would 
have a greater potential to bind to the exterior of exosomes in a capture conformation 
(Table 4.1). Where possible, antibodies were chosen with carrier-protein free buffer, such as 
GRID1 which only used PBS. However, all antibodies except for GRID1 had some element of 
carrier protein in the buffer, for example, sodium azide in GFAP buffer and BSA in NCAM 
buffer. It is foreseeable that these carrier proteins may cause a blocking effect in 
downstream assay development so are noted as potentially limiting. Unfortunately, carrier 
proteins are commonly used in antibody buffers so difficult to avoid. Therefore, the assay 
was developed as systematically as possible using these antibodies. 
Where amino acid residues were stated for the immunogen site, UniProt was cross-
referenced again for the protein topology. This confirmed that the antibody would target 
extracellular protein domains for GRIA4, GRID1 and NMDAR1, therefore, likely to be on the 
exterior surface of exosomes. 
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Figure 4.1: Gene expression plots accessed from GTEx Project (release: 2014-01-17 (dbGaP phs000424.v4.p1).  
Gene expression is reported in Reads Per Kilobase of transcript per Million mapped reads (RPKM, y-axis) for different tissues (x-axis) using the searchable GTEx portal database. 
Median is displayed with 25th and 75th quartiles, and outliers marked as circles. 
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Protein UniProt ID Cellular localisation ExoCarta 
entry 
Antibody 
company 
Antibody 
reference 
Immunogen Buffer 
ENO2 P09104 Cytoplasm. Cell 
membrane. 
Y Abcam ab53025 Synthetic peptide 
derived from human 
ENO2 
0.02% Sodium Azide, 50% Glycerol, 
PBS (w/o Mg2+ and Ca2+), 150 mM 
NaCl 
GFAP P14136 Cytoskeletal. Y Abcam ab7260 Full length human 
recombinant GFAP 
0.01% Sodium Azide 
GRIA4 P48058 Cell membrane. N Santa Cruz sc-271894 31-75 (Extracellular) 200 µg IgG2A, PBS, <0.1% sodium 
azide, 0.1% gelatin 
GRID1 Q9ULK0 Cell membrane.  Y Abcam ab55163 349-441 
(Extracellular) 
PBS 
L1CAM P32004 Cell membrane. Y Abcam ab24345 C-terminus Ascites, Ammonium sulfate, resus 
and dialyzed in PBS 
NCAM P13591 Secreted and Cell 
membrane. 
Y Abcam ab9272 Small cell lung 
carcinoma specimen 
0.02% Sodium Azide, PBS, 0.1% BSA 
NMDAR1 Q05586 Cell membrane. N Abcam ab134308 42-361 (Extracellular) 0.09% Sodium Azide, 49% PBS, 50% 
Glycerol 
 
Table 4.1: Antibodies used for immuno-phenotyping in this chapter and their respective immunogens. 
Cellular localisation was determined by functional annotation provided by UniProt. The immunogen and buffer was determined from the website of the antibody supplier and 
cross-referenced with the protein topology available on UniProt. 
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4.3.2 Relative expression of protein candidates on cell-cultured exosomes 
In order to determine the relative expression of protein candidates, and furthermore 
attempt to capture and detect exosomes, a number of different europium-linked 
immunosorbent assay-formats were used in this study (Figure 4.1). Initial immuno-
phenotyping of exosomes was performed as previously described (Welton et al., 2015). The 
use of high-affinity binding microtitre plates allowed for comprehensive adherence of 
exosomes to the well and probing for antigens of interest. Protein detection was provided 
using time-resolved fluorometry (TRF, Perkin Elmer) with Europium as the fluorophore.  
During assay development, the format of this assay was reconfigured in a number of 
different ways. For example, the initial immuno-phenotyping was performed with exosomes 
adhered directly to the microtitre plate but later this format was changed to start with 
adherence of capture antibodies before exosomes were added. The assay combinations are 
summarised graphically in Figure 4.2 and adjacent to figures. 
The potential suitability of the antibodies detailed above was analysed by probing exosomes 
from H4, IMR-32 and Du145 cell-lines (Figure 4.3) (n=2). A greater number of replicates 
would have been preferable so that statistical analyses could have been applied. Instead, 
with sample and antibody availability limited, a qualitative assessment was performed as a 
pre-requisite for developing an affinity capture assay.  
As expected, CD9 was strongly expressed on exosomes compared to the other, less 
abundant, protein ligands. For example, TRF ranged from 2.1x106 – 4.5x106 units for CD9 to 
0.1x106 – 0.3x106 units for ENO2. Whilst lower TRF units might be caused be poorly working 
antibodies, these differences are most likely to be caused by the lower ligand densities, as 
expected. 
Based on the gene expression data it was hypothesised that the seven CNS-enriched proteins 
would be selectively expressed on the neural-derived cell-lines H4 and IMR-32 in preference 
to Du145, a prostate-derived cell-line. ENO2, GFAP, L1CAM and NCAM were preferentially 
expressed on IMR-32 exosomes over Du145, thus showing good potential for selectively 
capturing and enriching for these exosomes later. GRIA4 and GRID1 were preferentially 
expressed on H4 exosomes over Du145, again showing good potential for affinity capture. 
None of the candidates showed preferential expression in both H4 and IMR-32 over Du145. 
Due to sample and antibody limitations only duplicate measures could be recorded so it was 
not appropriate to perform statistical analyses. This was a limitation in this part of the study 
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and it was desirable to increase the number of repeats. In this initial immuno-phenotyping 
screen, the antibodies did not appear to be perturbed by carrier proteins in the buffer and 
genuine ligand interactions have been measured. In summary, these protein candidates 
showed good suitability for further assay development based on their relative expression 
levels on cell culture-derived exosomes. 
 
 
Figure 4.2: Assay conformations used in this study.  
From left to right: initial screening format where exosomes were adhered directly to high-affinity 
binding plate wells; the first capture format where primary antibodies were adhered to high-affinity 
binding plate wells as capture antibodies; the second capture format where exosomes were detected 
using a rabbit anti-CD9 antibody; the third capture format where biotin-conjugated capture antibodies 
were adhered to a streptavidin-coated plate. 
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Figure 4.3: Relative expression of seven neural proteins on the surface of cell culture-derived exosomes.  
Relative expression is displayed as Time-resolved fluorescence (TRF, y-axis) for the panel of proteins as labelled on the x-axis. Cell-lines are represented by blue bars (H4), green 
bars (IMR-32) and brown bars (Du145). Exosomes were prepared by sucrose-cushion method and 1 µg loaded per well for immunophenotyping (n=2). Error bars represent 
95% confidence intervals. A schematic of the assay format is displayed to the right of the graph.  
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4.3.3 Affinity capture assays 
To test if these protein candidates could selectively capture neural-derived in preference to 
prostate-derived exosomes a second screen was carried out. The assay format was 
reconfigured whereby antibodies were coated onto microtitre plates to capture exosomes.  
Initially, the optimum antibody dose to fully coat the plate wells was determined by titration. 
A range of 0 – 1000 ng antibody was coated per well and coverage tested by directly probing 
with a biotin-conjugated anti-mouse antibody (n=2). TRF was measured and all antibodies 
tested, except for GRID1, reached a saturation of signal within the concentration range 
(Figure 4.4). Four of the antibodies reached saturation when 200 ng antibody was coated to 
the well: ENO2, GFAP, GRIA4 and L1CAM.  Four antibodies saturated with 500 ng: CD9, IgG1, 
NCAM and NMDAR1 but the GRID1 antibody did not reach saturation with 1000 ng coated 
to the well. It could be that the concentration of antibody provided by the manufacturer was 
not accurate or, alternatively, GRID1 had more capacity to coat the well of the plate as it was 
the only antibody in a carrier protein-free buffer. To test if this would be an issue for the 
downstream assay, the interaction between a bound capture antibody and exosomes would 
need to be investigated. 
The signal strength was strong for all antibodies, reaching 300,000 – 400,000 TRF units, 
suggesting that genuine coating of the plates had occurred. Thus, the optimum 
concentrations were determined to fully coat micro-titre plate wells with antibody and 
provide a surface for antigen-specific adherence of exosomes. 
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Figure 4.4: Determining the optimum antibody doses to coat high affinity binding wells.  
High affinity binding plates were coated with different concentrations of antibodies and measured by Time-resolved fluorescence (TRF, y-axis). Measurements were made in 
duplicate and averages displayed on the graphs. A schematic of the assay conformation is displayed adjacent to the graphs.  
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Using these capture antibody concentrations, a second screen was performed to investigate 
if this assay could capture H4 and/or IMR-32 exosomes in preference to Du145 exosomes 
(Figure 4.5). Developing an assay that could successfully do this with in vitro cell culture-
derived exosomes was a pre-requisite before isolation from biological fluids would be 
attempted. 
High-affinity binding plate wells were coated with capture antibody, blocked with 1% BSA, 
and a fixed concentration of 2 μg/well of exosomes was overlaid (n=2). To detect bound 
exosomes the assumption was made that neural marker-positive exosomes also presented 
CD9, so a fixed concentration of 200 ng/well biotin-conjugated anti-CD9 antibody was added. 
A signal would only be generated if CD9 and the target marker were co-expressed which 
presented a limitation to the assay as any exosomes that were absent of CD9 would not be 
detected with this configuration. Only GRIA4 showed selective capture of H4 and IMR32 
exosomes in preference to Du145 (Figure 4.5), but insufficient replicates were performed to 
assess this statistically.  
It was particularly noteworthy that TRF values were ~10-fold lower in this screen than the 
initial candidate screen e.g. <60,000 TRF units compared to >300,000. This suggested that 
genuine CD9 detection had not taken place. It may be that exosomes had not adhered to the 
capture antibodies, or alternatively, there was an inherent weakness in detection format. 
Furthermore, the signal recorded for the isotype control, IgG1, was greater than a number 
of the neural-specific ligands, suggesting that exosomes were not binding to the plate wells 
in a ligand-specific manner; if they were binding at all. 
It had already been determined that these protein candidates were significantly enriched on 
H4 or IMR-32 exosomes over Du145 (Figure 4.3) and that the wells of the plates were fully 
saturated with capture antibody (Figure 4.4). Therefore, it was hypothesised that either the 
exosomes were not adhering to the antibodies in this altered configuration or there was a 
weakness in the detection method. To further investigate these issues, the antibody against 
GRIA4 was chosen to optimise the assay as it had already shown selectivity for H4 exosomes 
in both screens but had not reached the level of significance in the second.  
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Figure 4.5: Relative CD9 expression on affinity captured exosomes.  
Relative expression is displayed as Time-resolved fluorescence (TRF, y-axis) for the panel of proteins as labelled on the x-axis. Cell-lines are represented by blue bars (H4), green 
bars (IMR-32) and brown bars (Du145) (n=2). Error bars represent 95% confidence intervals. Exosomes were prepared by sucrose-cushion method and 1 µg loaded per well 
for immunophenotyping (n=2). A schematic of the assay format is displayed to the right of the graph. 
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4.3.4 Troubleshooting affinity capture assay format 
Exosomes dose response curves to test assay limitations 
The first problem to address was assessing if H4 exosomes were genuinely adhering to the 
GRIA4 antibody in this altered configuration. An exosome titration was chosen to test the 
sensitivity of the assay. It was hypothesised that if the capture antibody had good affinity for 
exosomes then a dose response would be observed. H4 and Du145 exosome dose curves 
were run from 0 – 5 μg exosomes/well (Figure 4.6) (n=2).  
As expected from the previous screens H4 exosomes were selectively captured over Du145 
exosomes in a dose-dependent manner using the GRIA4 antibody.  The isotype control 
(IgG2a), however, matched this signal when 5 μg exosomes were loaded per well. This 
suggested that when high doses of exosomes were loaded into the assay, non-specific 
binding to IgG2a had occurred. Thus, the selectivity of the assay to capture exosomes that 
present the GRIA4 ligand was equivocal. 
In addition to this non-specific binding, the signal from this assay format was very poor 
reaching a maximum of 12,000 TRF units even with 5 μg exosomes in the system. This gave 
not only a potentially low dynamic range but also a low signal : noise ratio as IgG2a achieved 
the same signal. So as well as exhibiting non-specific binding, this suggested that there could 
also be a weakness in the detection method. A strong CD9 signal would be expected for a 
dose of 5 µg exosomes, albeit that in this case that a subset of those were being selected. It 
was hoped that a signal exceeding 100,000 TRF units could be achieved to provide a good 
dynamic range. Therefore, both problems of exosome adherence to the capture antibody 
and signal strength from the detection antibody still needed to be resolved. 
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Figure 4.6: Exosome dose curves to test the sensitivity of the assay.  
Exosomes were titrated from 0 – 5 μg/well (x-axis) with fixed concentrations of capture and detection 
antibodies (n=2). Relative expression was averaged and is displayed as Time-resolved fluorescence 
(TRF, y-axis). A schematic of the assay format is displayed adjacent to the graph. 
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Titration of mouse anti-CD9 detection antibody 
The easier problem to address first was the low signal provided by the detection format. If 
there was, indeed, a problem using the biotin-conjugated mouse anti-CD9 antibody it would 
be relatively straightforward to replace this component. Therefore, detection antibody dose 
curves were run with exosomes adhered directly to the high-affinity binding wells (n=2) 
(Figure 4.7). This removed the unknown element of exosome adherence to capture 
antibodies and could thus test the robustness of the detection method. 
There was no plateau in the signal within the 0 – 10 μg/ml detection antibody concentration 
range used. With 100 μl total volume used this equates to 1 μg antibody not providing a 
saturated signal. This would be considered a high, and costly, dose of antibody so a 
saturation of signal would have been expected. In addition to not reaching saturation, the 
TRF signal in general was still low, not exceeding 60,000 units even with 5 μg exosomes in 
the system. When the initial screen was performed (Figure 4.3) CD9 detection of 2 µg 
exosomes exceeded 200,000 TRF units for all cell-types using a different detection 
configuration. Together, these highlight that the detection antibody was a limiting 
component of the assay.  
The background signal observed with no exosomes in the system was barely distinguishable 
from a dose of 1 μg exosomes and only marginally lower than 2 or 5 μg exosome doses. This 
suggested insensitivity in the detection system to distinguish a genuine signal caused by 
exosomes over the background. Therefore, the current assay format had both a low dynamic 
range and a poor signal : noise ratio. 
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Figure 4.7: Determining the effectiveness of biotin-conjugated mouse anti-CD9 antibody to detect 
exosomes.  
H4 exosomes were directly adhered to high-affinity binding wells at set concentrations of 0, 1, 2 and 5 
μg per well (n=2). Detection antibody doses curves were ran from 0 – 1 μg antibody per well (x-axis) 
and averaged expression displayed as Time-resolved fluorescence (TRF, y-axis). A schematic of the 
assay format is displayed adjacent to the graph. 
 
Optimising an anti-rabbit secondary antibody to boost detection 
In an attempt to boost the signal of the assay, a second detection format was used. The 
biotin-conjugated mouse anti-CD9 was replaced with a rabbit polyclonal antibody against 
CD9. This was chosen because the antibody was raised in a different species to the capture 
antibody which was a mouse GRIA4 antibody. Therefore, the detection signal could be 
amplified using a secondary biotin-conjugated anti-rabbit antibody.  
This secondary antibody had not been used previously in the Clayton laboratory, so the 
optimal concentration was determined by titration (Figure 4.8). Microtitre plate wells were 
coated with anti-ENO2 (rabbit) antibody to provide a suitable ligand for the anti-rabbit 
antibody to bind to. Dose response curves were run from 0 – 5 μg/ml anti-rabbit antibody 
(n=2). The total volume was 100 μl which equates to 0 – 500 ng antibody per well. 
Fluorescence signal had not reached saturation with 500 ng in the system suggesting that 
higher values could be reached. A higher dose would have been too costly so 500 ng was 
chosen as the dose to be used in this assay.  
The TRF values were much higher: exceeding 600,000 TRF units with 500 ng ENO2 and over 
1,200,000 TRF units if 1 μg ENO2 was used. This suggested that the use of this secondary 
antibody amplification had the capacity to produce a stronger signal and improve the 
dynamic range of the assay compared to the configuration used previously.  
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Figure 4.8: Determining the optimum concentration of anti-rabbit secondary antibody. 
Microtitre plate wells were coated with rabbit anti-ENO2 antibodies to provide a ligand surface for the 
secondary antibody to be tested against (n=2). Titrations were run from 0 – 5 μg/ml (x-axis), that is 0 
– 500 ng antibody/well. Relative expression was averaged and is displayed as Time-resolved 
fluorescence (TRF, y-axis). A schematic of the assay format is displayed adjacent to the graph. 
 
Antibody dose response curves to optimise a rabbit anti-CD9 detection 
The optimal dose of anti-CD9 was next to be determined by titration. Exosome and anti-
rabbit antibody doses were fixed at 2 µg and 500 ng per well, respectively, and anti-CD9 dose 
curves were run from 0 – 500 ng antibody per well (n=1) (Figure 4.9).  
Saturation of the TRF signal was not reached with 500 ng in the system suggesting that 
greater signals could be achieved. Nevertheless, achieving ~400,000 TRF units was 
satisfactorily high to achieve a good dynamic range without increasing the costliness of the 
assay.  
There was a high background signal with no anti-CD9 antibody in the system at ~280,000 TRF 
units. This suggested a non-specific affinity of the anti-rabbit secondary antibody to bind to 
exosomes without the ligand specific detection antibody. By subtracting the TRF signal of 
500 ng anti-CD9 from the background signal, this format produced ~120,000 TRF units of 
genuine signal achieving a signal : noise ratio of 1.43:1. This highlighted the need to account 
for background signal. With lower doses of anti-CD9 antibody this signal : noise was reduced, 
confirming the choice to use of 500 ng anti-CD9 antibody.  
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Figure 4.9: Determining the optimum concentration of rabbit anti-CD9 antibody.  
Micro-titre plate wells were coated with 2 µg H4 exosomes prior to titration of anti-CD9 antibody from 
0 – 500 ng per well (x-axis, n=1). The secondary anti-rabbit antibody was set at a fixed dose of 500 ng 
per well as previously determined. Relative concentration is displayed as Time-resolved fluorescence 
(TRF, y-axis). A schematic of the assay conformation is displayed adjacent to the graph. 
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Exosome dose response curves to test the rabbit anti-CD9 detection format 
Up to this point, the optimum doses of capture antibodies, anti-CD9 detection antibody and 
anti-rabbit secondary antibody had been determined. To test the robustness of this assay, in 
its entirety, exosome dose response curves were run from 0 – 5 μg per well (n=2) 
(Figure 4.10). H4 and Du145 exosomes were used to test the selectivity of the assay and an 
IgG2a isotype control was included to test the specificity of antigen-antibody adherence.  
Whilst the dynamic range had successfully improved, exceeding 200,000 TRF units, a number 
of observations suggested that exosomes were not adhering to the capture antibody. Firstly, 
there was no increase in signal with exosome dose as would have been expected with this 
titration. Secondly, there was no selectivity for the GRIA4 antibody to bind H4 exosomes in 
preference to Du145 exosomes. This is in contrast to both Figure 4.3 and Figure 4.5 that 
demonstrated that GRIA4 was preferentially expressed on H4 exosomes. Thirdly, the signal 
produced when an isotype capture antibody was used was almost double that when GRIA4 
was used. This suggested that the capture antibody could cause non-specific binding of either 
exosomes or detection antibodies regardless of ligand. The signal : noise ratio would 
therefore be a negative value and not suitable for a future assay.  
Together, these observations highlighted that whilst the problem of low detection signal had 
been successfully addressed there was also a fundamental issue with exosomes not adhering 
to the capture antibody in this format. Indeed, by improving the detection signal and 
comparing GRIA4 to isotype control it was made clearer that a fundamental problem with 
this assay was that exosomes were not adhering to the capture antibody. 
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Figure 4.10: Testing the robustness of the second assay format that used rabbit anti-CD9 antibody 
for the detection of exosomes.  
Exosomes were prepared from H4 and Du145 cell-lines using the sucrose cushion method and dose 
curves were run from 0 – 5 μg per well (x-axis, n=2). Relative CD9 expression of exosomes captured 
with GRIA4 (blue, grey) or IgG2a (orange, yellow) antibodies were averaged and displayed as Time-
resolved fluorescence (TRF, y-axis). A schematic of the assay conformation is displayed adjacent to the 
graph. 
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A third assay format that used streptavidin--coated microtitre plates 
A robust assay had not been developed by altering the detection format, therefore a third 
assay was attempted that addressed the issue with exosomes not adhering to the capture 
antibody. Previously, high-affinity binding plates were coated with capture antibodies, 
instead, this assay used streptavidin-coated plates that were overlaid with biotin-conjugated 
capture antibodies. It was hypothesised that this would provide a surface of correctly 
orientated antibodies for improved exosome adherence. The detection method used was a 
europium-labelled anti-CD9 antibody. 
The use of streptavidin-coated plates limited the number of options to optimise this assay. 
Therefore, the exosome and detection antibody doses were set at 2 μg/well and 500 ng/well, 
respectively, and capture antibody dose curves were run from 0 – 1 μg/well (n=1) 
(Figure 4.11). Biotin was conjugated to the GRIA4 antibody using Lightning-Link® Rapid 
Antibody Labeling kits (Innova Biosciences). A biotin-conjugated pan-IgG antibody was used 
as a control. H4 and Du145 exosomes were used to test if the GRIA4 antibody had selectivity 
for capturing H4 exosomes.  
The expected dose response curves were not observed, rather, the signal produced with no 
GRIA4 capture antibody in the system exceeded that when no antibody was present. This 
suggested that the capture antibodies themselves had a blocking effect when added to the 
plate and the signal : noise ratio would be negative. Additionally, the signal produced with 
Du145 exosomes in the system exceeded that of H4 exosomes suggesting non-selective 
binding of exosomes regardless of ligand. This was further confirmed when comparing these 
to the isotype control, which produced a greater signal than the GRIA4 capture antibody. 
Together, these data suggest that once again the assay was not successfully capturing 
exosomes to the plate configuration. 
Three different assay configurations were attempted in this study but none captured H4 
exosomes over Du145 and thus, not suitable for taking further with biological fluids. The 
dynamic range of the assay could be improved by altering the detection format, but 
persistently the signal : noise ratio could not be improved. This suggests that an interaction 
between exosomes and the capture antibodies was not occurring. The same antibodies had 
worked successfully during the initial immuno-phenotyping screen but could not be re-
configured as capture antibodies in this study. Having such technical difficulties when the 
assay was being developed for cell culture-derived exosomes made for an increasingly 
challenging prospect of developing an assay that would be compatible with biological fluids. 
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Therefore, it was decided to stop pursuing an affinity isolation method, although this would 
be of future interest, and adopt a systems wide approach for the analysis of exosomes from 
biological fluids. 
 
 
 
Figure 4.11: Determining the optimum concentration of capture antibody to be used with 
streptavidin-coated plates.  
Capture antibody dose curves were run from 0 – 10 μg/ml (axis) on streptavidin coated plates (n=1); 
with 100 μl total volume, this is the equivalent of 0 – 1 μg/well. Relative CD9 expression of exosomes 
captured with GRIA4 (blue, grey) and IgG (orange, yellow) antibodies is displayed as Time-resolved 
fluorescence (TRF, y-axis). A schematic of the assay format is displayed adjacent to the graph. 
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4.4 Discussion 
It has been reported that neural-derived exosomes can be immuno-precipitated from 
biofluids such as plasma (Fiandaca et al., 2015, Goetzl et al., 2015b). Such techniques, in 
theory, will remove high background of non-neural exosomes secreted from other tissue 
types and allow the investigation of vesicles that are best representative of disease affected 
cells.  
This chapter aimed to identify proteins selectively expressed in the human brain and develop 
similar micro-titre plate assays for the selective capture of neural derived exosomes. Seven 
protein candidates were selected, based on promising in silico data, and were used to 
immuno-phenotype cell-cultured derived exosomes. These showed initial promise with six 
of the seven ligands showing significant preferential expression in H4 and/or IMR-32 
exosomes. Unfortunately, the assay format could not be reconfigured to selectively capture 
H4 exosomes over Du145. 
After identifying promising protein ligands a systematic approach was taken to develop an 
affinity capture assay. An exosomes titration was used with the first assay configuration, 
which used a mouse anti-CD9 detection antibody, and found that both the dynamic range 
and signal : noise ratio of the assay was poor. This suggested that there was an inherent 
weakness in the detection method and, potentially, an issue with exosome adherence to the 
capture antibody. It was more straightforward to address the detection method so a second 
assay configuration used a rabbit anti-CD9 antibody. This successfully improved the dynamic 
range of the assay but, using an exosome titration, it was determined that the signal : noise 
ratio had not been improved. Therefore, a final assay configuration altered the capture 
format by coating streptavidin plates with capture antibodies, in the hope that this would 
correctly orientate the antibodies to efficiently interact with ligands presented on exosomes. 
Unfortunately, the signal : noise ratio remained poor with this assay configuration when 
detection antibodies were titrated. It appears that in this study it was not possible to develop 
a plate-based assay where exosomes could bind to immobilised antibodies although this has 
been demonstrated elsewhere (Duijvesz et al., 2015, Kaminska et al., 2016). 
This study could have been greatly improved by the selection of different antibodies. All of 
the antibodies used, except for GRID1, contained carrier protein in the buffer. Whilst the 
initial immuno-phenotyping screen was not adversely affected by these carrier proteins, it is 
likely that by applying the same antibodies to high-affinity binding plates resulted in carrier 
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proteins also coating the wells. Titrations of capture antibodies were run and it appeared 
that the wells were fully coated (Figure 4.4), nevertheless, carrier proteins and the 
orientation of the antibodies could not be accounted for. In different settings, such as 
industry, large budgets can be allocated for thoroughly testing or developing new antibodies. 
This was not an option in this study so commercially available antibodies were used instead 
and the assay developed as systematically as possible. 
A group that has reported successful immuno-absorption of neural-derived exosomes used 
a streptavidin resin-based enrichment protocol (Fiandaca et al., 2015, Goetzl et al., 2015b) 
opposed to the micro-titre plate formats employed here. Briefly, this method precipitates 
exosomes out of plasma or serum, incubates with biotin-conjugated antibodies and uses a 
streptavidin resin to enrich for NCAM- and L1CAM-positive vesicles (Mustapic et al., 2017). 
Certainly the choosing of NCAM and L1CAM antibodies is in agreement with the expression 
data presented in this study (Figure 4.1). Of future interest is to pursue this resin-based 
approach rather than the microtitre-plate approach used in this study. It may be that by 
selecting different ligands, such as and NMDAR1 which is enriched in cortical regions 
(Figure 4.1), exosomes from different tissues within the brain could be enriched for. 
Exosomes from different cell-types could also be enriched, for example, astrocytes are 
enriched for GFAP (Liddelow et al., 2017) so a working assay would enrich for astrocyte-
derived vesicles. 
The Goetzl laboratory verified their exosomes against the CD81 antigen and, elsewhere, it 
has been suggested that CD81 is a more specific marker for exosomes than CD9 or CD63 
(Kowal et al., 2016). However, the isolation of exosomes in this study was determined by CD9 
expression, and it may be that CD81 would have been a better choice. Nevertheless, when 
the initial immuno-phenotyping screen was performed, CD9 was detected in relatively high 
abundance on H4 and IMR-32 exosomes, so it appears to have been appropriate with these 
cell-types.  
One assumption that was made was that the captured exosomes would express CD9, but this 
may not be the case. Exosomes that express a ligand, such as GRIA4, may not co-express CD9 
and would not have been detected with this system. The TRIFic™ assay captures and detects 
exosomes by the same ligand (Duijvesz et al., 2015, Kaminska et al., 2016). Therefore, to fully 
determine if exosomes were not adhering to the capture antibodies in this study it would 
have been beneficial to develop detection antibodies with the same ligands.  
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In summary, it may be that i) the reagents were of low affinity or quality, ii) the ligand density 
was so low on these exosomes that capturing was difficult with good sensitivity or iii) CD9 
was a poor choice for detection. If the assay concept could have been proved with cell-
culture derived exosomes it would have potential to be used with biological fluids. Ideally, 
the capacity to selectively capture neural-derived exosomes present in blood plasma or 
serum is hugely important; giving a more specific CNS-relevant signature. Options, such as 
streptavidin resins, or detecting exosome isolation with the same capture ligand are available 
to continue optimisation of these approaches in the future. This is something likely to be of 
academic and commercial interest. To continue this present study a system-wide approach 
of analysing exosomes from AD patients would be pursued instead. Whilst “noise” may be 
generated from exosomes derived from other, unwanted source tissues it may be that CNS-
relevant signals can be teased out of the bulk population or signals from unexpected sources 
may be of biomarker potential. 
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5.1 Introduction 
Exosomes contain functionally active RNA molecules: messenger RNA (mRNA) from 
exosomes can undergo translation into new proteins in recipient cells (Valadi et al., 2007) 
and micro RNA (miRNA) from exosomes can regulate gene expression and confer a 
phenotypic response in recipient cells (Narayanan et al., 2013). However, the repertoire of 
RNA within exosomes appears to differ from the source cells in some studies (Mittelbrunn et 
al., 2011, Li et al., 2015) but not others (Turchinovich et al., 2011, Tosar et al., 2015). Using 
electrophoretic analysis it has been determined that exosomes are devoid of rRNA, which is 
abundant within cells (Shelke et al., 2014). Rather, they are known to contain a variety of 
different RNA species including mRNA, miRNA, vault RNA, Y RNA, tRNA, siRNA and circRNA 
(Raposo and Stoorvogel, 2013, Dou et al., 2016, Nolte-'t Hoen et al., 2012). Many of these 
are not protein coding but instead play a role in gene regulation. Therefore, there appears 
to be a wide reach of gene regulatory effects that exosomal-RNA may influence. 
To the author’s knowledge a direct comparison between exosomes and the parent cells has 
only been performed with microarrays and small RNA-sequencing (Skog et al., 2008, Valadi 
et al., 2007, Nolte-'t Hoen et al., 2012, Cheng et al., 2014, Royo et al., 2013, Li et al., 2013, 
Ahadi et al., 2016b). It could be argued that these studies provide only a limited picture as 
the techniques used pre-select for a subset of the total population. Nevertheless, they have 
hinted that there is disparity between the RNA cargos of exosomes compared to the source 
cell.  
The investigation of exosomal-RNA, with the aim of identifying biomarkers or functionally 
active species in disease, has predominantly focussed on small RNA (Bellingham et al., 2012, 
Burgos et al., 2014, Lugli et al., 2015). By selecting a subset of the total RNA in these studies, 
there is a limit to how much biological understanding can be obtained. This was reflected in 
a 2017 position statement by the International Society of Extracellular Vesicles: “This 
position paper was written […] to clarify that our incomplete knowledge […] currently 
prohibits the implementation of gold standards in [Extracellular Vesicle]-RNA research” 
(Mateescu et al., 2017). 
The application of next-generation sequencing (NGS) technologies for the identification of 
non-coding RNAs (ncRNAs) has long been utilised (Jacquier, 2009, Kapranov et al., 2007). 
Such species do not map to protein coding regions, yet their transcription is pervasive 
(Carninci et al., 2005) and it has become clear that some species, such as miRNAs, have a 
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regulatory role in the expression of protein coding genes (Bartel, 2004). The addition of post-
transcription modifications may well add to the complexity of RNA within exosomes (Hill et 
al., 2013) so NGS was chosen here as the best method to deepen the understanding of 
exosomal-RNA. Not only does NGS provide a non-bias approach to analysing RNA but the 
depth of data allows superior detection of splice variants and fusions (Haile et al., 2017). In 
particular, whole-transcriptome sequencing, with rRNA removal only, was chosen here so 
that the fullest view of the transcriptome could be obtained compared to small RNAseq or 
microarray analyses. 
An emerging species of ncRNA are long non-coding RNAs (lncRNAs) also known as long 
intergenic non-coding RNAs (lincRNAs). Studies based on individual lncRNAs have previously 
shown a number of regulatory roles for this species. Such roles include X-chromosome 
inactivation by the 17 kb-long Xist ncRNA in mammals (Zhao et al., 2008), genomic imprinting 
and chromatin remodelling by 91 kb-long Kcnq1ot1 antisense ncRNA (Pandey et al., 2008), 
transcription repression in development by the 2.2 kb-long HOTAIR ncRNA (Rinn et al., 2007), 
epigenetic regulation of transcription through histone modifications by the 108 kb-long Air 
ncRNA (Nagano et al., 2008), gene silencing in response to p53 activation by the 3.1 kb-long 
lincRNA-p21 (Huarte et al., 2010) and regulation of pluripotency genes by the 17.6 kb-long 
lincRNA-RoR (Loewer et al., 2010). Large screens of lncRNAs have revealed that they can act 
in trans (Guttman et al., 2011), as enhancer RNAs (De Santa et al., 2010), or in cis (Orom et 
al., 2010). 
With such a wide variety of functions and mechanisms, lncRNAs are best described as a 
species of RNA with many sub-families which have yet to be defined. The tools needed for 
probing deeper into lncRNAs are currently emerging. Catalogues of lncRNA annotations are 
now being developed (Cabili et al., 2011) and utilised with RNA sequencing datasets. One 
such study, found differentially expressed lncRNAs in ischemic cardiomyopathy with 
suggested roles in fibrosis and regulating extracellular matrix synthesis genes (Huang et al., 
2016). Another study used this catalogue to find that the anti-cancer drug KR12 did not have 
an effect in colorectal cancer via lncRNAs (Lin et al., 2016). Directly probing the effects of 
lncRNAs, by in vitro knock-down or knock-up (Loewer et al., 2010), can only be done 
experimentally on a selected candidate level yet thousands of lncRNAs have now been 
annotated. Therefore, bioinformatics tools are being established that can link function to 
lncRNA expression by identifying protein coding-genes that have correlative expression 
(Huang et al., 2016). Two such publically available tools are lncRNA2function (Jiang et al., 
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2015) and Co-LncRNA (Zhao et al., 2015). As such, the tools for investigating lncRNAs are 
being developed and used to deepen understanding in this emerging field. 
Deep –omic profiling of extracellular particles, with similar characteristics to exosomes, 
released by mast cells showed an enrichment for lncRNAs (Lasser et al., 2016). In a prostate 
cancer dataset, microarray analysis has revealed the presence, and reported abundance, of 
lncRNAs in exosomes (Ahadi et al., 2016b). In this dataset, differentially expressed lncRNAs 
in exosomes were identified across the four different cell-lines investigated. These lncRNAs 
were enriched for miRNA seed regions and RNA binding protein motifs, suggesting a 
potential role for these lncRNAs in disease propagation (Ahadi et al., 2016a). Another study 
performed qPCR analysis of the lncRNAs HOTAIR, MALAT1 and MEG3 in exosomes derived 
from the cervicovaginal lavage of cervical cancer patients. These lncRNAs were differentially 
expressed in disease patients (Zhang et al., 2016b) and whilst this was only a small candidate 
study, it promotes the utility of exosomal lncRNAs as biomarkers of disease. 
In this current study, the H4 cell-line was chosen for whole transcriptome sequencing of 
exosomes and source cells. The aim was to deepen the understanding of exosomal-RNA and 
how it relates to the source cell and included an analysis of lncRNA expression. A thorough 
characterisation of exosomes secreted from this cell-line had been performed in Chapter 3 
to validate the type of EV being analysed. Furthermore, the cell-culture methods that had 
been developed could be scaled up to provide an abundant source of exosomes. Whilst this 
particular study performed first principle sequencing of cellular and exosomal-RNA the 
choice of the H4 cell-line would pave way for future work with relevance to AD. 
The H4 cell-line has previously been used as a cell model of AD due to its neural origin. A 
number of mechanistic, intracellular trafficking studies have utilised the cell-line to 
investigate the production of amyloid-β (Aβ). One study demonstrated that amyloid 
precursor protein (APP) is abundantly expressed in H4 cells and intracellular cleavage to 
amyloidogenic fragments has been shown to occur in late trans-Golgi network (Kuentzel et 
al., 1993). Another study adopted the H4 cell-line and found that APP associates with the 
low-density lipoprotein receptor of APOE (Rebeck et al., 2001).  
The cell-line is tolerant to genetic manipulation and has been adopted for numerous studies. 
One such study introduced a mutated form of presenilin-1 (C92S), discovered in an Italian 
family with familial Alzheimer’s disease, into H4 cells and found this caused increased 
production of pathogenic Aβ42 (Lewis et al., 2000). Another study introduced three different 
presenilin-1 mutations (A246E, L286V and deltaE10) and showed that H4 cells with mutated 
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PS1 were more susceptible to caspase-3 mediated cell death than cells transfected with wild 
type protein when induced with Staurosporine (Kovacs et al., 1999). Additionally, the H4 cell-
line was used to identify novel APP fragments that induce a pathogenic cascade of events 
which were then replicated in primary cultured neurons (Fiorelli et al., 2013). Thus, the H4 
cell-line has proved a useful tool for deepening the understanding of some of the cellular 
processes underlying AD. 
In this chapter, the use of the H4 cell-line has been used primarily as an abundant source of 
exosomes, to isolate exosomal-RNA, and analyse it in relation to the source cell. However, it 
has long been adopted to produce cell models of AD, so generation of cellular and exosomal 
transcriptome data may well complement, or drive, further studies In AD. 
5.2 Aim 
The aim of this chapter was to comprehensively profile RNA from H4 neuroglioma cells and 
compare to the RNA of secreted exosomes captured in the culture medium. To achieve this 
aim the following objectives were addressed: 
 Validate procedures for the isolation of RNA from H4 cells and secreted exosomes 
 Profile cellular and exosomal-RNA by global measurements of quality and next-
generation sequencing 
 Identify differentially expressed RNA transcripts and perform a functional 
annotation of cellular- and exosomal-RNA 
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5.3 Results 
5.3.1 Profiling cellular and exosomal-RNA using global measurements of 
quality 
To address the aim of profiling RNA from H4 cells and exosomes, total RNA was extracted 
from both. Exosome-rich cell-conditioned media was collected at the same time as cellular 
RNA isolation. This allowed the most direct comparison between the two sample types as 
possible. 
Prior to isolating RNA from exosomes the procedure for digesting non-vesicular RNA (Shelke 
et al., 2014) was validated to ensure that downstream extractions and analyses were based 
on genuine intra-luminal, vesicle cargo. 20 µg exosomes, isolated from bioreactor cultures, 
was subjected to proteinase K (PK) and RNase A (RA) digestion and compared to a PBS-
treated control. Electrophoretic analysis revealed a decrease in measured RNA with PK/RA 
treatment (Figure 5.1). Measured concentrations were 2.5 and 4.3 ng/µl for treatment and 
no-treatment, respectively, equating to a 42% digestion of RNA. The electropherograms also 
showed that a population of RNA with a small nucleotide length was removed with PK/RA 
digestion. This is reflected in the DV200 calculations where 89% of RNA was greater than 200 
nucelotides in length for the treated sample compared to 69% for the PBS-treated control 
(Table 5.1). This suggests that the non-vesicular RNA present in the exosome preparation is 
enriched for small RNA species, such as miRNAs, and that this population can be removed by 
PK/RA digestion. The RNA remaining, and extracted for analysis, is resistant to RNase 
digestion because of its protected location inside the vesicle. 
Chapter 5. Profiling of cellular and exosomal-RNA from a neuroglioma cell-line 
150 
 
 
Figure 5.1: Electrophoretic analysis of RNA isolated after Proteinase K and RNase A digestion.  
Exosome pellets, obtained by the pellet and PBS wash procedure, were subjected to PK/RA treatment 
to digest non-vesicular RNA. Agilent Bioanalyser instrumentation was used, with the RNA pico chip, to 
measure fluorescence units (FU, y-axis) of RNA samples (n=1 per treatment). Concentrations were 
calculated by the instrumentation as 2.5 and 4.3 ng/µl for PK/RA treatment (dark blue) and no-
treatment (light blue), respectively. Nucleotide (nt) length is displayed on the x-axis.  
 
 
Treatment Concentration 
(pg/µl) 
DV200 RIN 
With PK/RA 2520 89 n/a 
Without PK/RA 4343 69 n/a 
 
Table 5.1: Electrophoretic analysis of RNA isolated after Proteinase K and RNase A digestion.  
Agilent Bioanalyser instrumentation was used with the RNA pico chip to evaluate the quality of RNA 
samples that had been subjected to PK/RA treatment. A Smear analysis was performed to calculate 
DV200, that is, the proportion of the electropherogram that is >200 nucleotides in length. Without rRNA 
the RNA Integrity (RIN) score was not calculable from these traces.  
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With this validated digestion procedure in place the extraction of cellular- and exosomal-
RNA was pursued. Three biological replicates of the H4 cells were established by sub-
culturing in separate flasks for 2 passages prior to expansion into ten T75 flasks for each 
replicate. Once the cells had reached 70% confluency, the conditioned media was replaced 
with 10 ml fresh media supplemented with exosome-depleted FBS. This ensured that only 
exosomes from the H4 cells were collected, particularly avoiding bovine exosomes. After 7 
days, the conditioned media was collected, spun, filtered and frozen at -80°C whilst the cells 
were detached, washed in PBS and RNA extracted. Exosomes were prepared from the 
conditioned media by pelleting at 200,000 x g for 2h with a PBS wash. Exosome pellets were 
treated with PK/RA to remove non-vesicular RNA prior to extraction. Thus, three biological 
replicates of H4 cellular-RNA and secreted exosomal-RNA were established. 
RNA was initially profiled by two global measurements of quality, namely electrophoretic 
analysis with Bioanalyser instrumentation and fluorometric quantitation using Qubit 
instrumentation. 
Electrophoretic analysis revealed a stark difference between cellular- and exosomal-RNA 
(Figure 5.2) consistent with published data (Shelke et al., 2014). Cellular-RNA was replete 
with ribosomal RNA (rRNA), as observed with the 18S and 28S peaks at ~1800 and ~3800 
nucleotides, respectively. The traces for exosomal RNA did not contain such peaks. Instead, 
the trace for the exosomes was distinct from the respective small nucleotide peak observed 
in the cell samples. This suggested that there was a distinct population of RNA species within 
exosomes.  
Further evaluation of RIN and DV200 scores reflected these visual observations of the 
electropherograms (Table 5.2). An automatic calculation performed by the instrumentation 
is the RNA integrity (RIN) score. The cellular-RNA samples all had RIN scores of 10 reflecting 
intact samples with no RNA degradation. Thus, RNA extraction procedures were of good 
quality. The exosomal-RNA samples were much lower at ~2 but this can be explained by the 
absence of 18S and 28S rRNA peaks that RIN is calculated from. Indeed, RIN is an arbitrary 
measurement if there is no rRNA expected within the sample. Therefore, DV200 was chosen 
as an alternative measure of RNA quality. The DV200 scores were lower for the exosome 
samples with 57-64% of the traces being from species >200 nucleotides in length compared 
to 81-84% in cells. All of these samples would be considered of high enough quality (>30%, 
according to manufacturer’s specifications) to continue with downstream applications such 
as sequencing (Eikrem et al., 2016). 
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Fluorometric quantitation was also performed using Qubit instrumentation (Table 5.2). An 
abundance of RNA was extracted from cells (225-275 ng/µl) but much lower from exosomes 
(9.4-13.1 ng/µl). These concentration readings highlight the relative ease of extracting 
plentiful stocks of RNA from cells compared to exosomes.  
Standard quality checks were performed with these exosome preparations, as established in 
chapter 3, using NTA and BCA assay. The particle concentrations ranged from 9.44x1013 – 
1.20x1014 and protein concentrations ranged from 2284 – 2986 µg/ml. P:P ratios were 
calculated to be 4.62x1010 for Exosome A, 3.31x1010 for Exosomes B, and 4.13x1010 for 
Exosome C, all of which exceed the 3x1010 ratio to be considered highly pure preparations 
according to Webber and Clayton, 2013. The quantity of RNA per particle was calculated, 
using NTA and Qubit values, as a rough estimation of the RNA content of each vesicle, 
accepting the caveats of NTA, as discussed in chapter 3. Sample Exosome A had 9.7x10-14 pg 
RNA/particle, Exosome B had 1.32x10-13 pg RNA/particle and Exosome C had 9.96x10-14 pg 
RNA/vesicle. Whilst NTA provides an overestimation of the number of vesicles, by 
indiscriminately measuring particles, the values again highlight the technical difficulty of 
extracting plentiful quantities of RNA from exosomes. 
Sufficient material had been obtained for RNA sequencing to further profile both of these 
sample types. From global quality measurements these samples had already shown 
remarkable distinction but RNA sequencing would provide a greater depth of data to further 
understand these differences. 
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Figure 5.2: Electrophoretic analysis of RNA extracted from H4 cells and secreted exosomes.  
Three biological replicates (n=3 each for cells and exosomes) were prepared and processed on the 
Agilent Bioanalyser using the Nano chip. Fluorescence units (FU) are displayed on the y-axis and 
nucleotide length (nt) on the x-axis. 18S and 28S peaks, at ~1800 and ~3800 nucleotides respectively, 
indicated that the cells (blue lines) were replete with ribosomal RNA whilst exosomes (red lines) were 
deplete of these species. Traces from individual samples are plotted rather than plotting an average. 
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Sample Concentration 
(ng/µl) 
RIN DV200 (%) 
Cell A 225.0 10 84 
Cell B 320.4 10 82 
Cell C 275.4 10 81 
Exosome A 11.6 2.1 58 
Exosome B 13.1 2.1 64 
Exosome C 9.4 2.2 57 
 
Table 5.2: Electrophoretic analysis and fluorometric quantitation of RNA extracted from H4 cells and 
exosomes.  
The concentration of RNA extracted from cells and exosomes (n=3 each) was quantified using 
fluorometric analysis (Qubit instrumentation). RNA integrity (RIN) scores were automatically 
calculated using the Agilent Bioanalyser instrumentation as one readout of RNA quality. As an 
alternative assessment of quality, which is less reliant on ribosomal RNA in the sample, the DV200 score 
was calculated manually using a Smear Analysis. DV200 is a calculation of the percentage of the trace 
with nucleotide fragments greater than 200 bp. Individual samples are reported rather than displaying 
the average.   
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5.3.2 Profiling cellular and exosomal RNA using next generation sequencing 
– Quality control 
Total RNA sequencing libraries were prepared using TruSeq stranded Total RNA with ribo-
zero Gold kit (Illumina) at the Wales Gene Park (Cardiff University). The ribosomal RNA 
depletion step was chosen to eliminate these species but detect the total remaining RNA. 6 
libraries were pooled and sequenced over 2 lanes of a flow cell (HiSeq 2500) generating ~89 
gigabases of data. Wales Gene Park performed the initial conversion and de-multiplexing of 
sequencing files using the bcl2fastq software (Illumina) before making .fastq and insert size 
metric files available for download. 
The distinction between cellular and exosomal RNA, observed by electrophoretic analysis, 
was observed again with the library insert sizes after preparation (Figure 5.3). The insert size 
metrics relate to the length of RNA after conversion to barcoded cDNA in the library 
preparation. With rRNA depleted, a unimodal distribution of insert sizes, around 100 bp, was 
observed for Cell A-C. This is in contrast with a bimodal distribution for Exosome A-C libraries, 
which contained a sub-population of larger inserts. Again, this hints of a biological distinction 
inherent within the samples even before sequencing data was obtained. These libraries were 
subjected to 100 bp paired-end (PE) sequencing. 
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Figure 5.3: Insert size Histograms after total RNA library preparation.  
Sequencing libraries were prepared from cellular-RNA (top, 1 library indicative of n=3) and exosomal-
RNA (bottom, 1 library indicative of n=3). The insert sizes (measured in base pairs, bp, x-axis) were 
measured by Bioanalyser instrumentation at Wales Gene Park.  
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At the Wales Gene Park twenty-four .fastq files were generated from this sequencing run: 2 
read files for each library run in duplicate on separate lanes. These were downloaded and 
the following analyses were performed by the author. 
Fastq sequencing files were processed by the software FASTQC (Babraham Bioinformatics) 
which provided a plethora of tests to determine the quality of the sequencing run. For 
example: per base sequence quality was reported for each base along the 100 bp read in the 
.fastq files (Figure 5.4). Typically the first 5 bases of each read had lower scores and quality 
was slightly poorer after the paired-end turnaround. However, these all remained within the 
high quality range (28-40 Phred score), so overall the sequencing was performed well. This 
was observed across all 24 .fastq files indicating that base calling was accurate. 
FASTQC provides a traffic light system for a number of other tests that can be informative 
for evaluating the overall quality of the sequencing run. Two such warnings, at the base level, 
were for Kmer content and per base sequence content for the first 10 bases (Figure 5.5). 
According to manufacturer guidelines these are standard, and benign, artefacts of the 
Nextera transposase that ligates adaptor sequences during library preparation. As these 
would not have an impact on downstream analyses they were not trimmed out, although 
there are software packages such as FASTX-Toolkit (Hannon Lab) and Trimmomatic (Usadel 
Lab) that are able to do this if required.  
A second set of warnings were prompted at the sequence level, with per sequence GC 
content and sequence duplication levels (Figure 5.6). These tests aim to flag up a PCR bias 
within the library preparation. Such metrics are of concern in the case of DNA sequencing 
e.g. whole exome or whole genome sequencing. In these techniques, duplicate metrics 
should be analysed further as a percentage of the total reads, but in the case of RNAseq 
duplicates are explained and expected with the uneven nature of gene expression. 
Therefore, duplicates were marked using Picard but not removed as this may distort the 
expression profile downstream. 
Together, these data highlight that FASTQC, whilst a useful tool for identifying issues within 
the sequencing, is calibrated for whole genome and whole exome data where uniformity is 
desired. Therefore, careful interpretation of these RNAseq results was required. Overall, the 
sequencing was of good quality and, other than marking duplicates, no further processing 
was performed prior to downstream analyses. 
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Figure 5.4: Per base sequence quality report for paired-end reads of Cell A sequenced on one flow-
cell lane.  
Quality scores were recorded by the HiSeq sequencing instrumentation and displayed graphically using 
the FASTQC software. These graphs are representative of 24 .fastq files. Read 1 is shown on the top 
and read 2, after the paired-end turnaround, on the bottom. The position in read (x-axis) is measured 
in base pairs (bp) as the sequencing run was occurring and quality indicated with a Phred score ranging 
from 0 (poor quality) to 40 (good quality) on the y-axis. FASTQC indicates high, medium and low quality 
ranges using traffic light colour system. The mean and range of quality across the sample is displayed 
using box and whiskers.  
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Figure 5.5: FASTQC warnings at the base level.  
These reports were produced from Cell Sample A sequenced on one flow-cell lane but representative 
of all 24 .fastq files. Per base sequence content (top) was flagged up for the first 10 bases (bp, x-axis) 
with differing percentages (y-axis) of individual bases. Kmer content (bottom) was flagged up for the 
first 10 bases (bp, x-axis) with higher observations (y-axis) of the sequences indicated in the key.   
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Figure 5.6: FASTQC warnings at the sequence level.  
These reports were produced, by FASTQC software, from Cell Sample A sequenced on one flow-cell lane 
but representative of all 24 .fastq files. GC content (Top) was flagged up as differing from a theoretical 
distribution expected from the measured reads (y-axis). Duplication (Bottom) was flagged up at the 
sequence level as a percentages (y-axis) that differed from the deduplicated sequences.  
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5.3.3 Profiling cellular and exosomal RNA by next generation sequencing – 
read alignment, mapping and merging .bam files 
The next step in the analysis pipeline was to map and align reads to the human genome 
(hg19). This was performed using the TopHat software (Johns Hopkins University) to 
generate twelve .bam files (Table 5.3). The Bowtie 2 hg19 index was downloaded from 
http://bowtie-bio.sourceforge.net/bowtie2/manual.shtml (accessed May 2016) and gene 
model annotations provided in .gtf format downloaded from 
http://ftp.ensembl.org/pub/release-74/gtf/homo_sapiens/ (accessed May 2016). All Cell 
.fastq files mapped well with overall read mapping rates of ~90%. The Exosome files did not 
map as well with overall read mapping rates of ~70%.  Closer inspection of the alignment 
metrics (Table 5.3) revealed that whilst the left reads mapped fairly close to 90% it was the 
low mapping rates of right reads that were driving this poor overall mapping rate. This was 
investigated further to seek an explanation. 
The libraries for both cells and exosomes were prepared at the same time suggesting that 
this disparity of mapping rates is due to a difference inherent in the samples rather than a 
technical issue. The sequencing quality was good across both right and left reads, as reported 
above (Figure 5.4), again showing that a technical issue had not arisen in the sequencing run. 
So with identical preparation procedures, and accurately performed sequencing, there is a 
suggestion that these poor mapping rates for exosome right reads, is due to a divergence 
from the reference at the 3’ end. Therefore, the insert sizes (Figure 5.3) for exosomes was 
further investigated. 
As previously discussed, distribution plots revealed that exosome libraries had a second 
population of larger size inserts (Figure 5.3). To investigate if this population mapped poorly 
at the 3’ end, in general, a second mapping software was tested. The Burrows-Wheeler 
Aligner (BWA) was chosen to compare with TopHat as it typically has a lower threshold for 
read mapping. Paired-end reads from Exosome 1 (Lane 1) were mapped to hg19 using both 
pieces of software and the resultant .bam files were analysed using the Samtools flagstat 
tool (Table 5.4). BWA mapped more reads, particularly right reads, which TopHat did not. 
This confirmed the threshold differences within these software, whereby, TopHat is more 
stringent and does not map a proportion of these reads. 
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Sample #Left 
reads 
#Left reads 
mapped 
%Left reads 
mapped 
#Right reads #Right reads 
mapped 
%Right reads 
mapped 
Overall read 
mapping rate 
(%) 
Cell A (Lane 1) 39906314 36414515 91.3 39906314 35839860 89.8 90.5 
Cell A (Lane 2) 39830972 36426648 91.5 39830972 35854738 90.0 90.7 
Cell B (Lane 1) 46314074 41928379 90.5 46314074 41150666 88.9 89.7 
Cell B (Lane 2) 46487587 42168699 90.7 46487587 41392603 89.0 89.9 
Cell C (Lane 1) 45598728 41015278 89.9 45598728 40469754 88.8 89.4 
Cell C (Lane 2) 45576114 41072179 90.1 45576114 40534216 88.9 89.5 
Exosome A (Lane 1) 35870502 31409777 87.6 35870502 20923299 58.3 72.9 
Exosome A (Lane 2) 36162976 31731230 87.7 36162976 21162231 58.5 73.1 
Exosome B (Lane 1) 20822237 18440242 88.6 20822237 11084877 53.2 70.9 
Exosome B (Lane 2) 20857814 18502700 88.7 20857814 11143441 53.4 71.1 
Exosome C (Lane 1) 33243277 28537108 85.8 33243277 20555355 61.8 73.8 
Exosome C (Lane 2) 33435182 28752890 86.0 33435182 20741236 62.0 74.0 
 
Table 5.3: Mapping metrics from TopHat.   
Sequencing read mapping was performed and mapping rates calculated using TopHat. Individual samples, on individual sequencing lanes, are displayed rather than using the 
average. Raw read numbers (#) and percentages (%) are reported.   
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 TopHat BWA 
Total reads mapped and 
paired in sequencing 
67796052 72725273 
Read1 40182355 36129350 
Read2 27613697 36595923 
 
Table 5.4: Read numbers taken from Samtools flagstat report for TopHat and BWA mapping.  
Samtools software was used to compare the read numbers from two mapping softwares, TopHat and 
BWA. Paired-end reads from Exosome 1 (Lane 1, n=1) were chosen to compare these two software. 
Raw read numbers are displayed with a breakdown of left reads (Read1) and right reads (Read2). 
 
 
 
Next, the CollectInsertSizeMetrics tool in Picard (Broad Institute) was used to assess the 
insert sizes of these differently mapped .bam files (Figure 5.7). TopHat mapped reads of 
relatively uniform size compared to the wider spread of insert sizes in the BWA .bam file. The 
median insert size in the TopHat file was 178 ± 45 bp compared to 209 ± 73 bp for BWA 
(Table 5.5). This confirms that BWA, by reducing stringency, did not filter out the reads from 
larger insert size that TopHat did. This answers the original query about why TopHat had 
reduced mapping rates for exosomes: the sub-population of larger size inserts (Figure 5.3) 
map poorly at the 3’ end. This is unique to exosomal-RNA and not the cellular-RNA. 
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Figure 5.7: Insert size metrics for Exosome 1 (Lane 1) mapped with TopHat (top) and BWA (Bottom). 
Histograms were plotted, using the CollectInsertSizeMetrics tool in Picard, to compare .bam files 
mapped using TopHat and BWA (n=1 per software). Insert sizes were measured in base pairs (x-axis) 
and read counts displayed on the y-axis. 
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 TopHat BWA 
Median size (bp) 178 209 
Absolute median deviation 45 73 
Mean size (bp) 201 229 
SD 82 105 
 
Table 5.5: Insert size metrics for Exosome 1 (Lane 1) mapped with TopHat and BWA.  
Insert size metrics were calculated using the CollectInsertSizeMetrics tool in Picard, to compare .bam 
files mapped using TopHat and BWA (n=1 per software). Both median and mean measurements of 
insert size are reported with standard deviations (SD). 
 
 
 
 
 
To assess whether using BWA would be advantageous for a downstream differential gene 
expression analysis both .bam files were used for a gene count using HTSeq (EMBL, 
Heidelburg). The TopHat file provided 1053915 gene counts compared to 838121 for BWA 
(Table 5.6). This suggests that the mapped reads provided by BWA did not reside within 
standard gene regions and therefore detected by the gene count software. This confirmed 
that the lower read mapping rate of TopHat was being driven by the larger inserts observed 
for exosomes diverging from the reference. Furthermore, given the lower gene count and 
spread of insert size, the BWA mapping tool was not advantageous so TopHat was chosen 
for this analysis pipeline. 
The twelve .bam files output from TopHat were separated by sample and lane. Prior to 
further analysis, these were merged to produce six .bam files, one for each biological 
replicate, using the SAMtools merge tool. There were between 169 – 193 million reads in 
each of the cell files and 77 – 136 million reads in the exosome files (Table 5.7). As expected 
from the original mapping rates, the second reads mapped poorly for exosome samples 
when .bam files were merged. It may be that the library preparation procedure for exosome 
samples could be optimised to improve these but this was beyond the cost and sample 
limitations of this study. With these data available in .bam format, further analyses were 
then performed. 
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 TopHat BWA 
Sum of gene counts 1053915 838121 
 
Table 5.6: Sum of gene counts from Exosome 1 (Lane 1) using HTSeq.  
HTSeq was used to assess the number of gene counts possible from the mapping software TopHat and 
BWA from one sequencing file (n=1). The total sum of gene counts is displayed. 
 
 
 Mapped Paired in 
sequencing 
Read 1 Read 2 
Cell A 169280297 145232055 73189869 72042186 
Cell B 193759301 167473996 84513562 82960434 
Cell C 189580918 163865727 82480521 81385206 
Exosome A 136320008 105383314 63257700 42125614 
Exosome B 77557814 59367811 37067297 22300514 
Exosome C 129999401 98911477 57500125 41411352 
 
Table 5.7: Read numbers taken from Samtools flagstat report for merged .bam files.  
Samtools was used to merge .bam files from individual sequencing lanes (n=2 per sample) and report 
the total read numbers in the resultant files. Raw read numbers are reported. Read 1 refers to the left 
reads and Read 2 to the rights reads of the paired-end sequencing. 
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5.3.4 Profiling cellular and exosomal-RNA by next generation sequencing –
RNAseq metrics 
After aligning reads to hg19 and merging .bam files into each biological replicate, the next 
stage of the analysis pipeline was to evaluate the different species of RNA, on a global level, 
within the samples. The CollectRnaSeqMetrics tool on Picard was used to annotate reads 
within the six .bam files with reference to the gene model annotaton file (.gtf) used during 
the mapping stage (Figure 5.8). 
These metrics revealed a distinction between the cells and the exosomes. Reads mapping to 
coding regions only accounted for ~1% exosomal RNA compared to ~40% in cells. Rather, 
exosomal RNA was replete with reads that mapped to intronic and intergenic regions of the 
genome. Thus, the transcriptome of exosomes is fundamentally different to the cells they 
were secreted from. Binomial exact tests were statistically significant (p<0.001) across the 
coding, intergenic, intronic and UTR annotations. 
It should be noted that the extent of this difference may be exaggerated by the library 
preparation choice. These data would suggest that there is minimal or no coding RNA in 
exosomes, which is not in keeping with the literature which has demonstrated functionally 
active coding RNA in exosomes (Valadi et al., 2007). It would be expected that coding RNA 
would have been sequenced from exosomes if a different library preparation had been used, 
for example one that used Oligo dT beads to capture poly-A tails. Instead, the Total RNA with 
Ribo-Zero Gold used here may have caused a preferential sequencing of intronic and 
intergenic reads which may be exaggerating the observed profiles. Accepting the caveats, 
this library preparation technique provides the fullest view of the transcriptome possible 
with currently available techniques and additionally, cell and exosome libraries were 
prepared simultaneously so can be directly compared. Therefore, the difference in cell and 
exosome transcriptomes can be accepted, with the caveat that the extent of this difference 
may be exaggerated by the techniques used in sequencing. 
Whilst this observation shed light on an intriguing aspect of cell biology it also posed a 
problem for downstream analyses. To perform a differential gene expression analysis there 
is a normalisation step that takes into account the size of the library that gene counts were 
taken from. In this case, gene counts being based on ~1% of the exosome libraries but ~40% 
of cell libraries would skew the normalisation step. Indeed, directly comparing such 
fundamentally different samples in this way would be inappropriate.  
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So without directly comparing cells to exosomes based on their exonic gene counts two other 
avenues of investigation were pursued. Firstly, long non-coding RNAs (lncRNA) were chosen 
as they would come under the intronic and intergenic portions of the reads. The direct 
function of these molecules is poorly understood but identifying differentially expressed 
lncRNAs which have co-expressed mRNAs would then allow functional annotation of the 
samples. Secondly, the intronic reads were directly compared between samples. By linking 
back to the gene-names, functional annotation was again possible. These analyses are 
reported below. 
 
 
Figure 5.8: RNAseq metrics for cells and exosomes collected using Picard.  
Picard was used to assess the content of RNA within the sequencing samples (n=6). Each biological 
replicate is represented by a bar as indicated on the x-axis. Red colouring represents coding bases, 
green represents intergenic, blue represents intronic and purple represents untranslated regions. 
Percentages of each type is indicated on the y-axis. 
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5.3.5 Differential expression analysis of lncRNAs 
Count files give a count of the number of reads that reside within a given annotation, in this 
case, lncRNAs were counted. The HTSeq software was used to produce count files from the 
mapped reads using the Human lincRNA Catalog (Broad Institute), in .gtf format, as a 
reference 
(http://portals.broadinstitute.org/genome_bio/human_lincrnas/?q=lincRNA_catalog, 
accessed November 2016). This database was chosen as it has defined >8000 lncRNAs (Cabili 
et al., 2011) and has been used independently of the Broad Institute (Huang et al., 2016). 
Differential expression of counted lncRNAs was then performed using DESeq2 (Love et al., 
2014).  
Prior to directly comparing the samples from merged .bam files, the variability between lanes 
on the flow cell were assessed (Figure 5.9). Whilst this was only a visual check on variability 
there was no obvious issue of one lane providing anomalous counts. Therefore, the 
differential expression pipeline was pursued further with merged .bam files. 
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Figure 5.9: Heatmap showing 30 differentially expressed lncRNAs across all sequencing lanes.  
DESeq2 was used to assess lncRNA counts (y-axis), as indicated by colour intensity, across six RNA 
samples (x-axis, C = cell, E = exosome) measured on separate sequencing lanes (L1 = lane 1, L2 = lane 
2). Topological similarities were automatically generated by the software and indicated on both axes.  
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Firstly, sample relationships were explored to investigate the global differences between 
samples before individual lncRNAs were analysed. The dataset was run into DESeq2 and pre-
filtered to remove rows with no counts across the samples. This improved computation times 
as the number of rows was reduced from 8263 to 7978. Therefore, 285 lncRNAs had no 
counts across both cell and exosome samples. To allow the calculation of distances between 
samples the data was transformed using the regularised-logarithm transformation (rlog) as 
suggested in the software workflow (Love et al., 2014). This stabilises the variance across the 
mean making the data approximately homoscedastic. 
Using rlog transformed data, Euclidean distances between samples were calculated and 
plotted as a heatmap (Figure 5.10). This emphasised the biological picture that was already 
emerging: that the RNA profile of cells and the secreted exosomes are distinct. There was 
separation between cells and exosomes at a sample distance level but good similarity within 
these two groups. This reproducibility between biological replicates highlights the 
homogenous characteristics of cell-cultures which would not be expected for patient 
samples which would likely be highly variable between people. 
The sample-to-sample distances were further visualised with a principal component analysis 
(PCA). Samples were plotted across two dimensions where most of the variance (98%) was 
explained with the first principle component along the x-axis (Figure 5.11). There was 
distinction between the cell and exosome sample groups with complete separation along 
this x-axis. Within these groups, the cell samples showed greatest uniformity between 
biological replicates. There was variance picked up within the exosome samples where 
Exosome B (labelled “E2”) did not cluster as tightly with the other 2 biological replicates. 
However, there was little difference along the first principle component (x-axis). These 
observations reinforce the sample distances heatmap (Figure 5.10) both of which showed a 
clear distinction between cells and exosomes.  
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Figure 5.10: Euclidean distances between samples using rlog transformed data.  
Euclidean distances between samples in the RNA sequencing data was calculated by DESeq2. C1 – C3 
refer to cell samples A – C and E1 – E3 refer to exosome samples A – C. Sample similarity is indicated 
by colour intensity.  
 
Figure 5.11: Principle component analysis showing variance between samples.  
A PCA analysis was performed using DESeq2. The first principle component (PC1, x-axis) describes the 
majority of variance (98%). The second principle component (PC2) is displayed on the y-axis. C1 – C3 
refer to cell samples A – C and E1 – E3 refer to exosome samples A – C. 
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Secondly, differential expression analysis was performed on raw counts. DESeq2 provided a 
data frame whereby the lncRNA expression in cells can be compared with exosomes. Of the 
7978 lncRNAs tested, with >0 counts, 5325 (67%) showed an increase in log-fold change and 
701 (8.8%) showed a decrease in log-fold change (Figure 5.12). This emphasises the 
distinction between these two sample types; only 24.2% lncRNAs had comparable expression 
levels between cells and exosomes. 
With so many lncRNAs differentially expressed, stricter parameters were set in the analysis. 
The false discovery rate threshold was reduced to an adjusted Bonferroni p-value of 6.27x10-
6. With this, 1554 lncRNAs passed Bonferroni correction for multiple testing and were found 
to be differentially expressed between cells and exosomes (Figure 5.13). This Minus-Average 
(MA) plot demonstrated that those lncRNAs with a higher normalised count required a lower 
log fold change to reach significance as seen by the narrowing of red dots (where p<6.27x10-
6)  towards 0 along the x-axis. 
Next, a subset of these differentially expressed lncRNAs were focused on. DESeq2 offers a 
function that, using rlog transformed data, calculates the deviation of each lncRNA from the 
average across all samples and can be plotted for a gene clustering analysis (Figure 5.14). It 
appeared that an outlier from one sample was not driving the differential expression. Details 
of log fold change and statistical significance for the top 10 up-regulated in cells and top 10 
up-regulated in exosomes are displayed in Table 5.8. For example, XLOC_000670 had a log2 
fold change of -6.32 equating to a ~80 fold change increase in cells. Another example is 
XLOC_005754, which had a log2 fold change of 9.86 equating to a ~900 fold change increase 
in exosomes. Therefore, there can be large expression differences between cells and 
exosomes within the lncRNA repertoire. 
Together these data, from a sample and individual lncRNA level, revealed that the RNA cargo 
in exosomes is distinct from the cells they were secreted from. To investigate the nature of 
the samples they represent, functional annotations needed to be undertaken. 
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Figure 5.12: Heatmap showing log fold change of 7978 lncRNAs in cells and exosomes.  
Heatmaps were generated from sequencing data using DESeq2. Six samples were assessed (C=cell, 
E=exosome, x-axis) and lncRNA counts indicated by colour intensity. Topological relationships between 
individual lncRNAs and samples were automatically generated and presented on both axes. 
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Figure 5.13: An MA plot showing differential lncRNA expression after Bonferroni correction.  
A Minus-Average plot was generated from sequencing data using DESeq2. The mean of normalised 
counts for each lncRNA is displayed on the x-axis and the log fold change between cell and exosome 
samples (n=3 per type) displayed on the y-axis. Each lncRNA comparison is represented by a dot with 
1558 passing Bonferroni correction for multiple testing (red dots) whilst 6424 did not (black dots). 
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Figure 5.14: Heatmap showing differential expression of the top 40 lncRNAs after rlog 
transformation. 
A function to measure the deviation of each lncRNA from the average across all samples was used in 
DESeq2 using the sequencing data (n=6). The top 40 of these are plotted and identified on the y-axis 
and indicated by colour intensity. C1 – C3 refer to cell samples A – C and E1 – E3 refer to exosome 
samples A – C (x-axis). Topological relationships are automatically generated by DESeq2 and indicated 
on both axes. 
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lncRNA_ID baseMean log2FoldChange lfcSE pvalue padj 
XLOC_000670 1040.25 -6.32 0.28 1.82E-115 8.52E-113 
XLOC_000010 159.69 -6.66 0.49 2.29E-41 1.81E-39 
XLOC_008152 561.97 -6.77 0.32 1.20E-99 2.99E-97 
XLOC_011226 5703.25 -6.55 0.22 1.56E-202 4.14E-199 
XLOC_012681 139.81 -6.19 0.50 1.10E-35 6.91E-34 
XLOC_003506 178.58 -6.71 0.47 1.49E-45 1.25E-43 
XLOC_000166 268.53 -6.45 0.37 7.13E-68 1.03E-65 
XLOC_013856 176.02 -6.69 0.47 2.67E-45 2.22E-43 
XLOC_005517 134.47 -6.42 0.49 1.52E-38 1.09E-36 
XLOC_013739 166.07 -7.21 0.57 3.00E-37 2.03E-35 
XLOC_005754 1496.71 9.86 0.49 4.91E-90 1.12E-87 
XLOC_000992 71383.36 8.71 0.15 0.00E+00 0.00E+00 
XLOC_006043 42.15 7.45 1.15 1.06E-10 1.88E-09 
XLOC_001047 69.00 6.53 0.73 3.67E-19 1.25E-17 
XLOC_008785 74.48 7.50 0.95 2.49E-15 6.93E-14 
XLOC_009577 46.35 7.58 1.15 4.29E-11 8.15E-10 
XLOC_007173 31.04 7.93 1.17 1.19E-11 2.40E-10 
XLOC_005099 42.26 8.37 1.16 6.13E-13 1.45E-11 
XLOC_011677 40.51 8.31 1.16 9.38E-13 2.18E-11 
XLOC_012230 42.67 8.38 1.16 4.63E-13 1.10E-11 
 
Table 5.8: Logfold changes of lncRNAs expressed in cells and exosomes.  
The top 10 lncRNAs that were up-regulated in cells (XLOC_000670 – XLOC_013739) and up-regulated 
in exosomes (XLOC_005754 – XLOC_012230) were highlighted from sequencing data using DESeq2. 
The mean count across samples is displayed in the “baseMean” column followed by log2FoldChange 
and standard error. All lncRNAs showed a >6 log2 fold expression change between cells and exosomes 
and p-values passed Bonferroni correction for multiple testing. “lfcSE” refers to the standard error (SE) 
of the log2FoldChange. 
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5.3.6 Functional annotation of differentially expressed lncRNAs 
To date, not only the annotation onto the genome, but also the functional action of lncRNAs 
are poorly understood. One known feature is that lncRNAs can show co-expression with 
neighbouring genes (Cabili et al., 2011). Given this observation, the co-expression of up-
regulated lncRNAs in this dataset with mRNAs of known function was investigated further in 
order to establish a better understanding of possible functional relationships. One 
bioinformatics tool to perform this analysis is Co-LncRNA (Zhao et al., 2015). 
The top 10 differentially expressed lncRNAs for cells and exosomes (Table 5.8), separately, 
were uploaded into the Co-LncRNA web interface along with expression profiles of 
differentially expressed mRNAs. Co-LncRNA then provided lists of co-expressed mRNAs with 
p-value <0.1. These were submitted to the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID, v6.8) for functional annotation (Huang et al., 2008, Jiao et al., 
2012). DAVID was chosen as an appropriate tool to upload large lists of genes (up to 3000) 
and retrieve biological understanding from them.  
Co-expressed mRNAs in the cell samples pointed to numerous general cellular processes 
(Table 5.9) and enrichment maps were drawn using Cytoscape v3.4.0 (Figure 5.15). These 
showed enrichment of terms such as protein binding (p=5.63x10-5), chromosome 
(p=2.06x10-4), acetylation (p=2.5x10-4), phosphoprotein (p=2.59x10-4), nucleosome core 
(p=5.34x10-4) and ubiquitin-like protein conjugation (p=7.92x10-4). Such terms describe the 
intracellular functioning of cells in general. 
Co-expressed mRNAs in the exosome samples (Table 5.10) provided a very different 
enrichment profile (Figure 5.16). Here, terms included disulfide bond (p=3.02x10-23), 
Glycoprotein (p=1.10x10-21), glycosylation site:N-linked (p=7.33x10-21) and topological 
domain:Extracellular (p=9.59x10-16). These terms reflect the molecular structure and 
composition of exosome vesicles and a number of terms overlap with a previous proteomics 
study of exosomes (Webber et al., 2014). There were some unexpected terms such as 
“olfaction” and “Rhodopsin-like 7TM”. Whilst these unexpected terms loosely fit with a cell-
line of neural origin it is likely that these are artefacts of the enrichment analysis. A possible 
explanation is that genes of long length can be overrepresented due to their size, rather than 
their biological enrichment. Therefore the general observation, of enriched terms reflecting 
the composition of exosome vesicles, appears genuine. 
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Thus, by analysing genes that co-express with differentially expressed lncRNAs in these two 
sample types a biological understanding has been uncovered by enrichment analysis. Despite 
originating from these cells, the exosomes carry an RNA cargo that is dramatically different. 
The RNA is enriched for terms such as “glycosylation” and “transmembrane proteins”, which 
reflects the known molecular structure/composition of exosome vesicles. This suggests that 
the processes by which RNA has been loaded into exosomes are not random. However, there 
is a disconnection between the expression of functionally active genes and the abundance 
of non-coding RNA in exosomes. Translational machinery is absent from exosomes, most 
notably rRNA, so there is difficulty in understanding how the enrichment of these non-coding 
RNAs in exosomes can result in functionally relevant terms. 
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Category Term p-value Genes 
GOTERM_MF_DIRECT GO:0005515~protein binding 5.63E-05 LEPR, PREX1, FAM20C, RORB, MYLIP, SDC4, HOOK3, EPC1, RNF103, 
MAP1LC3B… 
UP_KEYWORDS Chromosome 2.06E-04 HIST1H2AB, HIST2H2AB, REC8, HIST1H2BN, NSMCE4A, HIST1H2BF, HJURP, 
HIST1H2BH, HIST1H4D, HMGA1… 
UP_KEYWORDS Acetylation 2.50E-04 ZFAND6, PSMB10, HIST1H2AB, KANSL1L, ZMYND8, HOOK3, HIST2H2AB, 
HIST1H2BN, PLIN2, VPS13C… 
UP_KEYWORDS Phosphoprotein 2.59E-04 LEPR, PREX1, FAM20C, RASSF8, HOOK3, HIST2H2AB, EPC1, HIST1H2BN, 
VPS13C, CCDC71L… 
UP_KEYWORDS Nucleosome core 5.34E-04 HIST1H2AB, HIST2H2AB, HIST1H2BN, HIST1H2BF, HIST1H2BH, HIST1H4D 
UP_KEYWORDS Ubl conjugation 7.92E-04 HIST1H2AB, SLC38A2, MYLIP, ZMYND8, ZFP36L1, HIST2H2AB, HIST1H2BN, 
N4BP1, ETAA1, HIST1H4D… 
GOTERM_CC_DIRECT GO:0000786~nucleosome 8.43E-04 HIST1H2AB, HIST2H2AB, HIST1H2BN, HIST1H2BF, HIST1H2BH, HIST1H4D 
GOTERM_BP_DIRECT GO:0045944~positive regulation of 
transcription from RNA polymerase 
II promoter 
9.54E-04 PLAG1, MAFF, TBL1XR1, FZD8, LUM, RELB, NCOA7, NR4A3, SIRT1, HMGA1… 
 
Table 5.9: Functional terms associated with mRNAs that co-express with the top 10 lncRNAs differentially expressed in cells over exosomes.  
Functional terms were provided by David software after differential lncRNA analysis of sequence data using DESeq2 and co-expression analysis using Co-LncRNA. The top 8 
terms (by p-value) are displayed here and where >10 genes are represented in each group the first 10 are listed. 
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Category Term p-value Genes 
UP_SEQ_FEATURE disulfide bond 3.02E-23 EDN3, MASP1, SCN3B, GDF6, ATP1B4, OR4C5, C1QC, APOB, HTR1A, OR6C3… 
UP_KEYWORDS Glycoprotein 1.10E-21 HCG22, SLC52A1, MASP1, SCN3B, LYPD5, GDF6, OR4C5, C1QC, AQP3, APOB… 
UP_SEQ_FEATURE glycosylation site:N-linked 
(GlcNAc...) 
7.33E-21 RARRES1, MASP1, SCN3B, LYPD5, GDF6, ATP1B4, OR4C5, AQP3, APOB, HTR1A… 
UP_KEYWORDS Disulfide bond 8.94E-21 EDN3, MASP1, SCN3B, GDF6, PTPN22, OR4C5, C1QC, APOB, HTR1A, OR6C3… 
UP_SEQ_FEATURE topological domain:Extracellular 9.59E-16 F2RL3, RARRES1, SCN3B, GRIK4, SLC6A4, ATP1B4, SLC7A9, TNFSF13, OR4C5… 
UP_SEQ_FEATURE signal peptide 7.30E-15 EDN3, SLC52A1, MASP1, LYPD5, SCN3B, GDF6, C1QC, APOB, SBSN, IGLL1… 
INTERPRO IPR017452:GPCR, rhodopsin-like, 
7TM 
2.44E-13 F2RL3, OR52A1, TACR2, OR4C5, GPR87, GPR88, OR10A7, EDNRA, HTR1A, 
GALR1… 
UP_KEYWORDS Secreted 2.17E-12 EDN3, HCG22, MASP1, GDF6, TNFSF13, C1QC, IL10, OLFML1, IFNL1, APOB… 
INTERPRO IPR000276:G protein-coupled 
receptor, rhodopsin-like 
2.35E-12 F2RL3, OR52A1, TACR2, GPR87, OR4C5, GPR88, OR10A7, EDNRA, HTR1A, 
GALR1… 
UP_KEYWORDS G-protein coupled receptor 3.23E-12 TAS2R1, F2RL3, OR52A1, TACR2, OR4C5, GPR87, GPR88, OR10A7, EDNRA, 
TAS2R60… 
 
Table 5.10: Functional terms associated with mRNAs that co-express with the top 10 lncRNAs differentially expressed in exosomes over cells.  
Functional terms were provided by David software after differential lncRNA analysis of sequence data using DESeq2 and co-expression analysis using Co-LncRNA. The top 10 
terms (by p-value) are displayed here and the first 10 genes in each group are listed. 
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Figure 5.15: Functional annotation of mRNAs that co-express with the top 10 lncRNAs differentially expressed in cells over exosomes.  
Functional terms were annotated from sequencing data using DAVID software and plotted using Cytoscape software. Each term is represented by circles with the size of each 
circle representing the number of genes within the term and the thickness of line represents the number of overlapping genes between terms. 
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Figure 5.16: Functional annotation of mRNAs that co-express with the top 10 lncRNAs differentially expressed in exosomes over cells.  
Functional terms were annotated from sequencing data using DAVID software and plotted using Cytoscape software. Each term is represented by circles with the size of each 
circle representing the number of genes within the term and the thickness of line represents the number of overlapping genes between terms. 
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5.3.7 qPCR validation of lncRNA differential expression 
So far, differential expression of lncRNAs has been described from RNA sequencing data. To 
validate these findings, six differentially expressed lncRNAs were tested using quantitative 
polymerase chain reaction (qPCR): three that had increased expression in cells 
(XLOC_000670, XLOC_011226 and XLOC_008152) and three that had increased expression in 
exosomes (XLOC_009577, XLOC_001047 and XLOC_006043). Validation was then performed 
using an independent technique and with independent samples. 
First, reagents and procedures for quantifying these lncRNAs were validated. SYBR green 
qPCR chemistry was chosen as it provided the most flexibility for self-design of primers. 
These were designed by downloading DNA sequences from the respective lncRNA regions 
from the UCSC genome browser (University of California Santa Cruz) and using Primer3 
(Untergasser et al., 2012, Koressaar and Remm, 2007) set to produce amplicon sizes of 80-
100 bp in length. In the case of housekeeping genes (GAPDH, PPIA and TUBA1A) DNA from 
exonic regions were chosen for primer design.  
Primers were tested initially by standard PCR using cDNA reverse transcribed from 80 ng 
cellular- or exosomal-RNA. These samples were extracted on a separate occasion to the RNA 
sequencing samples to represent an independent sample set for validation. Agarose gels 
were run (Figure 5.17) after 35 cycles of PCR where 3 ng forward and reverse primers used 
and 2 µl cDNA template. Three housekeeping genes (GAPDH, TUBA1A and PPIA) and three 
lncRNAs (XLOC_000670, 011226 and 008152) were tested with cDNA reverse-transcribed 
from cellular-RNA. Three lncRNAs (XLOC_009577, 001047 and 006043) were tested with 
cDNA reverse-transcribed from exosomal-RNA. All primer sets showed product bands at 
~100 bp, as expected, for the three biological replicates tested and no band for the negative 
control. Therefore, these primer sets were used at a concentration of 3 ng per reaction in 
quantitative experiments downstream. 
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Figure 5.17: Optimisation of primers by standard PCR.  
PCR primers were optimised by standard PCR and products visualised by agarose gel electrophoresis. 
Negative controls are rightmost for GAPDH, TUBA1A and PPIA but leftmost for all six lncRNAs 
(indicated on y-axis). Three housekeeping genes (GAPDH, TUBA1A and PPIA) and three lncRNAs 
(XLOC_000670, 011226 and 008152) were optimised by PCR with cDNA reverse-transcribed from 
cellular-RNA. Three lncRNAs (XLOC_009577, 001047 and 006043) were optimised by PCR with cDNA 
reverse-transcribed from exosomal-RNA. All primer sets showed product bands at ~100 base pairs (bp) 
for the three biological replicates tested (n=3) and no band for the negative control. 
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Next, these primer sets were used to measure relative gene/lncRNA expression in cells and 
exosomes by qPCR. RNA input was normalised to 80 ng before reverse transcription of 
cellular- and exosomal-RNA. 3 ng primer-set and 2 µl cDNA template were mixed with SYBR 
green mastermix (ThermoFisherScientific) and amplified for 40 cycles of Fast qPCR. Three 
biological replicates were measured in duplicate for each target. Raw CT values, the cycle at 
which amplification is detected over a given threshold, were calculated with automated 
baseline settings and cycle threshold set to 0.1 fluorescence units, as used previously 
(Enderle et al., 2015). 
Raw CT values were as expected from the RNA sequencing data (Figure 5.18). Three lncRNAs 
had lower CT values in cells (XLOC_000670, 011226 and 008152), reflecting increased 
expression, whilst three had lower CT values in exosomes (XLOC_009577, 001047 and 
006043). Of the three housekeeping genes tested, two (GAPDH and TUBA1A) saw higher CT 
values in exosomes. However, PPIA showed fairly uniform mean CT values with 25.18 ± 0.16 
cycles in cells and 25.27 ± 0.68 cycles in exosomes (Table 5.11). Melt curves were also 
analysed to detect any off target amplicons or primer dimers. All replicates showed single 
peaks (Table 5.11) across the samples showing that only the desired amplicons were 
contributing to the detected signal. 
Based on the Raw CT values alone, the trends in the data validate what had been observed 
in the RNA sequencing. However, statistical tests are not appropriate on Raw CT values as 
they are a recorded cycle number between 1 and 40 (Schmittgen and Livak, 2008), so further 
transformation of the data were required. One such transformation is to calculate 2-ΔCT 
where the raw CT values are transformed and normalised against a homogenously expressed 
housekeeping gene. This posed a problem as GAPDH and TUBA1A, although commonly used 
as housekeeping genes for cells and tissues, could not be assumed to be appropriate for 
exosomes and clearly these data showed differentially expression between cells and 
exosomes. Therefore, PPIA was chosen to perform these calculations as the mean CT values 
were comparable between samples (Table 5.11).  
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Figure 5.18: Box and whiskers plot to show differential expression of housekeeping genes and 
lncRNAs measured by qPCR.  
Quantitative PCR (qPCR) was used to measure cycle thresholds (CT, y axis) across cellular and exosomal 
RNA samples (n=3 per group). CT values reflect the cycle number where fluorescence units exceeded a 
set threshold of 0.1 FU. The upper and lower "hinges" of the boxes correspond to the first and third 
quartiles whilst whiskers extend to values within 1.5 x inter-quartile range. Raw CT values are reported 
here for 9 targets, as indicated in the title of each graph. 
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Target Cell CT Cell SD Exosome 
CT 
Exosome 
SD 
Melt curve 
analysis 
GAPDH 24.53537 0.408591 35.20336 1.052481 1 peak at 78.27°C 
TUBA1A 18.93377 0.316468 28.31364 0.566085 1 peak at 79.91°C 
PPIA 25.18366 0.164386 25.2714 0.68322 1 peak at 85.57°C 
XLOC_000670 23.12633 0.203302 29.59134 0.781028 1 peak at 80.5°C 
XLOC_011226 22.503 0.228325 30.3735 1.494005 1 peak at 89.45°C 
XLOC_008152 24.5147 0.198369 30.36 1.176592 1 peak at 76.34°C 
XLOC_009577 30.7341 0.446775 29.14086 0.761161 1 peak at 78.56°C 
XLOC_001047 30.81294 0.8759 28.60822 0.643157 1 peak at 85.58°C 
XLOC_006043 31.44327 1.435735 28.07689 1.50607 1 peak at 81.1°C 
 
Table 5.11: Raw CT values and melt curve analysis of qPCR data.  
Melt curve analysis was performed using qPCR instrumentation on cell and exosome RNA samples (n=3 
per group). CT values reflect the cycle number where fluorescence units exceeded a set threshold of 0.1 
FU. Mean CT values were calculated from three biological replicates measured in duplicate and 
standard deviation (SD) reported. 
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Using PPIA as an endogenous control, 2-ΔCT were calculated for the six lncRNAs. Box and 
whisker plots showed differential expression in the correct direction for each (Figure 5.19). 
Initially, these data were tested for normality using the Shapiro-Wilk test. The significance 
value for all lncRNA targets was greater than 0.05, therefore, the data was normally 
distributed. Parametric tests were appropriate for these data so independent t-tests were 
performed.  
Differential expression was statistically significant for the lncRNAs that showed increased 
expression in cells: XLOC_000670, t(10) = 31.122, p < 0.001; XLOC_011226, t(10) = 12.383, p 
< 0.001; XLOC_008152, t(10) = 23.376, p < 0.001; and increased expression in exosomes: 
XLOC_009577, t(10) = -8.198, p < 0.001; XLOC_001047, t(10) = -9.870, p < 0.001; and 
XLOC_006043, t(10) = -3.398, p = 0.007. Thus, the differential expression of lncRNAs 
observed by RNA sequencing was validated with an independent method and an 
independent sample set. 
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Figure 5.19: Box and whiskers plot to show differential expression of six lncRNAs measured by qPCR. 
Quantitative PCR was used to assess gene and lncRNA expression in cell and exosome RNA samples 
(n=3 per group, measured in duplicate). 2-ΔCT values (y-axis) are reported here by normalisation against 
PPIA expression. The upper and lower "hinges" of the boxes correspond to the first and third quartiles 
whilst whiskers extend to values within 1.5 x inter-quartile range. Independent t-tests were performed 
and p-values <0.05 indicated with *, <0.01 indicated with ** and <0.001 indicated with ***. 
  
Chapter 5. Profiling of cellular and exosomal-RNA from a neuroglioma cell-line 
191 
 
5.3.8 In silico confirmation of differential expression by functional 
annotation of introns 
To utilise more of the data available from the RNA sequencing, and to further confirm the 
findings from differentially expressed lncRNAs, the intronic reads were analysed. To do this, 
a gene model annotation file (in .gtf format) was required to itemise introns and their 
chromosomal positions. The table browser on UCSC (https://genome.ucsc.edu/cgi-
bin/hgTables, accessed November 2016) was used to download intron locations, +50 bases 
flanking sequence, in .bed format (hg19). An awk script was used to process the text into a 
.gtf format, in particular inserting a third column with each row labelled as an intron so that 
HTSeq could perform the count function. As detailed above, in sections 5.3.5 and 5.3.6, the 
same analysis pipeline was followed. 
HTSeq was used to produce intron count files from the mapped reads and DESeq2 to remove 
rows with no counts across the samples. 602508 rows were removed from 659327 resulting 
in a dataset containing 56819 introns. Again, the rlog was calculated to stabilise the variance 
across the mean and Euclidean distances between samples were plotted as a heatmap 
(Figure 5.20). There was separation between cells and exosomes at a sample distance level 
but good similarity within these groups.  This plot further confirmed the biological picture 
that had already emerged from lncRNA analysis: that the RNA profiles of cells and the 
secreted exosomes are distinct.  
The sample-to-sample distances were further visualised with a PCA (Figure 5.21). There was 
a striking distinction between the cell and exosome sample groups with complete separation 
along the x-axis. Within these groups the cell samples showed greatest uniformity between 
biological replicates. There was variance picked up within the exosome samples where 
Exosome B (“E2”) did not cluster as tightly with the other 2 biological replicates. However, 
there was little difference along the first principle component (x-axis). These observations 
reinforce the sample distances heatmap for introns (Figure 5.20) and respective figures for 
lncRNA (Figure 5.10 & Figure 5.11) all of which showed distinction between cells and 
exosomes whilst retaining good uniformity between biological replicates. 
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Figure 5.20: Euclidean distances between samples using rlog transformed data.  
Euclidean distances between samples in the RNA sequencing data was calculated by DESeq2. C1 – C3 
refer to cell samples A – C and E1 – E3 refer to exosome samples A – C. Sample similarity is indicated 
by colour intensity.  
 
Figure 5.21: Principle component analysis showing variance between samples.  
A PCA analysis was performed using DESeq2. The first principle component (PC1, x-axis) describes the 
majority of variance (98%). The second principle component (PC2) is displayed on the y-axis. C1 – C3 
refer to cell samples A – C and E1 – E3 refer to exosome samples A – C.  
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Of the 56819 introns, with >0 counts, 24972 had increased counts in cells and 31847 had 
increased counts in exosomes (Figure 5.22). The false discovery rate threshold was reduced 
to an adjusted Bonferroni p-value of 8.80x10-7. With this, 29919 introns passed Bonferroni 
correction for multiple testing and were found to be differentially expressed between cells 
and exosomes (Figure 5.23). 
Together these data, from a sample and individual intron level, revealed that the RNA cargo 
in exosomes is distinct from the cells they were secreted from. The same observations were 
made when lncRNA expression was analysed. Next, functional annotation of these 
differentially expressed introns was performed. 
In order to perform a functional annotation of these differentially expressed introns the 
intron names were linked to the gene name and sorted by log fold change. Due to 
computational capacity the top 3000 gene names were submitted to the functional 
annotation tool, DAVID, for cells and exosomes separately.  
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Figure 5.22: Heatmap showing log fold change of 30000 introns in cells and exosomes.  
Heatmaps were generated from sequencing data using DESeq2. Due to computational power only 
30000 of the 56819 introns could be plotted. Six samples were assessed (C=cell, E=exosome, x-axis) 
and intron counts indicated by colour intensity. Topological relationships between individual introns 
and samples were automatically generated and presented on both axes. 
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Figure 5.23: An MA plot showing differential intron expression after Bonferroni correction.  
A Minus-Average plot was generated from sequencing data using DESeq2. The mean of normalised 
counts for each intron is displayed on the x-axis and the log fold change between cell and exosome 
samples (n=3 per type) displayed on the y-axis. Each intron comparison is represented by a dot with 
29919 passing Bonferroni correction for multiple testing (red dots) whilst 26900 did not (black dots). 
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Differentially expressed introns in the cell samples pointed to numerous general cellular 
processes (Table 5.12) and enrichment maps were drawn using Cytoscape v3.4.0 
(Figure 5.24). These included enrichment of terms such as acetylation (p=3.21x10-116), 
phosphoprotein (p=1.07x10-99), nucleus (p=5.16x10-44), ubiquitin-like protein conjugation 
(p=1.74x10-38), cytoplasm (p=4.17x10-30) and ribosomal protein (p=5.69x10-26). Such terms 
describe the intracellular functioning of cells in general. Some terms, such as “Mental 
retardation” and “Neurodegeneration”, reflect that the cell-line was of neural origin, despite 
being slightly unexpected.  
Differentially expressed introns in the exosome samples pointed to the molecular 
composition of these vesicles (Table 5.13) and enrichment maps were drawn using Cytoscape 
v3.4.0 (Figure 5.25). These included enrichment of terms such as glycoprotein (p=7.17x10-
24), secreted (p=7.49x10-18), disulphide bond (p=3.41x10-15), ion channel (p=1.97x10-7) and 
transmembrane (p=2.52x10-5). Some unexpected terms came out of the analysis, such as 
“Vision”, “Hearing” and “Deafness”. Whilst these terms may reflect that the cell-line was of 
neural origin, these are more likely to be explained as artefacts from the enrichment analysis. 
Overrepresented genes, such as those of long length, can cause unexpected terms as 
discussed for the lncRNA analysis. For example, RP1 is a 211 kbp gene that contributed to 
the enrichment terms “Polymorphism” and “Vision”. Therefore, the general observation of 
enriched terms that describe the molecular composition of exosomes was accepted and 
confirmed what had been reported in the lncRNA analysis. In both cell and exosome 
enrichment maps, categories were limited to UP_KEYWORDS only to ensure they were 
visually interpretable. 
Again a strong biological distinction was made between the transcriptome of H4 cells and 
secreted exosomes. Whilst general processes within the cell are reflected in the 
transcriptome, terms such as “glycoprotein”, “disulphide bond” and “transmembrane” are 
enriched in the transcriptome of exosomes.  
These observations are in agreement with the enrichment maps drawn from lncRNA and co-
expressed mRNA. Indeed, a number of the terms were identical in both analyses e.g. 
“glycoprotein” in exosomes and “acetylation” in cells. Overall, the cell samples were 
enriched for general intracellular processes and exosomes for molecular features of these 
vesicles. As such, analysing the intronic data from the RNA sequencing provided a good in 
silico confirmation of the lncRNA differential expression analysis using a separate, although 
overlapping, part of the RNA sequencing data. These data must be carefully interpreted by 
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accepting that there is a disconnection between intronic reads in exosomes and enrichment 
of functional terms.   
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Category Term p-Value Genes 
UP_KEYWORDS Acetylation 3.21E-116 XRCC5, LDHA, PLEKHM2, RPL14, RPL13, XRCC6, NAA15, STOML2, INTS1, RPLP2… 
UP_KEYWORDS Phosphoprotein 1.07E-99 LDHA, OSMR, VPS54, RPLP2, AMOTL2, SART1, CUL3, MAK16, CUL7, CUL9… 
UP_KEYWORDS Nucleus 5.16E-44 XRCC5, SURF6, XRCC6, NAA15, INTS1, MED23, CIAPIN1, SART1, CTNNB1, CUL3… 
UP_KEYWORDS Ubl conjugation 1.74E-38 XRCC5, ADCY3, LDHA, HMGN2, SLC9A6, RPL19, RPL14, RPL13, U2AF2, XRCC6… 
UP_KEYWORDS Isopeptide bond 1.03E-31 XRCC5, ADCY3, RPL19, HMGN2, SLC9A6, RPL14, RPL13, U2AF2, XRCC6, RNF213… 
UP_KEYWORDS Ribonucleoprotein 1.80E-31 HNRNPA1L2, MRPS36, MRPS34, RPL19, RPL14, RPL13, RPL15, RPLP2, MRPS30, 
RPS19BP1… 
UP_KEYWORDS Cytoplasm 4.17E-30 KIFC2, LDHA, PLEKHM2, RUSC2, NAA15, STOML2, MYLIP, CIAPIN1, CTNNB1, 
MAGED1… 
UP_KEYWORDS Ribosomal protein 5.69E-26 MRPS36, MRPS34, RPL19, RPL14, RPL13, RPL15, RPLP2, MRPS30, RPS19BP1, RPS3… 
UP_KEYWORDS RNA-binding 4.30E-25 NCBP2, RNMT, DZIP3, ZC3HAV1, XPO5, SURF6, U2AF2, RBM3, NSUN5P1, NONO… 
UP_KEYWORDS Host-virus interaction 9.21E-19 PVR, DYNC1LI1, TLN1, LDLR, TBK1, COPS6, IL6ST, IDE, ANKRD17, ACOT8… 
 
Table 5.12: Functional terms associated with introns differentially expressed in cells over exosomes.  
Functional terms were provided by David software after differential intron expression analysis of sequence data using DESeq2. The top 10 terms (by p-value) are displayed 
here and the first 10 genes in each group are listed. 
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Category Term p-Value Genes 
UP_KEYWORDS Glycoprotein 7.17E-24 TEX101, GDF3, SLC52A1, SERPINA13P, MASP1, ATP1B2, LYPD5, SLC9A4, CRHBP, 
LHCGR… 
UP_KEYWORDS Signal 4.55E-21 TEX101, GDF3, SLC52A1, SERPINA13P, MASP1, LYPD5, CRHBP, LHCGR, GDF5, FSTL4… 
UP_KEYWORDS Secreted 7.49E-18 GDF3, SERPINA13P, MASP1, CRHBP, GDF5, FSTL4, SHH, APOB, SOSTDC1, CCBE1… 
UP_KEYWORDS Disulfide bond 3.41E-15 GDF3, MASP1, ATP1B2, CRHBP, GDF5, LHCGR, SYT9, FSTL4, CD48, APOB… 
UP_KEYWORDS Polymorphism 5.69E-14 RP1, SLC52A1, MASP1, SLC9A4, FSTL4, KIFC3, C16ORF78, TBPL2, TMEM145, 
GRIN2D… 
UP_KEYWORDS Ion transport 1.75E-08 SLC5A5, SLC5A4, GABRB3, ATP1B2, SLC9A4, SLC5A1, KCNK18, KCNJ10, KCNK12, 
CNGB3… 
UP_KEYWORDS Ion channel 1.97E-07 GABRB3, KCNK18, PANX3, KCNJ10, KCNK12, KCNA7, CNGB3, FXYD7, KCNMB2, 
PKD1L3… 
UP_KEYWORDS Vision 9.34E-06 RP1, GUCY2F, NDP, RP1L1, C2ORF71, BFSP2, RCVRN, RPGRIP1, VSX2, CNGB3… 
UP_KEYWORDS Serine protease inhibitor 9.99E-06 WFDC10A, HMSD, SERPINA13P, SERPINA11, SERPINA12, SPINK4, A2ML1, SPINK8, 
SERPINB9, CPAMD8… 
UP_KEYWORDS Transmembrane 2.52E-05 HIGD1C, SLC52A1, RARRES1, SERTM1, ATP1B2, SLC9A4, LHCGR, AQP4, SYT9, CD52… 
 
Table 5.13: Functional terms associated with introns differentially expressed in exosomes over cells.  
Functional terms were provided by David software after differential intron expression analysis of sequence data using DESeq2. The top 10 terms (by p-value) are displayed 
here and the first 10 genes in each group are listed. 
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Figure 5.24: Functional annotation of the top 3000 introns differentially expressed in cells over exosomes.  
Functional terms were annotated from sequencing data using DAVID software, limited to UP_KEYWORDS only, and plotted using Cytoscape software. Each term is represented 
by circles with the size of each circle representing the number of genes within the term and the thickness of line represents the number of overlapping genes between terms. 
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Figure 5.25: Functional annotation of the top 3000 introns differentially expressed in exosomes over cells.  
Functional terms were annotated from sequencing data using DAVID software, limited to UP_KEYWORDS only, and plotted using Cytoscape software. Each term is represented 
by circles with the size of each circle representing the number of genes within the term and the thickness of line represents the number of overlapping genes between terms. 
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5.4 Discussion 
This chapter aimed to validate procedures for isolating exosomal-RNA and to profile RNA 
from exosomes and the parent cell. It has previously been described that nuclease treatment 
should be used to ensure the analysis of genuine intra-luminal RNA (Hill et al., 2013) and 
procedures have been reported (Shelke et al., 2014). This PK/RA digestion was validated in-
house and showed a 42% digestion of RNA in the exosome preparation (Figure 5.1). Notably, 
the population of small RNAs was removed which was reflected in the DV200 calculations of 
89% for the treated sample, compared to 69% for the PBS-treated control (Table 5.1). This 
suggests that the non-vesicular RNA present in these preparations is enriched for small RNA 
species, such as miRNAs, and that this population can be removed by PK/RA digestion. This 
is in concordance with a previous study that showed Argonaute2 forms a complex with 
miRNA and is present in the circulation in vivo separately from vesicle-derived RNA (Arroyo 
et al., 2011). Based on these observations it was considered of great importance to include 
the PK/RA digestion in this study. Not all studies include this digestion step and subsequently 
analyse a mixed population of vesicular and non-vesicular RNA. It is questionable if the 
functional conclusions of such studies are overstated. Thus, the PK/RA procedure was 
validated and used in this study for extracting RNAse-resistant, intra-luminal RNA, which was 
protected by being located inside the exosomes. 
Three biological replicates of H4 cells and secreted exosomes were established for RNA 
analysis. Cellular-RNA was extracted at the same time as exosome isolation to allow the most 
direct comparison between the two sample types. Electrophoretic analysis revealed a 
difference between cellular- and exosomal-RNA, consistent with published data (Shelke et 
al., 2014). Cellular-RNA was replete with rRNA as observed with the 18S and 28S peaks whilst 
the traces for exosomal-RNA lacked such peaks (Figure 5.2). These observations were 
reflected in the RNA integrity (RIN) and DV200 scores (Table 5.2). The RIN scores were a 
maximum of 10 for cell samples indicating no degradation of RNA. These were much lower 
at 2.1-2.2 for exosome samples but this is an unsuitable measurement of RNA quality in 
exosomes as they lack rRNA which the score is calculated from. Instead, here proposed for 
the first time, the use of the DV200 calculation as an indication of RNA integrity in exosomes. 
This score calculates the percentage of fragments >200 nucleotides in length and has been 
used previously to assess the suitability of formalin-fixed paraffin-embedded tissue for RNA 
sequencing (Eikrem et al., 2016). In consensus with manufacturer guidelines, the exosome 
samples, ranging from 57-64% DV200, were of good quality for downstream sequencing. Thus 
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the DV200 calculation is of utility for assessing exosomal-RNA quality and worth incorporating 
into future workflows. 
Whole transcriptome sequencing was performed on the HiSeq 2500, where only rRNA was 
depleted in the library preparation stage (Benes et al., 2011). Thus, the most comprehensive 
RNA profiling that was possible for this study was performed; an approach that would be 
suitable for others in the field to follow. The sequencing was of high quality but the exosome 
reads did not map and align as efficiently as cell samples. This was investigated further and 
deemed to be an intrinsic property of exosomal-RNA, whereby longer inserts in the prepared 
libraries (Figure 5.3) caused a divergence from the reference. Therefore, it could be 
advantageous, prior to future work, to refine the library preparation procedure for 
exosomes, but this was beyond the time and cost limitations of this project. This divergence 
from the reference caused by long inserts was the first of many observations that revealed 
that the repertoire of exosomal-RNA is fundamentally different from the source cell. This 
was investigated further by analysis of the RNA sequencing data. GATK guidelines and a 
recent survey of RNAseq data analysis best practices (Conesa et al., 2016) where referred to 
in the establishment of the pipeline described here. 
The Picard tool CollectRnaSeqMetrics was used to get a global view of the cell and exosomes 
transcriptomes (Figure 5.8). An unprecedented difference between exosomal-RNA and the 
source cell was revealed. Over 96% of reads measured from exosomes were non-coding and 
thus, a completely different profile to cellular-RNA which contained a large proportion of 
coding RNA. It has been noted that the library preparation technique may have driven a 
preferential sequencing of intronic and intergenic reads which may have led to the difference 
between sample types being exaggerated. Considering the literature, which has 
demonstrated functionally active coding RNA in exosomes (Valadi et al., 2007), it should not 
be concluded that exosomes are devoid of coding RNA completely. Even if this library 
preparation technique has exaggerated the difference between cellular- and exosomal-RNA, 
the libraries were prepared simultaneously and the samples can be directly compared. It can 
be concluded then that the difference between transcriptomes is genuine. 
To date, different techniques have been used to analyse exosomes compared to the source 
cell (Skog et al., 2008, Valadi et al., 2007, Nolte-'t Hoen et al., 2012, Cheng et al., 2014, Royo 
et al., 2013, Li et al., 2013, Ahadi et al., 2016b). Microarray analysis has revealed non-
correlation between cells and exosomes (Skog et al., 2008) and small RNA sequencing 
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showed different profiles of small RNA species (Cheng et al., 2014), but not to this extent, as 
described with whole transcriptome sequencing. 
Functional enrichment analyses were then performed to investigate if RNA was randomly 
packaged into exosomes. However, the vastly different profiles of cells and exosomes posed 
a problem for such analyses. A differential gene expression analysis would be skewed by the 
normalisation step that takes into account the size of the library. Indeed, directly comparing 
exonic reads from such fundamentally different samples in this way would be inappropriate. 
So without directly comparing cells to exosomes based on their exonic gene counts, two 
other avenues of investigation were pursued. Firstly, long non-coding RNAs (lncRNA) were 
chosen as they would come under the intronic and intergenic portions of the reads. Secondly, 
the intronic reads were directly compared between samples. By linking back to the 
associated gene-names, functional annotation was possible. 
The analysis of differentially expressed lncRNAs and co-expressed mRNAs allowed the first 
functional analysis. Terms enriched in cells included “protein binding”, “chromosome”, 
“acetylation”, “phosphoprotein”, “nucleosome core” and “ubiquitin-like protein 
conjugation”. Such terms, in general, describe the dominant structures and processes within 
cells. Equivalent terms in exosomes included “disulfide bond”, “Glycoprotein”, “glycosylation 
site:N-linked”, “topological domain:Extracellular” and “Secreted”. With striking specificity 
these terms reflect the known protein composition of exosomes and appear similar to 
several proteomics based analysis of vesicles (Webber et al., 2014, Kalra et al., 2012, Simpson 
et al., 2012). Indeed, it has been described that glycosylation is one of the processes by which 
exosomal proteins are regulated (Kore and Abraham, 2016) and glycoproteins on the surface 
of exosomes play important physiological roles such as the binding of activated platelets in 
the coagulation cascade (Del Conde et al., 2005). Tetraspanins such as CD63, CD81 and CD9 
and tetraspanin webs are proteins that are characteristic of exosomes, as described in 
chapter 3, and are based on disulphide bonds to keep the structural integrity and stability of 
vesicles. One study demonstrated that most of the exosomal proteins, from B-cells, were 
insoluble in CHAPS-containing buffers and thus, extensively include tetraspanins to be 
detergent-resistant vesicles (Wubbolts et al., 2003). 
It is remarkable that by analysing lncRNA expression, and intron expression as discussed 
below, an enrichment of such functionally relevant terms has been demonstrated. LncRNA 
and intronic reads do not represent coding RNA so there is a disconnection between their 
presence in exosomes and their functional role. Most notably, there is no translation 
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machinery, such as rRNA, in exosomes so there is currently no apparent reason for why these 
species should be enriched. It is also notoriously difficult to interpret enrichment maps with 
absolute certainty. To provide further weight behind these observations qPCR replication of 
6 of the lncRNA candidates was performed and a differential expression analysis of introns, 
which did not require the co-expression step, retrieved similar results.  
One conclusion that can be drawn from these data, accepting the caveat of the disconnection 
between non-coding RNA and functional activity in exosomes, is that the sorting of RNA into 
exosomes is not an entirely random process. This is in concordance with other studies which 
have shown that the exosomal-RNA profile is altered when cells are subject to hypoxia (Li et 
al., 2016a, Gray et al., 2015, Yang et al., 2016) and oxidative stress (de Jong et al., 2012, Eldh 
et al., 2010). The observation here, using whole transcriptome RNAseq analysis, suggests 
that there are intracellular processes for sorting RNA into exosomes. According to the 
literature these processes appear to be sensitive to the state of the cell and, together with 
this current study, implies that the dynamics of vesicular RNA is functionally important. 
These processes, underlying the sorting of RNA into extracellular vesicles, are unknown but 
hypotheses were made in a 2017 position statement from ISEV (Mateescu et al., 2017). 
Leading this discussion was the observation that miRNA is prone to rapid degradation by 
nucleases (Mitchell et al., 2008b) but dramatically more stable when bound to RNA-binding 
proteins such as the Argonaute (AGO) family (Olejniczak et al., 2013). Thus, sorting RNA into 
vesicles is fundamentally a discussion on the interaction with RNA-binding proteins. Studies 
have shown that AGO2, and other miRNA-interacting proteins, can interact with components 
of the endocytic tracts such as multi-vesicular bodies (Gibbings et al., 2009, Lee et al., 2009), 
endoplasmic reticulum (Stalder et al., 2013) and endogenous prion protein which is a 
transmembrane protein in the endolysosomal network (Gibbings et al., 2012). Currently it is 
inconclusive if AGO proteins are generally associated with extracellular vesicles but it is likely 
that post-translational modification of the protein, and modulation of miRNA transcripts, 
would play a role in the incorporation into EVs (Mateescu et al., 2017). Indeed, a number of 
RNA motifs have been associated with incorporation into EVs (Szostak et al., 2014, Batagov 
et al., 2011) including a GGAG motif on miRNAs that binds to sumoylated heterogeneous 
nuclear ribonucleoprotein A2B1 for loading into exosomes (Villarroya-Beltri et al., 2013). 
Thus, it has been proposed that there may be active and passive loading of RNAs into EVs, 
such as exosomes, based on the interaction of RNAs with RNA-binding proteins, but as yet 
these processes have not been thoroughly investigated (Mateescu et al., 2017). 
Chapter 5. Profiling of cellular and exosomal-RNA from a neuroglioma cell-line 
206 
 
Here, it has been observed that the RNA packaged into exosomes and secreted out of the 
cell are indicative of the known protein composition of these vesicles and thus not packaged 
by random. This was not a phenomenon that might have been expected, yet is in agreement 
with, and provides additional evidence for, the current opinion in the field (Mateescu et al., 
2017).  
To ensure the validity of these observations two lines of inquiry were followed. First, 
differential expression of six of the lncRNAs was replicated with separately prepared samples 
and using qPCR as an independent method (Figure 5.19). Second, the equivalent differential 
expression analysis was performed with introns. Functional annotation and enrichment 
analysis of introns revealed similar and overlapping terms as described for the lncRNA 
analysis. These observations confirmed the original lncRNA analysis. 
In the future it would be beneficial to directly investigate the function of these differentially 
expressed lncRNAs. It has been demonstrated that exosomal miRNAs can be 
pharmacologically inhibited leading to physiological changes, for example, pathological 
changes in cardiac hypertrophy (Bang et al., 2014). It is also possible to target lncRNAs for 
overexpression and silencing. One study showed that expression of the lncRNA, Chast, can 
be altered in vivo and in an in vitro cell model of cardiac remodelling (Viereck et al., 2016). 
Another study showed differential expression of lncRNAs as a response to hypoxia in 
endothelial cells and experimental validation that two of these drove angiogenic defects 
(Fiedler et al., 2015). Thus, the tools are available to further the work in this study and more 
deeply investigate the roles of lncRNAs in exosomes. 
It can be concluded that the sorting of RNA into exosomes does not occur entirely by random. 
The processes that underlie this phenomenon are unknown and would require a different 
avenue of investigation to unearth. The whole transcriptome sequencing approach, used 
here, has also revealed an unprecedented distinction in the repertoire of RNA in exosomes 
compared to the source cell. Exosomes appear to be a route for ncRNAs, non-randomly 
sorted, to be eliminated from the cell and into the extracellular milieu. This affirms the 
direction of investigation in this thesis: that exosomes, and their encapsulated, nuclease-
resistant, stable RNA, have potential to be utilised for biomarkers of AD. Therefore, the 
direction of the final chapter was to move from cell culture-derived exosomes to patient-
derived exosomes. The challenges of isolating exosomes from biological fluids were 
addressed next. 
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6.1 Introduction 
Exosomes are of growing interest for biomarkers of AD, given the recent findings in the field 
of cancer. For example, the proteoglycan, glypican-1, was measured on exosomes isolated 
from pancreatic cancer patient serum and showed absolute specificity and sensitivity for 
identifying patients over healthy controls (Melo et al., 2015); although for many reasons, 
including image manipulation, this publication has questionable credibility. In the field of 
neurological diseases, such as AD, exosomes have good potential as a biomarker as they are 
known to pass bi-directionally over the blood-brain barrier. In one study, a glioblastoma 
specific mRNA, EGFRvIII, was detected peripherally in exosomes isolated from patient serum 
(Skog et al., 2008). Another study detected myelin proteins on serum-derived exosomes from 
patients with multiple sclerosis (Galazka et al., 2017). Exosomes passing the opposite 
direction has also been observed in a murine model. Exosomes loaded with siRNA were able 
to achieve knockdown of BACE1 in mouse brain (Alvarez-Erviti et al., 2011). In essence, 
exosomes from peripheral blood hold potential for use as a non-invasive “liquid biopsy” of 
processes occurring in the brain. 
Peripheral exosomes have been investigated for a number of neurological diseases. One 
technique, that has been adopted for multiple diseases, is to enrich for exosomes of neural 
origin and analyse protein expression in patients and healthy controls (Goetzl et al., 2015b, 
Fiandaca et al., 2015, Hamlett et al., 2016, Mullins et al., 2017, Goetzl et al., 2015a, Mustapic 
et al., 2017).  
Using this technique it has been demonstrated that the expression of a number of proteins 
are significantly altered in AD. These include: LRP6, HSF, REST, cathepsin D, LAMP-1, 
ubiquitin, HSP70, total tau, P-T181-tau, P-S396-tau and Aβ1–42 (Goetzl et al., 2015a, Goetzl 
et al., 2015b, Fiandaca et al., 2015). In these studies, similar observations were also made for 
frontotemporal dementia (FTD) (Goetzl et al., 2015a, Goetzl et al., 2015b, Fiandaca et al., 
2015). The same technique was used with Down’s syndrome (DS) patients to measure the 
AD-related proteins Aβ1–42, P-T181-tau and P-S396-tau for the early detection of AD 
pathology, which is often masked by intellectual disability (Hamlett et al., 2016). 
In the case of Parkinson’s disease (PD), plasma-derived exosomes have shown elevated 
protein concentrations of α-synuclein over healthy controls in a large cohort (Shi et al., 2014). 
Interestingly, this observation was in contrast to what was known previously: that α-
synuclein was consistently lower in patient CSF. Cells can transmit toxic forms of prion 
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protein (PrPsc) in association with exosomes as a potential route of propagating 
neurodegenerative Prion disease (Fevrier et al., 2004). In the case of Amyotrophic lateral 
sclerosis (ALS), exosomes have been shown to harbour misfolded forms of superoxide 
dismutase 1 (SOD1) (Grad et al., 2014) and TAR DNA-binding protein-43 (TDP-43) (Nonaka et 
al., 2013) and thus, a potential route of intercellular transfer. Observed using a cell culture 
model, polyglutamine huntingtin protein and RNA containing the expanded CAG repeat were 
transferred between cells, via exosomes, as a potential route of propagating Huntington’s 
disease (HD) (Zhang et al., 2016c). Thus, exosomes have been implicated in a number of 
neurodegenerative diseases and investigating the potential of utilising them as biomarkers 
has already begun in a number of these diseases. 
Isolating exosomes from peripheral blood comes with some difficulties. An issue for 
proteomic analyses, in particular, is the contamination of abundant proteins such as Human 
Serum Albumin (HSA) that can co-isolate with exosomes (Welton et al., 2015). Within the 
total population of exosomes there are many sub-populations representing different tissues, 
as discussed in Chapter 4. Solutions are available to select sub-populations of relevance to 
disease (Mustapic et al., 2017) which should enrich for the signal under investigation. 
However, this reduces the yield of material obtained in the isolation procedure which is likely 
to be a particular problem for isolating RNA which is present in low quantities in exosomes 
(Enderle et al., 2015). Not enriching for exosomes from disease-relevant tissue provides a 
larger amount of material to analyse but may be littered with “noise” from other, unwanted, 
tissue types.  
The availability of material to analyse is a limiting factor in exosome research. For example, 
RNA extracted from blood-derived exosomes is measured in the picogram range (Enderle et 
al., 2015). Nevertheless, a benefit of utilising exosomes from biological fluids is that they 
provide a source of nuclease-resistant RNA (Cheng et al., 2014). Exosomal-RNA is 
encapsulated in a lipid-bounded vesicle and this study demonstrated, in chapter 5 using cell 
culture-derived neuroglioma exosomes, that this provides protection from enzymes such as 
RNase A compared to circulating, free RNA which is susceptible to such degradation. 
A number of considerations have so far been highlighted for isolating exosomes from 
biological fluids. These considerations include overcoming the contamination of highly 
abundant proteins in a complex fluid, such as blood, and achieving a balance between 
selecting a sub-population of disease/tissue-relevant exosomes whilst maintaining sufficient 
yield for RNA analysis. It is worth noting that the scalability of the isolation method is also an 
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important consideration. In chapters 3 and 5, highly pure exosomes were isolated from the 
conditioned media of neuroglioma cell cultures by ultra-centrifugation, non-vesicular RNA 
was removed by PK/RA digestion and a sufficient yield of exosomal-RNA was obtained for 
sequencing. This workflow provided pure samples but was time- and labour-intensive. 
Therefore, the same methods of exosomal-RNA isolation may not be directly applicable to a 
biomarker study with patients where handling biological fluids have inherent technical 
challenges and large sample numbers are required. This chapter aimed to address these 
challenges whilst developing a scalable workflow for analysing exosomal-RNA from patient 
plasma. 
There have been two studies that have undertaken RNA sequencing of blood-derived 
exosomes for biomarker discovery in AD, to date. The first of these reported the use of 4 ml 
plasma to obtain less than 100 pg RNA (Lugli et al., 2015). Despite being below 
manufacturer’s guidelines for input, cDNA libraries were successfully prepared and small 
RNA sequencing performed. Screening of AD cases unveiled 20 miRNAs associated with 
disease, 7 of which worked well in a machine-learning model of predicting disease. The 
second of these studies reported the use of 1 ml serum to isolate exosomal RNA but did not 
report the yield of RNA (Cheng et al., 2015). Nevertheless, sequencing and qPCR replication 
was performed and a panel of 16 miRNAs showed sensitivity and specificity for AD prediction 
in combination with other risk factors. Both studies performed small RNA sequencing but 
there was little overlap in the results (Kumar and Reddy, 2016). However, one miRNA, miR-
342-3p, was down-regulated in AD across both studies. These results highlight the difficulty 
in finding consensus across biomarkers of AD and the capabilities of the sequencing 
platforms were stretched by the input material. Therefore, a challenge remains in isolating 
sufficient exosomal material from blood for such biomarker discovery studies. 
An added complication is that often a clean and conclusive diagnosis of AD is not possible 
until post-mortem. Yet the pre-clinical and symptomatic phases of disease, during which 
biomarkers are needed, occurs over decades (Villemagne et al., 2013). Whilst collecting 
stocks of biological fluids from probable AD cases is relatively easy, collecting biological fluids 
collected from definitively diagnosed AD cases can be difficult. These stocks can be easily 
depleted as participants may have deceased before a conclusive diagnosis had been made. 
This means that high volumes, such as the 4 ml plasma used by Lugli et al., are not readily 
available if the original collection was performed years previously. To address this 
complication, an assay to investigate exosomes from minute volumes of plasma is much 
needed so that easily-depleted, archived materials can be used to obtain meaningful data. 
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6.2 Aim 
The aim of this chapter was to identify and overcome the obstacles of isolating exosomal-
RNA from minute volumes of blood and develop an assay for the detection of AD biomarkers. 
To achieve this aim the following objectives were addressed: 
 Prior to accessing archived material, use Nanoparticle Tracking Analysis to assess the 
effects of freezing plasma samples over time and detect any gross aggregation or 
loss of particles  
 Assess the efficacy of ultra-centrifugation, size exclusion chromatography and spin-
column based isolation as techniques for obtaining sufficient yields of plasma 
exosomal-RNA for downstream analysis 
 Develop a scalable workflow for extracting exosomal-RNA from 0.5 ml plasma 
 Investigate a selection of candidate exosomal-RNA targets for their potential to be 
disease discriminating in a case:control cohort 
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6.3 Results 
6.3.1 Effect of freezing plasma over time on exosome size and concentration 
The first aim addressed was assessing the effect of freezing plasma samples over time on the 
size and concentration of exosomes. Blood was collected into potassium-EDTA tubes from 
four healthy donors and processed for the isolation of plasma. In short, these were 
centrifuged at 400 x g for 7 min, re-centrifuged at 6000 x g for 10 min, passed through 0.2 
µm filters and aliquoted before freezing. This procedure allowed for the assessment of 
exosomes and particles of similar size by NTA measurements. These were performed at Day 
0 (non-frozen plasma), Day 2, Day 7, Day 14 and Day 30. For the sake of clarity, NTA 
measurements will be referred to as “particles” due to the co-detection of other, non-
vesicular, particles of similar size. 
A histogram showing particle size against particle concentration is displayed in Figure 6.1A 
based on six NTA measurements of one donor, at Day 0, but indicative of the whole dataset. 
A sharp peak was observed at 64 nm. Alternatively, the mean can be averaged and in this 
instance would result in a size of 75.21 ± 1.66 nm compared to averaging the mode to give a 
size of 64.33 ± 0.84 nm. Due to the size distribution observed in the raw data (Figure 6.1A), 
averaged mode size was chosen as the standard measurement of particle size. 
Particle size was determined for each donor over the time course (Figure 6.1). There was a 
general trend for particles to increase in size over the time course reaching a peak on Day 14 
of ~100 nm. Assessing the donors individually (Figure 6.1C), this appears to be driven by a 
large spike in Donor 4. Such readings can occur if particles aggregate and are therefore 
detected as one larger particle by the system. It is important that this phenomenon is 
counteracted by taking repeated video measurements or increasing the time of recording. 
In this study, six videos of 30 s duration were taken as used elsewhere (Webber and Clayton, 
2013). By Day 30, this trend had plateaued and the size range over the time course was 70-
100 nm which was within the expected size range for exosomes (El Andaloussi et al., 2013). 
Shapiro-Wilk tests confirmed that data were normally distributed on each day, except day 
14. The Q-Q plot for day 14 was visualised and it was apparent that this lack of normality was 
driven by the outlying data point. Therefore, it was deemed that a parametric test was most 
appropriate for the whole dataset. A repeated measures ANOVA, using SPSS statistics 
software, determined that there was no statistically significant difference in particle size over 
30 days of freezing F(1.344, 4.032) = 2.441, p = 0.198. 
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Overall, these data suggest that there may be a small element of vesicle aggregation over 
time frozen. This phenomenon does not cause a statistically significant change in particle size 
and stayed within the range expected for exosomes. Therefore, it appears that the vesicles 
within plasma are stable at -80°C, however, the limitations of NTA must be considered. 
Firstly, NTA measure particles without discriminating between exosomes and non-vesicular 
particles of the same size, such as high-density lipoproteins. Secondly, NTA gives no 
indication of vesicle structure. In chapter 3, cryo-EM was performed on cell culture-derived 
exosomes that had been previously frozen at -80°C and detected intact vesicles of spherical 
structure with unilaminar lipid bilayers. Such methods would be required to conclusively 
determine that vesicle structure is not degraded by freezing plasma over time but this was 
beyond the scope of this thesis. However, cryo-EM has been performed on exosomes 
isolated from frozen plasma elsewhere, and similar structures were observed (Welton et al., 
2016). Thirdly, NTA gives no indication of molecular degradation caused by the freezing 
process. Enzymatic assays would need to be performed for the activity of proteins such as 
acetylcholinesterase (Lotvall et al., 2014) but particularly, for this study, there is no indication 
of the integrity of the exosomal-RNA. These assessments were performed with archived, 
frozen plasma samples in sections 6.3.5 and 6.3.7. Overall, this approach has given an 
indication that there is no gross aggregation of vesicles caused by the freezing process. 
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s 
disease 
214 
 
 
Figure 6.1: The effect of freezing plasma on particle size over time.  
Plasma samples were obtained from four donors, frozen over a 30 day period an assessed by 
Nanoparticle Tracking Analysis. A) A histogram showing particle size (x-axis) and concentration (y-axis) 
measured by NTA (n=6) for one sample but indicative of the whole dataset. B) A bar chart showing 
mode particle size for each donor separated (n=6 videos per donor at each time point). C) A line graph 
showing averaged mode size across all donors.  
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Next, the effect of freezing on particle concentration was assessed. NTA provided an output 
of concentration and size so the same sets of videos were used as above.  
Particle concentration for each donor, over the 30 day time course, were obtained 
(Figure 6.2). The concentration of particles remained stable over the time course with no 
overall trend showing an increase or decrease. Shapiro-Wilk tests confirmed that data were 
normally distributed on each day so parametric statistical tests were appropriate. A repeated 
measures ANOVA determined that there was no statistically significant difference in particle 
concentration over 30 days of freezing F(1.986, 5.959) = 2.674, p = 0.148. Particle 
concentrations stayed within a range of ~2.5x1013 particles/ml and ~4.5x1013 particles/ml. 
Overall these data suggest that there was no overall fluctuation in particle concentration 
over the time course. This confirmed that the process of freezing and storing plasma at -80°C 
caused no gross aggregation (determined by size) or gross loss of particles (determined by 
concentration) over the course of 30 days. 
The limitations of using NTA to draw these conclusions has been highlighted above, namely, 
that non-discriminate particles are measured in this technique with no indication of changes 
in structural or molecular degradation. Nevertheless, these observations bolster support for 
using frozen, archived plasma. The time course studied here was for plasma stored for up to 
30 days which may be a shorter time than archived material, however, no significant trends 
where observed for particle concentration or size. Therefore, there has been some indication 
that plasma samples are stable at -80°C and consequently frozen, archived plasma was used 
next for the isolation of exosomal-RNA.  
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Figure 6.2: The effect of freezing plasma on particle concentration over time.  
Plasma samples were obtained from four donors, frozen over a 30 day period an assessed by 
Nanoparticle Tracking Analysis. Top: a bar chart showing averaged particle concentration for each 
donor separated (n=6 per donor at each time point). Bottom: a line graph showing averaged particle 
concentration across all donors.  
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6.3.2 Isolating exosomes and exosomal-RNA from human plasma 
Different methods of isolating exosomes from plasma were compared with an aim to identify 
obstacles prior to the isolation and analysis of exosomal-RNA. Different solutions have been 
proposed for this including differential ultra-centrifugation (Thery et al., 2006), size-exclusion 
chromatography (Welton et al., 2015), density gradients or cushions (Thery et al., 2006), 
immuno-precipitation (Mustapic et al., 2017) and spin column-based isolation (Enderle et al., 
2015). Here ultra-centrifugation, size-exclusion chromatography using ExoSpin™ (Cell 
Guidance Systems) and spin column-based exoRNeasy™ (Qiagen) were compared. 
These three methods were selected as they provided a range of principally different isolation 
techniques. Ultra-centrifugation was used in chapter 5 to pellet exosomes from cell-
conditioned media and, in combination with PK/RA digestion, exosomal-RNA isolated for 
sequencing. It was expected that, when applied to plasma, this technique would 
indiscriminately pellet non-vesicular particles and soluble proteins with exosomes so would 
again require the PK/RA digestion step to ensure genuine vesicular RNA was isolated. 
Provided that the pelleting efficiency of exosomes in plasma is similar to cell-conditioned 
media, reported to be greater than 90% efficiency in the Clayton laboratory, this technique 
should pellet the majority of exosomes in the sample without preferentially selecting a sub-
population. However, a disadvantage of this technique is that ultra-centrifugation is time- 
and labour-intensive so technically challenging to scale up for numerous samples. Size-
exclusion chromatography allows exosome-containing fractions to be separated from human 
serum albumin (HSA). This provides a purer sample but increases the volume of exosome-
containing liquid that requires ultra-centrifugation (Welton et al., 2015). Again, this 
combination of steps is time- and labour-intensive and the pellet would again require PK/RA 
treatment. As an alternative method, a spin-based column does not require ultra-
centrifugation or PK/RA treatment. It has been reported that the exoRNeasy™ columns have 
high specificity for vesicular- over non-vesicular RNA and only requires standard centrifuge 
equipment. Therefore, this technique is principally different from ultra-centrifugation and 
size-exclusion chromatography, however, the commercial kit increases the cost of sample 
preparation. 
It is vital to strike the right balance between sample purity, cost and scalability for an isolation 
method to be tractable. This balance is considered and discussed below as exosomal-RNA 
was extracted using the three different isolation techniques. 
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6.3.3 Isolating plasma exosomes by ultra-centrifugation 
The plasma samples, used in section 6.3.1 above, were ultra-centrifuged at 200,000 x g for 2 
hours to obtain a pellet (Optima-MAX ultracentrifuge, with TLA-110 rotor, k-factor = 13). To 
assess the efficiency of ultra-centrifugation, NTA was used to measure particle concentration 
pre- and post-ultracentrifugation in the supernatant (Figure 6.3). Particle concentration was 
reduced from 3.67x1013 ± 2.88x1012 particles/ml before ultracentrifugation to 2.79x1013 ± 
2.58x1012 particles/ml in the supernatant afterwards. A Shapiro-Wilk test confirmed that 
data were normally distributed so parametric statistical tests were appropriate. Whilst a 
paired t-test showed a statistically significant difference in particle concentration, t(19) = 
3.328, p = 0.004, this corresponded to a pelleting efficiency of 24%. 
Analysing individual NTA traces more closely revealed that this pelleting efficiency was not 
uniform across the range of particles in these samples. There was a rightward shift in the 
trace that suggested that the smaller particles had pelleted more successfully than larger. 
The averaged mode size, across the dataset, increased from 86 ± 16 nm to 101 ± 20 nm 
(n=20). Whether these correspond to exosomes or other non-vesicular particles cannot be 
teased out of NTA data. 
Overall it appears that the pelleting of exosomes, and other non-vesicular particles, by ultra-
centrifugation is an inefficient process. However, the observation that smaller particles 
appeared to pellet more efficiency than larger particles may reassure that the efficiency for 
exosomes may be higher than reported. It is possible that by increasing ultra-centrifugation 
time, speed and rotor may well increase this efficiency. A thorough development of this 
method was beyond the scope of this thesis as it would require a large quantity of archived 
plasma to do so. Furthermore, changing the method in these ways would make it increasingly 
time- and labour-intensive and thus, less suitable for larger biomarker discovery studies. The 
isolation of exosomal-RNA was performed on the pellet (reported later in sections 6.3.5 
and 6.3.7) and would provide the best evaluation of this method compared to others. 
A consideration, prior to RNA extraction, is that ultra-centrifugation does not discriminate 
between vesicular and non-vesicular particles. Therefore, within the pellet there is likely to 
be co-isolation of exosomes and RNA-binding proteins such as Argonaute (Arroyo et al., 
2011) or high-density lipoproteins (Vickers et al., 2011). Nucleases can be used on pellets, 
prior to RNA extraction, to ensure the isolation of genuine intra-luminal RNA (Hill et al., 
2013). Procedures for doing so have been established (Shelke et al., 2014) and shown to be 
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important in chapter 5. The exosome pellet was similarly treated here prior to extraction 
using the mirVana RNA isolation kit (Ambion). 
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Figure 6.3: Pelleting efficiency of ultra-centrifugation.  
Plasma samples were obtained from four donors and assessed by Nanoparticle Tracking Analysis 
before and after ultra-centrifugation. Top: a box-plot showing particle concentration pre-and post-
ultracentrifugation in the supernatant (n=20). The upper and lower "hinges" of the boxes correspond 
to the first and third quartiles whilst whiskers extend to values within 1.5 x inter-quartile range. 
Bottom: A histogram of one sample, pre- and post-ultracentrifugation (light blue and purple lines, 
respectively), measured by NTA indicative of the dataset. 
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6.3.4 Isolating plasma exosomes by size exclusion chromatography 
A major obstacle in proteomic analysis of exosomes from human plasma is the co-isolation 
of Human Serum Albumin (HSA). One solution to overcome this has been the use of size 
exclusion chromatography (Welton et al., 2015). Using this method, fractions enriched for 
exosome protein markers can be separated from proteins otherwise abundunt in blood, such 
as HSA. 
This method, now available as the commercial product Exo-spin™ (Cell Guidance Systems 
Ltd.), was validated for this study using 0.5 ml plasma isolated from two human donors. 
Thirty equal volume fractions were collected and relative protein expression of CD81, IgG1 
and HSA were quantified by TRF (Figure 6.4). The exosome marker, CD81, was enriched in 
fractions 8-14 whilst HSA was detected in high concentrations from fractions 18-30. These 
data are reflective of what is expected in the literature (Welton et al., 2015) and 
demonstrates the separation of exosome-enriched fractions from HSA and the bulk of 
plasma proteins. 
This very simple approach therefore, provides a useful tool to isolate exosomes from plasma.  
However, the exosome-enriched fractions equated to 3.5 ml of liquid which is a larger, but 
purer, volume than the original 0.5 ml plasma and would require concentration prior to RNA 
isolation. Welton et al., discuss concentration efficiency in the original publication for Exo-
spin™ and reported a 9.6% protein recovery and 5% particle recovery after ultra-
centrifugation. Particle recovery was similar using a precipitation technique but less pure in 
terms of protein content. This highlights a potential problem for isolating exosomal-RNA. 
In sections 6.3.6 and 6.3.7 exosomal-RNA was isolated using this method and compared to 
ultra-centrifugation and spin-column based methods. For size-exclusion chromatography 
samples, the exosome-enriched fractions were concentrated by ultra-centrifugation to 
obtain a pellet. 3.5 ml of exosome-enriched fractions were poured into Quickseal ultra-
centrifuge tubes and topped up to 4.8 ml with PBS before ultra-centrifugation at 200,000 x 
g for 2 hours (Optima-LE ultracentrifuge, 70 Ti rotor, k-factor = 44). PK/RA digestion was 
performed on the pellet prior to RNA extraction using the mirVana RNA isolation kit 
(Ambion). 
Therefore, the same obstacles described for ultra-centrifugation, in section 6.3.3, are likely 
to pose a problem for exosomal-RNA yield and assay scalability with size exclusion 
chromatography. Whilst it has been demonstrated that this method successfully removed 
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HSA as a contaminant, the ultra-centrifugation volumes were greater and so increased the 
time- and labour-intensity. PK/RA digestion was still a necessary step as there was no 
indication if non-vesicular RNA would be present in the exosome-enriched fractions. Running 
plasma through the columns added additional financial and time cost which again reduces 
the potential to scale this method up for numerous samples. In summary, this method gives 
a purer sample by separating exosome-enriched fractions from abundant plasma proteins 
but comes at a cost of reducing exosome yield and increasing the time-, labour- and financial-
cost.   
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Figure 6.4: Relative levels of CD81, IgG1 and HSA in size exclusion chromatography fractions (Donor 1).  
Plasma samples from two donors were subjected to size exclusion chromatography, thirty fractions collected and relative protein levels measured by Time Resolved 
Fluorescence (TRF). The exosome marker, CD81, is represented with orange bars, IgG1 control with grey bars and Human Serum Albumin (HSA) with blue line. 
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Relative concentrations of CD81, IgG1 and HSA in size exclusion chromatography fractions (Donor 2).  
Plasma samples from two donors were subjected to size exclusion chromatography, thirty fractions collected and relative protein levels measured by Time Resolved 
Fluorescence (TRF). The exosome marker, CD81, is represented with orange bars, IgG1 control with grey bars and Human Serum Albumin (HSA) with blue line. 
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6.3.5 Isolating plasma exosomal-RNA using exoRNeasy™ spin-columns 
As a principally different isolation method, which does not require ultra-centrifugation or 
PK/RA treatment, a spin-column based method was evaluated. The exoRNeasy™ (Qiagen) 
workflow was chosen as it has demonstrated the isolation of RNA from extracellular vesicles 
with high specificity over non-vesicular RNA (Enderle et al., 2015).  
This technique required no ultra-centrifugation step, which removed the potential issue of 
pelleting efficiency and a major time and labour obstacle for scaling up the assay for 
numerous samples. However, intact exosomes are not typically eluted using this method, 
rather, RNA extraction is performed by direct lysis of vesicles bound to the spin-column. 
Therefore, routine characterisation assays and quality checks of the exosomes would not 
feature in a scaled-up assay. However, the original publication eluted vesicles off the spin-
column and performed characterisation (Enderle et al., 2015).  
The original study used SEM to visualise vesicles of the correct structure and WB analysis 
confirmed that TSG101 was present in the preparations. NTA measurements revealed an 
averaged mode particle size of 160 ± 15 nm which is slightly larger than typical exosomes 
but, similarly, ultra-centrifuged samples recorded an averaged mode particle size of 173 ± 29 
nm (Enderle et al., 2015). These size distributions give an indication that other vesicle 
subtypes may adhere to the exoRNeasy™ spin-columns, as may be the case with ultra-
centrifugation also, so that the isolation of RNA specifically from exosomes over other EV 
subtypes cannot be guaranteed. Recovery of particles from the original plasma sample were 
1% for both techniques highlighting the general difficulty of isolating exosomes from 
biological fluids.  
The original study also reported selectivity for isolating membrane-bound RNA on the 
columns, which removes the need of a PK/RA step. Non-vesicular RNA is detectable in the 
flow-through of the spin-column which is normally discarded. The removal of the digestion 
step, coupled with not requiring ultra-centrifugation, improves the scalability of the assay 
compared to ultra-centrifugation and size-exclusion chromatography. Large aggregates were 
removed from 0.5 ml plasma using 0.8 µm filters (Millipore) and the exoRNeasy™ workflow 
was followed, as per manufacturer’s guidelines, to obtain exosomal-RNA. 
  
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s 
disease 
226 
 
6.3.6 Electrophoretic analysis of exosomal-RNA extracted from 0.5 ml 
plasma using three different methodologies 
With the caveats of each of the three isolation methods now highlighted, exosomal-RNA was 
extracted, using all three methods, from 0.5 ml donor plasma and evaluated by 
electrophoretic analysis (Figure 6.5). The volume of 0.5 ml was chosen to assess if a method 
could be developed that produced meaningful data from low volume, easily-depleted, 
archival material. 
Electrophoretic analysis was chosen as a first evaluation of the three different exosomal-RNA 
isolation techniques. To ensure the isolation and analysis of genuine intra-luminal RNA, the 
ultra-centrifugation and size-exclusion chromatography samples were treated with 
proteinase K and RNase A. This treatment has been described elsewhere (Shelke et al., 2014) 
and validated in the previous chapter. An optional step in the Qiagen exoRNeasy workflow 
was the 0.8 µm filtering of plasma prior to isolation on the column. Whilst the plasma 
samples had been filtered before freezing this additional filtering step was included. 
Electrophoretic analysis was performed using the Agilent Bioanalyser with the Pico chip as 
minute RNA concentrations were expected. Plasma from three human donors were 
processed using each of the 3 isolation techniques (Figure 6.6). Ultra-centrifugation and size-
exclusion chromatography samples did not produce decent RNA yields, with concentrations 
ranging from 17-24 pg/µl and 8-17 pg/µl, respectively (Table 6.1). The exoRNeasy samples, 
however, did show traceable RNA and this was reflected in concentrations ranging from 11-
275 pg/µl. There was a wide range of concentrations using this technique which may be 
explained by donor variability or the dubious concentration estimates of the Agilent system 
(Mateescu et al., 2017). No rRNA was detected in these samples, as visualised by the absence 
of 18S and 28S peaks in the electropherograms and reflected in low RIN scores ranging from 
N/A (not calculable) to 1.5. Therefore, it appears that there was little or no cellular RNA 
contamination in the samples.  
Overall, these data give a hint that the exoRNeasy method was more effective at isolating 
RNA from 0.5 ml plasma. However, a more robust method, such as qPCR, would be required 
to conclusively compare the three techniques. The minute concentrations detected in these 
samples, in the picogram range, rules out the possibility of performing conventional 
sequencing, as would have been desirable to explore, so an amplification-based method was 
chosen next. 
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s disease 
227 
 
 
Figure 6.5: Workflows of three methods used to isolate exosomal-RNA from 0.5 ml plasma. 
Ultra-centrifugation, size-exclusion chromatography and exoRNeasy™ techniques were used to isolate exosomal-RNA from three donor plasma samples. These were 
evaluated by electrophoretic analysis (Bioanalyser) and quantitative polymerase chain reaction (qPCR). 
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Figure 6.6: Electropherograms of exosomal-RNA extracted from 0.5 ml plasma.  
Exosomal-RNA was extracted from plasma using three different techniques (n=3 per technique) and 
assessed using Bioanlayser instrumentation with the pico chip. RNA in the samples is indicated by 
fluorescence units (fu, y-axis) over time (x-axis) as the trace was obtained. A) RNA extracted from ultra-
centrifuged (UC) plasma. B) RNA extracted from plasma subjected to size-exclusion chromatography 
(SEC) and ultra-centrifugation. C) RNA extracted from plasma using exoRNeasy™ (Qiagen) spin-
column method.  
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Sample Concentration (pg/µl) RIN 
Ultra-centrifugation 1 24 1 
Ultra-centrifugation 2 27 1.1 
Ultra-centrifugation 3 17 1 
Size-exclusion chromatography 1 8 N/A 
Size-exclusion chromatography 2 11 N/A 
Size-exclusion chromatography 3 17 1 
ExoRNeasy 1 11 1.5 
ExoRNeasy 2 142 1.1 
ExoRNeasy 3 275 1 
 
Table 6.1: Concentrations of RNA extracted from 0.5 ml plasma.  
Three techniques were used to isolate RNA from healthy donor plasma (n=3 per technique) and 
measured using Agilent Bioanalyser instrumentation. Concentrations and RNA Integrity scores (RIN) 
are automatically generated by the instrumentation. Individual values for each sample is presented 
here rather than averages.  
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6.3.7 Quantitative polymerase chain reaction of exosomal-RNA extracted 
from 0.5 ml plasma using three different methodologies 
In the previous chapter reverse transcription and qPCR of cell culture-derived exosomal-RNA 
was described. The procedure was repeated here for the detection of TUBA1A, a house-
keeping gene and therefore most likely to be detectable, in plasma-derived exosomal-RNA.  
The three techniques for isolating exosomal-RNA were compared using 0.5 ml plasma from 
three separate donors. As the RNA could not be reliably quantified using electrophoretic 
analysis, equal volumes were reverse transcribed from each sample for qPCR analysis. Raw 
CT values were obtained, in duplicate, by SYBR green qPCR (Figure 6.7). Cell culture-derived 
exosomal-RNA was used as a positive control and non-template controls showed no 
amplification. Melt-curve analyses were performed and confirmed that only one amplicon 
was measured. 
Ultra-centrifugation (UC) and size exclusion-chromatography (SEC) samples did not reliably 
amplify TUBA1A. Raw CT values were not obtained across all biological and technical 
replicates, with two out of the 3 biological replicates not amplifying TUBA1A above the cycle 
threshold. Gene expression would be considered very low with CT values greater than 35 
cycles. For exoRNeasy samples, all 3 biological replicates showed TUBA1A expression, across 
duplicate technical replicates. These CT values were lower at 30.9-31.4 cycles, compared to 
>35.0 for UC and SEC samples, indicating greater detection of gene expression.  
Overall these data, coupled with electrophoretic analysis, highlights that the exoRNeasy 
technique was far more reliable for isolating exosomal-RNA from plasma and certainly easier 
to do so in terms of time- and labour-intensity. The methodology could be more easily be 
scaled up to obtain exosomal-RNA from numerous samples as there were no ultra-
centrifugation or PK/RA steps required. However, two problems can be highlighted. First, the 
CT values of 30.9-31.4 cycles indicate fairly weak detection of TUBA1A. Considering this is a 
house-keeping gene it would be preferable to observe CTs <30 cycles (Enderle et al., 2015) if 
less abundant targets, as expected for a disease biomarker, were to be detected in the 
future. Second, only a small volume of cDNA was obtained with this workflow; only enough 
volume was obtained to perform four qPCR reactions per sample. Therefore, in its current 
form this workflow could not be scaled up to investigate multiple targets or even to perform 
replicated experiments if a technical problem occurred. 
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To address these problems the qPCR chemistry was changed from SYBR green to Taqman. A 
pre-amplification step can be adopted into this workflow which allows for a higher sample 
volume prior to qPCR. Samples undergo 10-14 cycles of amplification with gene expression 
probes to obtain pre-amplified samples with which comparative CT values can be obtained. 
Pre-amplification requires pre-selection of gene targets and thus a limited number, up to 50, 
can be chosen. This step increases the sample volume to be large enough for multiple 
technical measurements.  
It was not known whether this would improve the detection of TUBA1A or if the starting 
quantity in the sample was a limiting factor. The Taqman quantitation chemistry differs to 
SYBR green. Taqman is based on the release of fluorescent dyes from primers that probe the 
gene of interest whilst SYBR green is based on non-discriminant fluorescent detection of 
double-stranded DNA. This difference may lead to different efficiencies in detecting the gene 
of interest. The pre-amplification step would also have an unknown effect on final CT. 
Therefore, this change of qPCR chemistry was pursued with potential to improve the 
performance of the workflow and to investigate the potential to scale up to larger sample 
sets. 
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Figure 6.7: Raw CT values comparing TUBA1A expression in ultra-centrifugation (UC), size-exclusion 
chromatography (SEC) and exoRNeasy samples.  
TUBA1A expression in three sets of RNA samples (n=3 per technique, measured in duplicate) was 
measured by qPCR and cycle thresholds (CT reported). CT values reflect the cycle number where 
fluorescence units exceeded a set threshold of 0.1 FU. The upper and lower "hinges" of the boxes 
correspond to the first and third quartiles whilst whiskers extend to values within 1.5 x inter-quartile 
range. UC and SEC samples did not reliably amplify TUBA1A with undetermined CTs for one of the 
biological replicates (n=2). All 3 biological replicates showed TUBA1A expression, across duplicate 
technical replicates, for exoRNeasy samples (n=3). Melt curve analysis was performed and confirmed 
the presence of only one amplicon. 
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6.3.8 Testing the suitability of the exoRNeasy™ workflow with a pre-
amplification step 
It has been determined that the exoRNeasy™ workflow was the most tractable, and 
practical, technique for extracting good yields of exosomal-RNA from 0.5 ml plasma. 
However, a pre-amplification step would be needed to address limitations, namely signal 
strength and sample volume, with this workflow.  
To test if the pre-amplification step would provide the desired improvements, 0.5 ml plasma 
from three human donors was spiked with either 0, 1, 10 or 100 µg of previously purified H4 
exosomes. Not only would this provide an assessment of the detection range of the assay in 
itself but also, give an insight into the sensitivity of the assay to detect gene expression 
changes in reference to different concentrations of target exosomes. The latter would be a 
particularly beneficial readout as the secretion of exosomes has previously been shown to 
be altered in disease (Zhang et al., 2015). 
After exosomal-RNA isolation, electropherograms were obtained using the Agilent 
Bioanalyser with the Pico chip (Figure 6.8). The quantity of RNA in each sample increased in 
a dose-dependent manner with exosomes spiked-in. Concentrations ranged from 11-275 
pg/µl with no spike in, 570 – 802 pg/µl with 1 µg spiked exosomes, 1430 -3820 with 10 µg 
spiked exosomes and 2639 – 4496 pg/µl with 100 µg spiked exosomes (Table 6.2). The 
working range of the Pico chip is 50 – 5000 pg/µl so it is likely that the signal was saturated 
in some of these samples and the concentration may be higher. 
This analysis has confirmed that dosing the plasma with exosomes does contribute to higher 
concentrations of RNA in the resultant sample. This is reassuring that the capacity of the 
spin-column to isolate vesicular-RNA is not limited even up to high, artificial doses of 
exosomes. Indeed this can be considered direct evidence, in addition to the original 
publication, that exosome vesicles adhere to the spin-column (Enderle et al., 2015). Using a 
global measure of RNA quantity, it has been determined that the method has sensitivity for 
differing doses of exosomes but qPCR would be used next to measure gene expression of 
candidate gene targets. Exosomal-RNA samples were reverse transcribed and cDNA samples 
pre-amplified with selected gene expression assays as detailed later.  
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Figure 6.8: Electropherograms of RNA extracted from 0.5 ml plasma with spiked-in H4 exosomes. 
Plasma samples were spiked with different quantities of H4 exosomes (see colours in key, n=3 per dose) 
and assessed using Bioanalyser instrumentation. RNA was detected using fluorescence units (fu, y-
axis) over time (x-axis) as the trace was obtained. Traces were averaged across three biological 
replicates (n=3) and individual concentration reported in Table 6.2.  
 
Sample Concentration (pg/µl) 
0 µg spike-in 1 11 
0 µg spike-in 2 142 
0 µg spike-in 3 275 
1 µg spike-in 1 802 
1 µg spike-in 2 570 
1 µg spike-in 3 642 
10 µg spike-in 1 1430 
10 µg spike-in 2 1598 
10 µg spike-in 3 3820 
100 µg spike-in 1 4496 
100 µg spike-in 2 2639 
100 µg spike-in 3 4406 
Table 6.2: Concentrations of RNA extracted from 0.5 ml plasma with spiked-in H4 exosomes. 
Plasma samples were spiked with different quantities of H4 exosomes and assessed using Bioanalyser 
instrumentation. Concentration was automatically calculated by the instrumentation 
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Twelve targets were selected for qPCR as the pre-amplification step allows multiple targets 
to be amplified: GAPDH, PPIA, TUBA1A, BLOC1S6, TBC1D8B, SHISA9, XLOC_000992, 
XLOC_003630, XLOC_004251, APOE, APP and BACE1. These twelve targets were chosen to 
provide an assessment of: 
i) House-keeping genes (GAPDH, PPIA and TUBA1A) which would be expected in 
relatively high abundance compared to other gene targets.  
ii) Genes that showed high expression in H4 exosomes from RNA sequencing data 
presented in the previous chapter (BLOC1S6, TBC1D8B and SHISA9) and 
therefore expected to be detectable in the spiked-in samples. 
iii) LncRNAs that showed high expression in H4 exosomes from RNA sequencing 
data presented in the previous chapter (XLOC_000992, XLOC_003630 and 
XLOC_004251), and therefore, expected to be detectable in the spiked-in 
samples. The primers for these had to be designed for this study so had not been 
previously validated. 
iv) Candidate gene targets with well-established relevance to Alzheimer’s disease 
(APOE, APP and BACE1) which would be expected in less abundance than house-
keeping genes. 
The pre-amplification step provided higher sample volumes for qPCR so a greater number of 
technical replicates could be performed. Therefore, three biological replicates were 
measured, in triplicate, for each target at each concentration of spike-in. 
Raw CT values were obtained for 10 of the 12 targets measured (Figure 6.9). TUBA1A 
recorded lower CT values in this assay than with SYBR green qPCR chemistry indicating 
greater detection of gene expression. Therefore, both problems of boosting signal for greater 
detection and increasing sample volume to allow multiple measurements had been 
addressed with this refined workflow.  
Dose-dependent responses to exosome spike-in were observed for GAPDH, PPIA, TUBA1A, 
BLOC1S6, TBC1D8B, APOE, APP and BACE1. Changes were detectable even with 1 µg of 
exosomes spiked-in compared to native, untouched plasma. This is equivalent to 2 µg of 
exosomes per ml plasma in vivo causing a detectable change. It would be inappropriate to 
calculate 2-ΔCT in these samples as there was no suitable, unchanging housekeeping target to 
normalise to. The house-keeping genes GAPDH, PPIA and TUBA1A recorded decreasing CT 
values with addition of spiked-in exosomes (Figure 6.9A). Therefore, no statistics were 
applied to these measurements. 
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Of particular note are the dose response curves for GAPDH, PPIA, TUBA1A, APP and BACE1 
(Figure 6.9A and B). These 5 targets saw considerable differences between the CT values for 
un-spiked and 1 µg spiked samples, for example, a difference of ~4 cycles for GAPDH 
between un-spiked and 1 µg spiked. There is certainly scope, for these targets in particular, 
that exosomes doses of 0.1 µg or perhaps 0.01 µg could be discriminated. This observation 
highlights a good, inherent sensitivity within the assay. 
Reassuringly amplification was observed for gene targets with an expected lower abundance 
than the house-keeping genes. Of these APOE, APP and BACE1 are Alzheimer’s disease-
relevant genes (Figure 6.9B). Whilst not necessarily drivers of pathology in all cases, 
detection of these genes suggests there is potential to utilise this assay for AD biomarkers. 
Furthermore, this has demonstrated that low-abundant targets can be measured despite the 
technical difficulties of using 0.5 ml plasma and obtaining low yields of exosomal-RNA. 
CT values could not be determined for SHISA9 across any of the samples including the cell 
culture-derived exosome only control. This suggested a technical problem with the assay 
itself. Dose-response curves for BLOC1S6 and TBC1D8B were observed, as expected from the 
RNA sequencing data reported in chapter 5.  
CT values were detected for the lncRNA, XLOC_000992, in non-template controls (NTC). 
These results were therefore disregarded as the gene expression assay was producing false 
positives. NTCs produced CT values of 36 cycles - undetermined for XLOC_003630. This 
observation again suggested that there was a small amount of self-amplification within the 
assay. This self-amplification may account for the relatively high detection (CT values 25 – 
27.5 cycles) for this target or these may be genuine. All NTCs were undetermined for 
XLOC_004251 so the gene expression assay was working as expected. Typical dose response 
curves were not observed for both XLOC_003630 and XLOC_004251 as it took 100 µg spiked-
in exosomes to produce a stronger signal. A puzzling observation from these curves were 
increasing CT values, suggesting weaker detection of gene expression, with 1 µg and 10µg 
exosomes spiked-in. A possible explanation is that the efficiency of the PCR was not well 
optimised and better primers needed to be designed. Nevertheless, these assays were novel 
designs used first in this study, and had not been previously validated, so it was reassuring 
to be able to demonstrate the detection of lncRNAs in plasma-derived exosomes. Further 
optimisation and designing of additional primers would be required to take this further, 
which is of future interest as chapter 5 demonstrated that meaningful data can be obtained 
from the lncRNA cargo of exosomes. 
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Overall, an assay has been developed that can measure RNA expression in vesicles from only 
0.5 ml plasma. The assay has capacity to measure multiple targets, 12 reported here but can 
be scaled up to 50, with multiple replications without exhausting the sample. Gene 
expression is measurable in targets that are less abundant than constitutively expressed 
house-keeping genes such as GAPDH, PPIA and TUBA1A giving reassurance that changes in 
some targets that are less abundant should be possible. Furthermore, this assay shows 
excellent sensitivity to small changes in exosome dose with changes in CT values observed 
when 1 µg of H4 exosomes spiked-in and some samples appeared to have scope for 
discriminating even lower doses than that. This sensitivity is likely to be of good utility for 
investigating diseases where exosome secretion is altered, for example, the increased 
secretion of tumours (Zhang et al., 2015). 
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Figure 6.9: Raw CT values for RNA extracted from 0.5 ml plasma with spiked-in exosomes.  
Exosomal-RNA was extracted from 0.5 ml plasma with different doses of H4 exosomes spiked in (see colours in key, n=3 per dose, measured in triplicate). Cycle thresholds (CT, 
y-axis) are reported for each target as indicated in the title of each graph.  
A. House-keeping genes: GAPDH, PPIA and TUBA1A. 
 
B. Alzheimer’s disease-relevant genes. 
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C. Genes that have previously shown high expression in H4 exosomes: BLOC1S6 and TBC1D8B. 
 
 
 
D. LncRNAs that have previously shown high expression in H4 exosomes: XLOC_003630 and 
XLOC_004251. 
 
 
  
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s 
disease 
240 
 
6.3.9 Participant selection in an Alzheimer’s disease case:control cohort 
Next, a small Alzheimer’s disease case:control cohort was used to test if this assay could 
detect any gene expression changes associated with disease. At this early stage of assay 
development, and with only a small cohort to measure, the aim was to validate the method 
by looking for trends towards significance in candidate genes and to test the sensitivity of 
the assay to detect low-abundant, CNS-enriched candidates. 
Plasma samples were available for 582 research participants with corresponding APOE 
genotypes: 211 Late-Onset AD (LOAD), 293 Early-Onset AD (EOAD) and 78 Controls. DNA was 
extracted from whole blood and APOE genotypes were determined by Taqman genotyping 
of SNP rs7412 and KASP genotyping of SNP rs429358 as shown previously (Butchart et al., 
2015, Ide et al., 2016). Distribution of APOE genotypes are shown in Figure 6.10. The rarity 
of the e2/e2 genotype is reflected in the observation of only one control sample with this 
genotype in the entire collection. Instead, there is a relative abundance of participants with 
the e3/e3 genotype. 
Carrying an e4 allele of the APOE gene confers a greater genetic risk of Alzheimer’s disease 
(Mahley et al., 2006). With so many e3/e3 samples available it was decided that this study 
should be a case:control analysis where APOE genotype was controlled for rather than 
investigated. Furthermore, the pathology of Late and Early Onset forms of AD vary greatly so 
the group was narrowed down to LOAD cases only. 
The gender and age distributions of both case and control groups was evaluated 
(Figure 6.11). There were more females than males in both parts of the cohort. Participant 
and next-of-kin interviews were used to determine the age at which the onset of symptoms 
took place. Age of AD onset ranged from 66-90 years old in cases. Age-matched controls with 
no cognitive deficits were recruited to the study. The age at their latest interview was 
recorded and ranged from 68-92 years old. In the final cohort for this study, gender was 
controlled for by choosing fairly equal numbers of males and females and matching these 
between cases and controls. Controls would be prioritised by their age at latest interview. 
Further cognitive data, rather than just age of AD onset, would be used to select cases. 
 
 
 
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s disease 
241 
 
 
 
Figure 6.10: Histograms showing distribution of APOE genotypes across research participants.  
Whole blood had been collected from LOAD, EOAD and Control participants and genotypes determined by single SNP genotyping of rs7412 and rs429358. Genotypes are 
indicated on the x-axis. 
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Figure 6.11: Histograms showing age and gender distributions across LOAD cases and controls.  
Age of AD onset (cases), age at interview (controls) and gender were determined at interview when entering the study. A) and B) Gender distributions for cases and controls. 
C) Age of AD onset was recorded for cases ranging from 66-90 years old. D) The age at their latest interview was recorded for controls and ranged from 68-92 years old. 
A) B)
C) D)
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A suite of cognitive and memory tests are performed with research participants by field team 
members of the research group at Cardiff University. These tests include Mini-Mental State 
Examination (MMSE) and Addenbrooke’s Cognitive Examination (ACE). From these tests, a 
research diagnosis of probable AD can be determined and a certainty rating (%) was 
calculated (Figure 6.12). A number of the research participants volunteer to donate their 
brain after death through the Brains for Dementia Research project 
(http://www.brainsfordementiaresearch.org.uk/). From this project, the top AD certainty 
score was 99% as an autopsy report confirmed “Alzheimer’s disease with some TDP-43 
pathology” (Wilson et al., 2013). There were 18 individuals with an AD certainty score greater 
than 75%. The certainty of diagnosis was chosen as a priority in patient selection because AD 
is difficult to cleanly diagnose using cognitive measures and often relies on autopsy to reveal 
co-morbidities and other dementia pathologies. 
The case:control cohort was chosen based on the priorities highlighted thus far: 
i. An APOE genotype of e3/e3 
ii. Males and females would be chosen equally and matched in case and control groups 
iii. Controls would be prioritised by individuals with latest age at interview 
iv. Cases would be prioritised by individuals with a higher certainty of diagnosis 
The final cohort consisted of 15 cases (6 male and 9 female) and 15 controls (6 male and 9 
female) and all APOE e3/e3 homozygotes. The controls were chosen by eldest at interview. 
The cases had a range of AD diagnosis certainty from 75 – 99%.  
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Figure 6.12: A Histogram showing distribution of AD Certainty across LOAD cases.  
AD certainty score was determined from phenotypic data collected in this study. The top AD certainty 
score was 99% as an autopsy report confirmed “Alzheimer’s disease with some TDP-43 pathology”. 18 
individuals had an AD certainty score greater than 75%. 
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6.3.10 Selecting targets for gene expression profiling 
The gene expression assay has already been demonstrated with ten gene and lncRNA targets 
(Figure 6.9) but this was extended to sixteen for the final study. Sixteen targets were chosen 
as it balanced a sufficient number of targets to validate the assay, but not too many that the 
number of participants had to be reduced.  An additional six gene targets needed to be 
identified. One aim of adding the additional gene candidates was to identify any targets that 
showed potential for being a biomarker of disease. A second aim was to test if the assay 
could detect CNS-enriched gene targets and therefore the suitability to apply this method to 
neurological disorders in general. The assay had already successfully been used for the 
detection of constitutively expressed, housekeeping targets despite using a small plasma 
volume to start with, so choosing CNS-enriched genes would further test the robustness of 
this assay. Therefore, gene candidates that could address both of these aims were identified 
and selected. 
There have been numerous studies into gene expression in Alzheimer’s disease brains which 
were reviewed in 2014 (Feng et al., 2014). In this review, 12 genes showed consistent 
expression changes with disease progression and were validated in independent datasets. 
Six showed higher expression throughout disease progression and six were lower. It was 
predicted that these genes would have good potential to discriminate disease in plasma 
exosomes as they had previously been implicated in AD brains. There was scope to select 6 
of the 12 targets. 
To address the second aim, the GTEx Portal (https://gtexportal.org/home/) was accessed to 
narrow the list to 6 genes ensuring that these were preferentially expressed in the CNS 
(Figure 6.13). All six showed enrichment in brain tissues: three that were upregulated in 
disease (ITPKB, GFAP and FAM107A) and three that were downregulated (GNG3, CDK5 and 
RGS4). It was not known whether the RNA transcripts of these genes would be loaded onto 
exosomes and transported into peripheral circulation, and indeed if the change in expression 
would be in the same direction as observed from the tissue-based analyses (Feng et al., 
2014). Therefore, half of the candidates chosen were upregulated and the other half were 
downregulated in disease. 
GFAP and GNG3, in particular, were almost entirely selectively expressed in brain tissues; 
other non-CNS tissues recorded no gene expression except a low detection of GNG3 in the 
testis (Figure 6.13). FAM107A, CDK5 and RGS4 had enriched signals in brain tissues with a 
wider spread of gene expression detected in other tissues. Interestingly, RGS4, is 
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preferentially expressed with particularly strong expression in cortical regions, namely, the 
anterior cingulate cortex, cortex and frontal cortex tissues. These tissues are known to be 
sites of degenerating neurons and the neuropathological hallmarks of AD, Aβ plaques and 
neurofibrillary tangles (Zilka and Novak, 2006). Of the six genes evaluated, ITPKB had the 
most widespread expression in other tissues but an enrichment in brain tissues, particularly 
the substantia nigra.  
These 6 genes were chosen to expand the list of targets to test in the case:control cohort. 
They fulfilled both criteria of i) being previously identified as differentially expressed in AD 
brain so have a stronger likelihood of being differentially expressed in peripherally-available 
exosomes and ii) showing enriched expression in brain tissues so able to test the sensitivity 
of the assay to measure lower abundant, CNS-specific candidates.  
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Figure 6.13: Gene expression profiles for six brain-enriched genes.  
Gene expression is reported in Reads Per Kilobase of transcript per Million mapped reads (RPKM, y-axis) for different tissues (x-axis) using the searchable GTEx portal database. 
Median is displayed with 25th and 75th quartiles, and outliers marked as circles. 
 
ITPKB
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s disease 
248 
 
 
 
GFAP
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FAM107A
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6.3.11 Quantitative polymerase chain reaction in a case:control cohort 
Analysis of Raw CT values 
Exosomal-RNA was isolated from 0.5 ml plasma in the case:control cohort (detailed in 
section 6.3.9). The selection of sixteen targets (detailed in section 6.3.10) were pre-amplified 
from reverse-transcribed cDNA. Relative expression was measured by qPCR and cases were 
compared to controls with the comparative CT method (Schmittgen and Livak, 2008). 
Raw CT values were plotted comparing cases against controls (Figure 6.14). This analysis was 
normalised by input volume with 0.5 ml plasma used per sample. The three housekeeping 
genes were detected in every sample and showed increased expression in controls. For 
example, GAPDH had an average CT of 27.19 cycles in cases and 26.15 cycles in controls 
(n=15 per group, measured in triplicate).  
The gene CDK5 was detected in all samples, except one case, and had previously shown to 
be downregulated throughout disease progression (Feng et al., 2014). This observation was 
also reflected in this study, with cases showing a higher average CT of 31.66 cycles compared 
to 30.68 in controls. Two other genes from the Feng et al. study were measured in similar 
numbers across this cohort: ITPKB (n=14 cases, n=15 controls) and FAM107A (n=15 cases, 
n=15 controls). However, the direction of expression differed from what had been 
demonstrated previously in post-mortem brain. One explanation for this may be that 
biomarkers of AD, associated with exosomes, differ in levels over the course of disease 
progression or with severity of condition. For example, phosphorylated tau is significantly 
increased on CSF-derived exosomes in mild cases of AD and not moderate or severe (Saman 
et al., 2012). The Feng et al. study had demonstrated consistent dysregulation of CDK5, ITPKB 
and FAM107A in the brain during disease progression but there may be an added complexity 
here of the unknown regulatory role of packing these transcripts into exosomes and their 
subsequent transport into peripheral blood (Feng et al., 2014). Indeed, in the case of 
Parkinson’s disease, toxic α-synuclein is reduced in patient CSF but increased in association 
with plasma exosomes (Shi et al., 2014). This suggests that elimination of certain factors from 
the CNS, into peripheral circulation, may go hand-in-hand with disease processes. 
Of the six genes chosen from the Feng et al. review three were not strongly detected (Feng 
et al., 2014). Firstly, GFAP did not produce a detectable signal in any samples (Figure 6.14). 
According to the gene expression data, obtained from the GTEx portal (Figure 6.13), GFAP is 
selectively expressed in the brain and so would be a highly specific tissue-discriminating 
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s 
disease 
254 
 
signal if detected in exosomes. It may be that plasma-derived exosomes contain an 
abundance of non-coding RNAs, as demonstrated for H4 exosomes in chapter 5, and of the 
proportion of remaining coding RNA, GFAP is in too low abundance to be detected from such 
low volumes of plasma. Alternatively, it may be that the gene expression assay itself was not 
working robustly. Secondly, GNG3 was detected in 9 samples (n=2 cases, n=7 controls). The 
GTEx portal expression plot was similar to GFAP as GNG3 was highly selectively expressed in 
brain tissues. As this worked in a number of the samples this is probably explained by a low 
abundance of the transcript in plasma-derived exosomes, rather than a technical problem 
with the assay. It may be that GNG3 is down-regulated in peripheral exosomes in AD as 2 
cases produced a detectable signal and 7 controls. This would need further experiments, 
likely with a higher volume of plasma to boost the signal, to be conclusive. Thirdly, RGS4 was 
detected in only two samples (n=1 case, n=1 control). As with the previous two candidates, 
RGS4 is highly selectively expressed in brain tissues so maybe a low abundant target in 
peripherally available exosomes or the assay itself may not be well optimised. 
Therefore, it is difficult to come to meaningful conclusions from GFAP, GNG3 and RGS4. 
However, the other three brain-enriched genes, CDK5, ITPKB and FAM107A (Figure 6.13), 
showed good detection across the cohort. Indeed, the detectable signal was good at below 
30 cycles for ITPKB and FAM107A and on the threshold of good detection at 29 – 34 cycles 
for CDK5. These observations meant that the aim producing an assay that could detect CNS-
enriched signals in peripheral exosomes had been achieved. To further test if the gene 
expression changes in CDK5, ITPKB and FAM107A were statistically significant between cases 
and controls, these data would need to be transformed from the raw CTs (Schmittgen and 
Livak, 2008) which has been reported later. 
Detection of gene expression in APOE and APP was achieved across the cohort with all 30 
samples detected for these targets and CT values ranging from 22 to 36 cycles. Both 
candidates were downregulated in disease. APOE had an average CT of 34.47 in cases and 
33.53 in controls whilst APP was 27.42 in cases and 26.03 in controls, suggesting down-
regulation in disease. BACE1 was less well detected across the cohort (n=10 cases, n=13 
controls) and showed the same direction of gene expression change with average CTs of 
34.16 in cases and 33.66 in controls. As LOAD does not typically have an APP or BACE1 genetic 
component, and as the cohort has been normalised by APOE genotype, it is not expected 
that these differences between cases and controls would be statistically significant when the 
data are transformed later. 
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Of the candidates identified as having strong expression in H4 exosomes, in the previous 
chapter, BLOC1S6 and XLOC_003630 were detected across the entire cohort (n=30, 
Figure 6.14). It must again be noted that NTCs in the XLOC_003630 assay did produce 
measurable CTs which suggested contamination or, more likely as this has occurred in a 
separate experiment, self-amplification inherent in the assay. Threshold detection in these 
NTCs was achieved late in the qPCR, after 37 cycles, so the patient data was still analysed.  
Both BLOC1S6 and XLOC_003630 appeared to be down-regulated in disease with BLOC1S6 
recording average CTs of 29.82 in cases and 28.29 in controls whilst XLOC_003630 recorded 
29.80 in cases and 29.04 in controls. Only 3 samples produced a detectable signal for 
XLOC_004251 (n=2 cases, n=1 controls) and 23 samples for TBC1D8B (n=9 cases, n=14 
controls). Of these 23 samples producing a detectable signal, 14 were controls so there may 
be a genuine down-regulation of TBC1D8B in disease, to the extent that cases became 
undetectable. This would require more samples, with a better detection rate, to be fully 
conclusive. 
Overall, these data demonstrated that detection was achieved across 12 of the 16 targets 
tested. Reassuringly, 3 of these were targets are preferentially expressed in brain tissues, 
according to the GTEx portal, which confirms an added utility of this assay: to detect CNS-
enriched signals from a small volume of peripheral blood. Using raw CT values, however, is 
not compatible with statistical tests so these results cannot currently be used to determine 
if any of the candidates are significantly dysregulated in AD. 
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Figure 6.14: Relative gene expression shown with raw CT values.  
Quantitative PCR (qPCR) was used to measure cycle thresholds (CT, y axis) in exosomal-RNA collected from plasma in a case:control cohort (n=30). CT values reflect the cycle 
number where fluorescence units exceeded a set threshold of 0.1 FU. The upper and lower "hinges" of the boxes correspond to the first and third quartiles whilst each circle 
represents a technical replicate data point. Raw CT values are reported here for 16 targets, as indicated in the title of each graph. Eight of the targets were detected in every 
sample (n=30): GAPDH, TUBA1A, PPIA, FAM107A, APOE, APP, BLOC1S6 and XLOC_003630. Four more targets were also detected in similar numbers: ITPKB (n=14 cases, n=15 
controls), CDK5 (n=14 cases, n=15 controls), BACE1 (n=10 cases, n=13 controls) and TBC1D8B (n=9 cases, n=14 controls). Four of the targets were not detected in high numbers 
and were thus not included in further analyses: GFAP (n=0), GNG3 (n=2 cases, n=7 controls), RGS4 (n=1 cases, n=1 control) and XLOC_004251 (n=2 cases, n=1 control). 
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B. Six brain-enriched genes: ITPKB, GFAP, FAM107A, GNG3, CDK5 and RGS4 
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C. Three AD-relevant genes: APOE, APP and BACE1 
 
 
D. Four candidates previously shown to be strongly expressed in H4 exosomes: BLOC1S6, TBC1D8B, XLOC_003630, XLOC_004251 
 
 
n=
15/15
n=
15/15
n=
15/15
n=
15/15
n=
10/15
n=
13/15
n=
15/15
n=
15/15
n=
9/15
n=
14/15
n=
15/15
n=
15/15
n=
2/15
n=
1/15
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s 
disease 
259 
 
Analysis of transformed CT values (2-CT) 
Transformation of these data from the raw CTs was performed next so that statistical tests 
could be applied. Four of the candidates were not detectable across many of the samples so 
were excluded and the following twelve taken further: GAPDH, TUBA1A, PPIA, FAM107A, 
APOE, APP, BLOC1S6, XLOC_003630, ITPKB, CDK5, BACE1 and TBC1D8B. Raw CT values were 
transformed to 2(-CT) as a numeric transformation of the number of cycles required to reach 
the threshold of detection (Figure 6.15). This meant that the data were still being normalised 
against sample input volume (0.5 ml plasma). This transformation allowed statistical analyses 
to be applied and thus indicate if a difference in CT value between cases and controls was 
significant. Shapiro-Wilk tests indicated that these data were not normally distributed so 
non-parametric tests were adopted. Mann-Whitney U tests were applied to the data using 
SPSS statistics software. 
Of the three targets previously shown to be dysregulated in disease, CDK5, ITPKB and 
FAM107A (Feng et al., 2014), all reached the threshold of significance (p<0.001) (Figure 6.15). 
This indicated that the difference in CT values between cases and controls was statistically 
significant, an indication that each of the three genes were down-regulated in AD. Being 
down-regulated in disease was expected for CDK5 but not ITPKB and FAM107A which had 
previously been reported as upregulated in AD brain. However, gene expression changes in 
brain may not correlate well with the RNA that is packaged into exosomes and transported 
into the periphery. For example, it has been demonstrated that the α-synuclein protein is 
present in lower concentrations in CSF but higher in plasma-derived exosomes in Parkinson’s 
disease (Shi et al., 2014). A similar phenomenon may be occurring here with ITPKB and 
FAM107A RNA in AD. 
In this analysis statistically significant changes in CT values were also detected for APOE, APP 
and BLOC1S6 (p<0.001) (Figure 6.15). Each of these were down-regulated in disease but this 
was not expected, particularly, for APOE and APP. However, an important consideration 
must be made of the house-keeping genes. Statistically significant changes in CT value were 
detected for GAPDH, TUBA1A and PPIA (p<0.001). These house-keeping genes were 
measured with the aim to either confirm uniform expression across the sample-set or, if that 
was not the case, to be used for data normalisation.  
These samples had been normalised by plasma volume prior to RNA extraction, so the 
observation of non-uniform expression of house-keeping genes suggests that uneven 
quantities of RNA where in the original samples. Therefore, normalising the data by sample 
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volume was not sufficient to draw meaningful conclusions. This variation between plasma 
samples was not entirely unexpected as person-to-person variation can be subject to disease 
status and many other factors, such as how recently the participant had drunk before 
venepuncture. 
In summary, it would not be appropriate to draw conclusions from these data after the 2-CT 
transformation. Rather, this analysis has highlighted that there is likely to be uneven starting 
quantities of RNA in the samples because there was statistically significant changes in the CT 
values of house-keeping genes. Whilst it is not necessarily the case that GAPDH, PPIA and 
TUBA1A are constitutively expressed in exosomes, and thus suitably used as house-keeping 
genes for normalisation, it would be most appropriate to account for these expression 
differences in another analysis.  
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Figure 6.15: Relative gene expression shown with 2(-CT) values.  
Quantitative PCR (qPCR) was used to measure cycle thresholds in exosomal-RNA collected from plasma in a case:control cohort (n=30). CT values were transformed to 2(-CT) for 
this analysis (y-axis). The upper and lower "hinges" of the boxes correspond to the first and third quartiles whilst each circle represents a technical replicate data point. Gene 
targets are indicated in the title of each graph. Mann-Whitney U tests were performed where * donates p<0.05, ** donates p<0.01 and *** donates p<0.001.  
 
A. Three housekeeping genes: GAPDH, PPIA and TUBA1A. 
 
B. Three brain-enriched genes: ITPKB, FAM107A and CDK5. 
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C. Three AD-relevant genes: APOE, APP and BACE1. 
 
 
D. Three candidates that were enriched in H4 exosomes: BLOC1S6, TBC1D8B and XLOC_003630 
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Analysis of CT values normalised to GAPDH expression (2-ΔCT) 
Calculating 2-CT values and observing statistically significant changes in the CT values of 
housekeeping genes had suggested that there was not uniform quantities of RNA in the 
plasma samples despite normalising by input volume. GAPDH, PPIA and TUBA1A are typically 
used housekeeping genes (Eisenberg and Levanon, 2013) so uniform expression would be 
expected if there were similar quantities of starting RNA. It is possible to normalise qPCR 
data by house-keeping gene expression by calculating the 2-ΔCT (Schmittgen and Livak, 2008). 
This is a similar numeric transformation of the CT as used in the previous section but this 
time the CT value of the candidate is subtracted from the CT value of the housekeeping gene 
before transformation. This accounts for the differences in starting material prior to qPCR. 
However, whilst GAPDH, PPIA and TUBA1A are typical housekeeping genes in cells and 
tissues (Eisenberg and Levanon, 2013), it is unknown which of these would be expected to 
have uniform RNA quantities in exosomes so the average across all three house-keeping 
genes was used in this calculation. 
The qPCR data for each candidate was transformed to account for GAPDH, TUBA1A and PPIA 
expression (averaged) by calculating 2-ΔCT (Figure 6.16). Shapiro-Wilk tests indicated that data 
were not normally distributed so non-parametric tests would be most appropriate.  
Mann-Whitney U tests confirmed statistically significant changes in the normalised CT values 
of ITPKB (p<0.001) and FAM107A (p=0.001). Both candidates were down-regulated in cases 
and, as discussed earlier, these were not in the expected direction of effect based on post-
mortem brain tissue datasets (Feng et al., 2014). The meaning of this is unclear but currently 
little is known about the sorting and packaging of specific RNA molecules into exosomes prior 
to secretion (Mateescu et al., 2017). There may be a regulatory reason why these particular 
RNAs are less-abundantly packaged into exosomes in AD, or alternatively, it may be that the 
passage of exosomes out of the CNS is perturbed in AD. The down-regulation of ITPKB and 
FAM107A in the peripheral exosomes of AD patients may prove of future utility as 
biomarkers of AD. Certainly, by reaching the threshold of significance in this small 
case:control cohort, the assay method is validated and the argument for utilising exosomal-
RNA as biomarkers of AD has been bolstered. 
Two other targets reached statistical significance in this analysis: BACE1 (p=0.041) and 
BLOC1S6 (p=0.044). BACE1 is the β-secretase enzyme that cleaves APP to pathogenic Aβ. It 
is difficult to make a biological inference from this having a lower expression in the RNA of 
exosomes without repeating in a larger sample set to confirm this observation. BLOC1S6 had 
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been identified as enriched in exosomes by RNA sequencing in the previous chapter and, 
independently, has been associated with human gliomas (Meyer, 2014). The gene-product 
plays a role in intracellular vesicle trafficking, which is intriguing when this observation has 
been made analysing exosomes. Mutations in the BLOC1S6 gene have been found to cause 
Hermansky-Pudlak Syndrome (Gahl and Huizing, 1993). Here, it was significantly down-
regulated in the exosomes of AD cases. Genetic variations of endocytosis genes have 
previously been associated with Alzheimer’s disease (Lambert et al., 2013, Karch and Goate, 
2015) including BIN1, PICALM, CD2AP, EPHA1 and SORL1. Pathological variations may not 
regulate expression of these genes but, in principle, there is a growing case for investigating 
endocytosis in Alzheimer’s disease from a biomarker and pathology perspective. 
Overall, this study has demonstrated a tractable method for detecting gene expression in 
exosomal-RNA isolated from small volumes of plasma. It has sensitivity to detect CNS-specific 
transcripts such as CDK5, ITPKB and FAM107A which are preferentially expressed in the 
brain. Furthermore, it has been demonstrated that this assay has potential to identify 
biomarkers of AD but larger cohorts would need to be tested to confirm the utility of 
candidates identified here. A non-hypothesis driven, RNA-sequencing approach would be 
preferable but with the limitations of RNA input described, this could not be performed in 
this study but would be of future interest. Nevertheless, these observations bolster the 
argument for analysing exosomal-RNA from peripheral blood for the future discovery of AD 
biomarkers.  
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Figure 6.16: Relative gene expression shown with 2(-ΔCT) values calculated from three housekeeping genes.  
Quantitative PCR (qPCR) was used to measure cycle thresholds in exosomal-RNA collected from plasma in a case:control cohort (n=30). GAPDH, TUBA1A and PPIA expression 
was averaged and used in the calculation of 2(-ΔCT) values (y-axis). The upper and lower "hinges" of the boxes correspond to the first and third quartiles whilst each circle 
represents a technical replicate data point. Gene targets are indicated in the title of each graph. Mann-Whitney U tests were performed where * donates p<0.05, ** donates 
p<0.01 and *** donates p<0.001. 
*
**
*
***
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6.4 Discussion 
The aims of this chapter were to assess the feasibility of isolating exosomes from frozen 
plasma, develop an optimised workflow for analysing exosomal-RNA and investigate the 
expression of multiple candidate genes in an AD case:control cohort. 
For the development and testing of any biomarker it is imperative that the assay is 
compatible with archival material. A brief analysis, by NTA, showed that storing plasma at -
80°C for extended periods of 30 days did not cause any gross changes in the concentration 
or size of particles. 
Three different techniques were evaluated for isolating exosomal-RNA from frozen plasma. 
Ultra-centrifugation appeared to be inefficient for pelleting exosomes from plasma, as has 
been reported elsewhere (Enderle et al., 2015). This inefficiency may be a peculiarity of 
plasma as pelleting exosomes from cell culture medium has been reported to be far more 
efficient, up to 90% recovery of particles, in the Clayton laboratory. This may be due to the 
relative viscosity of plasma compared to cell culture medium or the high protein content. 
The question remains: is it possible to alter the ultra-centrifugation procedure to improve 
this inefficiency? Solutions include testing rotors with more efficient k-factors, centrifuging 
at faster speeds, centrifuging for longer time or to pre-diluting the sample to decrease the 
viscosity. To test these options, and thereby hopefully improve the efficiency of ultra-
centrifugation, significantly more blood and time would be required and this could not be 
fully achieved in the scope of this current thesis. 
Size-exclusion chromatography was demonstrated to be effective at separating exosomes 
from the highly abundant blood protein HSA, as has been reported elsewhere (Welton et al., 
2015). However, low efficiency of recovering exosomes from enriched fractions has been 
reported in the original publication whether ultra-centrifugation or precipitation is used. 
Therefore, the third isolation method evaluated was the spin-column based exoRNeasy™ 
procedure  (Enderle et al., 2015) which had no requirements for ultra-centrifugation. 
These three techniques were principally different from each other but a major difference 
with the spin-column based method is not requiring ultra-centrifugation which could have 
posed a potential bottleneck for a future assay. The process of ultra-centrifugation is time-
consuming; in this study plasma samples were centrifuged for 2 hours yet did not efficiently 
recover particles. It is also labour-intensive as samples must be carefully prepared to cope 
with the sheer forces applied in pelleting exosomes. Furthermore, indiscriminately pelleting 
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exosomes with other particulates requires an addition PK/RA digestion step to ensure that 
intra-luminal RNA is extracted. These features would make it technically difficult to scale up 
an assay for numerous samples, as would be needed for a large-scale biomarker discovery 
study. Therefore, the spin-column based method was technically easier and quicker to 
perform and so had greater potential for being scaled up for multiple samples. 
To fully evaluate these procedures, the yield of exosomal-RNA extracted from 0.5 ml plasma 
was investigated. RNA was extracted from 3 donors for each technique and evaluated by 
electrophoretic analysis and SYBR-green qPCR of TUBA1A. It was clear that the spin-column 
technique not only provided a simpler workflow, which could be scaled up for multiple 
samples, but that the quantity of RNA isolated was far greater allowing more flexibility in the 
PCR-based analysis later on. However, the assay had to be refined to improve the measurable 
signal and increase sample volume so that multiple targets and replicates could be analysed. 
The qPCR chemistry as changed from SYBR-green to Taqman so that a pre-amplification step 
could be included. This addition addressed both the issues of increasing signal and sample 
volume. A drawback to using this pre-amplification step is that gene candidates have to be 
pre-selected and qPCR analysis is then limited to these. Amplification bias is an issue with 
sequencing studies but the relative expression of each gene candidate was measured 
independently of others in this study. The sensitivity of the assay was very good, being able 
to detect gene expression differences with 1 µg of H4 exosomes spiked-in. For a number of 
the targets there was a wide separation between the CT values suggesting that the exosome 
dose could have been much lower. For example, there was a difference in ~4 cycles for 
GAPDH between 0 and 1 µg of exosomes spiked-in so it is highly likely that lower titrations 
of 0.1 or 0.01 µg may also show differences in CT values. This means that there is very good 
sensitivity in the assay to detect minute changes in exosome dose, which is desirable for 
biomarker discovery. Thus, a workflow has been developed for the effective isolation of 
exosomal-RNA from 0.5 ml plasma, detection of multiple gene-targets and with very good 
sensitivity to changes in exosome concentration.  
With the workflow established the assay was tested on an AD case:control cohort. AD is a 
complex, progressive disorder with multiple genetic and environmental factors so deciding 
on a cohort is not simple. In this study, as much additional information as possible was sought 
to inform these decisions. 15 AD cases (6 male, 9 female) were selected with a diagnosis 
certainty score of 75-99% based on cognitive assessments and autopsy report. 15 controls (6 
male, 9 female) were selected with a priority of eldest at interview. Therefore, these 
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individuals were as well-defined as possible with the information available. All participants 
were tested for their APOE genotype and e3/e3 homozygotes were chosen to remove this 
strong genetic effect that could bias the results if not accounted for. 
The gene target list was increased to sixteen by the addition of six targets that are 
dysregulated throughout disease progression in AD (Feng et al., 2014) and showed 
preferential expression in the brain over other tissue types. Primarily, these candidates were 
chosen as, by previously showing dysregulation in AD brain over the course of disease, they 
would be most likely detected in plasma exosomes. Additionally, by demonstrating that the 
targets were preferentially expressed in brain tissues they provided an opportunity to test 
the sensitivity of the assay to detect CNS-enriched signals, despite the technical difficulties 
of analysing peripheral blood, only using 0.5 ml plasma and only having picograms of RNA 
available. 
The case-control cohort was analysed by Taqman qPCR but, despite plasma input volume 
being normalised to 0.5 ml, it became apparent that normalisation would have to be 
performed based on house-keeping gene expression. In future studies, quantitation of 
exosomes in the samples could be made by NTA and/or BCA. However, this would introduce 
additional assays that would increase the time taken to process the samples when house-
keeping gene expression is relatively simple to include in the qPCR. Therefore, gene 
expression was measured using the comparative CT method (Schmittgen and Livak, 2008) 
and 2-ΔCT values calculated against GAPDH expression. 
With these data, ITPKB and FAM107A showed significant down-regulation of expression in 
disease. This was contrary to the expected direction that showed up-regulation of these 
genes in post-mortem AD brain (Feng et al., 2014). These unexpected results may be a 
genuine insight into disease. In the case of Parkinson’s disease, toxic α-synuclein is present 
in lower concentrations in CSF but higher in plasma-derived exosomes (Shi et al., 2014). A 
similar phenomenon appears to be occurring here, whereby ITPKB and FAM107A are up-
regulated in diseased brain tissue but down-regulated in the peripheral exosomes. It may be 
that there is a disturbance in the mechanisms for packaging these transcripts into exosomes 
and so they remain within disease cells or, alternatively, the passage of exosomes out of the 
CNS is perturbed in AD. These hypotheses would need to be determined mechanistically. 
The ideal analysis to perform would have been RNA-sequencing as it would have been non-
hypothesis driven, rather than selecting gene candidates as done here. Unfortunately, the 
sequencing of plasma-derived exosomes was not possible as the RNA quantities obtained 
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were limiting. This could be increased if larger volumes of plasma were acquired but, based 
on the quantities of RNA extracted in this study, volumes greater than 1 ml would certainly 
be required. Indeed, one study reported using 4 ml plasma and still not isolating sufficient 
material for the technical requirements of RNA sequencing  (Lugli et al., 2015). Such volumes 
could be achieved in new sample collections but would likely prove difficult when obtaining 
archived material which could be lower than those requirements. Therefore, the aim of this 
chapter was purposefully to develop a workflow with minute volume samples. Another 
option would have been to perform a pre-amplification with random decamer and oligo-dT 
primers and then perform RNA sequencing. Such an approach would certainly introduce 
amplification bias so was not pursued. Pre-amplification of selected targets was chosen as 
relative gene expression changes of each candidate, independently of others, could be 
performed using the comparative CT method. 
Producing meaningful data by pre-amplification and qPCR does give some suggestion that 
this isolation method may be compatible with sequencing despite the low RNA quantities 
isolated. By performing 10 cycles of pre-amplification and 40 cycles of qPCR the exponential 
phase of amplification was achieved for a number of the candidates. The same level of 
amplification is not performed during sequencing library preparations but there is an 
element of amplification which may bring some transcripts into the detectable range. 
Alternatively, library preparations based on oligo-dT capture have lower sample input 
requirements than other methods. It is foreseeable that, with low RNA input, amplification 
bias will feature in these sorts of studies but, in principle, low volume samples isolated using 
the spin-column based method may be compatible with RNA sequencing.  
Another future approach is to isolate and sequence exosomal-RNA from a cell model, which 
can provide the quantities of RNA needed, and follow up potential disease-discriminating 
candidates in biological fluids using the qPCR method described in this study. An appropriate 
cell model for AD would be difficult to identify as the cells undergoing pathological damage 
in vivo are unobtainable without major invasive surgery. The advent of induced-pluripotent 
stem cells (iPSCs) allows the culture of cells, readily obtainable from patients, derived from 
a known phenotypic background and with potential to be differentiated to disease-relevant 
cell types. Even so it is not known how relatable this cell model is to disease. 
Rather than refining the choice of gene candidates, it may be beneficial to refine the 
case:control sample set in future. A larger sample set would of course provide more evidence 
for genuine gene expression changes by altering the statistical significance. However, there 
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is the added complexity that gene expression changes over time. A sample set from a 
longitudinal study would give more scope for assessing this phenomenon. It is known that 
symptomatic phase of AD covers a timeline of years but that a pre-clinical state of pathology 
maybe occurring over decades (Villemagne et al., 2013). Therefore, plasma samples collected 
at different points in this time-course may well have different expression patterns and this 
could not be dissected out of the dataset produced here. Furthermore, disease severity can 
lead to different protein profiles, for example, it has been observed that phosphorylated Tau 
is elevated in CSF exosomes only in mild AD, not moderate or severe (Saman et al., 2012). 
These observations highlight the challenge of using generalised sample sets to discover 
biomarkers of AD due to it being complex and progressive. 
Another future approach is to alter the workflow described her for the detection of exosome-
associated miRNAs. This would be a fundamental change to the workflow at the reverse 
transcription stage (Enderle et al., 2015). However, the success of measuring house-keeping 
genes, less-abundant targets, CNS-specific targets and the limited success of measuring 
lncRNAs suggests that such a change would be feasible. It was beyond the scope and 
resources of this study to develop this workflow as it would have to have been developed in 
parallel and thus require double the sample volumes. 
Exosomal miRNAs have been associated with Alzheimer’s disease by sequencing analysis 
(Cheng et al., 2015, Lugli et al., 2015) but have not shown any consensus across datasets yet 
(Kumar and Reddy, 2016). By altering the workflow described here for miRNA it would be 
possible to follow up some of these candidates to assess if they replicate in a separate cohort, 
even with minute volumes of plasma. The inconsistencies observed in these studies may be 
a general feature that again highlights the difficulty of identifying biomarkers of a complex 
and progressive disease. 
An additional gene target that showed significant down-regulation in AD cases in this study 
was BLOC1S6. This target had shown enrichment in exosomes over cells based on RNA 
sequencing in the previous chapter. As a regulator of intra-cellular vesicle trafficking it is 
intriguing that this target was down-regulated in cases, given the recent observations of the 
endocytic tracts being implicated in AD. There is growing evidence that exosomes (Rajendran 
et al., 2006) and the endo-lysosomal system (Lambert et al., 2013, Karch and Goate, 2015) 
are implicated in the pathology of AD. Therefore, the observation here, that the expression 
of a vesicle trafficking regulator is dysregulated in disease, adds to this mounting evidence.  
Chapter 6. Isolating exosomal-RNA from peripheral blood for biomarkers of Alzheimer’s 
disease 
271 
 
Sixteen gene targets were analysed in this study but manufacturer’s guidelines report that 
up to 50 targets can used and so the assay can be expanded to a wider target panel. If this is 
done it would be worthwhile to refine a list based on a specific hypothesis. This could be 
replicating candidates from other datasets, as discussed above, or alternatively, be informed 
by other genetic analyses. It is through genome wide association studies (Harold et al., 2009, 
Hollingworth et al., 2011, Lambert et al., 2013) that unexpected associations with AD were 
discovered, including cholesterol metabolism, endocytosis and immunity (Karch and Goate, 
2015). From these datasets, gene lists could be populated and the workflow adapted to 
investigate a narrower area of disease pathology, which is beneficial if a hypothesis-driven 
study is performed. 
Of particular success in this study was demonstrating the detection of CNS-enriched gene 
targets despite the technical limitations of using peripheral blood and obtaining picograms 
of RNA. It was not known whether low abundant targets, such as those from specific tissues, 
would be measurable with this workflow but three of the six attempted were detected in 
this dataset. This was reassuring after an assay was not developed for the isolation of neural-
derived exosomes in Chapter 4. Instead, an assay has been developed with sensitivity to 
measure neural-derived gene targets in a pool of exosomes derived from multiple tissues; in 
essence, finding the needle in the haystack. It is also worth noting that two of these CNS-
enriched genes, ITPKB and FAM107A, were significantly down-regulated in disease and thus 
have good biomarker potential. 
An alternative methodology, which also measures exosomal-RNA from small volumes of 
plasma is the use of molecular beacons for specific mRNAs of interest (Lee et al., 2016b, Wu 
et al., 2013). This allows the capture of EVs and measurement of gene expression from small 
sample volumes and can be scaled up for multiple targets using a tethered lipoplex 
nanoparticle (TLN) biochip. This technology has been utilised in a small number of studies 
including detection of mRNAs in lung adenocarcinomas (Lee et al., 2016b) and viral infection 
(Wu et al., 2013). This methodology provides an alternative to standard qPCR and, similarly 
to this study, can be utilised with small volumes of plasma. 
This chapter has shown that, using commercially available products, it is possible to detect 
disease-discriminating gene expression changes in exosomal-RNA, even for CNS-specific 
targets, from volumes as low as 0.5 ml peripheral plasma. The biomarker field in AD is 
complex but the tools here described can be used, and potentially improved, to help utilise 
exosomes as non-invasive biomarkers of AD and other disease of the CNS. 
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7.1 Summarising discussion 
Alzheimer’s disease (AD) is the most common form of dementia (Imtiaz et al., 2014). The 
prevalence of dementias, including AD, is a rapidly growing, global problem estimated to rise 
to 81.1 million people worldwide by 2040 (Prince et al., 2013). Definitive diagnosis of AD is 
only possible post mortem by identifying senile plaques and neurofibrillary tangles present 
in brain tissue (Knopman et al., 2003). During life, the disease manifests itself with cognitive 
deficits and decline over time (McKhann et al., 1984, McKhann et al., 2011). A “probable AD” 
diagnosis can be determined by cognitive and physical examinations coupled with patient 
history and has proved reliable and valid (O'Connor et al., 1996, Becker et al., 1994, Foy et 
al., 2007, Gearing et al., 1995, Holmes et al., 1999). To complement these assessments, a 
small number of biomarkers have been developed with robustness for the clinic  (Jack and 
Holtzman, 2013). These biomarkers measure either amyloid-β deposition or 
neurodegeneration by the analysis of proteins in cerebrospinal fluid (CSF) or by 
neuroimaging techniques. As yet, there are no clinically used peripheral biomarkers for AD. 
The research presented in this thesis assessed the potential of utilising exosomes in plasma 
to this end. It has been demonstrated that RNA appears to be actively packaged into 
exosomes, therefore functionally important, and a workflow for isolating exosomal-RNA 
from minute volumes of plasma was developed as a research tool that could be taken further 
with larger patient cohorts. Given the invasive nature of current biomarker analyses, it is of 
vital importance that new, peripherally-available, biomarkers are identified for better and 
earlier diagnosis of AD. 
Exosomes provide an ideal source material for biomarkers of disease and have already shown 
potential in diagnosing cancers (Duijvesz et al., 2011, Duijvesz et al., 2015, Melo et al., 2015). 
Exosomes are derived from multi-vesicular bodies fusing with the plasma membrane 
(Harding et al., 1983, Harding et al., 1984, Harding et al., 2013), with proteins, lipids and 
nucleic acids non-randomly incorporated into the vesicle, and represent many aspects of the 
source cell (Colombo et al., 2014, Hugel et al., 2005, Mateescu et al., 2017). This study 
focused on the RNA cargo within exosomes, as it has been demonstrated that this becomes 
altered in the cases of hypoxia (Li et al., 2016a, Gray et al., 2015, Yang et al., 2016) and 
oxidative stress (de Jong et al., 2012, Eldh et al., 2010). Therefore, if the RNA present within 
exosomes is indicative of the disease status of the source cell it is likely that it can be used to 
identify AD patients. With the knowledge that exosomes can pass bi-directionally over the 
blood-brain barrier (Skog et al., 2008, Alvarez-Erviti et al., 2011) and myelin protein can be 
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present on serum-derived exosomes from patients with multiple sclerosis (Galazka et al., 
2017), there is great potential that they can be utilised as peripherally-available biomarkers 
for neurological and neurodegenerative disorders, in general. 
A variety of methods are available for the isolation of exosomes which vary greatly in the 
yield and purity of preparations, as well as ease of use and time demands (Thery et al., 2006). 
It is also worth noting that isolating exosomes from cell-culture supernatant or from 
biological-fluids are vastly different disciplines, due to the complex nature of the latter 
(Welton et al., 2015). From the outset of this study, a large stock of neural-derived exosomes 
were required to establish and test methods, so the bioreactor method (Mitchell et al., 
2008a) of culturing H4 and IMR-32 cells, coupled with the sucrose cushion method of 
exosome isolation, were initially employed (Andre et al., 2002, Thery et al., 2006). 
In 2014, a position statement from the International Society of Extracellular Vesicles (ISEV) 
gave a minimum set of biochemical, biophysical and functional requirements for reporting 
the genuine isolation of exosomes (Lotvall et al., 2014). These guidelines are important as 
exosomes are technically difficult to isolate, so sufficient evidence should be supplied before 
biological inferences made from data. The research presented in this thesis took heed of 
these guidelines. Multiple proteins, both intra-luminal and transmembrane, were analysed 
with different techniques and intact exosomes were analysed by NTA and cryo-electron 
microscopy. Furthermore, running sucrose density gradients was not merely a pre-requisite 
for the sucrose cushion method, but also confirmed that the exosomes were buoyant at the 
expected density (Escola et al., 1998, Raposo et al., 1996, Webber et al., 2014).  
By using these methods, the exosomes secreted from H4 and IMR-32 cell-lines were 
thoroughly characterised in chapter 3 and, thereafter, the sucrose cushion method of 
exosome isolation was used to increase the yield of exosomes for bulk stocks, without 
compromising purity, as measured by P:P ratio (Webber and Clayton, 2013). Stocks of neural-
derived exosomes were established and used for assay development; particularly in chapter 
4, an immunocapture assay was attempted for the selective isolation of exosomes. 
It is a desirable prospect to isolate exosomes from a particular tissue sub-type, so that a more 
disease-relevant population can be analysed. However, narrowing the analysis for biomarker 
discovery in this way may well exclude a population of interest. In this study, an assay that 
would selectively capture H4 or IMR-32 exosomes, over prostate-derived Du145 exosomes, 
was attempted in chapter 4. The use of cell-culture derived exosomes was chosen to develop 
this assay in principle, prior to testing in biological fluids, due to the foreseen technical 
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difficulties of handling complex specimens, such as plasma (Welton et al., 2015). Good ligand 
candidates, which were preferentially expressed in CNS tissues, for immunocapture were 
identified bioinformatically, and experimentally found to be enriched on H4 or IMR-32 
exosomes over Du145. Reconfiguring the assay format to capture exosomes, based on these 
ligands, proved technically difficult. Detection methods were refined which improved the 
dynamic range of the assay. However, it appeared that exosomes were not efficiently 
adhering to capture antibodies because the signal : noise ratio could not be improved. These 
difficulties forced a change in direction for this study; as a result, exosomes were isolated en 
masse, rather than as a subset of the total population. Mounting evidence implicates not 
only neurons but also microglia and astrocytes in the pathology of AD (Sims et al., 2017, 
Askew and Gomez-Nicola, 2017, Liddelow et al., 2017). Depending on the ligand chosen, 
isolating a subset of exosomes may well exclude exosomes harbouring clinically useful 
information. So, for the scope of this study, and given the early stage of peripheral biomarker 
discovery in AD, analysing the total population of exosomes was considered an appropriate 
approach. 
This thesis has a particular focus on the RNA content of exosomes. Methods for isolating and 
analysing exosomal-RNA needed to be developed in-house. Therefore, the H4 cell-line was 
chosen to begin this work. The methods for cell-culture and exosome isolation had been 
established and verified for this. Not only did this cell-line provide technical benefits, such as 
coping well with high density culture, but it also gave a unique opportunity to analyse the 
RNA of the source cell in comparison to the RNA within exosomes. This is of particular 
interest as there is considerable need for a better understanding of the packaging of RNA 
into exosomes (Mateescu et al., 2017). In order to have access to culture H4 cells, at the 
same time as isolating exosomes, the standard 2D culture method was reverted to because 
harvesting cells from bioreactor flasks is not straightforward (Mitchell et al., 2008a). The 
pellet and PBS wash method was required to obtain a high enough yield of exosomes from 
this culture method to facilitate the analysis of RNA. Whilst this had the potential to reduce 
the purity of exosome preparation (Webber and Clayton, 2013), nuclease digestion was used 
to ensure that intra-luminal RNA was analysed and co-isolated extracellular RNA was 
degraded, and hence eliminated from the analysis (Shelke et al., 2014, Hill et al., 2013). Thus, 
there was a dual-benefit of beginning with cell cultured-derived exosomes rather than 
biological fluids: it gave an opportunity to develop methods without the complexities of 
biological fluids and to gain significant new insights by comparing exosomal-RNA with the 
source cell. 
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Previous observations suggest that RNA is both passively and actively packaged into 
exosomes prior to secretion (Colombo et al., 2014, Hugel et al., 2005). It has not been 
thoroughly determined yet but RNA-binding proteins appear to play a role in actively 
packaging miRNAs into exosomes (Villarroya-Beltri et al., 2013). There have been a number 
of studies that have used microarray and small RNA sequencing to compare exosomal-RNA 
with the source cell but these methods fail to provide a comprehensive picture of the RNA 
as they preselect for a sub-selection of RNA (Skog et al., 2008, Valadi et al., 2007, Nolte-'t 
Hoen et al., 2012, Cheng et al., 2014, Royo et al., 2013, Li et al., 2013, Ahadi et al., 2016b). In 
this thesis, whole transcriptome sequencing was performed, with only ribosomal RNA (rRNA) 
removed (Benes et al., 2011), in chapter 5. This unbiased approach is hitherto unused, so 
was chosen to provide novel insights into the entire RNA of exosomes compared to the 
source cell. 
RNA sequencing data were generated from H4 cells and exosomes, using TruSeq Stranded 
Total RNA with Ribo-Zero Gold library preparation kits (Illumina), sequenced on a HiSeq 2500 
(Illumina) at Wales Gene Park and analysed, by the author, using standard bioinformatics 
tools and best practices (Conesa et al., 2016, Mercken et al., 2013). The first novel and 
striking observation from these data came from annotating coding and non-coding RNA 
bases. Over 96% of reads measured from exosomes were non-coding, and thus, a completely 
different profile to cellular-RNA, which contained a large proportion (40%) of coding RNA. 
Disparity between the RNA of cells and exosomes has been reported before (Mittelbrunn et 
al., 2011, Li et al., 2015); however, other reports have shown good correlation between 
intracellular and exosomal RNA (Turchinovich et al., 2011, Tosar et al., 2015). In this thesis, 
an unprecedented difference between the RNA within cells and exosomes was shown. The 
profile of RNA within exosomes is mostly non-coding, demonstrating that the particular 
transcriptome of exosomes is fundamentally different from the source cell. On one hand, it 
may be that exosomes exist to eliminate junk RNA, such as spliced introns, from cells, as 
suggested from the relative abundance of intronic reads (43%) in this dataset. However, the 
non-coding transcriptome has not been well annotated and novel species, such as lncRNAs, 
are continually being identified and annotated. In this dataset, lncRNAs and introns were 
analysed and found to be informative, as discussed below, so it is likely that exosomes 
function as more than a route for eliminating junk RNA. 
A second observation from the sequencing data was that the functional annotation of 
differentially-expressed RNA found enrichment of terms in exosomes, which reflected the 
known protein composition of these vesicles (Webber et al., 2014, Kalra et al., 2012, Simpson 
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et al., 2012). Exosomes are secreted lipid-bounded vesicle structures often replete with intra-
luminal proteins and tetraspanins that are known to cross-link with other tetraspanins and 
membrane proteins to for tetraspanin-webs. The enrichment of terms such as “disulfide 
bond”, “topological domain:Extracellular”, “Secreted” and “transmembrane” are strikingly 
similar to the known molecular composition of exosomes and to the GO enrichment terms 
that have arisen from proteomic profiling. Protein array methods have identified enrichment 
of terms such as “Disulfide Bond”, “Transmembrane” and “Topological domain:Extracellular” 
(Webber et al., 2014). Additionally, in the RNA sequencing dataset, there was enrichment of 
terms such as “Glycoprotein” and “glycosylation site:N-linked”. It has previously been 
described that glycosylation is one of the processes by which exosomal proteins are 
regulated (Kore and Abraham, 2016) and glycoproteins on the surface of exosomes play 
important physiological roles, such as the binding of activated platelets in the coagulation 
cascade (Del Conde et al., 2005) and many other functions. Terms, such as “Glycosylation 
site:N-linked” and “Glycoprotein” were also identified by proteomic profiling (Webber et al., 
2014). Therefore, overlapping terms have been identified using both proteomic analysis and 
RNA sequencing, despite the technically different approaches. 
If RNA is non-randomly sorted into exosomes, they are representative of the cell they were 
derived from and functionally important. As a result, the analysis of exosomal-RNA is of great 
potential for biomarker discovery, as they will harbour select transcripts from diseased cells, 
as has been demonstrated in neuroglioma (Skog et al., 2008). The apparent disparity 
between cellular and exosomal-RNA suggests that unique biomarkers may well reside in 
these vesicles and not always be readily detected by pathological analyses in cells or tissues. 
A small number of studies, to date, have investigated the utility of peripherally available 
exosomes as biomarkers of AD. These include the analysis of proteins found on neural-
enriched plasma exosomes  (Goetzl et al., 2015b, Fiandaca et al., 2015, Hamlett et al., 2016, 
Mullins et al., 2017, Goetzl et al., 2015a, Mustapic et al., 2017), and small RNA sequencing of 
plasma (Lugli et al., 2015) and serum-derived (Cheng et al., 2015) exosomes. These latter two 
studies used 1 – 4 ml volume of biological fluid and yet struggled to obtain the 
manufacturer’s requirements of RNA input for sequencing. This highlighted a challenge that 
had to be considered in the design of this study. A small yield of RNA, in the picogram range, 
is available from biological fluids and this problem is exaggerated in the context of AD where 
elderly subjects can be difficult to obtain blood from and banks of samples soon become 
exhaustible resources as patients become deceased. This study investigated the possibility 
of using a small volume of 0.5 ml plasma to address this challenge. 
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Whilst methods had been validated for isolating RNA from cell culture medium, the final 
section of this thesis addressed the challenge of isolating exosomal-RNA from biological 
fluids. Three techniques for isolating exosomal-RNA from plasma were investigated in 
chapter 6: ultra-centrifugation, size-exclusion chromatography (Cell Guidance Systems) and 
exoRNeasy spin-columns (Qiagen). Using qPCR, it was determined that the exoRNeasy 
technique yielded greater concentrations of exosomal-RNA than the other two techniques, 
and more reliably. Furthermore, this technique did not require a centrifugation step which 
greatly increased the scalability of the assay to be increased for larger studies. 
The exoRNeasy method of RNA isolation was combined with Taqman qPCR chemistry and 
pre-amplification to refine and validate a workflow for analysing exosomal-RNA from plasma. 
This refined workflow was adopted in an AD case : control cohort, with the aims of measuring 
low-expressed gene targets and detecting significant differential gene expression changes to 
validate the assay.  
This approach required the selection of gene candidates prior to qPCR. According to a review 
of studies with post mortem brain tissue, twelve genes were consistently up- or down-
regulated in AD (Feng et al., 2014). Six of these were chosen, as they were ideal candidates 
to use in validating the workflow: the genes are preferentially expressed in the brain so 
would validate the detection of low-expressed, CNS-specific signals that have passed over 
the blood brain barrier via exosomes. By measuring gene expression in plasma-derived 
exosomes, the genes ITPKB and FAM107A were found to be significantly down-regulated in 
cases compared to controls. This was the opposite direction as had been reported in post 
mortem brain (Feng et al., 2014). It is difficult to make a biological inference from these 
observations. It has been observed, in Parkinson’s disease, that concentrations of the protein 
α-synuclein can be reduced in patient CSF, but increased in association with plasma 
exosomes (Shi et al., 2014). It can be hypothesised, therefore, that exosomes can serve as a 
route for eliminating harmful products from the brain. In the case of AD, it may be that the 
elimination of ITPKB and FAM107A is perturbed in disease. This idea is complemented still 
further with the observation that BLOC1S6 was differentially expressed. This gene plays a 
role in intracellular vesicle trafficking which hints at an already intriguing role for endocytosis 
and exosomes in AD. Regardless of these hypotheses, observing significant changes in gene 
expression, especially with brain-derived targets, was a good validation of the chosen 
approach and this workflow. 
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In summary, the research presented in this thesis showed a characterisation of neural-
derived exosomes which were used as bulk stocks in an attempt to develop an 
immunocapture assay, and to develop methodologies for isolating and analysing exosomal-
RNA. The latter revealed intriguing features of exosome biology: the profile of RNA within 
exosomes is vastly different from its source cell and the sorting of RNA into exosomes is not 
an entirely random process. These observations, coupled with current literature, suggest 
that exosomes are a prime candidate for developing peripheral biomarkers of AD. In light of 
this, a tractable workflow was developed to isolate exosomal-RNA from only 0.5 ml archival, 
frozen plasma. This technique was validated by qPCR and showed sufficient sensitivity to 
detect small changes in exosome dose and also to measure low-expressed, brain-enriched 
genes that have passed over the blood-brain barrier via exosomes. Thus, the potential utility 
of exosomes as peripheral biomarkers of AD has been confirmed, as well as a methodology, 
which can be used for the analysis of RNA from small volumes of plasma, has been 
developed. 
7.2 Future directions 
7.2.1 Future directions of analysing the RNA sequencing dataset 
In the RNA sequencing dataset, the profile of RNA in exosomes was fundamentally different 
from that of the source cell. A global annotation of the data found more than 96% RNA within 
exosomes to be either intronic or intergenic. This proved problematic for performing a 
standard differential gene expression analysis, so long non-coding RNAs and introns were 
analysed to provide functional annotations. However, the data could have been mined much 
further. 
One analysis that has been performed with small RNA sequencing data is to annotate the 
proportion of different RNA species in exosomes (Cheng et al., 2014). Using annotation files, 
the proportions of micro RNA, lncRNA, small nucleolar RNA, rRNA, transfer RNA and other 
RNA species was determined. It has since been determined that other species of RNA are 
also present in exosomes, including: mRNA, vault RNA, Y RNA, small interfering RNA and 
circular RNA (Raposo and Stoorvogel, 2013, Dou et al., 2016, Nolte-'t Hoen et al., 2012). A 
comprehensive annotation file that can capture these different species needs to be 
developed but this is not a trivial undertaking as the field is constantly changing with new 
species and novel annotations being reported. Indeed, it is possible to identify novel 
transcripts using RNA sequencing data (Mercken et al., 2013), which could be performed 
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with this current dataset. Given the disparity between cellular and exosomal-RNA, reported 
here and in the literature (Mittelbrunn et al., 2011, Li et al., 2015), this may well be a fruitful 
avenue of research. Of particular note, with the dataset produced here, is the novelty of 
performing whole transcriptome sequencing with exosomes and source cells, only rRNA was 
removed. There is good potential to identify an array of RNA species and perform de novo 
annotation that is not possible with microarray data and limited in small RNA sequencing 
datasets. However, it must be conceded that small RNA sequencing is technically more 
suitable for measuring the expression of miRNAs and other small RNA species, as the library 
preparation protocols enrich for these species, based on their size. 
This dataset has the potential to be mined further: RNA sequencing data can be used for the 
investigation of the structure of transcripts and, in particular, detecting splice variants and 
fusions (Haile et al., 2017). An additional analysis could be performed with this dataset if DNA 
sequencing data was available for the H4 cell-line. It has been shown that RNA sequencing 
data can be integrated with whole-exome DNA sequencing for the enhanced detection of 
somatic mutations in lung and breast cancer (Wilkerson et al., 2014). This method, termed 
UNCeqR, improved mutation detection, particularly in low purity tumours. To apply this 
method to the dataset developed in this thesis may be problematic given the dominance of 
non-coding RNA in exosomes. However, it would give a flavour of the possibilities of 
integrating different datasets and deepen the understanding of the nature of exosomal-RNA. 
The RNA sequencing also provided additional evidence that RNA is non-randomly sorted into 
exosomes (Mateescu et al., 2017). Despite this, direct mechanistic evidence is required. It 
has been shown that AGO2, and other miRNA-interacting proteins, can interact with 
components of the endocytic tracts such as MVBs (Gibbings et al., 2009, Lee et al., 2009), 
endoplasmic reticulum (Stalder et al., 2013) and endogenous prion protein in the 
endolysosomal network (Gibbings et al., 2012). Currently, it is inconclusive if AGO proteins 
are generally associated with extracellular vesicles, but it is likely that post-translational 
modification of the protein, and modulation of miRNA transcripts, would play a role in the 
incorporation into EVs (Mateescu et al., 2017). A number of RNA motifs have been associated 
with incorporation into EVs (Szostak et al., 2014, Batagov et al., 2011), including a GGAG 
motif on miRNAs that binds to sumoylated heterogeneous nuclear ribonucleoprotein A2B1 
for loading into exosomes (Villarroya-Beltri et al., 2013). As a result of this, further 
experimental work is required to provide mechanistic evidence. 
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The differential expression of lncRNAs was performed in this study and future work in this 
area may well increase the understanding of RNA packaging into exosomes. LncRNAs have 
been reported as enriched in exosome-like particles secreted by mast cells (Lasser et al., 
2016) and abundant in prostate cancer-derived exosomes (Ahadi et al., 2016b). The same 
group reported an enrichment of miRNA seed regions and RNA binding protein motifs on the 
lncRNAs being studied (Ahadi et al., 2016a). Whilst this was linked to disease propagation in 
the study, it should not be overlooked that the enrichment of these motifs in exosome 
lncRNAs may well point to the general mechanisms involved in loading these RNAs into 
exosomes, as reported for miRNAs (Villarroya-Beltri et al., 2013). Here, common sequence 
motifs present within sets of exosomal-enriched lncRNAs could be identified, pointing to a 
likely role in directing these towards a vesicle secretion fate. 
It would be beneficial to directly investigate the functional role of the lncRNAs identified as 
differentially expressed in exosomes. It has been demonstrated that viral induction can be 
used to alter the expression of the lncRNA Chast (Viereck et al., 2016). A similar study used 
a pharmacological agent to knock down cellular miR-21*, which would otherwise be enriched 
in exosomes in models of cardiomyocyte hypertrophy (Bang et al., 2014). Such techniques 
could be adopted to follow up on some of the lncRNA candidates reported as enriched in this 
study. However, it is unclear whether these would address questions about the packaging of 
RNA into exosomes in general or specifically for the H4 cell-line used. 
7.2.2 Future directions of RNA sequencing with cell culture-derived 
exosomes 
The H4 cell-line was chosen for this study for a number of reasons. Primarily, the cell-line 
proved useful for the bulk production of neural-derived exosomes as it did not reach 
senescence as a primary cell-line might, especially when using bioreactor culture methods. 
In addition, the H4 cell-line has been routinely manipulated to create cell-models of AD (Asai 
et al., 2007, Sung et al., 2016), yet there has only been one report of studying the exosomes 
secreted from it to date (Tsunemi et al., 2014). Therefore, it proved useful and reliable for 
the first principle investigations reported here and has the potential to be taken further by 
introducing genetic mutations. 
An immediate extension of the RNA sequencing work with the H4 cell-line and secreted 
exosomes, is to do similar analyses after introducing AD-relevant gene expression changes 
or mutations. For example, the H4 cell-line has been, and can relatively easily be manipulated 
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to stably express the Swedish mutated form of APP (Asai et al., 2007). More recently, CD2AP, 
which encodes for an adaptor protein implicated by GWAS, has been linked to exosome 
trafficking in HEK293 cells (Kwon et al., 2016). There is scope to take this cell-line further 
using gene manipulation. This thesis has demonstrated a number of techniques for 
measuring exosome secretion, protein composition and RNA analysis that could easily be 
adopted when introducing the Swedish mutation of APP or knocking in/out CD2AP, and other 
AD risk genes, in H4 cells.  
There are numerous options and careful considerations that should be made prior to gene 
manipulation experiments as a number of risk genes have been implicated in AD (Robinson 
et al., 2017). It is far more likely to achieve measurable changes in exosome secretion, or 
composition, if endocytosis related risk genes are perturbed (Lambert et al., 2013). Yet, the 
development of CRISPR-Cas9 genome editing allows far more subtle changes in gene 
expression such as the introduction of point mutations (Hockemeyer and Jaenisch, 2016). It 
also requires a careful choice of gene to perturb, or single nucleotide polymorphism to alter, 
as the genes reported in GWAS studies are determined by proximity to the SNP probe in the 
study. This means that the disease causing SNP or gene may not be the one reported to have 
statistical association. Indeed, many are situated in intronic or intergenic genomic regions. 
Deeper mining of GWAS data, such as the use of conditional analyses (Hoffmann et al., 2015), 
may narrow down to one SNP of interest or even highlight multiple SNPs with independent 
signals. The long range effects, such as chromatin remodelling, of these disease variants are 
also unknown. There are numerous options for manipulating the H4 cell-line with AD-
relevant gene changes and to monitor the impact of these on exosome number, protein and 
RNA. 
However, a primary, diseased cell type from AD patients would provide an ideal candidate 
for culture and for collection of exosomes for sequencing analysis. As AD is a disease of the 
brain, the cell types in question are not readily obtainable from patients. Alternatively, 
peripheral blood monocytes (PBMCs) are primary cells that are relatively easy to obtain non-
invasively. With the aid of Epstein Barr Virus transformation, it is also possible to immortalise 
B-lymphocytes, within PBMCs, to lymphoblastoid cell-lines (LCLs) for long term use (Gallo et 
al., 2017). Such cells can be expanded readily and maintained at high densities to yield 
plentiful stocks of exosomes. Whilst these cell-types are more readily obtainable from 
patients, the relevance to disease is questionable for both.  
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Alternatively, to transforming PBMCs to LCLs, it has been demonstrated that primary cells, 
such as fibroblasts, PBMCs and keratinocytes, can be modulated to a pluripotent cell-type 
known as induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006, Lee et al., 
2016a, Khazaei et al., 2016). These can be differentiated to the cell type of interest, including 
neurons (Hayakawa et al., 2017, Takahashi, 2017), microglia (Muffat et al., 2016) and 
astrocytes (Yamamizu et al., 2017). Protocols are now being developed that allow direct 
induction to neurons (Broccoli, 2017). It is an exciting prospect to obtain a primary cell from 
an AD patient, reprogram to iPSCs (Lee et al., 2016a) and derive a cell-type of relevance for 
further study. In theory, a suitable cell-type with the correct genetic background for disease 
is available this way, but it should be considered that the epigenetic background, either from 
the original cell or from the induction process, may not give the exact mimicry required 
(Khazaei et al., 2016). Nevertheless, exosomes from iPSC-derived cells can be of utility in 
disease therapeutics (Liu et al., 2017) and may have wider applications, including the 
identification of disease-discriminating RNA profiles, in the future. 
The use of iPSC-derived neurons comes with an additional complexity of trying to 
physiologically replicate the aged brain in vitro (Arber et al., 2017). For example, it can take 
up to 100 days of culture to generate functionally and electrically active neurons (Gaspard 
et al., 2008, Shi et al., 2012). Furthermore, a foetal form of the tau protein is predominately 
expressed in IPSC-derived neurons and can take up to 365 days of culture before multiple 
isoforms are present (Sposito et al., 2015, Wren et al., 2015, Iovino et al., 2015, Imamura et 
al., 2016). Even with such caveats highlighted, iPSCs provide a unique avenue to probe into 
the pathology and therapeutics of AD. The development of CRISPR-Cas9 genome editing 
technology has coincided with the growing use of iPSCs and shows promise in being used 
together (Hockemeyer and Jaenisch, 2016). As such, the possibilities are numerous for 
designing studies and, as discussed, careful consideration of the relevance of cell types and 
epigenetic background must be made.  
This thesis has described the first principle work of whole transcriptome sequencing using 
H4 cells and exosomes. The methods could be adopted for more complex, yet closer to 
disease relevance, research questions through the adoption of iPSC and CRISPR-Cas9 
technologies. This was beyond the scope of this study, but the sequencing data provided 
evidence that RNA is non-randomly sorted into exosomes and is a gold-mine for future 
explorations of the nature of exosomal-encapsulated transcriptomics. 
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7.2.3 Future directions of analysing RNA isolated from peripherally 
available exosomes 
A biomarker of disease is an objectively measured biochemical, physiological or anatomical 
change (Jack and Holtzman, 2013). A probable diagnosis of AD can be determined by 
cognitive and physical examinations coupled with patient history (McKhann et al., 1984, 
McKhann et al., 2011). Currently, clinical biomarkers of AD rely on lumbar puncture or 
neuroimaging which are prohibitively invasive and expensive, respectively, for routine use 
(Jack and Holtzman, 2013). Therefore, a blood test for AD would be of great utility. Until 
2017, consistent measurements of amyloid-β (Aβ) in the blood, using antibodies, proved 
difficult until the announcement of a mass spectroscopy-based method (Ovod et al., 2017). 
As an alternative, exosomes are showing promise of carrying protein and RNA biomarkers of 
AD  (Fiandaca et al., 2015, Goetzl et al., 2015b, Goetzl et al., 2015a, Hamlett et al., 2016, 
Mullins et al., 2017, Mustapic et al., 2017, Cheng et al., 2015, Lugli et al., 2015). In this thesis, 
a method of extracting exosomal-RNA from 0.5 ml plasma was validated by qPCR. This 
method has great potential to be taken much further. 
So far, the method has been used to measure gene expression of pre-selected targets by 
qPCR. According to manufacturer’s guidelines, the pre-amplification step allows up to 50 
targets to be measured so a natural extension of this work is to simply investigate additional 
genes. 
A hypothesis-driven approach gives numerous options. One option is to measure the gene 
expression of targets implicated by GWAS (Lambert et al., 2013). However, the functional, 
disease-causing variants have not necessarily been identified with such studies. 
Furthermore, they individually have weak effect sizes that required large genetic studies to 
reach a genome-wide significant association and so the likelihood of detecting significant 
changes in gene expression is dubious without large sample sets. The hypothesis could be 
narrowed by changing the sample set or target set. For example, familial, early onset AD is 
driven by causal mutations in APP, PSEN1 or PSEN2 (Tanzi and Bertram, 2005) and whilst 
these primarily affect amyloidogenesis, the strong genetic component may be more likely to 
affect gene expression than a hypothesis involving common variants. Mutations in TREM2, 
PLCG2 and ABI3 have been implicated by exome studies so coding variants have been 
identified (Sims et al., 2017). Alternatively, the sample set could be narrowed by accounting 
for genetic background such as APOE genotype (Robinson et al., 2017) or polygenic risk score 
(Escott-Price et al., 2015, Escott-Price et al., 2017); or a clinical measurement of disease state 
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(Mendez and Cummings, 2003); or a grouping by clinically-used biomarkers (Jack and 
Holtzman, 2013). A combination of these could be to narrow the study down to individuals 
with a polygenic risk score calculated for a particular biological pathway, for example, 
endocytosis, cholesterol metabolism or immunity, and then measuring gene expression for 
targets relevant to that pathway. 
Perhaps a better approach, with a view of discovering novel biomarkers, would be to adopt 
this method in a non-hypothesis driven study. Despite the challenge of a small quantity of 
starting material, this method has shown sensitivity to small exosomes dose changes and 
was able to detect gene expression changes in brain-enriched targets. The methodology of 
detecting gene expression was qPCR, which involves exponential amplification of the target 
(Harbison and Nguyen, 2017). Whilst there is an element of amplification in RNA sequencing 
library preparation, it is not to the same extent as qPCR. However, technologies have 
emerged for sequencing based on low sample input such as single cell genome (Navin et al., 
2011, Nawy, 2014), chromatin capture (Ulianov et al., 2017) and transcriptome (See et al., 
2017, Papalexi and Satija, 2017) sequencing. Whilst these studies are challenging, it has been 
reported that RNA sequencing data, of good quality, can be collected with as low an input as 
50 pg (Shanker et al., 2015). This was within the input range of the RNA yields in this study 
that used 0.5 ml plasma to isolate exosomal-RNA. Therefore, with the technical limitations 
of sequencing low input samples having been lessened, this method, already validated by 
qPCR, should be used in the future for RNA sequencing. An unbiased, non-hypothesis driven 
study based on sequencing should prove to be a fruitful avenue of research, even with 0.5 
ml plasma, as has been reported for higher volumes previously (Cheng et al., 2015, Lugli et 
al., 2015). 
Currently, the identification of peripheral biomarkers of AD is very much in the early stages. 
As such, studies have largely aimed to distinguish AD cases from controls and occasionally 
included patients with Mild Cognitive Impairment (MCI). The ultimate aim must be to identify 
biomarkers of pre-clinical AD pathology, as it has been determined that the harmful events 
of Aβ deposition occur years before the cognitive deficits present in the clinic (Villemagne et 
al., 2013). Using neuro-imaging techniques, differences in scene perception and short-term 
memory have been observed in young, healthy adults who carry the APOE e4 allele, 
compared to non-carriers (Shine et al., 2015). Exosomes, as discussed previously, carry an 
RNA cargo that is sensitive to the state of the source cell and, consequently, would be 
suitable candidates for harbouring biomarkers in these pre-clinical stages. Therefore, the 
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future work described could well drive forward the pursuit of a peripherally available, pre-
clinical biomarker of AD. 
7.3 Concluding comments 
This thesis has demonstrated the isolation and analysis of exosomal-RNA derived from cell 
cultures and biological fluids. The limitations and technical difficulties of both have been 
highlighted as methodologies have been developed. By analysing RNA enriched in exosomes, 
compared to source cells, it can be inferred that RNA is not entirely randomly sorted into 
exosomes. Indeed, this observation, with others in the literature, that exosomal-RNA is 
sensitive to the state of the source cell, makes exosomes excellent candidates for carrying 
biomarkers of AD. 
Follow up studies using cultured cells could further illuminate the mechanisms involved in 
sorting RNA into exosomes, or the mechanisms perturbed in disease by AD-associated 
mutations, particularly, the exosome biogenesis/secretion pathway. It would not be a trivial 
undertaking, but adopting the method for isolating exosomal-RNA from biological fluids and 
applying it to RNA sequencing technologies is a potential broad route to identifying novel 
biomarkers of AD, and other diseases. 
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